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Resumen Corto
Acinetobacter baumannii es un patógeno nosocomial versátil implicado en importantes
infecciones como la neumonía asociada a ventilación mecánica, infecciones del torrente
sanguíneo, del tracto urinario, de heridas y de quemaduras en pacientes críticamente enfermos.
Se han encontrado elevadas tasas de resistencia a muchos grupos de antibióticos en esta 
especie, incluyendo carbapenemas. La adquisición de resistencias se debe a su genoma elástico.
Por ejemplo, la adquisición de OXAs es uno de los mecanismos más comunes en A. baumannii
en su resistencia a carbapenemas, y las cepas resistentes a este antibiótico están asociadas con
algunos clones internacionales. A. baumannii expresa factores de virulencia de una manera 
diferente en las diferentes cepas y algunos estudios muestran una relación entre virulencia y 
antibiorresistencia, que aún no está muy desarrollada. En esta Tesis Doctoral, se investiga la 
relación entre clonalidad, virulencia, y antibiorresistencia en cepas aisladas en España y el 
Líbano, dos países de la cuenca Mediterránea. Nuestro objetivo con este estudio es apoyar a 
los expertos en el control de infecciones, y proporcionar las herramientas necesarias para
combatir la propagación de cepas resistentes a diferentes antibióticos. Además, con todo ello
intentamos comprender mejor la compleja relación entre virulencia y resistencia antibiótica. 
Cincuenta y nueve cepas de A. baumannii fueron aisladas del HU-LP (España) y 90 del 
SGH-UMC (Líbano). Se identificaron las cepas utilizando tiras API, amplificando por PCR
genes de OXA-51, y mediante análisis por MALDI-TOF MS. Se analizó la resistencia 
antibiótica de las cepas según la guía de CLSI, se determinó la clonalidad por PFGE y se realizó
la amplificación diferencial de genes “housekeeping”. Los genes de carbapenemasas se
detectaron por PCR y la formación de biofilms, hemólisis, movilidad, actividad proteolítica, y 
tiempos de generación se detectaron fenotípicamente. A continuación, se llevó a cabo la 
secuenciación del operón pmrCAB y el genoma de cepas resistentes a colistina. Además, se
investigaron los patrones de formación de biofilms, después de cultivar las cepas en soportes
de acero inoxidables, mediante recuento de las células adheridas y microscopía confocal.  
Los resultados obtenidos muestran tasas muy altas de resistencia a antibióticos,
especialmente a carbapenemas, en HU-LP, surgiendo la necesidad inmediata de intervención 
con programas de control de infección y de administración de antibióticos. El clon
internacional II fue el más común, y la familia OXA-24 fue la más frecuente en este hospital. 
Se encontraron 7 pulsotipos distintos por PFGE, que fueron responsables de la mayoría de las 
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infecciones en HU-LP, demostrando la capacidad que tienen sólo algunos clones de producir 
infecciones recurrentes. Los perfiles de virulencia fueron muy variables entre las cepas, pero 
se encontraron asociaciones entre el clon internacional II y OXA-23, y un mayor nivel de
virulencia en las cepas del HU-LP. Los otros clones y OXAs en este set se asociaron con una
menor virulencia. 
Se encontraron también altas tasas de resistencia a carbapenemas en SGH-UMC. El 
clon internacional II y la familia OXA-23 fueron los más frecuentes en este hospital. No se 
encontraron asociaciones entre los OXAs, clonalidad, y virulencia en el set de cepas libanesas.
Esto indica que estas asociaciones son locales y es necesario realizar estudios preliminares en
cada hospital. Las asociaciones entre virulencia, clonalidad y OXAs pueden emplearse, sin 
duda, para modificar los tratamientos y los protocolos de control de estas infecciones. Sin
embargo, encontramos asociaciones entre los factores de virulencia en el set de cepas libanesas, 
y una investigación más profunda a este respecto puede conducir a una mejor comprensión de
los mecanismos patogénicos de A. baumannii. 
Se detectaron dos mutaciones distintas en PmrB (P233S y deleción de Ile), que fueron 
responsables de causar resistencia a colistina en dos cepas distintas. La primera mutación se ha 
descrito en otros estudios y en nuestro trabajo se muestra su relación con la producción de
sideróforos y la actividad proteolítica. La segunda mutación ha sido detectada por primera vez
en nuestros estudios de Tesis Doctoral y se ha comprobado que no afecta a la virulencia.
Además, en este estudio se ha detectado el gen blaGES-5 por primera vez en A. baumannii, 
indicando el intercambio de carbapenemasas entre diferentes especies. 
Durante la investigación de la relación entre los patrones de formación de biofilms y
perfiles de antibiorresistencia, se observó una relación entre cepas formadoras rápidas de
biofilms y susceptibilidad a aminoglicósidos. Se detecta pigmentación para algunas cepas que
no fue asociada con la producción de sideróforos. Además, se estudió la relación entre
resistencia a carbapenemas y la formación de biofilms. Se encuentra una relación entre
formaciones densas de biofilms y cepas resistentes a carbapenemas. Analizar un mayor número
de cepas puede confirmar nuestros resultados preliminares y puede ayudar una mejor
comprensión de la relación entre la resistencia antibiótica y formación de biofilms.
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En resumen, se demuestra que existen tasas de resistencia a carbapenemas muy
elevadas, así como la predominancia del clon internacional II en HU-LP y SGH-UMC. Se 
muestra también la predominancia de OXA-24 en HU-LP en comparación con la
predominancia de OXA-23 en SGH-UMC. A continuación, se describe una asociación entre 
clonalidad y virulencia en las cepas de HU-LP, que será necesario verificar a nivel local, ya
que se encuentra una diferencia en las asociaciones de los diferentes hospitales. Se analiza,
además, una mutación previamente descrita y se describe, por primera vez, una nueva mutación 
en PmrB, que origina resistencia a colistina. Mientras que la primera afecta la virulencia, la 
segunda no muestra un efecto sobre ella. Finalmente, se observa una relación preliminar entre
formaciones densas de biofilms y resistencia a carbapenemas.
**********************************************************
Resumen Largo
Acinetobacter baumannii es un cocobacilo Gram negativo, aerobio, no fermentador,
catalasa positivo, y oxidasa negativo, que está incluido en la familia Moraxellaceae. Esta 
bacteria esta capaz de utilizar varias fuentes de carbono y crece fácilmente en medios de cultivo 
comunes. Se considera A. baumannii como un organismo ubicuo en la naturaleza, ya que se 
encuentra en muestras de origen ambiental y animal. A. baumannii forma parte del complejo 
Acinetobacter calcoaceticus – Acinetobacter baumannii (ACB) y puede formar parte de la 
microbiota normal de los seres humanos. Se han desarrollado varias técnicas para la 
identificación de A. baumannii que incluyen pruebas bioquímicas, secuenciación de la región
espaciadora 16S-23S en el ARN del ribosoma, y desorción-ionización de matriz asistida por 
láser de tiempo de vuelo espectrometría de masas (con abreviación común MALDI-TOF MS).
Es importante tener en cuenta que, puesto que la identificación mediante pruebas bioquímicas
sólo puede caracterizar el complejo ACB, es necesario complementar estas pruebas con la
amplificación del gen blaOXA-51-like, que es intrínseco en A. baumannii.
El patógeno Acinetobacter baumannii está implicado en varias infecciones
nosocomiales que incluyen neumonía asociada a ventilación mecánica, infecciones del torrente
sanguíneo, infecciones del tracto urinario, e infecciones de heridas y de quemaduras. A. 
baumannii está especialmente implicada en la infección de pacientes en las Unidades de 
Cuidados Intensivos (UCI) y puede resultar en tasas de mortalidad de hasta el 43% de estos 
 
 
   
   
     
    
     
   
      
  
     
    
     
 
    
      
     
   
 
  
   
 
      
    
      
  
 
    
    
 
   
    
      
 
   
6
pacientes. Se encuentran muchos mecanismos intrínsecos de resistencia en Acinetobacter
baumannii frente a un gran número de antibióticos y su genoma es muy elástico, permitiéndole 
adquirir resistencia frente a un número aún mayor de antibióticos. La resistencia natural de A. 
baumannii limita severamente las opciones de tratamiento y deja poco margen de tratamiento
mediante el uso de antibióticos con suficiente eficiencia en el curso de infecciones causadas
por este patógeno. Además, la gran capacidad de adaptación de este organismo resulta muy a
menudo en una mayor resistencia a otros antibióticos, hasta que el número de opciones de
tratamiento se limita de forma preocupante. Mientras en las últimas décadas se hablaba de 
cepas resistentes a dos o tres grupos de antibióticos, hoy en día se pueden encontrar bases de 
datos repletas de estudios que muestran resistencia a todos los grupos de antibióticos
exceptuando un par, e incluso cepas resistentes a todos los antibióticos. La elevación en la tasa
de resistencia a carbapenemas es especialmente alarmante, ya que estos antibióticos se reservan 
para su uso en el tratamiento de pacientes gravemente enfermos e infectados con cepas
resistentes a múltiples antibióticos. Estudios a nivel mundial muestran que la tasa de resistencia
frente a carbapenemas en cepas de A. baumannii ha aumentado del 41% al 63% en sólo 4 años.
Estudios recientes también muestran que la tasa de resistencia a carbapenemas puede alcanzar
el 93% en algunos países europeos y en regiones de Oriente Medio. En España, la tasa de 
resistencia a carbapenemas es notoriamente más alta que en otros países europeos. Los estudios 
muestran que la susceptibilidad a carbapenemas ha disminuido desde el 33,8% hasta el 19,3%
durante diez años. En el Líbano, un estudio nacional muestra que la tasa de resistencia a 
carbapenemas es el 88% en las cepas clínicas de A. baumannii. Estas elevadas tasas ponen en 
peligro la continuidad en el uso de esta crucial familia de antibióticos en el futuro. El dato más 
alarmante es que las cepas resistentes a carbapenemas son las responsables de tasas de
mortalidad muy elevadas en pacientes infectados. 
Acinetobacter baumannii tiene la capacidad de adquirir resistencia frente a varios 
antibióticos a través de la trasferencia horizontal de genes que codifican beta-lactamasas y a
través de varias mutaciones en su genoma y la regulación de la expresión de genes intrínsecos. 
La familia más común de carbapenemasas encontrada en A. baumannii es la familia de 
oxacilinasas (OXAs). En particular, las familias OXA-23, OXA-24, y OXA-58 son las más
frecuentes entre cepas de A. baumannii resistentes a carbapenemas. Estas OXAs se encuentran
distribuidas por todo el mundo y están asociadas con algunos clones internacionales que han 
demostrado una importante capacidad para evadir el tratamiento antibiótico. El clon 
internacional II, anteriormente conocido como clon europeo II, es el clon más frecuente a nivel 
 
 
     
  
     
   
  
 
   
  
      
 
 
  
   
  
   
    
   
   
   
 
    
 
  
 
 
 
    
      
   
 
  
   
7
mundial. Las cepas de este clon normalmente son resistentes a varios grupos de antibióticos y
entre ellas se pueden encontrar las tres familias de OXA, siendo común encontrar más de una
familia de OXA en la misma cepa. Además de este clon, los clones internacionales I y III y
varios otros clones internacionales con resistencia a más de tres grupos de antibióticos se
encuentran distribuidas muy frecuentemente a nivel mundial. 
La prevalencia global de cepas de A. baumannii resistentes a carbapenemas ha 
empujado a los profesionales clínicos a reutilizar la colistina y experimentar su uso en terapias,
combinándola con diferentes antibióticos. La colistina fue un antibiótico poco utilizado debido 
a sus efectos adversos a nivel renal, pero hoy en día se utiliza cada vez más por su eficacia en
el tratamiento de infecciones con cepas resistentes a carbapenemas. Sin embargo, ciertas cepas 
de A. baumannii han podido desarrollar resistencia a colistina durante el tratamiento con este 
antibiótico. Aunque esta resistencia aparece de forma esporádica y dispersa, se han detectado 
varios brotes causados por cepas resistentes a colistina y todos los demás antibióticos en varios 
países del mundo. En España, un estudio muestra que el 40,67% de las cepas de A. baumannii
aisladas durante seis años resultaron resistentes a colistina. La causa de la resistencia a colistina
en A. baumannii es, en la mayoría de los casos, una mutación genética que da lugar a
modificaciones en el lipopolisacárido (LPS), la molécula responsable del efecto de la colistina. 
Mutaciones en los genes lpx que provocan la pérdida del Lipido A, el ancla del LPS, causan
resistencia a colistina, alteraciones en la virulencia, y mayor susceptibilidad a otros antibióticos 
en A. baumannii. Estas mutaciones son frecuentes entre cepas que desarrollan resistencia a
colistina in-vitro. Las mutaciones en el operón pmrCAB, que codifica para ciertas moléculas
que actúan como un sistema regulador del sensor quinasa que modifica el Lipido A en respuesta 
a estímulos ambientales, también producen resistencia a colistina en A. baumannii. Estas 
mutaciones son frecuentes entre cepas que desarrollan resistencia a colistina durante el 
tratamiento con este antibiótico. 
La patogenicidad de A. baumannii todavía no está completamente descrita, pero varios
factores de virulencia se han asociado con su capacidad de causar enfermedades y persistir en 
el hospital. La formación de biofilms es uno de estos factores identificados en A. baumannii y 
resulta en el secuestro de este organismo y su protección frente al efecto de los antibióticos y
desinfectantes. Por eso, este factor se ha considerado como un factor de virulencia y un factor 
de persistencia al mismo tiempo en A. baumannii. Además, se han detectado diferentes
patrones de formación de biofilms en las diferentes cepas y clones de A. baumannii estudiadas
 
 
    
  
    
  
      
    
    
   
    
   
  
    
   
   
 
    
   
   
    
   
    
   
 
 
  
  
  
  
 
  
    
    
8
hasta el momento. Esta bacteria también es capaz de producir sideróforos, lo que le permite
captar hierro de su ambiente. La superproducción de sideróforos puede disminuir notablemente
las reservas de hierro del paciente, por lo que este factor está considerado como un factor de 
virulencia. Además, se ha observado que algunas cepas clínicas de A. baumannii son capaces
de producir hemólisis en agar sangre mediante la producción de hemolisinas. Estas enzimas
pueden causar la lisis de las células rojas en la sangre, con la subsiguiente liberación de los 
grupos hemo, portadores de hierro. La producción de enzimas proteolíticas está también
descrita en A. baumannii y está considerada como otro factor de virulencia en este organismo.
Más adelante, aunque A. baumannii se consideraba un organismo no móvil, algunos estudios
demostraron que ciertas cepas clínicas son capaces de tener movilidad de superficie. Todos
estos factores pueden estar expresados en combinaciones que en ocasiones originan cepas con 
altos niveles de virulencia, capaces de producir altas tasas de mortalidad. Sin embargo, varios 
estudios muestran que la expresión fenotípica de estos factores puede variar mucho entre las
diferentes cepas por razones que aún no son completamente conocidas. 
Parece existir una relación entre virulencia y resistencia antibiótica en A. baumannii. 
Algunos estudios muestran que la expresión fenotípica diferencial de la virulencia entre las 
diferentes cepas puede relacionarse con perfiles de resistencia frente a varios antibióticos.
Además, genes que codifican ambos determinantes de virulencia y antibiorresistencia pueden
coexistir en el mismo elemento genético móvil. Las interacciones complejas entre estos dos
fenómenos no están bien estudiadas en A. baumannii. Sin embargo, varias moléculas se están
investigando actualmente, debido a sus efectos anti-virulencia, con el posible objetivo de
aplicarlas junto con los antibióticos en el tratamiento de infecciones. 
En esta Tesis Doctoral, cepas clínicas de A. baumannii aisladas de España y el Líbano,
dos países mediterráneos con altas tasas de resistencia a carbapenemas, fueron caracterizadas 
fenotípica y genotípicamente en términos de antibiorresistencia, clonalidad, virulencia, y el 
efecto de estos factores sobre el crecimiento de las células. Además, se investigaron las causas 
de resistencia a colistina en dos sets distintos de A. baumannii que habían desarrollado
resistencia a este antibiótico durante el tratamiento. A continuación, se investigaron los 
patrones de formación de biofilms de algunas cepas seleccionadas con diferentes perfiles de
antibiorresistencia para determinar si existe una relación entre estos patrones y la resistencia a 
ciertos antibióticos. Nuestro objetivo es proporcionar a médicos y especialistas en control de
infecciones, herramientas epidemiológicas e información sobre posibles asociaciones entre los 
 
 
   
    
    
  
     
  
 
 
   
    
     
   
  
  
    
 
   
        
      
 
    
  
  
     
  
 
 
   
      
   
     
  
9
complejos mecanismos de antibiorresistencia y virulencia en A. baumannii. Estos datos pueden
ayudar a obtener un mayor éxito terapéutico y protocolos más enfocados al control de las
infecciones. Si se implementa correctamente, esta información puede ser clave para reservar la
eficacia de los antibióticos más importantes para su uso en el futuro, limitar la propagación de
cepas resistentes a varios grupos de antibióticos, y comprender de una manera más clara la 
relación existente entre los diferentes factores que provocan el gran éxito patogénico de A.
baumannii. 
Para realizar este estudio, 59 cepas clínicas de A. baumannii fueron recogidas en el 
Hospital Universitario – La Paz (HU-LP) en Madrid, España y 90 cepas del Hospital Saint
Georges – University Medical Center (SGH-UMC) en Beirut, Líbano. Se realizó la 
identificación de las cepas mediante pruebas bioquímicas, la amplificación del gen blaOXA-51, 
y, cuando fue necesario, por MALDI-TOF MS. A continuación, se determinó el perfil de
antibiorresistencia según la guía de “Clinical and Laboratory Standards Institute”. Más
adelante, se determinó la clonalidad de las cepas llevando a cabo PCRs para distintos genes 
“housekeeping” y comparando el perfil de amplificación con datos publicados y, cuando fue
necesario, por Pulsed-Field Gel Electrophoresis (PFGE). Además, se amplificaron por PCR los
genes blaOXA-23, blaOXA-24, blaOXA-58, blaOXA-48, blaNDM, y blaKPC. La formación de biofilms se
determinó en tubos de poliestireno, tras teñirlos con 1% de cristal violeta. La hemólisis se
determinó mediante cultivo de las cepas en agar sangre durante seis días consecutivos. La
producción de sideróforos se evaluó mediante el ensayo de CAS en medio líquido. La actividad 
proteolítica se analizó realizando el ensayo de azoalbúmina. La movilidad en superficie se 
evaluó inoculando la superficie de un gel de agar Luria Bertani (LB) al 0,3% tras 14 horas de
incubación. Los tiempos de generación se determinaron para ciertas cepas con distintos perfiles
de antibiorresistencia durante su cultivo de 8 horas en caldo de LB. El análisis estadístico se
realizó utilizando varios programas para determinar las posibles relaciones entre los diferentes
factores estudiados. 
Los datos obtenidos muestran tasas muy altas de resistencia a carbapenemas en HU­
LP, alcanzando el 84,75%. Se detecta también altas tasas de resistencia a otros antibióticos en 
el 80% de estas cepas. El clon internacional II fue el más frecuente y se detectó en el 71,19% 
de las cepas. También se detectaron los clones internacionales I y III en el 8,47% y el 6,78% 
de las cepas, respectivamente, mientras el 13,56% de las cepas no pertenecieron a ningún clon
internacional y una cepa pertenecí al grupo internacional 14. El análisis de PFGE muestra que 
 
 
  
  
    
   
 
  
  
   
  
    
  
 
    
   
    
   
    
  
   
 
    
    
   
     
   
  
 
   
  
   
 
  
  
10
estas cepas se encuentran distribuidas en 7 grupos distintos y que 5 aislados no pertenecieron 
a ningún grupo. La familia OXA-24 fue la más frecuente entre las cepas de HU-LP y se
encuentra en el 62,71% de estas cepas mientras las familias OXA-23 y OXA-58 se encontraron 
en el 1.86% y el 13.56% de las cepas, respectivamente. Estos resultados muestran que la familia 
OXA-24 continúa siendo la más frecuente en España, donde fue descrita por primera vez.
En la mayoría de los casos, los perfiles de virulencia obtenidos muestran una gran
variación entre las cepas. En las cepas del HU-LP, el 69,5% fue positivo para la producción de 
sideróforos, el 84,4% para formaciones fuertes de biofilms, y el 54,2% para hemólisis. La 
actividad proteolítica entre estas cepas fue 26,6 ± 8,4 U/L y los tiempos de generación fueron
desde 0,324 ± 0,027 hasta 0,666 ± 0,037 horas. Muy pocas cepas fueron positivas para 
movilidad en superficie. Sin embargo, se encuentran algunas relaciones estadísticas entre los 
factores estudiados. En las cepas del HU-LP, las cepas que pertenecieron al clon internacional
II fueron asociadas positivamente con hemólisis, producción de sideróforos, y formaciones
fuertes de biofilms (p<0,05). En comparación, las cepas que pertenecieron a los clones
internacionales I y III han mostrado menores niveles de virulencia. De forma similar, las cepas
positivas para la familia OXA-24 fueron positivamente asociadas con estos mismos factores
de virulencia (p<0,05). Estas asociaciones pueden ser muy útiles para médicos y especialistas 
en control de infección en HU-LP, ya que les permiten desarrollar tratamientos más agresivos
dirigidos a estos factores cuando aparezca una cepa del clon internacional II y positiva a OXA­
24. Además, se puede utilizar la asociación negativa entre virulencia, el resto de clones
internacionales y las otras familias de OXA para limitar el uso de antibióticos de amplio
espectro, si la condición del paciente lo permite, y de esta manera reservar estos antibióticos
para su uso en el futuro. Una ventaja adicional de este estudio es que la determinación de la
clonalidad y la presencia de las familias de OXAs se pueden realizar de forma fácil y rápida 
utilizando dos PCR multiplex, de manera que se aprovechen las asociaciones entre estos
factores y la virulencia, para adaptar los tratamientos a los resultados obtenidos. 
El 90% de las cepas del SGH-UMC fueron resistentes a carbapenemas y el 85,6% fue
también resistente a otros antibióticos. El clon internacional II fue detectado en el 88,9% de las
cepas mientras el 6,7% de las cepas pertenecieron al grupo internacional 4, el 2.2% al grupo
14, el 1,1% al grupo 10, y una cepa no perteneció a ningún clon internacional. En las cepas 
aisladas del SGH-UMC, la familia OXA-23 se encuentra en el 93,8% de las cepas resistentes
a carbapenemas mientras OXA-24 se encuentra en sólo dos cepas y OXA-58 no se encuentra 
 
 
     
 
   
    
 
  
 
  
   
 
    
      
  
    
      
  
   
  
    
 
   
  
 
 
  
  
  
  
   
   
  
 
11
en ninguna. Los datos de los dos hospitales muestran que hay una tasa de resistencia a
carbapenemas muy elevada en ambos lugares. Este hecho necesitaría una intervención 
inmediata y rápida mediante la implantación de protocolos adecuados de control de infección
y programas de administración de antibióticos que asegurasen que estos antibióticos 
importantes siguen siendo una opción válida en el futuro. Además, estos resultados muestran
la gran propagación del clon internacional II, que se encuentra con una elevada y alarmente
frecuencia en dos países distanciados geográficamente. 
En las cepas del SGH-UMC, el 57,8% fue positivo para producción de sideróforos, el 
85,6% para formaciones fuertes de biofilms, y el 47,6% para hemólisis. La actividad 
proteolítica fue 17,7 ± 9,5 U/L y los tiempos de generación fueron desde 0,262 ± 0,021 hasta
0,653 ± 0,049 horas. La mayoría de las cepas estudiadas han sido positivas para movilidad en 
la superficie. A pesar de haber encontrado asociaciones entre clonalidad, OXAs, y virulencia
en las cepas españolas, estas asociaciones no fueron detectables entre las cepas libanesas. Esto 
sugiere que las asociaciones presentes en las cepas aisladas del HU-LP no son aplicables a las
cepas en otros hospitales sino que sólo se pueden utilizar de manera local en el mismo hospital.
Además, esto sugiere la necesidad de realizar investigaciones preliminares en cada hospital 
sobre la relación entre virulencia, clonalidad y resistencia antibiótica antes de poder aprovechar 
esta asociación. Otro factor que puede haber evitado la detección de asociaciones entre las 
cepas libanesas es que dichas cepas han sido mucho más homogéneas en comparación con las
cepas españolas. Sin embargo, se encuentran asociaciones estadísticas entre movilidad, 
producción de sideróforos, y formación de biofilms en las cepas estudiadas. Investigar estas 
relaciones en el futuro puede conducir a un mejor nivel de comprensión de las complejas 
interacciones entre estos factores, así como entre virulencia y resistencia antibiótica.
A continuación, se secuenciaron pmrCAB y el genoma completo en dos sets de cepas 
que habían desarrollado resistencia a colistina durante el tratamiento, para tratar de determinar
la causa de esta resistencia. El análisis genómico muestra que dos mutaciones distintas en 
pmrCAB pueden causar esta resistencia. La primera mutación (P233S en PmrB) es una
conocida causa de resistencia a colistina en A. baumannii. Cuando se compara con su cepa
sensible, esta mutación parece tener un efecto sobre la virulencia, ya que la cepa resistente fue 
positiva para la producción de sideróforos y mostraba casi la mitad de actividad proteolítica.
Esta observación puede relacionarse con el papel de PmrB en respuesta a cambios en los niveles
de hierro en el ambiente, pero se necesitan más investigaciones sobre el efecto exacto de esta 
 
 
    
 
    
     
   
      
    
 
 
 
   
    
     
 
 
   
 
     
   
  
    
       
   
  
  
 
  
     
   
    
   
  
 
    
12
mutación a PmrB antes de obtener conclusiones sobre su efecto sobre el metabolismo de la
célula. Le segunda mutación encontrada (Δ19Ile en PmrB) en el segundo set fue descrita por 
primera vez en nuestro estudio y no parece tener efecto sobre la virulencia de la cepa. Mas 
investigaciones en el futuro sobre los cambios exactos que produce esta mutación en PmrB
pueden ayudar a comprender mejor el mecanismo de resistencia a colistina en A. baumannii. 
El segundo set de cepas fue positivo para el gen blaGES-5, también descrito por primera vez en
A. baumannii en este trabajo. La presencia de este gen en A. baumannii es un indicador
importante del intercambio de genes de resistencia entre las diferentes especies bacterianas. 
Los patrones y tasas de formación de biofilms se investigaron también para ciertas 
cepas con distintos perfiles de resistencia, con el objetivo de determinar si existe una asociación 
entre resistencia a ciertos antibióticos y patrones específicos de formación de biofilms. Esto se
realizó mediante cultivo de las cepas en soportes de acero inoxidables y recuento de las células
viables tras 5, 12, y 24 horas de incubación. Además, se realizó un análisis de la composición
de ciertas cepas utilizando microscopia confocal. La investigación dio lugar a la identificación 
de tres patrones de formación de biofilms tras 5 horas de incubación: formadores rápidos,
formadores intermedios, y formadores lentos. El primer grupo mostraba una alta tasa de células 
adherentes en soportes de acero inoxidables y se trataba de cepas susceptibles a
aminoglicósidos. Sin embargo, no todas las cepas susceptibles a esta familia de antibióticos
formaban parte del grupo de formadores rápidos de biofilms. Todas las cepas resistentes a más 
de dos grupos de antibióticos fueron formadores rápidos o intermedios de biofilms, pero
algunas cepas sensibles a carbapenemas se encuentran en estos grupos. El grupo de formadores 
lentos incluía sólo una cepa que fue susceptible a carbapenemas. Durante el experimento,
algunas cepas mostraron una pigmentación que no estaba relacionada con la producción de
sideróforos. A continuación, dos cepas pigmentadas y resistentes a carbapenemas y dos cepas 
sin pigmentación y sensibles a carbapenemas fueron analizadas por microscopia confocal. No 
se detectó ninguna relación directa que explicase la formación de pigmentación, pero las 
imágenes obtenidas mostraron una relación entre las cepas resistentes a carbapenemas y la 
formación de biofilms densos y que cubren todo el substrato tras 24 horas de incubación. Las
cepas sensibles a carbapenemas mostraron formaciones de biofilms débiles y dispersas que no
cubrían todo el substrato tras 24 horas de incubación. La realización de este experimento 
utilizando más cepas puede confirmar nuestra observación preliminar que establecería una 
relación entre formaciones densas de biofilms y resistencia a carbapenemas. Esta relación
puede ser muy útil para su uso clínico, ya que los especialistas podrían predecir el patrón de
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formación de biofilms utilizando los datos de resistencia antibiótica y, en consecuencia, adaptar 
sus tratamientos.  
En resumen, se encontraron tasas muy altas de resistencia a carbapenemas en ambos 
HU-LP y SGH-UMC, donde el clon más frecuente fue el clon internacional II. Se detectaron
siete distintos pulsotipos en HU-LP, además de cepas aisladas con resistencia a varios 
antibióticos capaces a producir infecciones. El gen blaOXA-24 fue el más frecuente entre las 
cepas españolas, mientras que blaOXA-23 fue el más frecuente entre las cepas libanesas. Estos
datos sugieren una necesidad inmediata de implementación de programas de control de 
infección y administración de antibióticos para disminuir la prevalencia de estas cepas de A. 
baumannii en dichos hospitales. Los perfiles de virulencia en las dos poblaciones fueron muy
variados, detectándose una asociación entre cepas españolas del clon internacional II y blaOXA­
24 por un lado, y una mayor virulencia, por otro lado. Esta asociación no se detectó entre las
cepas libanesas, lo que sugiere que estas asociaciones son locales, y se necesita una mayor
investigación sobre la presencia de estas asociaciones en cada hospital antes de poder
aprovechar esta información para modificar tratamientos basándose en la clonalidad y
detección de OXAs. Además, la mutación P233S en PmrB, previamente descrita en cepas de
A. baumannii resistentes a colistina, se ha encontrado en este trabajo y parece tener un efecto 
sobre la producción de sideróforos y la actividad proteolítica. Investigar el efecto exacto de
esta mutación en el futuro puede ayudar a comprender la relación entre virulencia y resistencia 
a colistina. Se detectó además una segunda mutación en PmrB (ΔIle19) en otra cepa de A.
baumannii, descrita por primera vez en nuestro estudio. Esta mutación parece que no afecta a 
la virulencia de la cepa e investigar su efecto sobre la función de PmrB puede ayudar a
comprender más en profundidad los mecanismos de resistencia a colistina en A. baumannii. 
Finalmente, se detectó una asociación preliminar entre formaciones densas de biofilms y
resistencia a carbapenemas. Esta hipótesis necesita un estudio más profundo, utilizando un 
mayor número de cepas, antes de consolidarla y poder utilizarla clínicamente. Precisamente,
su interés clínico radica en la posibilidad de modificar los tratamientos aplicando el 
conocimiento de estas asociaciones de factores, que se podrían conocer de forma rápida 
mediante los datos de resistencia antibiótica.
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Short Summary
Acinetobacter baumannii is a highly versatile nosocomial pathogen that is implicated
in several nosocomial infections among critically ill patients and results in high mortality rates.
These infections include ventilator associated pneumonia, bloodstream infections, urinary tract 
infections, and burn wound infections. Multi-Drug Resistant (MDR), and especially
Carbapenem Resistant Acinetobacter baumannii (CRAB) isolates are also sharply increasing
in frequency, forcing clinicians to revert to the use of colistin. This organism has numerous
intrinsic resistance mechanisms, virulence determinants, and an elastic genome that allows it 
to acquire resistance to almost all antimicrobial agents rather easily. The acquisition of 
oxacillinases (OXAs) is one of the most common mechanisms of acquiring carbapenem
resistance. Moreover, some clinically important International Clones (ICs) with MDR profiles
are disseminated all over the world. A. baumannii is known to differentially express virulence 
determinants and few studies hint at their relationship with antimicrobial resistance. However, 
this relationship is not extensively investigated. In this Doctoral Thesis, the relationship 
between clonality, virulence, and antimicrobial resistance is investigated in two sets of clinical 
isolates obtained from Spain and Lebanon, two countries in which the rate of CRAB isolates 
is notoriously high. Our aim is providing clinicians and infection control specialists with tools
that could be used to assess the infecting strain based on initial clinical data that could improve
the chances of successful therapy and limit the spread of MDR and CRAB isolates.
Additionally, it is our aim to better understand the interaction between virulence and antibiotic
resistance.
Fifty nine clinical A. baumannii isolates were obtained from Hospital Universitaro - La
Paz (HU-LP), Spain and 90 from Saint Georges Hospital - University Medical Center (SGH­
UMC), Lebanon. Identification was performed using 20NE API strips, PCR amplification of 
blaOXA-51-like, and Matrix Assisted Laser Desorption-Ionization Time of Flight Mass
Spectrometry (MALDI-TOF MS). Susceptibility testing was performed according to CLSI
guidelines and clonality analysis was performed by tri-locus sequence typing and Pulsed-Field
Gel Electrophoreis (PFGE). PCR for the detection of common carbapenemases was then 
performed and biofilm formation, hemolysis, siderophore production, surface motility,
proteolytic activity, and doubling times were phenotypically determined. Additionally,
sequencing of the pmrCAB operon and the whole genome was performed for two sets of 
isolates that acquired colistin resistance during therapy. Also, the patterns of biofilm formation
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for isolates with different susceptibility profiles were determined through growth on steel 
coupons and Confocal Laser Scanning Microscopy (CLSM) analysis. 
Our data show very high rates of antimicrobial resistance, especially to carbapenems,
in both hospitals, indicating an immediate need for intervention though antimicrobial 
stewardship programs and infection control protocols. IC II was predominant in both countries 
while OXA-24-like was predominant in HU-LP as opposed to the predominance of OXA-23­
like in SGH-UMC. PFGE analysis showed that strains pertaining to 7 pulsotypes were
responsible for most infections. This shows the ability of a handful of clones to cause repeated 
infections and the international spread of ICs and OXAs. The virulence profiles were highly
variable among the different isolates. However, among the Spanish set, IC II and OXA-23-like
were associated with increased virulence as opposed to ICs I and III and the other OXAs. This
association was absent among the Lebanese set, suggesting the locality of the association and
the need for preliminary local analyses before being able to exploit the relationship between 
these factors in the modification of treatment approaches and infection control protocols. 
Nevertheless, associations between the different virulence factors was evident and further
investigating this relationship could help better understand the poorly understood pathogenicity 
of A. baumannii. 
Genomic analysis of colistin resistant strains showed that P233S and deletion of Ile in
PmrB cause colistin resistance. The former mutation is known and was shown in our study to
affect virulence while the latter mutation is novel and had no effect on virulence. Moreover,
blaGES-5 was identified for the first time in A. baumannii among these isolates indicating inter­
species exchange of carbapenemases. Investigating the patterns of biofilm formation showed a
possible relationship between aminoglycoside sensibility and fast rates of biofilm formation
and between carbapenem resistance and dense biofilm formations. These relationships, 
however, are preliminary and require further investigations using larger pools of isolates. 
In conclusion, this study shows high rates of CRAB isolates and predominance of IC II 
in HU-LP and SGH-UMC. It also shows a predominance of OXA-24-like in HU-LP as opposed
to OXA-23-like in SGH-UMC. An association between virulence and clonality seems to exist
but needs to be determined on a local since different associations were detected in the different 
hospitals. Additionally, a previously identified and a novel mutation in pmrB conveyed
resistance to colistin but only the P233S mutation had an effect on virulence. Finally, a
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preliminary relationship between dense biofilms and carbapenem resistance has been 
identified.
**********************************************************
Extended Summary
Acinetobacter baumannii is a Gram-negative aerobic, non-fastidious, non-fermenting,
catalase-positive, oxidase-negative coccobacillus that is classified under the family 
Moraxellaceae. This bacterium can utilize a wide range of carbon sources and is easily grown
on common laboratory media. It is thought to be ubiquitous in nature where it has been isolated 
from environmental, animal, and insect specimens. A. baumannii is part of the Acinetobacter 
calcoaceticus– Acinetobacter baumannii (ACB) complex and could be part of the human
normal flora. Numerous techniques have been developed over the years for the identification 
of A. baumannii that range from biochemical tests to the sequencing of the 16S-23S ribosomal
RNA spacer. Matrix Assisted Laser Desorption-Ionization Time of Flight Mass Spectrometry 
(MALDI-TOF MS) has also been employed in the identification of this organism. Additionally,
though traditional biochemical identification of A. baumannii can only reach the level of
identifying the ACB complex, the subsequent amplification of the intrinsic blaOXA-51-like is
indicative of A. baumannii.
It was shown that Acinetobacter baumannii is implicated with nosocomial infections 
that include ventilator associated pneumonia, bloodstream infections, urinary tract infections,
and burn wound infections. A. baumannii is especially implicated in infecting patients in the 
Intensive Care Unit (ICU) and produces mortality rates among these patients that could be as 
high as 43%. Acinetobacter baumannii has a wide range of intrinsic resistance mechanisms to
antimicrobial agents and a highly elastic genome that allows it to acquire resistance to even 
more antibiotics. The natural resistance of A. baumannii severely limits treatment options to 
just a handful of antimicrobial agents that retain a good activity against this pathogen.
Nevertheless, the high capacity for adaption of this organism often results in the acquisition of 
resistance and limits even more the available treatment option. While in previous decades,
reports of Multi-Drug Resistant (MDR) A. baumannii isolates were considered alarming, we
find nowadays databases full of reports of Extensively-Drug Resistant (XDR) and even Pan-
Drug Resistant (PDR) isolates. The increase in the rate of resistance towards carbapenems is
especially alarming since these agents are usually the treatment of choice for critically ill
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patients infected with MDR organisms. Resistance to carbapenems among A. baumannii 
isolates have been found to increase from 41% to 63% over just a four-year period in large­
scale studies. Moreover, recent global studies have reported carbapenem resistance rates among
A. baumannii to be as high as 93% in certain European and Middle Eastern regions. A nation­
wide study in Lebanon that included nine hospitals over a one-year period showed a rate of 
carbapenem resistance of 88%. In Spain, the rate of carbapenem resistance is notoriously higher 
than in other European countries where susceptibility to imipenem was shown to drop from
33.8% to 17.3% over ten years. These high rates of carbapenem resistance seriously endanger 
the continued use of this valuable family of antimicrobial agents for the treatment of future
infections. To make matter worse, resistance to carbapenems has been associated with even
higher mortality rates among infected individuals.
This versatile organism is able to acquire resistance to various antimicrobial agents 
through the acquisition of beta-lactamases by horizontal gene transfer and through a wide range 
of mutations in its genome, in addition to regulation of expression of several intrinsic genes. 
The most common group of beta-lactamases that are found to convey resistance to carbapenems
in A. baumannii are the oxacillinases (OXAs). OXA-23-like, OXA-24-like, and OXA-58-like 
are the most commonly detected OXAs among Carbapenem Resistant Acinetobacter 
baumannii (CRAB) isolates. These OXAs are globally disseminated and are associated with
certain International Clones (ICs) that have shown much success as pathogens all across the 
globe. IC II, formerly known as European Clone II, is the most widely worldwide disseminated
clone. This MDR clone is reported to harbor all three types of OXAs and sometimes more than 
one OXA at a time. IC I and III, in addition to several other MDR clones have also been
reported to be present across large geographical regions around the globe. 
The global prevalence of CRAB isolates has forced clinicians to revert to the use of 
colistin and experimenting with different combination therapies that often contain this 
antibiotic. Colistin is an antimicrobial agent that was not used for a long time in treatment due 
to its nephrotoxic effects. However, it has returned to clinical use since it has shown very
promising results in terms of treating MDR and XDR infections. Nevertheless, A. baumannii 
infections resistant to this antibiotic have been reported to emerge during therapy. Though
reports are normally sporadic and dispersed, outbreaks caused by PDR isolates that have
acquired colistin resistance have been reported from several countries. In Spain, one study even
showed that 40.67% of A. baumannii isolates collected over six years were colistin resistant. 
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Most reported cases of colistin resistance trace back the cause of resistance to one of two main
sets of genes, both resulting in the modification of the Lipopolysaccharide (LPS) molecule, the
target of colistin. Mutations in the lpx genes that result in the loss of Lipid A, the LPS anchor,
have been reported to cause colistin resistance, in addition to alteration of virulence and
increased susceptibility to other antimicrobial agents. The second set of genes are within the
pmrCAB operon which codes for sensor kinase regulatory molecules that result in
modifications of lipid A in response to environmental stimuli. While the former mutations are 
commonly reported from in-vitro studies, the latter mutations are commonly reported among
clinical isolates that have acquired colistin resistance during therapy. 
The pathogenicity of A. baumannii is still not yet fully understood but several virulence
factors have been identified as part of its disease-causing ability and to contribute to its
persistence in the hospital environment. Biofilm formation is one virulence factor identified in 
A. baumannii that is known to sequester this organism and protect it from the effect of 
antimicrobial agents and disinfectants. This factor therefore contributes to both the virulence 
and persistence of A. baumannii. Moreover, varying rates and patterns of biofilm formation
have been reported among different A. baumannii isolates and clones. Iron uptake through the 
production of siderophores is another factor of virulence in this organism. Siderophores capture 
iron from the environment and their overproduction could result in iron-deprivation in the host.
Hemolysis is another related virulence factor observed in some A. baumannii isolates that 
produce hemolysins. These enzymes in turn cause lysis of red blood cells and the subsequent
release of the iron-containing hemes to the surroundings. A. baumannii is also known to
produce proteolytic enzymes that exert exoprotease activity and add to the virulence of this 
organism. Additionally, though A. baumannii has been long thought of as a non-motile, several 
clinical isolates have shown surface motility. All these factors could act together in the 
production of virulent isolates that are capable to attain relatively high mortality rates.
Nevertheless, several studies showed that the phenotypic expression of these factors could vary
greatly between different isolates due to reasons that are not yet fully understood.
A relationship seems to exist between virulence and antimicrobial resistance in A. 
baumannii. A few studies reported the differential expression of the various virulence factors 
produced by A. baumannii and have linked it to MDR profiles. Moreover, genes encoding
virulence determinants and those encoding resistance determinants have been found to co-exist
on mobile genetic elements. The complex interaction between virulence and resistance has not 
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been extensively investigated in A. baumannii. Nevertheless, several molecules are being 
investigated for their anti-virulence effect in an attempt to use them in the clinical setting in 
conjunction with antimicrobial therapy. 
In this Doctoral Thesis, clinical A. baumannii isolates obtained from Spain and 
Lebanon, two Mediterranean countries with notoriously high rates of carbapenem resistance,
are phenotypically and genotypically characterized. The characterization is in terms of 
antimicrobial susceptibility, clonality, virulence determinants, and effect on cell growth. 
Moreover, molecular investigation was performed for two sets of isolates that acquired colistin 
resistance during therapy in order to determine the cause of this resistance. Finally, the rates of 
biofilm formation for a subset of isolates was performed in order to determine whether or not 
a link between antimicrobial susceptibility and biofilm formation patterns exist. Our aim is to
provide clinicians and infection control specialist with epidemiological tools and insight on the
complex that mechanisms that govern resistance and virulence in A. baumannii that could result 
in improved clinical success and more targeted infection control protocols. If properly
implemented, such information could be key for safeguarding antimicrobial agents for future 
use, limiting the spread of MDR clones, and better understanding the interplay between the 
different factors that make A. baumannii such a successful nosocomial pathogen.
To that end, 59 clinical A. baumannii isolates were collected from Hospital
Universitario – La Paz (HU-LP) in Madrid, Spain and 90 isolates from Saint Georges Hospital 
– University Medical Center (SGH-UMC) in Beirut, Lebanon. Identification of the isolates was
performed by biochemical testing using 20NE API strips, amplification of the blaOXA-51-like gene
by PCR, and where applicable, by Matrix Assisted Laser Desorption-Ionization Time of Flight 
Mass Spectrometry (MALDI-TOF MS). Antibiotic Susceptibility Testing (AST) was then 
performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. 
Clonality analysis was performed by tri-locus sequence typing and, when possible, by Pulsed-
Field Gel Electrophoresis (PFGE). PCRs for the detection of blaOXA-23-like, blaOXA-24-like, blaOXA­
58-like, blaOXA-48, blaNDM, and blaKPC were also performed. Biofilm formation in polystyrene
tubes after staining with 1% crystal violet was then determined. Hemolysis by growth on blood 
agar plates for 6 consecutive days and siderophore production using the CAS liquid assay were
also determined. Also, proteolytic activity using the azoalbumin assay and surface motility
through the inoculation of the surface of 0.3% Luria Bertani (LB)-Agar were performed.
Doubling times through growth in LB broth were then determined for selected isolates with 
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varying profiles. Statistical analysis was performed in an attempt to determine associations 
between the different factors that were determined. Additionally, sequencing of the pmrCAB
operon and whole-genome sequencing for two sets of isolates that developed resistance to
colistin during therapy were performed in order to determine the cause of this resistance.
Finally, the rates and patterns of biofilm formation were investigated for a subset of isolates
with different AST profiles in order to determine whether or not a relationship between these 
factors exist. This was performed by counting viable cells grown on steel coupons and Confocal 
Laser Scanning Microscopy (CLSM).
In this study, a very high rate of carbapenem resistance was encountered in both HU­
LP and SGH-UMC. These rates were, respectively, 84.75% and 90%. Both sets of isolates also 
showed high rates of cross-resistance to other antimicrobial agents that reached 80% for the 
Spanish isolates and 85.6% for the Lebanese set. Two isolates from the Spanish set of isolates
were resistant to colistin whereas only one isolate was colistin resistant among the Lebanese 
set. This low resistance rate provides a valuable alternative for the treatment of infections 
caused by CRAB isolates, when no other options are available. IC II was the most prevalent 
clone in both hospitals where it represented 71.19% of the isolates from HU-LP and 88.9% of 
those from SGH-UMC. ICs I and III where also detected in HU-LP where they represented
8.47% and 6.78% of the isolates, respectively. 13.56% of the Spanish set of isolates did not
pertain to any IC and one isolate pertained to tri-locus PCR group 14. Among the Lebanese set, 
6.7% of the isolates pertained to tri-locus PCR group 4, 2.2% to group 14, 1.1% to group 10,
and one isolate did not pertain to any defined clone. PFGE analysis showed the presence of 7 
distinct pulsotypes among the Spanish set of isolates and 5 sporadic isolates that did not pertain
to any cluster. 
OXA-24-like was predominant among the HU-LP isolates at 62.71% whereas OXA­
23-like and OXA-58-like were detected in 1.86% and 13.56% of the isolates, respectively. On
the other hand, 93.8% of the CRAB isolates were positive for OXA-23-like while OXA-24­
like was only detected in two isolates and OXA-58-like was not detected. These results 
demonstrate the extremely high rates of carbapenem resistance among A. baumannii isolates
in both these hospitals. This warrants immediate intervention through the application of 
adequate infection control protocols and antibiotic stewardship programs in order to safeguard
these valuable antimicrobial agents for future use. Moreover, these results show the
predominance of IC II in two geographically distinct regions, highlighting the ability of this
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clone to disseminate across vast distances. Additionally, these results show the continued high
prevalence of OXA-24-like in Spain, where it was first discovered, as opposed to the high
prevalence of OXA-23-like in the Lebanese hospital. 
For the most part, the virulence profiles obtained showed great variation between the
isolates. Nevertheless, a few statistical associations were made. Among the Spanish set of 
isolates, isolates pertaining to IC II were positively associated with hemolysis, siderophore 
production, and strong biofilm formation (p<0.05). In comparison, isolates pertaining to ICs I
and III in this set were associated with reduced virulence. Similarly, harboring blaOXA-24-like was
positively associated with hemolysis, siderophore production, and strong biofilm formation
(p<0.05). These associations could prove to be very useful in the clinical setting were clinicians
and infection control specialists in HU-LP could design more aggressive approaches towards
isolates of IC II, and especially those harboring blaOXA-24-like. Moreover, if the patient condition 
permits it, clinicians might opt for restraining from using broad spectrum antibiotics for isolates
of ICs I and III which contributes to their safeguarding for future use. An additional advantage
for the implementation of such approach is that clonality and determination of which
carbapenemase is present could be easily performed in three quick multiplex PCR reactions. 
Despite the associations encountered among the Spanish set of isolates, no statistical
association between clonality, the presence of a particular OXA, and any specific virulence
factor was detected among the Lebanese set of isolates. This suggests that the data obtained
from the HU-LP isolates could not be projected for other hospitals but rather should be used
locally in that hospital. Additionally, this suggests that a preliminary investigation in each
hospital is needed before being able to successfully predict what virulence factors an isolate 
with a specific genotype could express. Moreover, another factor that could have contributed
to the lack of detection of these associations is the higher level of homogeneity among the 
isolates as compared to the Spanish set of isolates. Nevertheless, statistical associations 
between motility, siderophore production, and biofilm formation have been detected among
the Lebanese set of isolates. Further investigating these associations could help better
understand the complex interactions between antimicrobial resistance and virulence. 
Among the Spanish set of isolates, 69.5% produced siderophores, 84.4% produced 
strong biofilms, and 54.2% showed hemolysis. These percentages are somewhat similar to 
those detected among the Lebanese isolates, where 57.8% produced siderophores, 85.6% 
produced strong biofilms, and 47.8% showed hemolysis. Proteolytic activity for the Spanish
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set of isolates (26.6 ± 8.4 U/L) was only slightly higher than that of the Lebanese isolates (17.7
± 9.5 U/L). Moreover, the doubling times for the selected isolates in both populations, though
not associated with any other factor, showed similar ranges (0.324 ± 0.027 to 0.666 ± 0.037 
hours for the Spanish isolates and 0.262 ± 0.021 to 0.653 ± 0.049 hours for the Lebanese 
isolates). However, very few Spanish isolates showed surface motility as opposed to the 
majority of the Lebanese isolates that showed diffusion patterns on the surface of LB-agar 
plates, indicating surface motility. This finding further contributes to the “locality” of virulence
since a large difference was observed between the two populations in regard to motility, 
although the majority of both populations pertained to the same IC. 
Genomic analysis of the two sets of isolates that developed colistin resistance 
throughout the course of treatment revealed two mutations in pmrCAB that led to colistin
resistance. The first mutation was previously reported from various studies and is the P233S
mutation in PmrB. This mutation seems to affecting siderophore production and proteolytic 
activity in the colistin resistant isolate where it was positive for siderophore production and 
had almost half the proteolytic activity of its sensitive counterpart. The fact that PmrB plays a 
role in responding to iron changes in the surrounding environment could explain this 
observation. However, the exact interactions of PmrB with the various factors involved in the
expression of these virulence factors require further investigation before determining the exact
effect PmrB is having on the cellular metabolism. The second mutation that was detected was 
a deletion of isoleucine in PmrB in the colistin resistant strain. This mutation does not seem to
affect the virulence determinants of the resistant strain, as compared to its sensitive 
counterparts, and is not previously reported in the literature. Investigating the exact effect this 
mutation has on PmrB could help better understand the mechanism of colistin resistance in A.
baumannii. Moreover, one of these two sets of isolates harbored blaGES-5. This gene has not
been previously identified in A. baumannii and could be an indicator of inter-species exchange
of resistance genes. 
Investigating the biofilm formation rates and patterns for isolates with different AST
profiles showed that three distinct rates of biofilm formation were evident after 5 hours of 
incubation. The first group had a high rate of attached cells on steel coupons and isolates of 
this group were susceptible to aminoglycosides. However, not all isolates that were susceptible
to aminoglycosides pertained to this group. The second group was consisted of intermediate
biofilm formers and harbored most of the tested isolates. All of the isolates that showed MDR 
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and XDR profiles were part of these two groups, although these groups also contained some
carbapenem sensitive isolates. The third group harbored a single carbapenem sensitive isolate 
and had a slow rate of biofilm formation. Some isolates showed pigmentation while performing
the experiments that was not associated with siderophore production. Therefore, analysis by 
CLSM was performed for two pigment-forming carbapenem resistant and two pigment-non­
forming carbapenem sensitive isolates in order to further investigate the composition of their 
biofilms. Though no direct explanation was encountered for the pigmentation, the carbapenem 
resistant isolates showed more voluminous biofilms on steel coupons after 24 hours. These
results, though preliminary show an association between dense biofilm formations and 
carbapenem resistance. Performing similar analyses on larger pools of isolates could reveal
clinically important associations that could be useful for infection control specialists and
clinicians in the development of biofilm eradication protocols based on AST data.
In conclusion, a very high rate of CRAB isolates was detected in both HU-LP and SGH­
UMC with a predominance of IC II in both hospitals. Isolates pertaining to seven distinct
pulsotypes, in addition to sporadic isolates were able to produce MDR and XDR infections in
HU-LP. blaOXA-24-like was predominant among the Spanish set of isolates whereas blaOXA-23-like
was predominant among the Lebanese set. These findings suggests an urgent need for 
intervention in an attempt to decrease the prevalence of CRAB isolates in these hospitals. 
Though virulence profiles showed high variability in both sets of isolates, IC II and blaOXA-24­
like were associated with increased virulence in the Spanish set of isolates but not in the 
Lebanese set. This suggests that local studies need to be performed before being able to 
clinically employ associations between virulence, clonality, and antibiotic resistance. 
Additionally, the previously reported P233S mutation in PmrB was found to convey colistin 
resistance in one set of isolates. This mutation seems to affect mechanisms of siderophore
production and proteolytic activity. A novel ΔIle19 mutation was detected in another colistin 
resistant isolate that developed resistance during therapy which did not seem to affect the
virulence factors tested for. Finally, a preliminary association between dense biofilm
formations and carbapenem resistance has been detected in a subset of isolates. Further 
consolidation of this association using larger pools of isolates could prove useful in the 
prediction of biofilm formation patterns in A. baumannii from AST data. This information, in 
turn, could be valuable for clinicians and infection control specialists in the development of 
targeted eradication protocols. 
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II. LIST OF ABBREVIATIONS
 
A. baumannii: Acinetobacter baumannii
A/S: Ampicillin/Sulbactam
AAC: Aminoglycoside Acetyltransferases 
ABC: ATP-Binding Cassette
ACB: Acinetobacter calcoaceticus– Acinetobacter baumannii
Acinetobacter spp.: Acinetobacter species
ADC: Acinetobacter Derived Cephalosporinase
AFLP: Amplified Fragment Length Polymorphism
AK: Amikacin
AME: Aminoglycoside Modifying Enzymes
ANT: Adenyltransferases
APH: Phosphoryltransferases 
ARDRA: Amplified Ribosomal DNA Restriction Analysis
AST: Antibiotic Susceptibility Testing
BES: N-bis-(2-hydroxymetyl)-2-aminoethanesulfonic acid
BHI: Brain Heart Infusion Broth
C1-7: Clusters 1-7
CARB: Carbenicillin-hydrolyzing Beta-lactamase
CAS: Chrome Azurol S
CC: Clonal Complex
CCCP: cyanide 3-chlorophenylhydrazone
CCNU: Critical Care Nursing Unit
CFP: Cefepime
CFU: Colony Forming Unit
CHEF: Contour-Clamped Homogeneous Electric Field
CHEF: Contour-Clamped Homogeneous Electric Field
CIP: Ciprofloxacin
CLSI: Clinical and Laboratory Standards Institute
CLSM: Confocal Laser Scanning Microscopy
COL: Colistin 
CRAB: Carbapenem-Resistant Acinetobacter baumannii
CSF: Cerebrospinal Fluid
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CT: Cardio/Thoracic  
CTX-M: Cefotaximase
CTZ: Ceftazidime
CVC: Central Venous Catheterization
DNA: Deoxyribonucleic Acid
EDTA: Ethylenediaminetetraacetic
EM: Emergency 
EPS: Extracellular Polymeric Substances
ESBL: Extended Spectrum Beta-Lactamases
G: Gentamicin 
GES: Guiana Extended Spectrum
GS: General Surgery
GTP: Guanosine Triphosphate
HDTMA: HexaDecyl TriMethyl Ammonium bromide
HO: Hematology/Oncology 
HU-LP: Hospital Universitario-La Paz
I: Intermediately resistant
IC: International Clone
ICU: Intensive Care Unit
IM: Internal Medicine 
IMI: Imipenem
IMP: Imipenem metallo-beta-lactamase
KPC: Klebsiella pneumoniae Carbapenemase
LAMP: Loop-Mediated Isothermal Amplification 
LB: Luria-Bertani
LEV: Levofloxacin 
LPS: Lipopolysaccharides
MALDI-TOF MS: Matrix Assisted Laser Desorption-Ionization Time of Flight Mass 
Spectrometry
MATE: Multi-drug and Toxic compound Extrusion 
MBL: Metallo-Beta-Lactamase
MDR: Multi-Drug Resistant
MER: Meropenem
MFS: Major Facilitator Superfamily 
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MIC: Minimum Inhibitory Concentration 
MIC: Minimum Inhibitory Concentrations
MIN: Minocycline
MLST: Multi-Locus Sequence Typing
mRNA: Messenger Ribonucleic Acid
MV: Mechanical Ventilation
NCBI: National Center for Biotechnology Information
NDM: New Delhi Metallo-beta-lactamase
NE: Nephrology
NEO: Neonatal
NGS: Next-Generation Sequencing
OD: Optical Density
OmpA: Outer Membrane Protein A
ORF: Open Reading Frame
OXA: Oxacillinase
P/T: Piperacillin/Tazobactam
PBA: Phenylboronic Acid
PBP: Penicillin Binding Protein
PCR/ESI-MS: Polymerase Chain Reaction / Electrospray Ionization - Mass Spectrometry
PCR: Polymerase Chain Reaction
PCR-RFLP: Polymerase Chain Reaction – Restricted Fragment Length Polymorphism
PDR: Pan-Drug Resistant
PER: Pseudomonas Extended-Resistant
PFGE: Pulsed Field Gel Electrophoresis
PIP: Piperacillin
qPCR: Quantitative Polymerase Chain Reaction
QS: Quorum Sensing
R: Resistant
RAPD: Random Amplified Polymorphic DNA
RE: Restriction Enzyme
RE: Resuscitation 
RNA: Ribonucleic Acid
RNA: Ribonucleic Acid
RND: Resistance-Nodulation-cell Division
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RPM: Round Per Minute
RPP: Ribosomal Protection Protein 
S: Susceptible
SBA: Sheep Blood Agar
SEM: Scanning Electron Microscopy 
SGH-MC: Saint Georges Hospital-Medical Center
SHV: Sulfhydryl Variable
SIM: Seoul Imipenemase
SMR: Small Multi-drug Resistance
SNP: Single Nucleotide Polymorphism
SNP: Single Nucleotide Polymorphism
SS: Stainless Steel
ST: Sequence Type
T/S: Trimethoprim/Sulfamethoxazole
TEM: Temoneira 
TIC: Ticarcillin
TO: Tobramycin
tRNA: Transfer Ribonucleic Acid
TSA: Tryptone Soy Agar
UC: Urethral Catheterization
UPGMA: Unweighted Pair Group Method with Arithmetic Mean
USA: United Stated of America
UTI: Urinary Tract Infection
VAP: Ventilator Associated Pneumonia
VEB: Vietnamese Extended-spectrum Beta-lactamase 
VIM: Verona Integron-encoded Metallo-beta-lactamase
WGS: Whole-Genome Sequencing
XDR: Extensively-Drug Resistant
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III. LIST OF FIGURES
INTRODUCTION
Figure 1. Timeline of the history of the genus Acinetobacter.
Figure 2. Acinetobacter baumannii colonies grown on Blood Agar.
Figure 3. Antimicrobial agents recommended for the treatment of A. baumannii 
infections.
Figure 4. Innate Mechanisms of Antibiotic Resistance in A. baumannii.
Figure 5. Acquired beta-lactamases detected in A. baumannii according to the Ambler 
classification system.
Figure 6. Global dissemination of clinically important clones. The Dots within each
country are not meant for geographical accuracy but are a graphical 
representation of which clones were reported from that country.
RESULTS 1.
Figure 1. Percentage of sensitive (blue), intermediately resistant (yellow), and resistant 
(red) isolates to the different antimicrobial agents. “TIC” stands for ticarcillin,
“PIP” for piperacillin, “A/S” for ampicillin/sulbactam, “P/T” for
piperacillin/tazobactam, “CTZ” for ceftazidime, “CFP” for cefepime, “IMI”
for imipenem, “MER” for meropenem, “COL” for colistin, “G” for 
gentamicin, “TO” for tobramycin, “AK” for amikacin, “MIN” for 
minocycline, “CIP” for ciprofloxacin, “LEV” levofloxacin, and “T/S” for 
trimethoprim/sulfamethoxazole.
RESULTS 3.
Figure 1. Timeline of treatment and strain isolation of each patient.
RESULTS 4.
Figure 1. Attached cell density of each A. baumannii strain after 5 h (A), 24 h (B) and
48 h (C) of incubation. The dots represent the average of three independent 
experiments (n = 6) where two coupons were sampled for each time point in
each experiment, while the bars represent the standard deviation.
Figure 2. Pigment production during incubation of strains 52 (above) and 38 (below).
Figure 3. CLSM images (zenital view) of 24 h-biofilms formed by A. baumannii 
strains. Pigment (+): 45 and 52 and pigment (−): 30 and 38. Cells were in
green and EPS in blue.
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RESULTS 4.
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infection prior to bacteremia, underlying disease, and clinical outcome of the 
patient.
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1. CHARACTERISTICS OF Acinetobacter baumannii
1.1. History of the Genus Acinetobacter
Acinetobacter is a genus that is currently classified under the family Moraxellaceae, 
which also includes the genera Moraxella, Psychrobacter, and other related organisms. This 
family is within the order Pseudomonadales of the class Gammaproteobacteria (Rossau et al.,
1991). Nevertheless, the genus Acinetobacter has undergone extensive taxonomic changes ever 
since it was first discovered in 1911. This is mainly because members of this genus can adapt
to most substrates by using different catabolic pathways and thus resulting in confusion while
interpretating biochemical tests (La Scola et al., 2006). The first bacterium belonging to this
genus was identified in 1911 by a Dutch microbiologist named Martinus Willem Beijerinck.
The isolate was obtained from an environmental sample and was called Micrococcus 
calcoaceticus back then (Beijerinck, 1911). Since then, and up until the 1970s, several species
and genera were described that later turned out of to be part of the Acinetobacter genus. These 
species were summarized by Henriksen in 1973 and they include Achromobacter anitratus,
Achromobacter mucosus, Alcaligenes haemolysans, Bacterium anitratum, Diplococcus
mucosus, Herellea vaginicola, Micrococcus calcoaceticus, Mima polymorpha, Moraxella 
lwofﬁ, Moraxella lwofﬁ var. glucidolytica, and Neisseria winogradskyi (Henriksen, 1973).
Many common characteristics were found among those bacteria until, in 1968, it became
widely accepted to group them under the current genus name, Acinetobacter, after an extensive
review of their phenotypic characteristics (Baumann et al., 1968). This, in turn, led to the 
official acknowledgement of this genus and its separation from the genus Achromobacter by 
the Subcommittee on the Taxonomy of Moraxella and Allied Bacteria in 1971 (Lessel, 1971).
Interestingly, around that time, the first clinical isolate pertaining to Acinetobacter was isolated 
from the Intensive Care Unit (ICU) in 1969 (Stirland et al., 1969). Subsequently, this genus 
was listed in Bergey’s Manual of Systematic Bacteriology with only one species described 
(Lautrop, 1974) and the “Approved List of Bacterial Names” with the description of 
Acinetobacter calcoaceticus and Acinetobacter lwofﬁi (Skerman, 1980).
In 1986, DNA-DNA hybridization studies resulted in the description of 12 species 
within the genus Acinetobacter that had more than 70% DNA-DNA relatedness. These species
included Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, 
Acinetobacter johnsonii, Acinetobacter junii, and Acinetobacter lwofﬁi (Bouvet et al., 1986). 
Nevertheless, not all of the discovered species were given names at the time. In subsequent
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years, a total of 31 genomic species have been identified, 17 of which were given species
names. The rest were referred to as “Genomic Species” followed by a number that could vary,
depending on the nomenclature scheme followed (Bouvet and Jeanjean, 1989; Tjernberg and 
Ursing, 1989; Nishimura et al., 1988, Nemec et al., 2001; Nemec et al., 2003; Carr et al., 2003). 
In 2012, due to the increase in the amount and accuracy of identification techniques, the number
of genomic species identified rose to 36 and a total of 27 species were given a valid name 
(Peleg et al., 2012). Nowadays, the identification of new species pertaining to the genus 
Acinetobacter is still occurring in addition to giving species names to the previously described 
genomic species after exhaustive phenotypic and genotypic characterization (Nemec et al., 
2015; Nemec et al., 2016). Currently, 51 species within this genus have been identified and
given valid or provisional names (Al Atrouni et al., 2016a).
The early studies using DNA-DNA hybridization also showed that within the genus 
Acinetobacter, the species Acinetobacter calcoaceticus, Acinetobacter baumannii, Genomic
Species 3 and Genomic Species 13TU shared a high degree of similarity among each other as 
compared to the others (Tjernberg and Ursing, 1989; Bouvet and Grimont, 1986). These four
species later became known as the Acinetobacter calcoaceticus– Acinetobacter baumannii
(ACB) complex, a term first coined by Gerner-Smidt et al., (1991). More recent studies have
further confirmed the relatedness of these species using advanced molecular techniques, such
as comparison of the sequences of housekeeping genes (Périchon et al., 2014) and whole­
genome analysis (Touchon et al., 2014). Moreover, using similar techniques, Genomic Species 
3 has been identified as Acinetobacter pittii whereas Genomic Species 13TU was identified as
Acinetobacter nosocomialis (Nemec et al., 2011). In addition to the aforementioned species 
that make up the ACB complex, two additional Genomic Species were identified as being part
of this complex. These Genomic Species were called “Close to 13TU” and “Between 1 and 3” 
due to their similarities to the respective genomic species. A recent study has further 
characterized Genomic Species “Close to 13TU” and called it Acinetobacter seifertii (Nemec
et al., 2015). Members of the ACB complex could not be easily distinguished one from another 
using routine biochemical tests. As a result, throughout different times in history, infections
caused by members of this complex were referred to as being caused by Acinetobacter
calcoaceticus, Acinetobacter baumannii, or the ACB complex. Nevertheless, with the 
advancement of identification techniques, Acinetobacter baumannii was identified as the 
member of this complex most frequently isolated from human infections (Peleg et al., 2008). 
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Figure 1 shows a visual representation of the timeline of the complicated history of the
Acinetobacter genus.
Figure 1. Timeline of the history of the genus Acinetobacter.
1.2. General Characteristics of Acinetobacter spp.
The word Acinetobacter was first proposed by Brisou and Prevot (1954) from the Greek
word “Akinetos” which literally translates to “non-motile”. This name was suggested in order 
to separate the non-motile species from the motile ones within the genus Achromobacter and
grouping the non-motile species under the new genus, Acinetobacter. This was because
members of this genus failed to show motility by traditional motility testing (Brisou and Prevot 
1954) and were considered as non-motile organisms for a long time. Nevertheless, more recent 
studies have shown that some strains within the Acinetobacter genus are able to display surface, 
or twitching, motility (Antunes et al., 2011). The motility of Acinetobacter spp. will be
discussed in later sections.
Acinetobacter spp. are easily grown on common solid and liquid growth media. On 
solid agars, they have a similar appearance to Enterobacteriaceae where they show smooth,
grayish-white colonies that could sometimes be mucoid and have a diameter of 1.5 to 3 mm 
after an overnight incubation (Peleg et al., 2008). Figure 2 shows the shape of Acinetobacter
baumannii colonies after growth on Blood Agars. Most species in this genus grow well in
temperatures ranging from 25°C to 45°C, with optimal growth at 37°C for species implicated 
with human infections. Environmental species, however, seem to prefer temperatures that are 
below 30°C (Antunes et al., 2011). Biochemically, most members of the Acinetobacter genus
can produce acid from glucose, galactose, mannose, rhamnose, lactose, and xylose. They are 
also positive for the Simon’s citrate test but are not able to produce acid from mannitol and 
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sucrose. Moreover, these species are negative for the indole, nitrate, esculin hydrolysis, 
production of H2S, and Voges-Proskauer tests (Constantiniu et al., 2004). Acinetobacter spp. 
have also been found to be able to degrade xenobiotic compounds such as alkanes, herbicides,
and even some pharmaceutical compounds (Tenover, 2006; Antunes et al., 2014).
Members of the genus Acinetobacter share several characteristics among one another. 
They appear by Gram staining as Gram-negative coccobacilli that could be in diploid formation
or chains of variable length. However, they are difficult to de-stain and therefore could be 
mistakenly observed as Gram-negative or Gram-positive cocci (Peleg et al., 2008). These 
organisms are also strictly aerobic, non-fastidious, non-fermenting, catalase-positive, oxidase­
negative, and have a G+C content that varies from 39% to 47% (Rossau et al., 1991).
Figure 2. Acinetobacter baumannii colonies grown on Blood Agar (adapted from image obtained from
http://www.slideshare.net/alfredobambang/acinetobacter-28595602).
1.3. Identification of Acinetobacter spp.
Studies have shown that it is very difficult to differentiate members of the Acinetobacter
genus one from another based solely on simple routine biochemical tests (La Scola et al., 2006; 
Fournier and Richet, 2006). Nevertheless, a wide array of more advanced tests have been 
developed for the identification of Acinetobacter baumannii, the main pathogen of this genus 
(Peleg et al., 2008). The DNA-DNA hybridization scheme first proposed by Bouvet and 
Grimont (1986) remains a valid identification method for the detection of several Acinetobacter
species. In subsequent years, several additional tests were developed and successfully applied 
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for the identification of Acinetobacter at the species level. One such test is Amplified
Ribosomal DNA Restriction Analysis (ARDRA). This test relies on the amplification by 
Polymerase Chain Reaction (PCR) of the bacterium’s 16S ribosomal DNA and its subsequent
digestion by four different Restriction Enzymes (REs). The digested DNA would then be
electrophoresed on agarose gels and the pattern generated by REs would be visualized and 
compared to previously identified patterns, allowing for the identification of the species 
(Vaneechoutte et al., 1995). This test has proven to be reliable in the identification of several 
Acinetobacter species, including Acinetobacter baumannii (Kong et al., 2011). 
A technique similar to ARDRA that is used for identification of Acinetobacter species
is PCR-Restricted Fragment Length Polymorphism (PCR-RFLP). In this technique, the 16S 
ribosomal RNA gene is amplified by PCR and then digested by the HaeIII RE. The fragments
are then run on agarose gels, visualized, and compared to known patterns of Acinetobacter spp. 
(Lu et al., 2000). This technique successfully detects Acinetobacter baumannii isolates, even
those missed by automated detection through growth in blood cultures (Rohit et al., 2016). 
Amplified Fragment Length Polymorphism (AFLP) is another useful technique for the 
identification of Acinetobacter spp. that produces high resolution DNA fingerprints. In this
technique, the entire bacterial genome is digested with two REs (EcoRI and MseI), resulting in 
a large number of fragments that would vary, depending on the amount and locations of Single
Nucleotide Polymorphisms (SNPs). Adapters would then be ligated to the fragments and 
selective amplification would occur (based on the adapters for one of the REs). The amplified
fragments would then be labeled and electrophoresed on agarose gel in order to produce DNA 
fingerprints and identify the species (Janssen et al., 1997). 
Ribotyping, a technique somewhat similar to AFLP has also been successfully used in
the identification of Acinetobacter spp. (Gerner-Smidt, 1992). This technique relies on the
endonuclease digestion of whole genomes by REs. The fragments would then be separated by 
electrophoresis, transferred by Southern Blot, and hybridized with radiolabeled ribosomal
operon probes. The visualized bands would correspond to the multiplicity of ribosomal RNA
in each sample and would generate a unique pattern corresponding to a specific species 
(Bouchet et al., 2008). Another technique that is used in the identification of Acinetobacter 
spp. is restriction analysis of the 16S-23S ribosomal RNA spacer sequence. This technique is 
very similar to ribotyping with the difference being that the digestion by the RE EcoRI would 
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be carried out on PCR products of the 16S-23S ribosomal RNA spacer region, using the 
respective probes (Dolzani et al., 1995). 
All the previously described techniques are accurate in identifying members of the 
genus Acinetobacter at the species level. However, they are highly laborious and time 
consuming. This makes them, despite being still used in reference laboratories, not suitable for
routine diagnostic labs (Peleg et al., 2008). With the advancement of technology and interest 
in members of this genus, especially in the pathogenic Acinetobacter baumannii, numerous
less laborious techniques have been developed. One such technique is the genetic sequencing 
of the 16S-23S ribosomal RNA gene spacer region. This technique relies on the amplification 
of the spacer region between the aforementioned genes and its subsequent sequencing by 
automated sequencers. The obtained sequences would then be compared to known sequences 
in the National Center for Biotechnology Information (NCBI) database and the species would 
be identified (Chang et al., 2005). An offshoot from this technique that is widely used
nowadays is the sequencing of the 16S ribosomal DNA gene and identification based on the
comparison with published sequences in the NCBI database. Identification by this method is 
becoming increasingly used due to the increase in the available sequences in the NCBI
database. This technique is fast and simple and has shown very good accuracy in identifying 
bacterial species (Loon et al., 2016). Moreover, recent advances in sequencing techniques and
next-generation sequencing led to labeling whole-genome sequencing as the definitive
identification, epidemiological, and genomic investigative technique (Karah et al., 2012). This
technique is, however, expensive and requires access to next-generation sequencing systems. 
Another fast technique that could identify the species in around 4 hours is PCR
Electrospray Ionization Mass Spectrometry (PCR/ESI-MS). In this technique, seven 
housekeeping genes are amplified by PCR and then ESI-MS is performed in order to determine 
the number of adenines, thymines, guanines, and cysteines in each sample. This would, in turn, 
reflect the identity of each species (Ecker et al., 2006). Mass spectrophotometry is also used 
for the identification of bacterial isolates through Matrix Assisted Laser Desorption-Ionization 
Time of Flight Mass Spectrometry (MALDI-TOF MS). In this technique, bacterial isolates are 
grown in liquid cultures and then concentrated by centrifugation. The samples are then properly
processed and placed in the mass spectrophotometer. The spectra obtained would be compared 
to reference spectra in databases that are normally provided by manufacturers, and the identity 
of the isolate would be determined (Romero-Gómez et al., 2012). These techniques, though 
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fast, require the presence of a mass spectrophotometer that is limited in availability in most
laboratories. 
In order to facilitate the identification of bacterial species in clinical laboratories, 
several manual and semi-automated commercial tools have been developed over time. These
tools, that include the API 20NETM (BioMérieux) manual test, and the semi-automated Vitek
2TM (BioMérieux), PhoenixTM (Becton Dickinson), and MicroScan WalkAwayTM (Beckman
Coulter) systems, have been implicated in the identification of Acinetobacter spp. in clinical 
laboratories (Bernards et al., 1995; Bernards et al., 1996; Horrevorts et al., 1995). They rely
on a wide array of phenotypic tests and provide fast and reproducible methods for the
identification of a wide range of bacterial species. However, they largely depend on the 
databases provided by the manufacturers for identification. Although these databases are 
updated on a regular basis, the identification does not cover all possible species and none of
these tools is specifically tailored for the identification of the complex species within the genus
Acinetobacter (Karlowsky and Richter, 2015). Nevertheless, the ACB complex could be
differentiated from the rest of the Acinetobacter spp. using these commercial tools (Peleg et 
al., 2008).
A major breakthrough in the identification of Acinetobacter baumannii, and its
separation from other species within this genus, was the discovery of the intrinsic blaOXA-51-like
gene (Héritier et al., 2005a; Turton et al., 2006a). This gene was shown to only convey 
carbapenem resistance when the insertion sequence ISAba1 was adjacent to it (Turton et al.,
2006b). However, the presence of this gene in the vast majority of Acinetobacter baumannii
isolates led to the wide acceptance of its amplification as indicitave of A. baumannii and its use
as a rapid and accurate method for identifying this species (Tomaschek et al., 2016; Turton et 
al., 2006a). Finally, a combination of any number of the aforementioned techniques, when
possible, could capitalize on the strengths of each one of them and reach a fast, cost-effective, 
and reliable method for the identification of Acinetobacter baumannii. One such combination
could be the use of API 20 NE for the identification of the ACB complex, followed by PCR 
for the detection of blaOXA-51-like for the identification of Acinetobacter baumannii. The choice
of which technique(s) to use largely depends on the availability of funds, speed required, and 
the purpose of the identification. 
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1.4. Natural Habitat of Acinetobacter spp.
Acinetobacter spp. could be isolated after enrichment from a wide range of soil and 
surface water specimens. Additionally, members of this genus that are generally less implicated 
with human disease have been isolated from vegetables with varying rates that could reach up
to 51% (Berlau et al., 1999a; Houang et al., 2001). Moreover, Acinetobacter spp. in general,
and occasionally Acinetobacter baumannii in particular, have been isolated from animal
specimens (Francey et al., 2000; Vaneechoutte et al., 2000) and body lice specimens obtained
from homeless persons (La Scola and Raoult, 2004). The presence of these organisms in these
different habitats led to the consideration of this genus as ubiquitous in nature (Baumann, 1968;
Fournier and Richet, 2006). Nevertheless, a systematic study that evaluates the prevalence of 
the main human pathogen of this genus, Acinetobacter baumannii, was not performed in order 
to confirm the ubiquitous distribution of this species in nature (Peleg et al., 2008). 
Acinetobacter spp. have been identified as part of the normal micrbiota among healthy
individuals in studies dating back to 1997. The most prevalent species known to colonize the 
skin and mucous membranes of healthy humans are Acinetobacter lwofﬁi, Acinetobacter 
johnsonii, Acinetobacter junii, Acinetobacter pittii, Acinetobacter radioresistens, 
Acinetobacter nosocomialis, Acinetobacter variabilis, and, to a much lesser extent,
Acinetobacter baumannii (Seifert et al., 1997; Berlau et al., 1999b; Chu et al., 1999).
Moreover, seasonal variation in skin colonization among medical staff by Acinetobacter spp. 
has been demonstrated. The prevalence of these species was shown to be higher in summer as
compared to winter, mirroring the seasonal variation observed for Acinetobacter baumannii
infections (Chu et al., 1999; McDonald et al., 1999). Acinetobacter johnsonii, Acinetobacter 
guillouiae (formerly genomic species 11), and rarely Acinetobacter baumannii, were also
reported from fecal samples of healthy humans indicating their presence in the normal human
gut flora (Dijkshoorn et al., 2005; Nemec et al., 2010). 
2. PATHOGENESIS AND VIRULENCE OF Acinetobacter baumannii
Pathogenicity is defined as the ability of a bacterium to cause disease, whereas
virulence is the degree to which a bacterium is pathogenic (Beceirt et al., 2013). In humans,
although several members of the genus Acinetobacter have been implicated with a certain 
degree of pathogenicity (Seifert et al., 1993; Seifert et al., 1994), Acinetobacter baumannii
remains the key pathogenic organism of this genus (Gonzalez-Villoria and Valverde-Garduno
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2016). Although community acquired pneumonia caused by Acinetobacter baumannii has been
documented, especially among patients with a history of alcohol abuse (Kroeger et al., 2007),
the vast majority of infections caused by this organism are hospital acquired infections (Peleg
et al., 2008). Moreover, Acinetobacter baumannii is considered as one of the ESKAPE
pathogens, which are regarded as the leading cause of nosocomial infections all over the world.
ESKAPE is an acronym that is short for Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and
Enterobacter spp. (Santajit and Indrawattana, 2016).
2.1. Virulence of Acinetobacter baumannii
Virulence could be assessed by testing for several factors that affect the host with 
different consequences (Antunes et al., 2011). Part of what makes Acinetobacter baumannii
successful as a nosocomial pathogen is its ability to express several virulence factors. Although 
the pathogenicity of this organism is not yet fully understood, numerous virulence factors have 
been attributed to it (Peleg et al., 2012). In the following sections, the virulence factors that
have been identified in A. baumannii will be presented.
2.1.1. Formation of Biofilms
Biofilms are a mesh constituted of pili and exopolysaccharides wherein bacterial 
populations can grow and exchange genetic material (Tomaras et al., 2003; Doi et al., 2015).
They protect the bacterial cells they harbor against various hazards, such as antimicrobial
agents and macrophage attacks (Ciofu and Tolker-Nielsen, 2011), in addition to stress 
conditions such as desiccation and disinfection (Lebeaux et al., 2014). They make bacteria
difficult to eradicate and contribute to the persistence of A. baumannii for prolonged periods
of time in hospitals (Loehfelm et al., 2008). This protective barrier creates a microenvironment 
where bacterial cells can exist in a wide range of physiological states and be protected from
eradication (Stewart and Franklin, 2008; Longo et al., 2014). Additionally, biofilms create an 
environment with a high density of microorganisms and thus facilitate horizontal transmission
of genetic material that could contain genes of virulence and/or resistance (Aminov, 2011). 
Moreover, A. baumannii living in biofilms have been found to be able to communicate one 
with another through quorum sensing (Niu et al., 2008). Through this communication, A.
baumannii is able to induce the formation of the slow dividing persister cells in deep layers
that are tolerant to antimicrobial agents (Bhargava et al., 2014). These persister cells could 
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serve as a reservoir for the renewal of the bacterial population and are shielded from the action
of the antibiotics by the biofilm itself. The freshly dividing cells could also pick up genetic 
material from their surroundings, possibly leading to the acquisition of resistance to 
antimicrobial agents. To add to all of this, bacterial cells on the topmost layers of a biofilm
were shown to be able to detach from it (Derlon et al., 2009). This would allow bacterial cells
to spread and form new colonies, in addition to the reservoir that is formed within the biofilm
that could serve as a source of repeated hospital outbreaks.
Expression of biofilms by A. baumannii clinical isolates, accompanied with changes in
genetic expression, has been reported by several studies (Rodriguez-Baño et al., 2008, Lee et 
al., 2008, Longo et al., 2014). The characterization of the complex mechanisms governing 
biofilm formation and its regulation is still ongoing (Liou et al., 2014). Nevertheless, several
genes have been associated with biofilm formation in A. baumannii. CsuE, bap, OmpA, and 
pgaABCD are some of these genes (Gaddy et al., 2009; Tourton et al., 2007; Loehfelm et al., 
2008; Choi et al., 2009). Nevertheless, the absence of some of those genes has been reported 
among biofilm forming A. baumannii isolates indicating the presence of alternative 
compensatory mechanisms for biofilm formation (Gaddy et al., 2009; De Breij et al., 2009).
Finally, a positive relationship between biofilm formation and antibiotic resistance has been
described in several studies (Olsen, 2015; Gurung et al., 2013; Ciofu and Tolker-Nielsen,
2011). Previous antibiotic use was also determined as a driving factor for the development of 
biofilms (Rodriguez-Baño et al., 2008; He et al., 2015). Moreover, a study by Badmasti et al.
(2015) showed that both antibiotic resistance and biofilm formation depend on genetic diversity
and expression. Furthermore, they postulated that understanding the connections between these 
two phenomena has a threading potential for understanding the mechanisms of persistence of 
A. baumannii in the hospitals and its colonization of various hospital equipment, such as 
catheters and mechanical ventilators.
2.1.2. Proteolytic Activity and Siderophore Production
A. baumannii has the ability to produce proteases and iron-uptake molecules that 
negatively affect the patients’ cells and metabolism. Production of phospholipase C and
phospholipase D has been reported in this organism (Cerqueira and Peleg, 2011). While
phospholipase C was found to have a modest cytotoxic effect on epithelial cells (Camarena et 
al., 2010), Phospholipase D was found to be important for the bacterium’s survival and growth 
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in human serum, in addition to invasion of epithelial (Jacobs et al., 2010). Moreover, analysis 
of full genomes of A. baumannii isolates led to the prediction of the presence of exoprotease­
related genes in certain Open Reading Frames (ORFs). This, in turn, led to the phenotypic 
detection of proteolytic activity among clinical A. baumannii isolates (Antunes et al., 2011). 
The proteolytic and phospholipase enzymes add to the virulence of A. baumannii and
demonstrate this species’ ability to cause harm to the human host.
A. baumannii isolates are also able to produce siderophores, especially in iron-deficient 
media (Mihara et al., 2004). Several genes for the production of siderophores were identified
in this organism and they have been found to be upregulated upon iron depletion (Eijkelkamp 
et al., 2011a). This ability is especially important in the host environment where iron is a very 
limited micronutrient that is usually bound up within hemes. Production of siderophores puts 
the bacterium in competition with the host for iron and could result in the deprivation of the
patient from this crucial micronutrient (Wandersman and Delepelaire, 2004). Moreover, a link 
between pigmentation and virulence and/or antibiotic resistance was reported after an outbreak
caused by a pigmented A. baumannii strain in Argentina (Vilacoba et al., 2013). Since 
pigmentation was found to be related to the production of siderophores (Meyer et al., 2000), 
one can assume that strong siderophore production was exhibited by these strains. This also
further justifies the consideration of siderophore production as a virulence factor. In addition,
iron has been described as being essential for the formation of biofilms, another important
virulence factor in A. baumannii (Gentile et al., 2014), indicating a possible interplay between
production of siderophores and biofilm formation. 
2.1.3. Hemolysis and Surface Motility
Hemolysis and motility are two factors that were previously thought to be non-existent
in A. baumannii. Hemolysis among Acinetobacter spp. has been thought to be limited to
Acinetobacter haemolyticus (Peleg et al., 2008). Nevertheless, it has been demonstrated that 
some A. baumannii clinical isolates could actually show some in-vitro hemolytic activity on 
Sheep Blood Agar (SBA) plates after prolonged incubation times (Antunes et al., 2011). Taken
together, production of siderophores and hemolytic activity could result in the fast depletion of 
iron available to the host and the eventual overwhelming of the patient. Motility is another
virulence factor that has long been thought to be absent from Acinetobacter spp. (Brisou and
Prevot, 1954). Nevertheless, studies have shown that A. baumannii has the genes coding for
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the Type IV pili secretion system (Peleg et al., 2008). These pili are known to form a surface­
associated movement through their extension and retraction. This type of bacterial motility is 
designated as twitching motility (O’ Toole and Kolter, 1998). Recent studies have shown that,
although not applicable to all isolates, several A. baumannii strains were able to phenotypically
express this type of motility on the surface of agar plates (Mussi et al., 2010; Antunes et al.,
2011). Moreover, this type of motility was associated with the ability to form biofilms (Mussi 
et al., 2010).
2.1.4. Other Factors Contributing to Virulence in Acinetobacter baumannii
It has been shown that A. baumannii is able to bind to epithelial cells, colonize them 
and induce their apoptosis (Lee et al., 2008). This induction is thought to be mediated by certain
outer membrane proteins that are able to bind to the cells’ death receptors, which in turn 
activate the caspase pathway. This pathway leads to the disintegration of the mitochondria and 
the subsequent release of cytochrome c and apoptosis-inducing factor, leading to cellular
apoptosis (Choi et al., 2005). One such outer membrane protein present among A. baumannii
isolates is Outer Membrane Protein A (OmpA). Although OmpA is a porin that is involved in 
variety of cellular processes that allow the bacterium to survive and adapt to its environment,
its implication in inducing apoptosis makes it an important virulence factor (Turton et al.,
2007). 
Another virulence factor associated with A. baumannii is the production of
lipopolysaccharides (LPSs) that aid in resistance to normal human serum (Luke et al., 2010).
LPSs are typically is formed of lipid A, an inner core, an outer core, and the O antigen. Lipid 
A is what anchors the LPS to the bacterium’s outer membrane and is the most immunogenic
part of LPSs (Moran, 2007). The inner and outer cores are non-repeated oligosaccharides that 
are proximal to lipid A, and the O antigen is a segment of repeated oligosaccharides of variable 
lengths (Raetz and Whitﬁeld, 2002). In addition to the protective role LPSs play for the
bacterial cell, these molecules, and especially the Lipid A segment, are able to induce
overwhelming immune responses in the patient that are often fatal (Moran, 2007). On a similar 
note, A. baumannii was found to be able to produce the K1 capsular polysaccharide. This 
capsule was found to protect the bacterium against the harsh environment the human body 
provides, and thus acts as a major virulence factor (Russo et al., 2010). 
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2.2. Nosocomial Infections Caused by Acinetobacter baumannii
A nosocomial infection is defined as an infection that occurs within forty eight hours 
after hospital admission, three days after discharge, or thirty days after surgery. It is estimated
that one in ten patients admitted to a hospital are affected by a nosocomial infection (Inweregbu 
et al., 2005). Patients in the ICU have been found to be particularly susceptible to nosocomial
infections, mostly due to mechanical ventilation, invasive procedures, and their 
immunocompromised status (Chatterjee et al., 2016). 
A. baumannii has been implicated in nosocomial infections with alarming mortality 
rates from studies dating back to the 1970s (Glew et al., 1977). This still holds true today where 
this pathogen is causing a wide range of infections, especially among critically ill patients. A.
baumannii is most commonly implicated with bacteremia, Ventilator Associated Pneumonia
(VAP), Urinary Tract Infections (UTIs), meningitis, and wound infections (Peleg et al., 2008).
VAP is inflammation in the lungs presenting 48 to 72 hours after endotracheal intubation of 
the patient. It is characterized by malaise, sputum-producing coughs, shortness of breath, fever,
chills, and chest pain. Up to 20% of intubated patients suffer from VAP and this kind of 
infection is associated with a 2-fold increase in mortality, longer hospital stay, and higher 
hospital costs. Moreover, VAP is more common among critically ill patients and patients with 
several co-morbidities (van Diepen et al., 2016). UTIs are infections of the urinary tract and 
are among the most commonly acquired types of infections in the community. UTIs can affect
any of the organs of the urinary tract, including the bladder, kidneys, and urethra. Symptoms
of UTIs include frequent urination, burning sensation during urination, and pain around the 
bladder region. Though these types of infections are generally self-limiting, the infecting agent 
could invade the urinary tract and cause complications that are usually limited by the 
administration of antimicrobial agents (Foxman, 2010). 
Meningitis is the inflammation of the meninges, the tissue that engulfs the brain and
spinal cord, and could also include infecting the area in-between the meningeal layers. 
Common symptoms indicative of meningitis are variations in body temperature (too high or
too low), vomiting, stiff neck, fever, headache, confusion, light sensitivity, and low
concentration ability. Meningitis could be life threatening and is associated with several co­
morbidities, mainly since it involves organs in the central nervous system (Qian et al., 2016).
Wound infections are infection of the skin and soft tissue layers around an open wound. It can 
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present with a wide variation of features, depending on the infecting agent. Acinetobacter spp. 
are most commonly implicated with colonizing burn wound sites. These infections could also
pose a challenge to infection control since they are capable of imbedding into the mattresses of 
patients and persist in the hospital for prolonged periods of time (Sherertz and Sullivan, 1985).
Bacteremia is defined as the presence of bacteria in the blood, regardless of the source.
Clinically significant bacteremia manifests as fever, chills, and/or hypotension. Bacteremia 
could be transitory where symptoms disappear in under 8 hours, but could also progress to 
septic shock and disseminated intravascular coagulation which could be deadly. Almost all
bacteremia cases caused by A. baumannii are nosocomial infections that occur around 20 days 
after hospitalization and could originate from any of the aforementioned primary infections 
(Cisneros et al., 1996). Less frequent reports also show that A. baumannii is capable of causing
endocarditis (Rizos et al., 2007). This infection of the heart’s endocardium could lead to the
formation of blood clots, their dislocation, and subsequent clotting of arteries. Also few reports 
indicate that A. baumannii could cause and endophthalmitis (Levy et al., 2005), an infection 
inside the eye that causes severe pain, redness of the eye, and may lead to loss of vision. Both
endocarditis and endophthalmitis were mostly linked to previous surgical procedures and/or
use of prosthetic heart valves and contact lenses, respectively. 
Risk factors associated with infection by A. baumannii include long hospitalization 
times, use of central venous catheters, prior hospitalization, residence in nursing homes, and
reduced immunity (Fishbain and Peleg, 2010). Although the discrimination between infection
and colonization after the isolation of A. baumannii is difficult, the recovery of this organism 
is believed to be an indicator of severe illness and is associated with relatively high mortality
rates (Perez et al., 2007). Mortality rates for patients infected by A. baumannii in non-ICU 
wards range from 8% to 23% whereas mortality rates among infected patients in the ICU range
from 10% to 43% (Fishbain and Peleg, 2010; McConnell et al., 2013; Doi et al., 2015). Some
studies even demonstrate a mortality rate that is as high as 67.8% among patient with A.
baumannii bacteremia (Cuang et al., 2011). A retrospective study performed in USA showed
that 6.78% of bloodstream isolates from patients undergoing severe sepsis pertained to A.
baumannii (Zilberberg et al., 2014). A similar study showed that 49.6% out of 131 patients
with bacteremia caused by A. baumannii died (Shorr et al., 2014). Interestingly, mortality rates
caused by A. baumannii bacteremia was shown to be higher than those caused by other Gram­
negative organisms, including Klebsiella pneumoniae (Robenshtok et al., 2006). This shows
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that, although the frequency of A. baumannii is relatively low as compared to other nosocomial
pathogens, the high mortality rates associated with it makes it an opportunistic pathogen that 
is not be to taken lightly.
3. TREATMENT OPTIONS FOR Acinetobacter baumannii
Most available antimicrobial agents were successfully used in the treatment of 
Acinetobacter spp. infections in the 1970s (Bergogne-Bérézin et al., 1996). However,
increasing rates of resistance to various antimicrobial agents started being reported in the 1980s
up until the early 1990s, when resistance to imipenem was first reported (Doi et al., 2015). Due
to the plethora of resistance mechanisms among A. baumannii, resistance to several 
antimicrobial agents could be found in the same isolate. This, in addition to resistance to many
antimicrobial agents among other species, led to the classification of isolates as Multi-Drug
Resistant (MDR) if they are non-susceptible to at least one agent in three or more antibiotic 
categories; Extensively-Drug Resistant (XDR) if they are non-susceptible to at least one agent
in all but two or fewer antibiotic categories; and Pan-Drug Resistant (PDR) if they were non-
susceptible to all antibiotic categories (Magiorakos et al., 2011). The wide dissemination of 
MDR A. baumannii isolates has severely limited the treatment options for this organism
nowadays (Zarilli et al., 2013). Treatment of MDR A. baumannii infections, as well as other 
Gram-negative non-fermenters, is considered one of the greatest challenges of contemporary 
medicine (Mehrad et al., 2015). The mechanisms of resistance to antimicrobial agents in A.
baumannii will be discussed in later sections. In the following sections, the antimicrobial agents 
that are used nowadays for the treatment of A. baumannii infections are presented. These
antimicrobial agents are summarized in Figure 3.
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Figure 3. Antimicrobial agents recommended for the treatment of A. baumannii infections.
3.1. Beta-Lactams
Beta-lactams are a class of antimicrobial agents that encompass a wide range of 
bactericidal molecules routinely used in the treatment of bacterial infections (Elander, 2003).
These agents are grouped into penicillins, cephalosporins, monobactams, and carbapenems
(Dalhoff et al., 2006). All these antimicrobial agents have in common a beta-lactam ring which
acts as an analog of d-alanyl-d-alanine. They inhibit the synthesis of the bacterial peptidoglycan
layer by binding with varying affinities to DD-transpeptidases, otherwise known as Penicillin
Binding Proteins (PBPs). This, in turn, inhibits the cross-linking of the nascent peptidoglycan 
layer, which disrupts the synthesis of the cell wall (Fisher et al., 2005). Moreover, due to the 
production of enzymes that hydrolyze beta-lactams (discussed later), several beta-lactamase 
inhibitors are being combined with beta-lactams. The most common combinations include
amoxicillin with clavulanic acid, ampicillin with sulbactam, and piperacillin with tazobactam 
(Drawz and Bonomo, 2010).
Owing to the numerous natural resistance mechanisms present in A. baumannii, a 
limited number of beta-lactams are recommended for use against this organism. Of the many
penicillins available for use in the clinical practice, only piperacillin, mezlocillin, ticarcillin,
ampicillin/sulbactam, piperacillin/tazobactam, and ticarcillin/clavulanic acid are recommended
for treatment. Moreover, monobactams are not recommended for the treatment of A. baumannii
infections (CLSI, 2014). Ampicillin/sulbactam has shown promising clinical success against 
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A. baumannii infections, mainly due to the intrinsic antimicrobial activity of the beta-lactamase 
inhibitor sulbactam against this organism (Rafailidis et al., 2007). Clinical response rates after
use of this agent have been reported to range from 60% to 93% (Oliveira et al., 2008; Wood et 
al., 2002). However, decreasing rates of susceptibility to this antimicrobial agent are being 
increasingly reported, leading to its decreasing clinical success (Doi et al., 2015). 
Acinetobacter baumannii naturally produces a potent cephalosporinase which renders
most cephalosporins obsolete against this bacterium (Hujer et al., 2005). Nevertheless, the third
generation ceftazidime and ceftriaxone, in addition to the fourth generation cefepime
cephalosporins, retain good activity against A. baumannii. A global surveillance study showed
that susceptibility to these antimicrobial agents in 2010 was 54.8%, 49.4%, and 65.5%,
respectively. However, these rates decreased to 43.3%, 40.4%, and 41.3%, respectively in 2014
(Tärnberg et al., 2016). A similar drop in susceptibility rates to cephalosporins among A.
baumannii isolates has also been reported in another study (Chen et al., 2015), suggesting that 
the continued use of these antimicrobial agents is threatened. 
Carbapenems are the most potent broad spectrum antimicrobial agents within the beta­
lactams. They are reserved for the hospitals and are usually used as last-line therapy and for 
the treatment of critically ill patients (Breilh et al., 2013). The carbapenems include ertapenem,
doripenem, imipenem, and meropenem. Ertapenem in not recommended for use against A.
baumannii infections due to its limited efficacy against this organism and relatively narrower 
spectrum of activity (Oliver et al., 2004). Doripenem has shown some in-vitro activity against 
A. baumannii however its in-vivo efficacy is still in question, making it not highly
recommended for use (Drzewiecki et al., 2012). Meropenem has a slightly reduced potency
against A. baumannii as compared to imipenem (Oliver et al., 2004). Nevertheless, both these
antimicrobial agents are the most recommended carbapenems for the treatment of A. baumannii
infections among critically ill patients (Goncalves-Pereira and Povoa, 2011). Moreover, these 
antimicrobial agents were shown to have favorable pharmacokinetic/pharmacodynamic
properties (American Thoracic Society and Infectious Diseases Society of America, 2005).
This led to the consideration of carbapenems as “last line agents” for the treatment of critically 
ill patients (Nowak and Paluchowska, 2016). However, the extensive use of these carbapenems
lead to the inevitable steep rise of resistance against them among A. baumannii isolates
throughout the past two decades (Chen et al., 2015). A surveillance study across USA showed
that 33% of nosocomial A. baumannii isolates were resistant to carbapenems (Hidron et al.,
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2008). Another study from USA showed an increase in CRAB isolates from 1% in 2003 to 
58% in 2008, as well as a two-fold increase in A. baumannii infections in that time period
(Reddy et al., 2015). A study conducted from 2004 to 2006 that spanned 266 centers across the
globe showed that resistance to carbapenems was less than 26% in North America and Europe,
30.8% in Asia, 40.4% in the Pacific Rim, and ranged from 39.4% to 76.6% in Latin America 
(Reinert et al., 2007). Nowadays, global resistance rates against carbapenems is 62.5% 
(Tärnberg et al., 2016) with some studies reporting rates as high as 85% among MDR A.
baumannii isolates (Perez et al., 2010). In addition, by the time A. baumannii isolates acquire 
resistance to carbapenems, they often acquire resistance to several other antimicrobial agents
as well (Doi et al., 2015). Moreover, carbapenem resistance among A. baumannii isolates is 
significantly correlated with increased mortality rates (Nowak and Paluchowska, 2016). All of 
this has forced clinicians and researchers alike to search for alternative treatment approaches.
3.2. Aminoglycosides
Aminoglycosides are bactericidal concentration-dependent antimicrobial agents that
act through the inhibition of protein synthesis (Gilbert, 1995). They are highly polar molecules 
that cross the bacterial outer membrane through a self-promoted uptake process after disruption
of the LPS bridges. They then bind to the 30S subunit of the cytosolic, membrane-bound 
ribosomes. This, in turn, leads to the truncation of proteins being synthesized and/or
mistranslation of mRNA, causing disruption of the cells’ metabolic processes (Mingeot-
Leclercq et al., 1999). Although aminoglycosides have a wide spectrum of activity, their
nephrotoxicity and ototoxicity resulted in the reluctance of clinicians in using them.
Nevertheless, the increase in resistance against other antimicrobial agents and a revision of 
dosing regimens that attenuate toxicity have re-kindled their clinical use (Durante-Mangoni et
al., 2009).
Aminoglycosides that are recommended for use in the treatment of A. baumannii
infections include gentamycin, tobramycin, and amikacin (CLSI, 2014). In general, A.
baumannii seems to be more susceptible to tobramycin and amikacin than to gentamycin
(Fishbain and Peleg, 2010). In addition to intravenous administration, the use of 
aminoglycosides in aerosol form has been approved for cystic fibrosis patients and has shown
promising results among VAP patients (Hallal et al., 2007). However, a great discrepancy in 
the detection of susceptibility to these antimicrobial agents has been reported, which depends 
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on the method used for the determination of the Minimum Inhibitory Concentration (MIC). 
This could result in falsely reporting isolates as being susceptible with often deadly
consequences (Akers et al., 2010). Despite the many concerns regarding the use of 
aminoglycosides, they retain their clinical usefulness due to the rise in resistance rates to other 
antimicrobial agents and their good activity against A. baumannii (Gounden et al., 2009).
3.3. Polymyxins
Colistin is an amphipathic lipopeptide that belongs to the polymyxins class of 
antimicrobial agents. This molecule is cationic and acts upon Gram-negative bacteria through
the interaction with lipid A and the subsequent disruption of the negatively charged outer
membrane (Vaara et al., 1985). Disruption of the stability of the membrane through the 
displacement of the divalent cations bridging the LPS molecules by colistin would in turn
promote its self-uptake into the cell (Arroyo et al., 2011). This would activate the second
reported mechanism of antibacterial activity which acts through the induction of rapid killing
of bacterial cells through the activation of a hydroxyl radical death pathway (Sampson et al.,
2012). Colistin is administered intravenously and has a rapid bactericidal effect that is 
concentration-dependent (Bergen et al., 2012). Moreover, this antimicrobial agent is 
administered in an inactive form and it takes two to three days for its conversion in the plasma
to its active form. In order to circumvent this, colistin is usually administered with a high
loading dose and then treatment continues with maintenance doses (Mohamed et al., 2012). 
Varying degrees of nephrotoxicity have been associated with colistin, which limits its
administration at high doses (Bergen et al., 2012). However, despite its nephrotoxic effects,
clinicians are opting for its use against imipenem resistant MDR A. baumannii infections,
mainly because it attains cure rates similar to carbapenems (Cai et al., 2012). Nevertheless, A. 
baumannii isolates have been reported to acquire resistance to colistin during treatment and
subsequently cause devastating outbreaks (Valencia et al., 2009; Li et al., 2006). 
Recently, attempts to avoid nephrotoxicity caused by colistin have been made in VAP
infections where this agent is delivered in aerosol form directly to the infection site. This 
method of delivery is usually combined with intravenous administration of colistin and has
been associated with good bacterial clearance rates (Yapa et al., 2014). However, its definitive
effect on positive clinical outcomes is not yet fully established (Doi et al., 2015). Additionally,
Colistin has poor penetration into the Cerebrospinal Fluid (CSF) but ventriculitis and 
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meningitis could be cured by intrathecal or intraventricular administration (Karaiskos et al.,
2013). Finally, the clinical success of colistin led to an increased interest in using polymyxin
B, a closely related antimicrobial agent. Polymyxin B is administered in its active form and has
lower nephrotoxic effects as compared to colistin (Phe et al., 2014). Nevertheless, its clinical
efficacy in comparison with colistin is not yet fully investigated (Doi et al., 2015). 
3.4. Tetracyclines and Glycylcyclines
Minocycline and doxycycline are two tetracyclines that have been used for the 
treatment of A. baumannii infections (Wood et al., 2003). Their value lies in their good
clearance rates against Carbapenem-Resistant Acinetobacter baumannii (CRAB) infections
and relative low toxicity (Chan et al., 2010). Tetracyclines bind to the 30S ribosomal subunit 
and prevent the incorporation of the aminoacyl-tRNA into the A site, therefore inhibiting
protein synthesis (Connell et al., 2003). However, the wide dissemination of efflux pumps and
Ribosomal Protection Proteins (RPPs) in A. baumannii protect this bacterium against
tetracyclines and limits their therapeutic use (Doi et al., 2015). 
Tigecycline is the first antibiotic to be developed in a new class of antibiotics called 
glycylcyclines. It is a semi-synthetic derivative of minocycline and is not affected by most
efflux pumps and RPPs that affect tetracyclines (Livermore, 2005). In-vitro resistance against 
tigecycline in A. baumannii is rare and usually results from over-expression of efflux pumps
during treatment (Rumbo et al., 2013). Tigecycline shows very good in-vitro activity against
A. baumannii but clinical outcomes for patients treated with tigecycline have been sub-optimal, 
despite the in-vitro susceptibility. Moreover, its use at the currently approved dose in 
bacteremia was shown to not positively affect bacterial clearance from the blood (Kim et al.,
2013). All of this led to the lack of its recommended routine use against A. baumannii infections 
(CLSI, 2014). Nevertheless, its relatively low toxicity and positive clinical outcomes in certain
cases make it useful, especially when other therapeutic options are severely limited (Chan et
al., 2010). 
3.5. Fluoroquinolones
Fluoroquinolones are derived from quinolones, a fully synthetic class of antimicrobial 
agents (Suto et al., 1992). They are able to enter the bacterial cell through porins and bind to 
DNA gyrase and topoisomerase IV. This would subsequently lead to cleavage of the bacterial
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DNA resulting in double-strand DNA breaks and ultimately the fragmentation of the 
chromosome, and cell death (Hooper, 1999). They have also been shown to be able to exert
their action on eukaryotic cells which results in toxicity, manifesting as neurotoxicity, 
cardiotoxicity, tendinopathies, and musculoskeletal pain (Strauchman and Morningstar, 2012). 
The second generation ciprofloxacin, third generation levofloxacin, and fourth generation
gatifloxacin fluoroquinolones are recommended for use in the treatment of A. baumannii
infections (CLSI, 2014). However, the use of fluoroquinolones in the treatment of the widely 
disseminated CRAB isolates is not recommended since resistance rates against these 
antimicrobial agents among CRAB isolates is as high as 97.9% (Huang et al., 2015). Moreover, 
A. baumannii have been found to have a natural tendency to readily develop resistance to
fluoroquinolones (Nwadike et al., 2014), making their usefulness in the treatment of critically 
ill patients very limited.
3.6. Folic Acid Synthesis Inhibitors
Trimethoprim/sulfamethoxazole, also known as co-trimoxazole, is a folic acid
synthesis inhibitor that acts through the inhibition of the dihydrofolate pathway, resulting in a
bactericidal effect (Goldberg and Bishara, 2012). It consists of one part trimethoprim and five 
parts sulfamethoxazole since the synergistic effect between these two components is optimal 
at this ratio (Böhni, 1969). Sulfamethoxazole exerts its effect through competition with p­
aminobenzoic acid and the subsequent disruption of de novo synthesis of dihydrofolate.
Trimethoprim, on the other hand, competitively inhibits dihydrofolate reductase resulting in an 
inhibition of the production of tetrahydrofolate, the biologically active form of folic acid
(Wormser et al., 1982). This antimicrobial agent has a broad spectrum of activity and is used 
in the treatment of a wide range of infections. Nevertheless, its conventional use in A. 
baumannii is not recommended (Karageorgopoulos and Falagas, 2008). However, with the 
great increase in resistance among A. baumannii isolates, many clinicians are opting for its use
when no other options are available. Reported sensitivity rates of A. baumannii isolates to 
trimethoprim/sulfamethoxazole range from 50% to 30% but the sensitivity among CRAB
isolates is less than 20% (Falagas et al., 2015). This makes it only useful in non-MDR A.
baumannii isolates, if they show susceptibility to this antimicrobial agent.
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3.7. Combination Therapies 
The increasing rates of non-susceptibility of A. baumannii to antimicrobial agents and
lack of development of new antibiotics resulted in attempts at optimizing the use of available 
antibiotics (Doi et al., 2015). One such attempt is the use of combination therapies with
synergistic antimicrobial agents, even if one of these agents is not recommended for use as 
monotherapy (Fishbain and Peleg, 2010). Rifampin is an antibiotic that works through the
inhibition of RNA synthesis by binding to the RNA polymerase. Its use in monotherapy is not
recommended for A. baumannii since rapid development of resistance is observed during
treatment (Ng et al., 2006). However, its combination with sulbactam, colistin, or imipenem
showed promising results in terms of clearance rates and synergistic effects (Pachón-Ibáñez et 
al., 2010). Similar synergistic effects have also been reported between the peptidoglycan
synthesis inhibitor fosfomycin and colistin or sulbactam (Sirijatuphat and Thamlikitkul, 2014).
A recent study also showed promising results when combining fosfomycin with amikacin
(Leite et al., 2016). Moreover, a surprising synergy between vancomycin, an antibiotic usually
used for Gram-positive bacteria, and colistin showed promising results in its clearance rates of 
PDR A. baumannii isolates (Liu et al., 2016). 
Combining colistin with imipenem, sulbactam, or ampicillin/sulbactam showed better 
patient survival rates and bacterial clearance as compared to using each antibiotic separately 
for treating CRAB isolates (Batirel et al., 2014). Moreover, triple therapy with colistin,
sulbactam, and meropenem showed a synergistic effect against 96.7% of MDR A. baumannii 
isolates (Pongpech et al., 2010). The combination between colistin and tigecycline failed to 
show a synergistic effect (López-Cortés et al., 2014), but in-vitro synergy between imipenem
and tigecycline has been demonstrated (Principe, et al., 2009). Moreover, the combination of 
carbapenems with sulbactam also showed promising synergistic effects for the treatment of 
patients with CRAB infections (Lee et al., 2007). Combination therapy with meropenem and
ciprofloxacin (Ermertcan et al., 2001) or minocycline (Tängdén, 2014) also showed some
synergistic effect. Most of the aforementioned combinations are tested for in-vitro while in-
vivo studies are still scarce and limited to a small number of patients. This makes combinations
therapies, though promising, last resort options instead of standard treatment regimens (Doi et 
al., 2015).
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4. RESISTANCE TO ANTIMICROBIAL AGENTS
Resistance to antimicrobial agents is a phenomenon that was identified as soon as these
molecules were discovered several decades ago. However, studies show that this phenomenon
is an ancient one that was present in nature long before the discovery of antibiotics (D' Costa
et al., 2011). The mechanisms by which bacteria show resistance to antimicrobial agents are
numerous and diverse. Most commonly, resistance to antimicrobial agents is mediated by
enzymatic degradation of antibiotics, modifications of the target of antimicrobial agents,
decreased permeability, and/or efflux of antibiotics (Coyne et al., 2011). The resistance
mechanisms relevant to A. baumannii will be discussed next.
4.1. Innate Mechanisms of Resistance in Acinetobacter baumannii
Acinetobacter baumannii innately possesses mechanisms of resistance to several 
antimicrobial agents. One such mechanism is harboring AmpC, the Ambler Class C 
cephalosporinase. This enzyme gives A. baumannii the ability to be resistant to most broad 
spectrum cephalosporins (Bou and Martínez-Beltrán, 2000a). Moreover, the presence of the 
insertion sequence ISAba1 upstream of this gene provides it with a strong promoter and causes
a subsequent resistance to ceftazidime and cefepime (Héritier et al., 2006). The group of 
cephalosporinases identified in this species has been labeled Acinetobacter Derived
Cephalosporinase (ADC). Moreover, some allelic variants of ADCs have been found to have a
broader spectrum of activity against cephalosporins than others, without the need of over­
expression (Tian et al., 2011b). A. baumannii also naturally harbors the Ambler Class D 
oxacillinase (OXA), blaOXA-51-like (Héritier et al., 2005a). This OXA does not normally result
in resistance to broad spectrum antibiotics unless it was over-expressed after association with 
ISAba1 (Turton et al., 2006b). Additionally, the cellular membrane of A. baumannii was shown 
to be much less permeable to antimicrobial agents as compared to other Gram-negative bacteria
(Obara and Nakae, 1991). This is mainly due to the small amount and size of porins this 
bacterium has on its outer membrane (Vila et al., 2007). Finally, A. baumannii is known to 
constitutively express various efflux pumps at a basal level that play a role in its intrinsic 
resistance to several antimicrobial agents (Vila, 1999). The main intrinsic efflux pump
identified in A. baumannii that contributes to its innate resistance is the adeIJK pump (Yoon et
al., 2015). The presence and regulation of efflux pumps in this organism will be discussed in
the following section. All these factors contribute to the intrinsic resistance of A. baumannii to 
a wide range of antimicrobial agents and are represented in Figure 4.
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Figure 4. Innate Mechanisms of Antibiotic Resistance in A. baumannii
4.2. Acquired Mechanisms of Resistance in Acinetobacter baumannii
Resistance to antimicrobial agents could be acquired by several means. Mutations in 
endogenous genes could lead to the over-expression of certain cellular functions, such as efflux 
systems, and under-expression of others, such as outer membrane porins (Coyne et al., 2011). 
Moreover, single mutations could cause an alteration of the antimicrobial agent’s target, 
rendering it ineffective (Liou et al., 2006). Finally, and most importantly, the horizontal
transfer of mobile genetic elements, such as plasmids and transposons, carrying resistance 
genes lead to the acquisition and dissemination of antibiotic resistance (Goldstein et al., 1983).
Moreover, these mobile genetic elements could be incorporated into A. baumannii’s genome
and form resistance islands that could contain up to 45 genes of resistance (Fournier et al.,
2006). Due to the plasticity of A. baumannii’s genome (Antunes et al., 2014), this organism is 
able to acquire resistance to virtually all antimicrobial agents by different means which will be
discussed next.
4.2.1. Non-Enzymatic Mechanisms of Resistance
Although the most common mechanism of resistance in A. baumannii is enzymatic
degradation of antimicrobial agents, several non-enzymatic mechanisms exist. These include
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over-expression of efflux pumps in combination with down-regulation of porins and
modifications of the target of antibiotics (Doi et al., 2015).
4.2.1.1. Efflux Pumps
Efflux pumps are part of bacteria’s normal metabolism where they pump toxic material 
out of the cell and protect it from various environmental hazards (Vila et al., 2007). There are
five super-families of efflux pumps that have been associated with drug resistance. These are
the ATP-Binding Cassette (ABC) transporters, Multi-drug and Toxic compound Extrusion
(MATE), Resistance-Nodulation-cell Division (RND), Major Facilitator Superfamily (MFS),
and Small Multi-drug Resistance (SMR) families (Coyne et al., 2011). These families of efflux
pumps are the most clinically relevant since they cross both inner and outer membranes and 
are able to extrude a wide range of substances (Nikaido, 2009). The ABC transporters utilize 
ATP for the expulsion of unwanted molecules whereas the other types of transporters are drug­
proton antiporters that use the proton motive force as a source of energy for expulsion (Poole,
2002). 
Over-expression of efflux pumps is implicated in the efflux of several antimicrobial 
agents, in addition to detergents, antiseptics, biocides, and dyes (Coyne et al., 2011). Acquired
resistance to macrolides, tetracyclines, and quinolones in association with over-expression of 
efflux pumps was reported since the 1990s (Barker, 1999). Although efflux pumps belonging 
to all super-families mediate certain degrees of resistance, those belonging to the RND super­
family are the most commonly encountered among MDR A. baumannii isolates (Yoon et al., 
2016). These pumps are tightly regulated and several mutations in their transcriptional
regulators lead to their overexpression (Yoon et al., 2013). RND efflux pumps are formed of 
multiple components that are: an inner membrane protein that acts as the pump, a major fusion
protein linked to it, and an outer membrane factor that allows the extrusion of substrates 
(Nikaido, 2009). The adeABC operon was the first to be characterized in A. baumannii to code 
for an RND efflux pump (Magnet et al., 2001). Prevalence of AdeABC efflux pumps is
reported to range from 53% to 97% among clinical MDR A. baumannii isolates from regions 
all over the world (Coyne et al., 2011). Up-regulation of this operon is involved in resistance
to cefepime, cefpirome, and cefotaxime, in addition to other beta-lactams (Bratu et al., 2008). 
This efflux system is also involved in resistance to aminoglycosides, tetracyclins,
chloramphenicol, and trimethoprim (Damier-Piolle et al., 2008). Moreover, up-regulation of 
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this pump is involved to a certain degree in resistance to carbapenems (Lee et al., 2010).
Finally, over-expression of AdeABC pumps were found to be able to extrude tigecycline, an
antibiotic that resistant to expulsion by most other efflux systems (Yuhan et al., 2016).
AdeIJK is another RND efflux pump that is intrinsic to A. baumannii. It works in
synergy with the overexpression of AdeABC and is involved in resistance to penicillins,
cephalosporins, monobactams, tetracyclines, tigecycline, fluoroquinolones, rifampin,
lincosamides, novobiocin, chloramphenicol, trimethoprim/sulfamethoxazole, and fusidic acid 
(Damier-Piolle et al., 2008). In addition to the intrinsic AdeIJK efflux pump, overexpression
of AdeFGH is also involved in resistance to antimicrobial agents (Rosenfeld et al., 2012). 
These agents include chloramphenicol, trimethoprim/sulfamethoxazole, fluoroquinolones,
clindamycin, tigecycline, and tetracyclines (Coyne et al., 2011). However, over-expression of
AdeFGH is not very commonly reported as compared to the other RND efflux pumps (Yoon
et al., 2016). Another efflux pump involved in resistance to fluoroquinolones, trimethoprim,
and chloramphenicol is AbeM, which belongs to the MATE superfamily (Su et al., 2005). A 
recent study also showed that efflux systems that could be inhibited by cyanide 3­
chlorophenylhydrazone (CCCP), a proton motive force inhibitor, are involved in colistin
resistance (Ni et al., 2016). In addition, the AbeS, an SMR efflux pump, is also able to expunge 
ammonium antiseptics, as well as erythromycin, chloramphenicol, fluoroquinolones, and 
novobiocin. This gives this bacterium a degree of resistance against disinfection as well as 
against several antimicrobial agents (Fournier et al., 2006). 
An association between antimicrobial resistance and resistance to several biocides has
been described. It was shown that resistance to aminoglycosides, tetracyclines, 
fluoroquinolones, and carbapenems through efflux pumps makes A. baumannii more resistant 
to biocides (Fernández-Cuenca et al., 2015). Nevertheless, the former study, and another recent 
study, suggest that some isolates have reduced virulence and fitness after over-expression of 
efflux pumps (Yoon et al., 2016). Finally, A. baumannii has been shown to be able to acquire
genes coding for efflux pumps from its surroundings (Coyne et al., 2011). These pumps include 
TetA and TetB, members of the MFS superfamily. These pumps convey high level resistance
to tigecycline and are detected in several MDR A. baumannii isolates (Vila et al., 2007).
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4.2.1.2. Down-Regulation of Porins
Another mechanism that works in synergy with the up-regulation of efflux pumps is 
the down-regulation of porins. This mechanisms acts by decreasing the permeability of the 
bacterium’s membrane which prevents antimicrobial agents from re-entering the cell after
expulsion and protects it against future exposure (Bonomo and Szabo, 2006). Porins are outer 
membrane proteins that form channels through which several molecules, including
carbapenems, enter the bacterial cell (Peleg et al., 2008). CarO is one such porin identified in
A. baumannii whose down-regulation is associated with carbapenem resistance (Siroy et al., 
2005). One study showed that the disruption of the carO gene by mobile elements resulted in
carbapenem resistance (Mussi et al., 2005). Other outer membrane porins whose down­
regulation has been involved in carbapenem resistance have also been identified in A. 
baumannii. These include porins homologous to OmpF and OprD found in Pseudomonas
aeruginosa and to OmpW found in Escherichia coli and Pseudomonas aeruginosa (Peleg et 
al., 2008). 
Outbreaks of CRAB isolates associated with down-regulation of outer membrane
proteins have been reported from USA (Quale et al., 2003) and Spain (Bou et al., 2000b) in
the early 2000s. Additionally, the involvement of several porins, including CarO, has been 
found to work synergistically with carbapenem hydrolyzing enzymes in order to convey
carbapenem resistance (Poirel and Nordmann, 2006). Another study showed that mutations in 
carO and oprD, accompanied by up-regulation of RND efflux pumps in A. baumannii could
also lead to carbapenem resistance (Yang et al., 2015). Analysis of outbreaks caused by CRAB
isolates showed that all of those isolates had reduced carO expression contributing to 
carbapenem resistance in parallel to other mechanisms of resistance (Sen and Joshi, 2016). This
suggests that decreased permeability of the membrane could act synergistically with other
mechanisms of resistance and contribute to carbapenem resistance in A. baumannii. 
4.2.1.3. Changes in the Target of Antimicrobial Agents
Another non-enzymatic mechanism of resistance found in A. baumannii is modification 
of the target of antimicrobial agents. Point mutations in the DNA gyrase and topoisomerase IV
genes (gyrA and parC, respectively) result in the modification of the target of fluoroquinolones 
and the subsequent resistance to these antibiotics (Bonomo and Szabo, 2006). A recent study 
showed that the Ser83Leu in gyrA and Ser80Leu in parC mutations are the most common
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among the topoisomerase genes mutations in A. baumannii (Güler and Eraç, 2016). Another 
study conducted in USA showed that all the 38 A. baumannii isolates responsible for two
separate outbreaks were resistant to fluoroquinolones through mutations in gyrA and parC. The
mutations caused the same amino acid changes as reported by the previous study (Warner et
al., 2016). A study investigating 34 fluoroquinolone-resistance A. baumannii isolates in China
showed that 48.7% of them had single mutations in gyrA, 21.6% had single mutations in parC, 
and 5.4% had mutations in both genes (Sun et al., 2015). Finally, a study from Sweden showed
that all the A. baumannii isolates that were resistant to quinolones acquired this resistance 
through the aforementioned mutations (Karah et al., 2016).
Resistance to aminoglycosides could be acquired by reduced permeability, efflux 
pumps over-expression, and amino acid substitutions in ribosomal proteins. However, the most
potent form of acquiring resistance to these antimicrobial agents is through the alteration of 
their target by 16S rRNA methylases (Doi and Arakawa, 2007a). Of the ten 16S rRNA
methylases identified in Gram-negative organisms, ArmA and RmtB seem to be the most
prevalent among A. baumannii (Potron et al., 2015). Analysis of the G+C content of the genes 
coding for these enzymes suggested that they are not intrinsic to this species but were rather
acquired through horizontal gene transfer and incorporated into the genome (Doi et al., 2007b). 
The RmtB methylase does not seem to be widely disseminated where it was detected in a few 
studies, one of which was in Vietnam (Tada et al., 2013). ArmA, on the other hand, has been 
identified in A. baumannii isolates from regions all over the world. 
Around 60% out of 101 clinical A. baumannii isolates were found to harbor armA in
Vietnam (Tada et al., 2013). In South Korea, a study across two hospitals showed that A. 
baumannii isolates that were highly resistant to aminoglycosides carried armA on a plasmid
(Cho et al., 2009). Another study from the same country showed that 90.32% of 31 A.
baumannii isolates were positive for ArmA (Hong et al., 2013). In Japan, ArmA was detected 
in highly aminoglycoside-resistant A. baumannii isolates obtained from 8 different patients
(Yamada and Suwabe, 2013) whereas in China ArmA was detected in 221 out of 342 CRAB
isolates (Zhou et al., 2009). In Iran, 26% of amikacin-resistant A. baumannii isolates produced 
ArmA (Aghazadeh et al., 2013) and 8.5% of amikacin-resistant CRAB isolates had ArmA in 
Algeria (Bakour et al., 2014). This methylase was also found to be widely disseminated in
Egypt were it was detected in 141 out of 150 aminoglycoside highly-resistant A. baumannii
isolates (El-Sayed-Ahmed et al., 2015). Moreover, all MDR A. baumannii isolates that had a
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high level of resistance to aminoglycosides were found to produce ArmA in a study in Bulgaria 
(Strateva et al., 2012). A single clone producing both OXA-23 and ArmA was detected in 19 
out of 21 A. baumannii isolates in Italy (Brigante et al., 2012) and four out of eleven A. 
baumannii MDR isolates produced ArmA in a study from Norway (Karah et al., 2011a). A 
study from Sweden showed that all 16 isolates from the pool being studied that were highly 
resistant to aminoglycosides were positive for ArmA (Karah et al., 2016). Investigating an 
outbreak in Latvia caused by 30 A. baumannii isolates showed that 26 of these isolates had this
methylase (Saule et al., 2013). In Pennsylvania, USA, five aminoglycoside highly-resistant A.
baumannii isolates produced ArmA (Doi et al., 2007a). All these reports are in agreement that
ArmA conveys high-level resistance to aminoglycosides and is highly disseminated all around 
the globe. 
Another form of modification of the target of antimicrobial agents is the ribosomal 
protection mechanism coded by several tet genes. In this mechanism, ribosomal protection
proteins bind to the ribosome and sequester it from the action of tetracyclines, leading to
resistance to these antimicrobial agents (Li et al., 2013). This mechanism is very widely spread
among A. baumannii isolates and works in synergy with efflux pumps in order to convey a very
high level of resistance to tetracyclines (Potron et al., 2015). However, tigecycline is able to 
evade this mechanism and show, at least in-vitro, good activity against tet harboring A. 
baumannii isolates (Hawkey and Finch, 2007). Nevertheless, mutations in the trm gene, which
codes for a methyltransferase, were found to lead to resistance to tetracycline in A. baumannii 
through a mechanism that is still not well defined (Chen et al., 2014). Finally, modifications of 
the many types of PBPs found in A. baumannii, the target of beta-lactams, have been found to 
convey low-level resistance to carbapenems (Gehrlein et al., 1991). A study showed that, in 
addition to modification of PBPs, their reduced expression works in synergy with other
mechanisms in order to convey low-level carbapenem resistance (Fernández-Cuenca et al.,
2003). However, data concerning the prevalence and exact mechanisms regarding
modifications of PBPs in A. baumannii is very scarce (Nowak and Paluchowska, 2016).
4.2.2. Enzymatic Mechanisms of Resistance
Enzymatic degradation of antimicrobial agents is another mechanism by which bacteria 
become resistant to antimicrobial agents. More than 900 enzymes that degrade antimicrobial
agents have been described in pathogenic bacteria (Mehrad et al., 2015). Due to their genomic
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plasticity, a large number of antibiotic-hydrolyzing enzymes have been detected among clinical
A. baumannii isolates (Antunes et al., 2014). Some A. baumannii isolates have even acquired
enough enzymatic and non-enzymatic mechanisms so as to become resistant to all known 
antimicrobial agents (Leite et al., 2016).
4.2.2.1. Beta-Lactamases
Among the numerous enzymes that hydrolyze antibiotics, beta-lactamases, which 
hydrolyze beta-lactams by breaking the amide bond of the beta-lactam ring, are the most
common among Gram-negative bacteria (Xia et al., 2016). Beta-lactamase enzymes are
classified into Classes A, B, C, and D according to the ambler classification which is based on 
molecular structure (Ambler, 1980). Within this group of enzymes, the Extended Spectrum
Beta-Lactamases (ESBLs) hydrolyze a broad range of beta-lactams, and carbapenemases are
capable of hydrolyzing carbapenems (Weldhagen et al., 2003). In the following sections, the 
prevalence of the different beta-lactamases, with an emphasis on carbapenemases, among A.
baumannii isolates will be discussed. These enzymes are summarized in Figure 5.
Figure 5. Acquired beta-lactamases detected in A. baumannii according to the Ambler classification system.
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4.2.2.1.1. Ambler Class A Enzymes
Class A beta-lactamases are a set of enzymes that hydrolyze beta-lactams through the
formation of an acyl enzyme and have an active site that contains serine (Bush and Jacoby, 
2010). Numerous ESBLs of this class of beta-lactamases are extremely common among 
Enterobacteriaceae but only a few types are commonly found in A. baumannii (Potron et al.,
2015). The ESBL that was first identified in A. baumannii was the Pseudomonas Extended-
Resistant (PER) ESBL, PER-1. PER-1 conveys resistance to ceftazidime and has a limited 
carbapenemase activity. It is detected in A. baumannii isolates spread across several countries
around the world (Potron et al., 2015). This enzyme was detected in 53 of 97 A. baumannii
isolates in South Korea (Yong et al., 2003) and 35 of 37 isolates in China (Zhang et al., 2010).
Another study from China that spanned across 11 teaching hospitals over six years showed that
77.8% of 221 A. baumannii isolates had PER-1 (Wang et al., 2007). In Turkey, PER-1 was
detected in 31% of A. baumannii isolates obtained from seven university hospitals (Kolayli et 
al., 2005) whereas 51% of isolates in Iran produced this enzyme (Farajnia et al., 2013). 
Additionally, two out of eight A. baumannii isolates obtained from four medical centers in
Belgium were positive for PER-1 (Naas et al., 2006b). One case of an isolate obtained from a
Hungarian tourist returning from Egypt was also positive for this enzyme (Szabó et al., 2008). 
In USA, PER-1 is present but was only detected in two out of seventy five isolates indicating 
a low prevalence in this country (Hujer et al., 2006). PER-1 was also detected in isolated cases 
in India (Litake et al., 2009), Romania (Naas et al., 2007b), Russia, (Naas et al., 2007a), and 
Bulgaria (Strateva et al., 2008). A novel structure of PER-1 was also reported in a study
performed on an A. baumannii isolate obtained from Kuwait (Opazo et al., 2014). PER-2 is 
another enzyme detected in A. baumannii that has 86% amino acid identity with PER-1.
However, its occurrence seems to be limited to South America (Pasterán et al., 2006). PER-3 
is yet another ESBL identified in A. baumannii isolates from Egypt (Al-Hassan et al., 2013).
One last variant, PER-7, was also identified in isolates obtained from the United Arab Emirates
(Opazo et al., 2012), France (Bonnin et al., 2011a), and Sweden (Karah et al., 2016).
Vietnamese Extended-spectrum Beta-lactamase (VEB) is another ESBL that was first
detected among A. baumannii isolates in France (Poirel et al., 2003). A subsequent study 
showed that VEB-1 is widely disseminated among A. baumannii isolates across the entire
nation (Naas et al., 2006a). In Belgium, six VEB-1 positive A. baumannii isolates were
collected from 2003 to 2005 (Naas et al., 2006b) whereas 10 out of 100 A. baumannii isolates 
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were VEB-1 positive in Iran from 2008 to 2009 (Farajnia et al., 2013). VEB-1 was also detected 
in six A. baumannii isolates from Argentina (Poirel et al., 2009) and its variant VEB-3 was
detected in a single isolate from Taiwan (Huang et al., 2008). The Guiana Extended Spectrum 
(GES) beta-lactamase is another type of beta-lactamase with varying degrees of hydrolytic 
activity towards carbapenems. GES-11, was first identified in an A. baumannii isolate in France 
showing reduced susceptibility to carbapenems (Moubareck et al., 2009). A subsequent study
in Belgium showed that GES-11, as well as two other variants, were present in 9 out of 125
MDR A. baumannii isolates obtained from 18 hospitals. The two other variants detected in this
study were GES-12, which hydrolyzes ceftazidime, and GES-14, which hydrolyzes imipenem
(Bogaerts et al., 2010). A study in Kuwait targeted at 63 A. baumannii isolates surprisingly 
showed that all those isolates had GES genes on plasmids suggesting that the Middle East 
region could act as a reservoir for this ESBL. Of the 63 GES positive isolates, only one showed
GES-14 whereas all the rest had GES-11 (Bonnin et al., 2013). The GES-14 carbapenemase
was also detected in France among A. baumannii isolates in 2011 (Bonnin et al., 2011b). In a 
study performed in Turkey on 101 A. baumannii isolates collected over one year showed that
16 of them had GES-11 while 8 had another carbapenem hydrolyzing variant, GES-22 (Cicek
et al., 2014). Furthermore, GES-11 was detected among A. baumannii isolates in a study from
Sweden (Karah et al., 2011b) and another one from Tunisia (Charfi-Kessis et al., 2014).
Another class A beta-lactamase that is the Klebsiella pneumoniae Carbapenemase
(KPC). This enzyme could be spread through mobile genetic elements and has a high intrinsic 
activity against carbapenems (Naas et al., 2008). Although this enzyme is commonly reported
among Enterobacteriaceae, its dissemination among A. baumannii isolates is rare. Ten A.
baumannii isolates from Puerto Rico were positive for KPC enzymes, seven of which had KPC­
3 and the rest had KPC-2, KPC-4, and KPC-10, respectively (Robledo et al., 2010). However,
the presence of KPC in A. baumannii seems to still be scarce and limited to one geographical
area (Martinez et al., 2016). The Temoneira (TEM), Sulfhydryl Variable (SHV), and
Cefotaximase (CTX-M) class A ESBLs that are widely disseminated among
Enterobacteriaceae are also rarely detected in A. baumannii (Potron et al., 2015). The plasmid­
carried SHV-12 and TEM-116 ESBLs were found in three A. baumannii isolates in a study
from the Netherlands (Naiemi et al., 2005). Another seven-year study from Italy showed that
31 A. baumannii isolates carried the plasmidic TEM-92 ESBL (Endimiani et al., 2007) while
the chromosomal blaSHV-5 was detected in one PDR A. baumannii isolate in New York City,
USA (Naas et al., 2007). The cefotaxime-hydrolyzing CTX-M-2 was detected in three A.
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baumannii isolates from Japan (Nagano et al., 2004) and five out of 49 isolates from USA
(Adams-Haduch et al., 2008). Another novel cefotaximase variant, CTX-M-43, was found to
be disseminated among A. baumannii isolates in a multi-center study performed in several
Bolivian hospitals (Celenza et al., 2006). Two out of six CRAB isolates from India (Shakil and
Khan, 2010) and two A. baumannii isolates obtained from Haiti (Potron et al., 2011) were
shown to be positive for CTX-M-15. Finally, a novel Carbenicillin-hydrolyzing Beta-lactamase
(CARB), the chromosomally-coded, cefepime-hydrolyzing CARB-10, was identified in A.
baumannii in France (Potron et al., 2009). The distribution of Ambler class A beta-lactamases
is summarized in Table 1.
Table 1. Worldwide Distribution of Ambler Class A Beta-Lactamases.
Africa
Egypt PER-3
 
Tunisia GES-11
 
Asia
China PER-1
India PER-1 and CTX-M-15
Iran PER-1 and VEB-1
Japan CTX-M-2
Kuwait PER-1, GES-11, and GES-14
Russia PER-1
South Korea PER-1
Taiwan VEB-3
Turkey PER-1, GES-11, and GES-22
United Arab Emirates PER-7
Europe
Belgium PER-1, VEB-1, GES-11, GES-12, and GES-14
Bulgaria PER-1
France PER-7, VEB-1, GES-11, GES-14, and CARB-10
Hungary PER-1
Italy TEM-92
Netherlands SHV-12 and TEM-116
Romania PER-1
Sweden GES-11, PER-7
North America
Haiti CTX-M-15
Puerto Rico KPC-2, KPC-3, KPC-4, and KPC-10
United States of America PER-1, SHV-5, and CTX-M-2
South America
Argentina PER-2 and VEB-1
Bolivia CTX-M-43
4.2.2.1.2. Ambler Class B Enzymes
Ambler class B enzymes are metalloenzymes that utilize a zinc ion at their active site 
in order to hydrolyze beta-lactams (Bush and Jacoby, 2010). These enzymes are referred to as
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Metallo-Beta-Lactamases (MBLs), are very efficient at hydrolyzing carbapenems, and are not
inhibited by clavulanic acid nor tazobactam (Nordmann et al., 2012). Although MBLs are not 
the most common cause for carbapenem resistance in A. baumannii, the Verona Integron­
encoded Metallo-beta-lactamase (VIM), Imipenem metallo-beta-lactamase (IMP), New Delhi
Metallo-beta-lactamase (NDM), and Seoul Imipenemase (SIM) MBLs have been detected in 
several regions around the world (Potron et al., 2015). Five VIM-1 positive isolates were 
detected among A. baumannii isolates obtained from two Greek hospitals between 2004 and
2005 (Tsakris et al., 2006). In South Korea, a study across 28 hospitals showed that VIM-2 
was present in 27 out of 267 A. baumannii isolates over a one-year period (Lee et al., 2003).
Eighteen out of 94 consecutive A. baumannii isolates obtained within a year were positive for 
VIM-2 in Kuwait (Al-Sweih et al., 2012). In China, 8 out of 143 A. baumannii isolates were
positive for VIM-2 (Wang et al., 2015). Additionally, A. baumannii isolates producing VIM­
4, VIM-6, and VIM-11 were detected in Italy (Mammina et al., 2011), India (Potron et al., 
2015), and Taiwan (Huang et al., 2008), respectively.
IMP-type MBLs seem to be disseminated among A. baumannii isolates throughout 
Eastern Asia and the Pacific Rim, but are not limited to that region (Potron et al., 2015). In a
one-year study in Japan, 30 A. baumannii isolates were found to be positive for IMP-1 and five 
were positive for IMP-2 (Shibata et al., 2003). IMP-11 (Potron et al., 2015) and IMP-19
(Yamamoto et al., 2011) were also found among A. baumannii isolates in Japan. In southern
India, 23 of 55 A. baumannii isolates were positive for IMP-1 (Uma Karthika et al., 2009)
whereas 8 of 35 isolates in Taiwan were positive for this enzyme (Chiu et al., 2010). IMP-1 
was detected in 27 of 38 A. baumannii isolates in South Korea (Lee et al., 2003) and IMP-4 in 
23 of 35 isolates in Hong Kong (Chu et al., 2001). IMP-4 was also detected in one A. baumannii
clinical isolate in Australia (Peleg et al., 2007) and four isolates in Singapore (Koh et al., 2007). 
In China, a single A. baumannii isolate producing IMP-8 was detected in a study that spanned
six years (Wang et al., 2007). Another study from Taiwan showed the presence of IMP-14 
among A. baumannii isolates in that country (Kansakar et al., 2011). In Kuwait, 8 of 94 A.
baumannii isolates were positive for IMP-1 (Al-Sweih et al., 2012) and IMP-6 was present in 
a single isolate in Brazil (Gales et al., 2003). Another A. baumannii isolate was positive for 
IMP-5 in Portugal (Da Silva et al., 2002) and one was positive for IMP-1 in Italy (Cornaglia et
al., 1999). 
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The SIM-1 carbapenemase seems to be widespread in South Korea, where it was first
identified (Lee et al., 2005). However, its dissemination seems to be limited to that country
(Nowak and Paluchowska, 2016). NDM-1 was relatively recently discovered and was reported 
for the first time to be present among three A. baumannii isolates in India in 2010 (Karthikeyan 
et al., 2010). NDM-1 was also detected in an A. baumannii isolate in Japan obtained from a
patient that was transferred from India (Nakazawa et al., 2013). In China, four A. baumannii 
isolates obtained from four different provinces were positive for NDM-1 and the blaNDM-1 gene
was present on transferrable plasmids (Chen et al., 2011). One out of sixteen CRAB isolates
collected over one year in Kenya was positive for NDM-1 (Revathi et al., 2013) whereas 11 
out of 47 CRAB isolates in Algeria were positive for this carbapenemase (Bakour et al., 2014). 
Moreover, an outbreak of seven NDM-1 positive A. baumannii isolates was detected in France 
from January to May, 2013 and was traced back to two patients transferred from Algeria 
(Decousser et al., 2013). Another case of an A. baumannii isolate carrying blaNDM-1 from a
patient transferred from Algeria was recorded in Belgium (Bogaerts et al., 2012). Two blaNDM­
1 carrying A. baumannii isolates from a Balkan origin were detected in two different European
countries; one in Switzerland (Poirel et al., 2012) and the other in Germany (Pfeifer et al., 
2011). Single NDM-1 positive A. baumannii isolates were also detected in Slovenia (Bonnin
et al., 2012), Czech Republic (Krizova et al., 2012), and Brazil (Pillonetto et al., 2014). In 
Lebanon, four A. baumannii isolates producing NDM-1 were detected among patients wounded
in the Syrian civil war (Rafei et al., 2014b). NDM-2 was detected in one A. baumannii isolate 
from Egypt (Kaase et al., 2011), two from United Arab Emirates (Ghazawi et al., 2012), and
five from Israel (Espinal et al., 2011). The NDM-2 carrying isolates were shown to be clonally 
related in a subsequent study (Espinal et al., 2013) suggesting that this region could act as a 
reservoir for NDM-2 producing A. baumannii. Finally, an extensive study showed that blaNDM­
1 most probably got transferred from A. baumannii to Pseudomonas aeruginosa and 
Enterobacteriaceae and not the other way around (Bonnin et al., 2014). This suggests that A.
baumannii could also act as a reservoir of resistance genes for other bacteria. Table 2 
summarizes the above distribution of Ambler class B beta-lactamases.
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Table 2. Worldwide Distribution of Ambler Class B Beta-Lactamases.
Africa
Algeria NDM-1
Egypt NDM-2
Kenya NDM-1
Asia
China VIM-2, IMP-4, IMP-8, and NDM-1
India VIM-6, IMP-1, and  NDM-1
Israel NDM-2
Japan IMP-1, IMP-2, IMP-11, and IMP-19
Kuwait VIM-2 and IMP-1
Lebanon NDM-1
Singapore IMP-4
South Korea VIM-2, IMP-1, and SIM-1
Taiwan VIM-11, IMP-1, and IMP-14
United Arab Emirates NDM-2
Europe
Belgium NDM-1
Czech Republic NDM-1
France NDM-1
Germany NDM-1
Greece VIM-1
Italy VIM-4 and IMP-1
Portugal IMP-5
Slovenia NDM-1
Switzerland NDM-1
Oceana
Australia IMP-4
South America
Brazil IMP-6 and NDM-1
4.2.2.1.3. Ambler Class C Enzymes
Ambler class C enzymes are beta-lactamases with a broad spectrum of activity against
cephalosporins. They hydrolyze beta-lactams in a way similar to class A enzymes (Bush and
Jacoby, 2010). No acquired genes producing this type of enzymes have been detected in A.
baumannii (Potron et al., 2015). This bacterium does, however, intrinsically produce AmpC, a
class C cephalosporinase. Production of AmpC normally is at a low basal level and therefore
does not contribute much to the resistance towards broad spectrum cephalosporins (Bou et al.,
2000a). However, insertion of ISAba1 upstream of the AmpC genes was found to increase their
expression to the point of acquiring resistance to broad spectrum cephalosporins, but not to 
carbapenems (Héritier et al., 2006). Additionally, some AmpC variants, such as ADC-33 
(Rodríguez-Martínez et al., 2010) and ADC-56 (Tian et al., 2011b) have a broader spectrum
of activity against cephalosporins. They have been found to hydrolyze ceftazidime and
cefepime more efficiently. However, their clinical significance is yet to be defined (Potron et
al., 2015).
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4.2.2.1.4. Ambler Class D Enzymes
Ambler class D enzymes are the most common cause of carbapenem resistance among 
A. baumannii isolates (Nowak and Paluchowska, 2016). They are a heterogeneous group of 
enzymes that are collectively referred to as Oxacillinases (OXAs). They work in a way similar
to class A and class C enzymes, are able to hydrolyze cefalotin and amoxicillin, and are not 
inhibited by clavulanic acid (Poirel et al., 2007). Several OXAs have been identified in A. 
baumannii and those that convey resistance to carbapenems are grouped into six families. 
These are the OXA-51-like, OXA-23-like, OXA-40/24-like, OXA-58-like, OXA-143-like, and
OXA-235-like families (Evans and Amyes, 2014). The OXA-24-like and OXA-40-like
enzymes were found to be the same group of enzymes but referred to differently in different
studies (Tian et al., 2011a). These two identical groups will be referred to as OXA-24-like from
here on. OXAs are known to often work synergistically with other mechanisms of resistance,
such as reduced membrane permeability or increased efflux pump expression, in order to 
convey a high level of resistance to carbapenems (Poirel and Nordmann, 2006). A. baumannii 
intrinsically expresses OXA-51-like enzymes, but their expression alone does not convey
resistance to carbapenems, unless over-expressed with the help of ISAba1 upstream of its gene 
(Turton et al., 2006b). More than 95 chromosomally encoded enzymes have been described as
belonging to the OXA-51-like family, to date (Nowak and Paluchowska, 2016). Two
commonly encountered OXA-51-like alleles among CRAB nosocomial isolates are the OXA­
66 and OXA-69 variants (Turton et al., 2007). An outbreak of 31 CRAB isolates over­
expressing OXA-66 was reported over a one-year period in Spain (Culebras et al., 2010). OXA­
51-like over-expressing CRAB isolates were also reported in 93.7% of isolates causing an 
outbreak in Korea that affected 77 patients (Chaulagain et al., 2012). Nevertheless, carbapenem
resistance resulting from over-expression of OXA-51-like is relatively infrequent (Nowak and
Paluchowska, 2016).
The OXA-23-like family contains the enzymes OXA-23, OXA-27, and OXA-49 
(Potron et al., 2015). blaOXA-23-like genes are usually a part of a transposon and could be found 
on bacterial chromosomes or plasmids (Corvec et al., 2007). This family of OXAs is the most
prevalent among CRAB isolates causing nosocomial infections (Merino et al., 2014). Although 
this family has intrinsic activity against carbapenems, enhanced carbapenemase activity is 
associated with the presence of ISAba1 upstream of blaOXA-23-like genes (Turton et al., 2006b). 
OXA-23 in A. baumannii was first identified in an isolate obtained from Edinburg (Scaife et 
 
 
     
     
 
       
     
    
   
     
   
 
   
  
  
  
     
     
    
     
      
   
     
  
 
  
  
    
   
  
   
    
    
     
   
 
74
al., 1995). Nowadays, OXA-23-like enzymes are reported with varying rates from countries all
around the world among Acinetobacter spp., mainly owing to its wide dissemination through
plasmid-mediated transfer (Evans and Amyes, 2014). OXA-23 was identified in a single isolate
from Japan with ISAba1 upstream of its gene in a study that spanned from 2003 until 2011 
(Kishii et al., 2014). However, another multi-center study from that country showed that 23 
out of 49 MDR A. baumannii isolates were positive for OXA-23-like (Tada et al., 2014). 
Alarmingly, 97.7% of 221 CRAB isolates obtained from 11 Chinese medical centers were
positive for OXA-23-like (Wang et al., 2007). A more recent nation-wide study in China
showed that 71.3% of 143 A. baumannii nosocomial isolates were positive for this enzyme
(Wang et al., 2015). A national survey in South Korea showed that 32.64% of CRAB isolates
were positive for OXA-23-like (Lee et al., 2009). Another study from that country showed that
80% of 190 CRAB isolates were positive for OXA-23-like (Kim et al., 2010). In Australia, two
blaOXA-23-like harboring A. baumannii isolates were detected in a 10-year study (Nigro et al., 
2011). On the other hand, in Brazil, 46 OXA-23-like positive A. baumannii isolates were 
collected from eight different hospitals in a two-year period (Cieslinski et al., 2013). Another
study from Brazil showed that 87.3% of 139 A. baumannii isolates with reduced carbapenem
susceptibility were positive for OXA-23-like (Cortivo et al., 2015). Thirty nine CRAB isolates
harboring blaOXA-23-like were collected from three hospitals in Egypt over one year (Fouad et 
al., 2013). Another study from Egypt showed that 50% of 40 CRAB isolates harbored this gene
(Al-Agamy et al., 2014). In Algeria, 23 out of 24 CRAB isolates obtained within a year from
two university hospitals were positive for OXA-23-like (Touati et al., 2012). Moreover, three
OXA-23-like positive A. baumannii isolates were detected in Nigeria, one in South Africa, and
fifty three in Madagascar (Olaitan et al., 2013). Screening for OXA-23-like positive A. 
baumannii isolates among human lice and fecal samples in Senegal resulted in a total of nine 
positive isolates in one year. This suggests that human lice and stool samples in Senegal could 
act as a reservoir for blaOXA-23-like harboring CRAB isolates (Kempf et al., 2012b). In a multi­
center study across the Gulf Cooperation Council States (Saudi Arabia, United Arab Emirates,
Oman, Qatar, Bahrain, and Kuwait), 91.45% of CRAB isolates were positive for OXA-23-like
(Zowawi et al., 2015). In northwestern Iran, the prevalence of OXA-23-like among CRAB
isolates is reported to be 88.7% (Sohrabi et al., 2012). Another study from that country showed 
that 68% of CRAB isolates infecting patients with burns had this carbapenemase (Pajand et al.,
2013). A more recent study that investigated 30 CRAB isolates from Iranian burn units showed
that they all harbored blaOXA-23-like (Salimizand et al., 2015).
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A study across 10 ICUs in Italy from 2005 to 2009 showed an incidence of 71.1% of 
OXA-23-like among CRAB isolates (D’Arezzo et al., 2011). In a similar study across 22 Italian
hospitals from 2004 until 2009, 48 out of 202 CRAB isolates were positive for OXA-23-like
(Mezzatesta et al., 2012). A study performed in Poland from 2005 to 2010 showed that 47.12%
of 104 A. baumannii isolates harbored blaOXA-23-like (Nowak et al., 2012). Another study from
Poland conducted from 2009 to 2011 showed that 27.9% of CRAB isolates were positive for 
OXA-23-like (Nowak et al., 2014). In France, 11 CRAB isolates expressing OXA-23-like were
collected over one year from several hospitals in Marseille (Kempf et al., 2013). Moreover, a
five-year study across 15 medical centers in Germany showed that 14 out of 25 CRAB isolates
were positive for OXA-23-like (Schleicher et al., 2013). Another study investigating 28 CRAB
isolates in Sweden showed that 20 of these isolates were positive for OXA-23-like (Karah et
al., 2016). In Latvia, an outbreak caused by 35 OXA-23-like positive CRAB isolates across
several medical centers was reported between 2008 and 2009 (Saule et al., 2013). Sixteen of 
28 CRAB isolates obtained from Serbia were reported to be positive for OXA-23-like (Novovic
et al., 2015). Additionally, 77.8% of 116 MDR A. baumannii isolates from Portugal were found 
to harbor blaOXA-23-like in one study (Manageiro et al., 2012) and 63.4% of 213 CRAB isolates 
in another study harbored this gene (Grosso et al., 2011). In Greece, 72.4% of CRAB isolates
from were positive for this gene (Liakopoulos et al., 2012) whereas a study from Finland
reported that 33 out of 51 CRAB isolates harbored blaOXA-23-like (Pasanen et al., 2014).
Moreover, 9% of 64 CRAB isolates in a multi-center study in Croatia were positive for OXA­
23-like (Vranić-Ladavac et al., 2014). In Turkey, a surveillance study from 2000 to 2006
showed that 26 A. baumannii isolates were positive for OXA-23-like (Gur et al., 2008). 
Another study from Turkey showed that 46.6% of CRAB isolates had this enzyme (Keyik et 
al., 2014). A recent study across 24 hospitals distributed across Germany, Poland, Sweden, and 
Turkey showed that OXA-23-like was accountable for carbapenem resistance among 83.33%
of CRAB isolates (Tomaschek et al., 2016). Another study that characterized 35 A. baumannii 
strains isolated during 28 outbreaks in four Mediterranean countries (Italy, Turkey, Greece,
and Lebanon) from 1999 to 2009 showed that OXA-23-like was present in one isolate from
Italy and another from Turkey (Di Popolo et al., 2011).
In USA, a study performed in the Miami area from 1994 to 2011 showed that 96 of 
9,334 A. baumannii isolates were positive for OXA-23-like (Munoz-Price et al., 2013).
Another multi-center study in Ohio, USA showed that 18 of 39 A. baumannii isolates collected
over one year were positive for OXA-23-like (Perez et al., 2010). Yet another study from USA 
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investigating CRAB isolates obtained from wounded soldiers returning from Iraq showed that
40 out of 42 CRAB isolates had this enzyme (Huang et al., 2012). In Canada, OXA-23-like
producing CRAB strains caused an outbreak in 2012 (Ahmed-Bentley et al., 2013). Moreover,
a study by Mugnier et al. (2010) investigated 20 OXA-23-like positive A. baumannii isolates
obtained from Vietnam, Thailand, New Caledonia, Australia, Réunion island, South Africa,
Tahiti, Libya, Algeria, Egypt, Bahrain, United Arab Emirates, Brazil, France, and Belgium,
indicating presence of this carbapenemase in these countries (Mugnier et al., 2010). In Spain, 
an outbreak of OXA-23-like positive A. baumannii strains was reported between October 2010 
and May 2011 that affected 17 patients (Mosqueda et al., 2013). Another case of blaOXA-23-like
harboring A. baumannii infecting a patient, with a history of hospitalization in Lisbon, was
reported in Spain (Espinal et al., 2013). Subsequently, another outbreak between 2011 and
2012 of OXA-23-like producing A. baumannii isolates obtained from 50 patients was reported 
in that country (Merino et al., 2014). In Lebanon, a study from nine hospitals during 2012
showed that 97.89% of 142 CRAB isolates expressed OXA-23-like, indicating a very high
prevalence of this enzyme in this country (Hamoudi et al., 2015a). Another study from a
Lebanese hospital showed that four A. baumannii isolates were positive for OXA-23-like in a
three month period in 2011. In the same time frame one year later, seven CRAB isolates that 
were positive for OXA-23-like were detected (Hamoudi et al., 2015b). Investigation of 42 A.
baumannii strains collected from Lebanese hospitals between 2009 and 2012 showed that 28
out of 31 carbapenem resistant isolates had OXA-23-like (Rafei et al., 2014a). In northern 
Lebanon, 65 out of 70 CRAB isolates were found to be positive for OXA-23-like in a two-year 
period (Rafei et al., 2015b). Interestingly, another study from north Lebanon showed that five
CRAB isolates that were obtained from fecal swabs from different livestock animals were all
positive for OXA-23-like (Al Bayssari et al., 2015). This indicates that livestock animals could 
act as a reservoir for CRAB isolates positive for this enzyme in Lebanon.
Another widely disseminated family is the OXA-24-like which consists of OXA-24,
OXA-25, OXA-26, and OXA-72. This family could also be located on plasmids or the bacterial 
chromosome (Potron et al., 2015). Much like OXA-23-like, this family of OXAs is
disseminated among A. baumannii isolates all around the globe. The first OXA-24 enzyme was
identified from A. baumannii isolated from Spain (Bou et al., 2000c). Subsequently, in the 
early 2000s, OXA-24, OXA-25, and OXA-26 were characterized from A. baumannii isolates 
obtained from Spain, Belgium, Kuwait, and Singapore (Afzal-Shah et al., 2001). OXA-72 is 
predominantly detected among A. baumannii isolates in Asian countries such as Japan, China,
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South Korea, and Taiwan but is not limited to that region (Poirel et al., 2010). In a study across 
12 medical centers in Japan, 5 out of 49 MDR isolates were positive for OXA-72 (Tada et al., 
2014). In China, only one out of 221 CRAB isolates was positive for OXA-72 (Wang et al.,
2007). Another study across 23 Chinese provinces showed that 11 isolates were positive for
OXA-24-like (Ji et al., 2014). One Acinetobacter baylyi of 144 MDR Acinetobacter spp. was
also positive for this carbapenemase in South Korea (Lee et al., 2009). Moreover, 64.13% of 
92 CRAB isolates obtained from a hospital in Taiwan over two years were positive for OXA­
72 (Lu et al., 2009). In Europe, OXA-72 positive A. baumannii strains were responsible for an 
outbreak in France that lasted for 14 months and affected 16 patients (Barnaud et al., 2010). 
Another outbreak of A. baumannii strains positive for this enzyme was reported to affect 23
patients in Croatia (Goic-Barisic et al., 2011). A study across several Lithuanian hospitals that 
investigated 444 A. baumannii isolates showed that 95% of CRAB isolates were positive for
OXA-72 (Povilonis et al., 2012). Isolated cases of CRAB isolates harboring blaOXA-72 were also
reported from Brazil (Werneck et al., 2011; de Sá Cavalcanti et al., 2013), Colombia
(Montealegre et al., 2012), and Spain (Candel et al., 2010).
blaOXA-24-like has also been detected among 127 CRAB isolates obtained from Algeria 
(Olaitan et al., 2012). In Egypt, 7.5% of 40 CRAB isolates were positive for OXA-24-like (Al-
Agamy et al., 2014). blaOXA-24-like was also detected in outbreak strains in Turkey that affected
22 patients (Sarı et al., 2013). Moreover, five of 117 CRAB isolates obtained from the
Cooperation Council for the Arab States of the Gulf were positive for OXA-24-like (Zowawi 
et al., 2015). In Iran, one study showed that the prevalence of OXA-24-like among CRAB
isolates was 1.6% (Sohrabi et al., 2012) while another study showed a prevalence of 49% 
among isolates obtained from burn patients (Pajand et al., 2014). Furthermore, investigation of 
30 CRAB isolates obtained from that same country showed that 73% of them were positive for
OXA-24-like (Salimizand et al., 2015). In Lebanon, one A. baumannii isolate harboring blaOXA­
24-like was reported from one hospital in 2012 (Hammoudi et al., 2015b) and from two isolates 
in a multi-center study during that same year (Hammoudi et al., 2015a). Another study
investigating 31 CRAB isolates from different Lebanese hospitals detected blaOXA-24-like in one
CRAB isolate (Rafei et al., 2014a). Additionally, one OXA-24-like producing CRAB isolate 
was detected in a study across Italy, Greece, Turkey, and Lebanon from 1999 to 2009 (Di 
Popolo et al., 2011).
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The first OXA-24-like detected in USA among CRAB isolates was in 2005 (Lolans et 
al., 2006). Subsequently, four A. baumannii isolates positive for OXA-24-like were identified 
in Ohio (Perez et al., 2010), three in Pennsylvania (Tian et al., 2011a), and thirteen in Miami
(Munoz-Price et al., 2013). CRAB isolates harboring blaOXA-24-like have been reported with 
varying incidences in countries all across Europe. In a study of 99 CRAB isolates from medical
centers in Germany, Poland, Turkey, and Sweden, only two OXA-24-like positive A. 
baumannii were detected over six years (Tomaschek et al., 2016). In Finland, only one out of 
51 CRAB isolates was positive for OXA-24-like (Pasanen et al., 2014). Six out of 24 isolates 
obtained in Sweden over one year were also positive for OXA-24-like (Karah et al., 2016). 
Additionally, four A. baumannii isolates were detected in a study from Bulgaria (Todorova et 
al., 2014) whereas in Croatia, 27% of 64 CRAB isolates were positive for OXA-24-like 
(Vranić-Ladavac et al., 2014). Another study from Serbia showed that 82.14% of 28 CRAB
isolates had this carbapenemase (Novovic et al., 2015). In Poland, 46.15% of 104 CRAB
isolates in one study (Nowak et al., 2012) and 65.6% of 61 CRAB isolates in another were 
positive for this enzyme (Nowak et al., 2014). 
The family OXA-24-like seems to be highly prevalent among A. baumannii isolates in
the Iberian Peninsula. In Portugal, a study across three medical centers showed that 65 of 162 
CRAB isolates had OXA-24-like (Da Silva et al., 2004). Another Portuguese study showed
that 23.6% of 116 MDR A. baumannii isolates harbored blaOXA-24-like (Manageiro et al., 2012). 
Yet another study from this country showed a prevalence of 22% of OXA-24-like positive 
isolates among CRAB isolates (Grosso et al., 2011). In Spain, where OXA-24 was first 
identified in an outbreak of CRAB strains (Bou et al., 2000c), the prevalence of this enzyme 
remains high nowadays. 42% of 83 CRAB isolates were positive for this enzyme in a study 
across 25 Spanish hospitals (Ruiz et al., 2007). In 2006, a large outbreak caused by OXA-24­
like producing CRAB isolates was reported in Madrid (Acosta et al., 2011). Moreover,
although A. baumannii mainly infects patients in the ICU, five CRAB isolates obtained from
the internal medicine ward of a Spanish hospital over a six-week period were all positive for 
OXA-24-like (Tena et al., 2013). Another study from Spain investigating 59 MDR A.
baumannii isolates showed that 57.6% of these isolates had OXA-24-like (Villalón et al., 
2013). A comparative study performed in Spain showed that the prevalence of OXA-24-like 
rose among CRAB isolates from 48.7% in 2000 to 51.6% in 2010 (Mosqueda et al., 2014).
Another long-term study from this country showed that the prevalence of OXA-24-like among
CRAB isolates in a single hospital was 40% (Villalón et al., 2015). 
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The OXA-58-like family is composed of OXA-58, OXA-96, OXA-97, and OXA-164.
This family of OXAs can be plasmid-borne or chromosomal and is associated with insertion 
sequence elements at the origin of its expression (Nowak and Paluchowska, 2016). These
enzymes convey a low-level resistance to carbapenems by themselves but their over­
expression, due to the presence of insertion sequences, leads to high-level resistance to these 
antimicrobial agents (Lopes et al., 2012). Though not limited to Europe and Mediterranean
countries, most OXA-58-like positive CRAB isolates seem to be reported from that region. The
first detection of OXA-58 in Acinetobacter baumannii was in France in 2003 (Poirel et al., 
2005). Subsequently, six OXA-58-like positive CRAB isolates caused an outbreak in the same
region in France among burn patients (Héritier et al., 2005b). OXA-96 was identified in one
CRAB isolate from Singapore (Koh et al., 2007) and OXA-97 was identified in 19 isolates 
from Tunisia (Poirel et al., 2008). Furthermore, OXA-164 was identified in the first six isolates
out of thirteen CRAB isolates that caused an outbreak in Germany (Higgins et al., 2010). 
In China, OXA-58-like was identified in 7 out of 221 non-repetitive CRAB isolates 
(Wang et al., 2007). More recently, the prevalence of this enzyme among 143 nosocomial A.
baumannii isolates was shown to be 51% (Wang et al., 2015). Additionally, OXA-58-like was
detected in 32 isolates in a study that spanned across 23 Chinese provinces (Ji et al., 2014). In 
Taiwan, only two out of 92 CRAB isolates collected over two years were positive for this 
enzyme (Lu et al., 2009). Four non-repetitive A. baumannii isolates positive for OXA-58-like 
were also detected in USA in 2004 (Lopes et al., 2012). Moreover, one OXA-58-like positive
CRAB isolate was detected in the USA among soldiers returning from Iraq (Huang et al., 
2012). A study investigating 28 outbreaks affecting 484 patients in 20 hospitals across Greece,
Turkey, Italy, and Lebanon showed that 27 of the 35 studied A. baumannii isolates were 
positive for OXA-58-like (Di Popolo et al., 2011). Another study from Greece showed that
27.6% of 174 CRAB isolates had OXA-58-like and one additional isolate co-expressed this
enzyme with OXA-23-like (Liakopoulos et al., 2012). In Turkey, 17 OXA-58-like positive 
CRAB isolates were detected between 2000 and 2006 (Gue et al., 2008). In another study from
Turkey, 53.3% of 105 CRAB isolates were positive for OXA-58-like (Keyik et al., 2014). 
Additionally, 11 out of 28 CRAB isolates from Serbia were positive for OXA-58-like (Novovic 
et al., 2015). A study from two Egyptian hospitals over a period of four months showed that
5% of 40 CRAB isolates harbored blaOXA-58-like (Al-Agamy et al., 2014). In Algeria, only one
of 24 CRAB isolates was positive for OXA-58-like and another had both OXA-58-like and
OXA-23-like (Touati et al., 2012). In Lebanon, an outbreak caused by 17 MDR A. baumannii 
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isolates with plasmid-borne OXA-58-like was reported between 2004 and 2005 (Zarrilli et al.,
2008). Additionally, two CRAB isolates positive for OXA-58-like were detected in a study
from 2009 to 2012 across several Lebanese hospitals (Rafei et al., 2014a). One A. baumannii 
isolate harboring both blaOXA-58-like and blaOXA-23-like was also isolated from livestock animals in
north Lebanon (Al Bayssari et al., 2015).
Several studies in Italy have shown the dissemination of OXA-58-like in this country.
One study showed that out of 111 MDR A. baumannii isolates obtained from 10 Italian ICUs, 
22.8% were positive for OXA-58-like (D'Arezzo et al., 2011). Another study from 22 hospitals
in that country showed that 154 of 202 CRAB isolates were positive for OXA-58-like alone 
and an additional 21 isolates co-expressed OXA-58-like with OXA-23-like (Mezzatesta et al., 
2012). A study from Rome across eight ICUs showed that half of the 30 MDR A. baumannii 
isolates investigated produced OXA-58-like (Minandri et al., 2012). In Germany, ten OXA­
58-like producing A. baumannii isolates were detected in a study that spanned from 2005 to 
2009 across 15 medical centers (Schleicher et al., 2013). blaOXA-58-like harboring CRAB strains 
were also responsible for an outbreak that lasted two years and affected 28 patients in a French 
hospital (Barnaud et al., 2010). In Finland, 8 out of 17 CRAB isolates were positive for OXA­
58-like (Pasanen et al., 2014) and 33% of 64 CRAB isolates were positive for this enzyme in
a study from Croatia (Vranić-Ladavac et al., 2014). A recent study that span across 24 hospitals
in Poland, Sweden, Germany, and Turkey over 6 years showed that 11 of 84 CRAB isolates 
harbored blaOXA-58-like (Tomaschek et al., 2016). In Spain, one study showed that 20% of 83
CRAB isolates were positive for OXA-58-like (Ruiz et al., 2007). A more recent study showed
that 57% of 46 A. baumannii isolates selected from 25 Spanish hospitals were positive for
OXA-58-like (Fernández Cuenca et al., 2012). In another study from that country, 20.3% of 
59 MDR A. baumannii isolates were positive for this enzyme (Villalón et al., 2013). A very
similar rate was detected in another Spanish study where 20.5% of 101 CRAB isolates were 
positive for OXA-58-like (Mosqueda et al., 2014). blaOXA-58-like was also identified in six 
CRAB strains that were part of three sequential outbreaks that took place in a Spanish hospital
between 2009 and 2011 (Alvargonzalez et al., 2014). Finally, analysis of A. baumannii isolates 
from a Spanish hospital over 12 years showed that 60% of CRAB isolates harbored blaOXA-58­
like (Villalón et al., 2015).
In 2009, a novel class D beta-lactamase with carbapenemase activity was identified in 
Brazil and was called OXA-143 (Higgins et al., 2009). A variant of this enzyme, the OXA-182
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was detected among 12 CRAB isolates obtained from various Korean hospitals (Kim et al.,
2010). Two other variants of OXA-143 were detected in Brazil and Honduras and are OXA­
231 and OXA-253, respectively (Zander et al., 2014). OXA-253 was also identified in another 
clinical A. baumannii isolate from Brazil (Girlich et al., 2014). This family of OXAs does not
seem to be widely disseminated nor highly prevalent, to date. Nevertheless, one A. baumannii 
isolate was positive for OXA-143-like in a study that screened for the presence of A. baumannii
among environmental and foodstuff samples in Lebanon (Rafei et al., 2015a). Another novel 
family of OXAs has been identified in a study that investigated 10 A. baumannii strains from
USA and Mexico. This family includes the chromosomal or plasmid-borne OXA-235, OXA­
236, and OXA-237 carbapenemases (Higgins et al., 2013). However, no further reports
regarding the prevalence of these enzymes among A. baumannii isolates seem to exist. OXA­
48-like is another carbapenem hydrolyzing family whose prevalence is mainly reported among
Enterobacteriaceae. However, one A. baumannii isolate obtained from a fecal sample of a
nursing home resident in Portugal was shown to be positive for this enzyme (Nowak and
Paluchowska, 2016). Nevertheless, the prevalence of this enzyme among A. baumannii isolates
seems to be very limited. OXAs, as presented above, are widely disseminated all over the globe 
and pose a real threat to the continued use of carbapenems in the treatment of A. baumannii 
infections. Moreover, their associations with mobile genetic elements facilitates their transfer 
in between clones and further complicates the global antibiotic resistance problem that we are 
facing nowadays. The distribution of oxacillinases across the different countries in the world
are shown in Table 3.
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Table 3. Distribution of Acquired Oxacillinases across the Globe.
OXA-23-like OXA-24-like OXA-58-like OXA-143-like OXA-235-like OXA-48
Algeria Algeria Algeria Brazil Mexico Portugal
Australia Bahrain China Honduras USA
Bahrain Belgium Croatia Lebanon
Belgium Brazil Egypt South Korea
Brazil Bulgaria Finland
Canada China France
China Colombia Germany
Croatia Croatia Greece
Egypt Egypt Italy
Finland Finland Lebanon
France France Serbia
Germany Iran Singapore
Greece Japan Spain
Iran Kuwait Taiwan
Iraq Lebanon Tunisia
Italy Lithuania Turkey
Japan Oman USA
Kuwait Poland
Latvia Portugal
Lebanon Qatar
Libya Saudi Arabia
Madagascar Serbia
New Caledonia Singapore
Nigeria South Korea
Oman Spain
Poland Sweden
Portugal Taiwan
Qatar Turkey
Réunion island UAE
Saudi Arabia USA
Scotland
Senegal
Serbia
South Africa
South Korea
Spain
Sweden
Tahiti
Thailand
Turkey
UAE
USA
Vietnam
4.2.2.1.4. In-vitro Detection of Beta-Lactamases
Due to the large dissemination and importance on clinical outcome of beta-lactamases,
numerous laboratory techniques have been developed for their detection. The following section
will discuss the different methods available for the detection of these enzymes, with emphasis 
on the detection of carbapenemases. The presence of ESBL among clinical isolates could be
detected by the double disk synergy test. In this test, the “keyhole effect” resulting from the
increase of the inhibition zone of ceftazidime, cefotaxime, and/or aztreonam disks after the
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action of clavulanic acid indicates the presence of ESBL (Uzunović et al., 2016). Over­
expression of AmpC could also be phenotypically detected by the use of boronic acid or 
cloxacillin as inhibitors of this enzyme. An increase in the inhibition zone of ceftazidime or
cefoxitin disks after the addition of these agents is indicative of AmpC over-production
(Reuland et al., 2014). “Blunting” of the inhibition zones of ceftazidime and/or cefotaxime
while in proximity of a cefoxitin disk could also be indicative of over-expression of AmpC
(Bhattacharjee et al., 2008). Several phenotypic tests have been developed for the detection of 
the different types of carbapenemases. These include a screening for carbapenemases
performed by the modified Hodge test. In this test, the visualization of a “clover leaf” in the 
inhibition zone of carbapenem disks where the tested isolate is streaked indicates 
carbapenemase production (Ouertani et al., 2016). KPCs could be phenotypically detected by
the increase of the inhibition zones of imipenem and/or meropenem disks after the addition of 
phenylboronic acid (PBA), its chelator. Similarly, MBLs could be detected by the addition of 
their chelator, ethylenediaminetetraacetic (EDTA) to carbapenem disks (Tsakris et al., 2010). 
Another test for the phenotypic detection of MBLs is the use of double disk synergy tests and 
E-test MBL strips (bioMeriéux, France) that utilize the chelating property of EDTA (Yan et 
al., 2004). Moreover, a four-fold increase in the MIC as detected by broth dilution methods or
E-test strips after the addition of NaCl to the medium could be indicative of OXA production 
(Pournaras et al., 2006). 
Biochemical tests have also been developed for the detection of carbapenemases among
A. baumannii isolates. These tests include the CarbAcineto NP test (bioMeriéux, France) which
detects a change in pH resulting from the carbapenemase activity of the tested isolate (Dortet
et al., 2014). Another colorimetric test that detects changes in pH after carbapenem hydrolysis 
is the Rapid CARB Blue Kit (Rosco Diagnostica, Denmark). This test is able to phenotypically
detect the presence of several carbapenemases directly from bacterial cultures (Pires et al.,
2013). Ultra violet spectrophotometry for the measurement of the breakdown of imipenem
when incubated with sonicated overnight bacterial cultures could also be used for the detection 
of carbapenemases. However, this technique did not show adequate detection of NDM and
OXAs (Bonnin et al., 2012). The detection of the breakdown of imipenem after the
identification of the carbapenemases and their metabolites using MALDI-TOF MS could also 
be used to detect carbapenem hydrolyzing enzymes. This method, though requiring expensive 
equipment, was shown to be rapid and highly effective at detecting carbapenemases (Kempf et
al., 2012a). 
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Despite the several phenotypic and biochemical tests developed for the detection of 
carbapenemases, molecular methods remain the golden standard. Numerous singleplex PCRs
(for the detection of single genes) and multiplex PCRs (for the detection of several genes at 
once) have been developed for the detection of all known carbapenemase genes (Nowak and
Paluchowska, 2016). Another molecular technique that could also be applied for the detection
of carbapenemases is Real-Time, or quantitative qPCR. In this technique, DNA dyes are 
applied to reaction mixtures similar to those of PCRs and are used for the detection and
quantification of the amplified gene after each cycle of amplification. One study has shown the
effective detection and quantification of almost all carbapenemase genes identified in A. 
baumannii in just two assays (Pasanen et al., 2014). The Loop-Mediated Isothermal 
Amplification (LAMP) assay is another technique that could be applied for the detection of 
carbapenemases. This technique is similar to PCR but does not require a change in temperatures
for each amplification step. Additionally, a polymerase with high replication and strand
displacement activities is used (Nagamine et al., 2002). In this technique, six different primers
targeting eight different regions of the target gene are incubated with the other needed reagents 
for around an hour under constant temperature conditions. The amplification of the target gene 
would then occur in a specific and intense manner, to the point where amplification could be
detected by the naked eye through visualizing turbidity in the tube. Amplicons could also be 
detected by spectrophotometric measurements, gel electrophoresis and even in real time if 
DNA dyes are added to the mixture (Solanki et al., 2013). DNA microarrays that depend on 
the hybridization of DNA from a nucleic acid sample to oligonucleotide probes fixed on a solid
surface is another technique employed for detecting carbapenemases. The presence of a large
number of genes could be simultaneously, rapidly, and accurately tested for using this 
technique (Dally et al., 2013). Finally, Next-Generation Sequencing (NGS) is a technique that
could provide a wealth of information regarding the bacterial isolates. NGS not only could 
detect carbapenemase genes, but it also reveals the entire genetic makeup of the cell and is 
being increasingly used in the epidemiological investigation of health care-associated 
outbreaks (Kanamori et al., 2015). The choice of which of these techniques to apply will always 
have to depend on the aim, availability of funds and equipment, and the required accuracy,
speed, and efficiency of the study. 
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4.2.2.2. Aminoglycoside Modifying Enzymes
Aminoglycoside Modifying Enzymes (AMEs) convey resistance to aminoglycosides
through the enzymatic modification of the amino or hydroxyl groups of these antimicrobial 
agents. This would result in a poor binding between aminoglycosides and ribosomes and would 
allow the survival of bacterial isolates despite their presence in the cell (Vakulenko, and
Mobashery, 2003). AMEs found in A. baumannii include the Aminoglycoside 
Acetyltransferases (AAC), Phosphoryltransferases (APH), and Adenyltransferases (ANT) 
(Zavascki et al., 2010). The genes that code for these enzyme include aac(6')-Ih, aac(3)-Ia,
aac(3)-IIa, aac(6')-Ib, aph(3')-Ia, and aph(3')-VI that could be incorporated into mobile genetic 
elements and co-exist with each other (Nowak et al., 2014). Studies reporting the frequency of 
AMEs among A. baumannii clinical isolates are, relatively, not very common. 97% of the 
amikacin-resistant A. baumannii isolates obtained from 75 military and civilian patients in a 
medical center in USA were positive for the APH gene aphA6. Moreover, the ANT genes 
aadA1 and aadB and the AAC genes aacC1 and aacC2 were detected in 39%, 48%, 56%, and
5% of these isolates, respectively (Hujer et al., 2006). A study that investigated 12 A.
baumannii strains that are representatives of a clone circulating in Europe, in addition to four
strains obtained from Belgium, showed that all these isolates harbored the aphA6 and aadB
genes (Huys et al., 2005). Another study investigating 106 MDR A. baumannii isolates
obtained from several European countries showed that 84% had more than one gene coding for
AMEs. Seventy six of these isolates were positive for aphA1, 55 for aphA6, 68 for aadA1, 31 
for aadB, 68 for aacC1, 7 for aacC2, and 3 for aacC4 (Nemec et al., 2004). In South Korea, 
out of 56 Acinetobacter spp. isolates, aac(6')-Ib was detected in 52, aph(3')-Ia in 31, and 
aph(3')-VI in 12 isolates (Sung et al. 2011). Another study showed that 8 A. baumannii isolates
of veterinary origin pertaining to the same clone were all found to have the aadA1, aacC1, and
aacC2 genes (Endimiani et al., 2011). 
A study from Algeria investigating 71 A. baumannii clinical isolates showed that
aph(3')-VI was present in 50.7%, aadA in 63.4%, ant(2″)-I in 14.1%, aac(3)-Ia in 91.1%, and 
aac(6')-Ib in 4.2% of the isolates (Bakour et al., 2013). In Iran, one study showed that more
than 60% of 60 A. baumannii isolates harbored both aphA6 and aacC1, 41.7% harbored aadA1, 
3.3% harbored aadB, and 21.7% harbored aphA6, aadA1, and aacC1 (Moniri et al., 2010).
Another study from Iran showed that the most prevalent AME gene was aph(3')-VIa where it 
was detected in 90.6% of 75 A. baumannii clinical isolates (Aghazadeh et al., 2013). A study
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from Venezuela showed that three out of seven amikacin resistant A. baumannii isolates had
the aph(3')-VIa gene (Salazar De Vegas et al., 2007). An early study from Spain showed that
all three types of AMEs were detected among 54 A. baumannii isolates. Moreover, the AME 
coded by aph(3')-VI was the most prevalent where it was detected in 28% of the isolates (Vila 
et al., 1993). Another study from northern Spain showed a predominance of the aph(3')-VI
gene among amikacin-resistant A. baumannii isolates. Moreover, the activity of the ANT(2”)
and AAC(6’)-Ib was detected among 70 A. baumannii clinical isolates in this study (Gallego
and Towner, 2001). A study in Australia between 2000 and 2010 determined the presence of 
aphA1b, aphA6, aadB, and aacC1 co-existing in different combinations in all the 
aminoglycoside-resistant A. baumannii isolates obtained (Nigro et al., 2011). Nevertheless, 
several studies have concluded that there isn’t always a correlation between the detection of 
these genes and the susceptibility profile of the isolate (Aghazadeh et al., 2013; Salazar De 
Vegas et al., 2007; Nemec et al., 2004; and Nowak et al., 2014). This could explain the scarcity 
of studies investigating the prevalence of these isolates in A. baumannii.
4.3. Resistance to Colistin 
The wide dissemination of CRAB isolates all over the world and the lack of 
development of new antimicrobial agents have forced clinicians to revert to the use of colistin,
despite its nephrotoxic effects (Cai et al., 2012). Colistin has shown very good activity against 
MDR A. baumannii isolates, further encouraging its use in the treatment of these organisms (Li
et al., 2006). The increased use of colistin as last-line therapy for infections with CRAB isolates
led to the inevitable rise in resistance to this antimicrobial agent. Moreover, resistance to 
colistin among A. baumannii isolates is accompanied by a co-resistance to innate cationic 
antimicrobial compounds that are produced by the host (Napier et al., 2013). The mechanisms
of resistance to colistin are not yet fully understood but several different mutations in the A. 
baumannii genome have been shown to lead to colistin resistance. The common factor between
all these mutations is the reduction of the net negative charge of the outer membrane which 
impedes the interaction between colistin and the bacterial cell (Olaitan et al., 2014). Mutations 
in the first three genes that are involved in the synthesis of Lipid A have been found to lead to 
resistance to colistin. These genes are lpxA, lpxC, and lpxD, and mutations in them would result 
in the complete loss of LPS production and deprive colistin of its target (Moffat et al., 2010). 
Moreover, transcriptomic analysis by high-throughput RNA sequencing of colistin-sensitive 
and colistin-resistant A. baumannii isolates showed the involvement of six genes in colistin 
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resistance. These genes are all involved in LPS biosynthesis or electrostatic changes in the
bacterial cells. They include the three genes of the pmrCAB operon and genes coding for a 
poly-β-1,6-N-acetylglucosamine deacetylase, a glycosyltransferase, and a putative membrane 
protein. Moreover, all the colistin-resistant isolates in this study were found to have a modified
structure of Lipid A mediated by the addition of phosphoethanolamine (Park et al., 2015). 
Nevertheless, the most frequently reported cause of colistin resistance in A. baumannii is a 
wide array of mutations in the pmrCAB operon (Olaitan et al., 2014).
The pmrCAB operon codes for a two-component response regulator and sensor kinase 
system called pmrA/B. These enzymes respond to environmental change in Fe3+ and Mg2+ 
levels and are involved in modifications of Lipid A through pmrC, which codes for a
phosphoethanolamine transferase (Arroyo et al., 2011). Mutations in pmrB are the most
frequent mutations reported among clinical colistin-resistant A. baumannii isolates (Olaitan et 
al., 2014). Specifically, a P233S mutation in pmrB is commonly reported to lead to colistin 
resistance (Pournaras et al., 2014; Kim et al., 2014; Beceiro et al., 2011; and Adams et al., 
2009). This activating mutation in pmrB falls within the histidine kinase domain and is 
involved in dimerization (Durante-Mangoni et al., 2015). Moreover, over-expression of pmrA
and pmrB was found to lead to colistin resistance (Park et al., 2011). The down-regulation of 
these genes was also found to reverse the modifications in Lipid A and colistin resistance 
(Harris et al., 2014). This shows that the pmrCAB operon is a key factor in acquired resistance 
to colistin. 
A. baumannii has been shown to be able to develop in-vitro resistance to colistin upon
exposure to this antimicrobial agent (Tan et al., 2007). Colistin resistance in A. baumannii is 
normally reported in isolated sporadic cases in regions all over the world (Cai et al., 2012).
Surveillance studies indicate that, although A. baumannii isolates that are resistant to colistin
are usually PDR, their incidence is relatively rare (Falagas and Bliziotis, 2007). However, this 
could be due to the fact that MIC determination by broth dilution techniques, which are 
considered as the golden standard for testing for this resistance, are not routinely applied in all 
laboratories (Hindler and Humphries, 2013). Nevertheless, infection with colistin-resistant 
PDR isolates is associated with high mortality rates and these isolates deserve special attention 
(Falagas et al., 2008). The first colistin-resistant A. baumannii isolate was reported in the Czech 
Republic in 1999 (Cai et al., 2012). In 2005, another colistin-resistant A. baumannii clinical 
isolate was reported from South Korea. However, after further investigation, 15 out of 16
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studied isolates developed heteroresistance to colistin. Colistin heteroresistance was henceforth 
defined as the emergence of resistance through a sub-population from an otherwise susceptible 
population (Li et al., 2006). Heteroresistance has usually a higher rate than that of resistance
but its detection is laborious and requires special equipment. Therefore, detection of 
heteroresistance is not routinely performed in all laboratories (Cai et al., 2012). One study 
investigating heteroresistance among clinical A. baumannii isolates showed that although all
75 isolates studied showed sensitivity to colistin, 14 of them showed heteroresistance to this
antimicrobial agent (Herrera et al., 2011). Another study from Argentina showed that 46.4%
of 28 isolates obtained from ICU patients were heteroresistant to colistin (Rodriguez et al.,
2009). Yet another study from Argentina showed that 6 out of 14 A. baumannii isolates were 
heteroresistant to this antimicrobial agent (Rodriguez et al., 2010). In Brazil, 26 out of 29
randomly selected CRAB isolates showed heteroresistance to polymyxin B (Barin et al., 2013).
Furthermore, a surveillance study from the western Pacific region showed that, of the 30 A.
baumannii isolates obtained from various countries, one was resistant to colistin and seven 
showed heteroresistance (Yau et al., 2009).
A study across two hospitals in South Korea showed that 18.1% of 214 clinical A.
baumannii isolates were resistant to polymyxin B and 27.9% were resistant to colistin (Ko et 
al., 2007). Another study in Iran showed that 14.2% of 91 A. baumannii isolates were resistant
to colistin (Bahador et al., 2013). In USA, half of 28 XDR A. baumannii isolates longitudinally
recovered during colistin therapy were shown to be colistin-resistant (Lesho et al., 2013). In
Malaysia, 25.9% of clinical A. baumannii isolates collected from a tertiary care center were 
resistant to polymyxin B (Lean et al., 2014). A surveillance study across European countries
reported a rate of colistin resistance among A. baumannii isolates of 2.7% (Souli et al., 2008).
A study from Bulgaria investigating 18 A. baumannii clinical isolates showed that 3 of these
isolates were resistant to colistin (Dobrewski et al., 2006). Although rates of colistin resistance
are reported to be low in most studies around the world, several Spanish studies have reported
an alarmingly high rate of resistance to this antimicrobial agent. In one Spanish study, colistin 
resistance was detected in 19.1% of 115 A. baumannii isolates (Arroyo et al., 2005). Another
study from Spain over six years showed that 40.67% out of 150 A. baumannii isolates were
resistant to colistin (Arroyo et al., 2008). Additionally, an outbreak affecting 12 patients in a 
tertiary care center in Spain that lasted for around one year was shown to be caused by colistin­
resistant PDR A. baumannii strains (Valencia et al., 2009). Finally, it is worth mentioning the
recently discovered plasmid-borne mcr-1 gene that conveys resistance to colistin. This gene 
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has been detected among a large number of Gram-negative organisms isolated from all over 
the world. It has even been detected through retrospective studies in isolates obtained in the 
1980s (Skov and Monnet, 2016). However, to date, this gene has not yet been identified in A.
baumannii (Thi Khanh Nhu et al., 2016).
5. GLOBAL EPIDEMIOLOGY OF RESISTANT Acinetobacter baumannii
Advances in molecular biology have allowed the investigation of the clonality of MDR
A. baumannii isolates and their tracking all throughout the world. The strengths and weaknesses
of some of the most commonly used molecular techniques in clonality analysis, as well as the 
global dissemination of MDR A. baumannii clones, will be discussed in the following sections. 
5.1. Common Molecular Tools Used for Epidemiological Studies
These molecular tools used for epidemiological studies range from unspecific 
amplification of the different segments of the DNA to whole-genome sequencing. Random
Amplified Polymorphic DNA (RAPD) analysis is a fast molecular tool that could be used in
order to determine clonality. This technique has been developed in the early 1990s and has 
been extensively used since then in the differentiation of bacterial clones (Sharma et al., 2002).
In this PCR-based technique, random 10-mer primers are used that selectively amplify different 
DNA segments depending on their ability to anneal to- and trigger the amplification of- each 
fraction of the chromosome (Williams et al., 1990). Low annealing temperatures are usually
used in this technique and the amplified segments would then be run on agarose gels and
visualized. The Single Nucleotide Polymorphisms (SNPs) present in the chromosome will
result in the amplification of a unique clone-specific pattern (Hsueh et al., 1998). This
technique has proven to be a powerful typing method that is fast and cheap to implement. It
produces specific patterns of amplicons that could allow for the determination of clonality 
without the need of prior knowledge of the nucleotide sequence. However, the results heavily
depend on the type of primers used and inter-laboratory comparison of results is not possible 
without the physical exchange of the strains’ DNA (Mbawna et al., 2006).
Another technique that allows for the detection of clonality, with a higher
discriminatory power than RAPD, is Pulsed Field Gel Electrophoresis (PFGE) (Mbawna et al.,
2006). In this technique, the whole genome of the tested strain is digested by a RE which
generates a unique DNA fingerprint for each clone. The DNA segments are then run on an
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agarose gel using a Contour-Clamped Homogeneous Electric Field (CHEF) apparatus which 
generates alternating currents in different directions. This would result in a high resolution 
image of DNA bands of different sizes that could be analyzed by imaging software. Then, 
specific patterns obtained are assigned to a specific clone (Seifert et al., 2005). PFGE has
several advantages that include a high rate of reproducibility, a high discriminatory power, and 
not requiring prior knowledge of the genomic sequences. However, it is a laborious and time­
consuming technique and interpretation of the patterns may vary according to the person 
performing the experiment. Moreover, inter-laboratory comparison of results is often not 
possible without the physical exchange of the bacterial isolates (Kjeldsen et al., 2015). 
In 2007, a simple and fast method for the detection of clonality was developed by 
Turton et al., (2007). This method exploits the SNPs present in three housekeeping genes in 
the A. baumannii genome, allowing for the differential amplification of the different alleles 
present in different clones. Two sets of primers divided among two multiplex PCRs were
developed that were targeted at the intrinsic OmpA, CsuE, and blaOXA-51-like genes. The primers 
were designed in such a manner that they would amplify different combinations of alleles in 
the different multiplex PCRs and would generate a specific pattern of amplified genes. Once
the pattern has been associated with a certain clone through further investigation, other 
laboratories could allocate their isolates to one of these clones and determine the international 
clonality of their strains by the use of these PCRs (Turton et al., 2007). Fourteen different 
amplification patterns have been allocated to International Clones (ICs), the most widely 
disseminated of which are IC I, IC II, and IC III. The patterns of groups 1, 2, and 3 identified 
using this method were found to pertain to IC II, IC I, and IC III, respectively (Karah et al., 
2012). This technique is fast, simple, and does not require complicated machinery nor
expensive material. Moreover, it allows for the comparison of the isolates on a world-wide
scale, in addition to the local determination of clonality. Nevertheless, since it targets only three
genes, it does not provide a high discriminatory power for subdivisions among clones.
Additionally, not all the clones could be detected by the identified patterns and characterization 
of new patterns needs to be done before being able to rely on their multiplex PCR profile
(Martins et al., 2016). 
Multi-Locus Sequence Typing (MLST) is yet another technique used in the
identification of clonality that produces data that is comparable on a world-wide scale 
(Hamouda et al., 2010). This technique is based on the comparison of the sequences of seven
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housekeeping genes that, in turn, generate a profile that allows for the determination of 
clonality. The generated profiles could then be uploaded to online databases, allowing for the
comparison and determination of clonality on a local and international level (Karah et al.,
2012). Two MLST schemes have been developed for A. baumannii. The first is called the 
Oxford, or Bartual, scheme and is based on the sequencing of gltA, gyrB, gdhB, recA, cpn60, 
gpi, and rpoD (Bartual et al., 2005). The second scheme is called the Pasteur scheme and relies
on the sequencing of gltA, recA, cpn60, fusA, pyrG, rpoB, and rplB (Diancourt et al., 2010).
Both schemes were shown to yield comparable results. However, the Oxford scheme has been
shown to have a higher resolution than the Pasteur scheme (Grosso et al., 2011). The 
determined clones are often referred to as Sequence Types (STs) and from here onwards, the
superscript “O” will be used to indicate that the MLST data was obtained using the Oxford
scheme and “P” will indicate the use of the Pasteur scheme. Moreover, Clonal Complexes (CCs) 
is an MLST-based nomenclature used to describe a group of STs that share the same sequences 
of 5 or 6 out of the 7 housekeeping genes (Karah et al., 2012). MLST is highly advantageous 
in terms of exchangeability of data on a world-wide scale and relative ease of performing it.
However, sequencing services may not be readily available in all laboratories, the two different
schemes may result in some confusion when comparing the data, and its resolution is limited 
to the seven genes. Moreover, using this method as a basic epidemiological tool could be time 
consuming as compared to other methods (Pobeiga et al., 2013). 
One high-throughput alternative to MLST is Whole-Genome Sequencing (WGS). This
technique provides a complete record of the isolates’ genome and allows the tracking of all the 
genetic changes taking place. WGS is being used in epidemiological studies and provides
highly accurate information that could be the definitive form of clonality analysis (Harris et 
al., 2010). WGS is undoubtedly a very powerful analytical tool that has numerous advantages
that include the comparability of data worldwide, the wealth of information provided, and the 
accuracy of the data. However, this method is very expensive to be implicated in routine 
laboratory testing and requires access to next generation sequencers, which are not readily 
available to all laboratories. Moreover, the assembly algorithms used, as well as the annotation 
pipelines chosen, could result in discrepancies of reported data between different laboratories.
Finally, the prolonged times needed for the assembly and analysis of the vast amount of data
obtained from genomes could be time consuming and overwhelming if a large number of 
isolates is to be analyzed (Kwong et al., 2015). 
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5.2. Worldwide Dissemination of Multi-Drug Resistant A. baumannii Clones
There are several MDR A. baumannii clones that are more widely disseminated than 
others. International Clones I, II, and III are the most commonly reported from all over the 
world (Karah et al., 2012). These clones were previously called European clones since they
were first identified in European countries. However, their increased detection in countries all 
around the world resulted in the change of their name to International Clones (Diancourt et al., 
2010). Although these three ICs are the most widely disseminated, other international clones
have also been shown to be prevalent in certain regions. Studies have shown that most A.
baumannii infections caused all over the world are caused by a few ancestrally related clones. 
One such study investigating the clonality of 496 A. baumannii isolates from all over the world 
showed that 283 non-sporadic strains pertained to only 26 clones. Of the 26 clones, 18 were
disseminated in more than one continent, 6 were restricted to Europe, and 2 restricted to Asia 
(Karah et al., 2012). This shows the success of certain clones to persist and disseminate cross
vast regions.
In the aforementioned study, CC92B/CC2P was found to be by far the most widely
disseminated clonal complex. It was detected in 34 countries spread across the five continents 
(Karah et al., 2012). This clonal complex is very similar to IC II and STs within this complex
are considered as pertaining to this IC (Hamouda et al., 2010). IC II is implicated in numerous
MDR A. baumannii outbreaks and is commonly reported to harbor a wide array of resistance
mechanisms, which include production of OXA-23-like, OXA-24-like, and/or OXA-58-like.
Additionally, though some carbapenem-sensitive isolates belonging to IC II have been 
reported, strains pertaining to this clone are almost always MDR (Karah et al., 2012). Different 
pulsotypes, as detected by PFGE, could be found among MDR isolates pertaining to IC II. This 
is probably due to the different selection pressures in different regions (Nemec et al., 2004).
Additionally, PDR A. baumannii isolates resistant to colistin (Park et al., 2010) and to colistin
and polymyxin B (Park et al., 2009) were reported to pertain to this clone.
An intercontinental study showed that MDR A. baumannii isolates harboring blaOXA-23­
like obtained from three different continents pertained to IC II and that these isolates had similar 
PFGE patterns (Mugnier et al., 2010). In another study, A. baumannii isolates pertaining to IC
II were detected in Singapore, China, Portugal, Spain, Belgium, Italy, Greece, United 
Kingdom, and USA (Zarrilli et al., 2013). IC II was found to be widely disseminated in China, 
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where it was detected in both carbapenem-resistant and carbapenem-sensitive isolates. 86.8%
of the CRAB isolates obtained from 16 different Chinese cities pertained to this clone and were
positive for OXA-23-like. However, not all the strains belonging to IC II had the same
pulsotype (Fu et al., 2010). Another study from China showed that 72 CRAB isolates belonged
to this clone but had at least three different pulsotypes (Ho et al., 2010). In western China, 36
representative A. baumannii isolates obtained from ten hospitals were all found to belong to IC 
II (He et al., 2011). A study from Japan investigating 79 A. baumannii isolates collected from
2001 to 2012 also showed a predominance of ST2P (Suzuki et al., 2014). Another study from
this country showed that eight A. baumannii isolates obtained between 2004 and 2013 had a
similar pulsotype and pertained to ST2P (Yamada et al., 2016). Moreover, an MBL-positive A. 
baumannii isolate obtained from Taiwan was found to pertain to this clone (Zarrilli et al., 
2013). In South Korea, a large outbreak of OXA-23-like-positive CRAB strains pertaining to 
CC92B was reported in 2008 (Lee et al., 2011). A study in the Miami area in USA showed that 
14% of 144 CRAB isolates collected from 1994 to 2011 pertained to ST2P (Munoz-Price et al., 
2013). Moreover, 12 A. baumannii isolates pertaining to IC II were responsible for an outbreak 
that took place in Los Angeles (Warner et al., 2016). Additionally, though this clone is not pre­
dominant in Brazil, it was detected for a limited time in this country (Martins et al., 2013). 
A study from Kenya showed that 8 out of 16 selected CRAB isolates pertained to IC II
(Revathi et al., 2013). In South Africa, the presence of IC II among CRAB isolates was detected 
although it wasn’t the pre-dominant clone in that country (Lowings et al., 2015). IC II was also
detected among 15 A. baumannii isolates that were representative of 117 CRAB strains
obtained from Saudi Arabia, Oman, Qatar, United Arab Emirates, Bahrain, and Kuwait
(Zowawi et al., 2015). In the Kurdistan region in Iraq, IC II was found to be predominant
among ACB isolates (Ganjo et al., 2016). In Iran, 36 out of 62 A. baumannii isolated pertained
to IC II (Bahador et al., 2015) and 22 of 98 A. baumannii isolates were found to belong to IC
II in Turkey (Metan et al., 2013). A study that involved several Mediterranean countries
showed that isolates pertaining to IC II were identified from two hospitals in Italy and three 
hospitals from Greece (Giannouli et al., 2009). Another study investigating 35 MDR A.
baumannii isolates from Mediterranean countries showed that IC II is present in Italy, Greece, 
and Lebanon (Di Popolo et al., 2011). In Lebanon, a study investigating 42 A. baumannii 
isolates collected from different hospitals showed a predominance of IC II, where it was 
detected in 34 of these isolates (Rafei et al., 2014a). Another study from northern Lebanon
analyzing 57 randomly selected A. baumannii isolates also showed that IC II is the most
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prevalent (Rafei et al., 2014b). Yet another Lebanese study investigating isolates obtained from
livestock animals showed that one out of five CRAB isolates pertained to IC II (Al Bayssari et 
al., 2015). Interestingly, a study from Switzerland also showed the prevalence of this clone 
among A. baumannii isolates obtained from pets and horses (Endimiani et al., 2011). 
IC II has also been reported to be widely disseminated in Europe. Similarly to what was 
reported in China, a study from Norway showed that isolates pertaining to this clone had several
discreet pulsotypes (Karah et al., 2011a). Sixteen out of 28 CRAB isolates obtained over a one
year period pertained to IC II in Sweden (Karah et al., 2016). In Greece, CRAB isolates
pertaining to IC II have been reported on several occasions (Zarrilli et al., 2013). IC II was also 
shown to be the predominant clone in a study that investigated 26 distinct outbreaks in 24
hospitals spread across Sweden, Poland, Germany, and Turkey (Tomaschek et al., 2016). In
Croatia, 19% of 150 A. baumannii isolates pertained to IC II, all of which were carbapenem­
resistant (Vranić-Ladavac et al., 2014). An outbreak caused by 30 A. baumannii isolates, most 
of which pertained to IC II, was reported between 2008 and 2009 in Latvia (Saule et al., 2013). 
Moreover, investigation of 28 CRAB isolates obtained from Serbia showed that 67.68% of 
them pertained to IC II (Novovic et al., 2015). In Italy, a multi-center study showed that 95.6% 
of MDR A. baumannii isolates obtained from ICUs between 2005 and 2009 pertained to IC II. 
Moreover, these strains showed genetic similarity to the OXA-58-like positive strain that 
previously caused outbreaks across several ICUs in Rome (D'Arezzo et al., 2011). Another
study from Italy showed that, although all 30 A. baumannii isolates investigated pertained to
IC II, there seems to be a shift from harboring blaOXA-58-like to harboring blaOXA-23-like among
those clonally related strains (Minandri et al., 2012). More recently, an outbreak caused by a
strain pertaining to IC II was also reported from northeast Italy (Milan et al., 2016). A study 
across 15 German medical centers showed that only 32% of 140 A. baumannii isolates
belonged to ICs, 34 of which pertained to IC II (Schleicher et al., 2013). Another study from
Germany showed that the majority of CRAB isolates collected over four years pertained to IC
II, although they were of different sequence types (Rieber et al., 2016). In Portugal, ST92B and 
closely related single-locus variants, all pertaining to IC II, were found to be endemic in the 
country (Manageiro et al., 2012). Another study from southern Poland also showed the high
prevalence of IC II where it was detected in 79 out of 125 A. baumannii isolates (Chmielarczyk 
et al., 2016). In Spain, an OXA-23-like positive strain belonging to IC II was responsible for 
an outbreak in Barcelona that affected 17 patients and lasted from October 2010 to May 2011
(Mosqueda et al., 2013). Another study from Spain investigating 405 ACB isolates showed
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that 60% of these isolates belonged to IC II (Villalón et al., 2015). Moreover, comparison of 
A. baumannii isolates over a ten-year period in Spain showed that IC II is still the predominant
clone nowadays (Garnacho-Montero et al., 2016).
Another widely disseminated clonal complex that was detected in 31 countries all over 
the world is CC109B/CC1P (Karah et al., 2012). This complex was found to be closely related 
to IC I and isolates within it are considered as such (Evans et al., 2008). MDR A. baumannii 
isolates pertaining to this clone harboring blaVIM-4, blaOXA-23-like, and/or blaOXA-58-like have been
reported from different studies around the world (Karah et al., 2012). CRAB isolates belonging
to IC I were detected from Greece, Germany, Belgium, United Kingdom, France, Czech 
Republic, Turkey, Algeria, Iraq, South Korea, China, India, Brazil, USA, Bangladesh,
Singapore, and Taiwan (Zarrilli et al., 2013). Another study that investigated A. baumannii
isolates from all around the world identified isolates pertaining to IC I from India, Greece, Iraq, 
Czech Republic, Romania, Norway, Sweden, France, Germany, USA, and Canada (Karah et 
al., 2015). In Japan, although a predominance of IC II was shown, three A. baumannii strains 
collected over eleven years pertained to IC I (Suzuki et al., 2014). IC I was also detected in 
USA among soldiers that were wounded during the conflicts in Iraq (Huang et al., 2012).
Twenty clonally related A. baumannii isolates pertaining to IC I were also responsible for an
outbreak in Los Angeles, USA (Warner et al., 2016). IC I is also reported to be one of the pre­
dominant clones in Brazil (Martins et al., 2016), certain regions of Argentina (Stietz et al.,
2013), and South Africa (Lowings et al., 2015). This clone was also detected in 29% of 62 A.
baumannii strains in Iran (Bahador et al., 2015) and 18 of 98 A. baumannii strains in Turkey 
(Metan et al., 2013). Additionally, in one study involving several Mediterranean countries, 
strains belonging to IC I were identified from Greece, Italy, and Lebanon (Giannouli et al., 
2009). In another Mediterranean study, IC I was present among CRAB isolates obtained from
Italy and Greece (Di Popolo et al., 2011). In Lebanon, seventeen A. baumannii isolates 
pertaining to IC I and positive for OXA-58-like were responsible for an outbreak in a Lebanese
hospital (Zarrilli et al., 2008). Moreover, A. baumannii isolates pertaining to IC I were detected 
in 12 out of 57 isolates obtained from north Lebanon (Rafei et al., 2014b). 
Six strains pertaining to IC I were involved in outbreaks as reported by a study 
investigating 78 outbreak-related strains from Germany, Sweden, Poland, and Turkey 
(Tomaschek et al., 2016). In Croatia, although a predominance of IC II was shown among
CRAB isolates, IC I was highly prevalent among 185 A. baumannii isolates, without
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necessarily being carbapenem-resistant (Vranić-Ladavac et al., 2014). In Serbia, only one out 
of 28 CRAB isolates pertained to IC I (Novovic et al., 2015) whereas a study from a Belgian
burn center reported that ten A. baumannii strains obtained from patients wounded in North
Africa were XDR and pertained to IC I (De Vos et al., 2016). In a study from Germany, 6 out 
of 45 isolates that were grouped into clones belonged to IC I (Schleicher et al., 2013).
Moreover, this clone was detected among A. baumannii isolated from pets and horses in a study
from Switzerland (Endimiani et al., 2011). ST-81P, which is closely related to IC I and is
considered as such, was detected in northern Spain in 10.2% of 729 A. baumannii isolates 
collected from 12 Spanish hospitals. Nevertheless, this clone was only detected between 1999
and 2002 and seems to disappear in subsequent years, as reported by this eleven-year study
(Villalón et al., 2011).
CC187B/CC3P is another widely disseminated clonal complex that is considered as IC 
III. This clone has been detected in several European countries such as France, Germany,
Netherlands, Italy, Spain, and Belgium, in addition to USA and Lebanon (Karah et al., 2012). 
MDR A. baumannii isolates pertaining to this clone have been reported to harbor blaOXA-58-like
(Diancourt et al., 2010). In USA, this clone was detected among wounded soldiers returning
from Iraq (Huang et al., 2012). IC III was also detected among representative CRAB isolates
obtained from Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, and Bahrain 
(Zowawi et al., 2015). A clone pertaining to IC III, which was negative for all tested 
carbapenemases, was also identified in Beirut, Lebanon (Giannouli et al., 2009). In another
study in that country, one sporadic isolate detected in a Lebanese hospital was found to belong 
to IC III (Zarrilli et al., 2008). Yet another study from Lebanon showed that CRAB isolates
obtained from four patients pertained to this clone (Di Popolo et al., 2011). Sporadic A.
baumannii isolates pertaining to IC III were also detected from north Lebanon in two separate 
studies (Rafei et al., 2014a; Rafei et al., 2014b). In Serbia, seven CRAB isolates obtained over 
two years were found to belong to IC III (Novovic et al., 2015) while in Spain 26.7% of 405 
ACB isolates pertained to IC III (Villalón et al., 2015). Another study that lasted for 11 years
across 19 Spanish hospitals showed that 5.1% of 729 A. baumannii isolates belonged to IC III
(Villalón et al., 2011). This clone, though detected in various countries around the world, was 
shown to have a limited intra-clonal diversity that could indicate a relatively short-term
existence (Karah et al., 2012).
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ST25P is another well-established international clone that has been reported for around
25 years (Di Nocera et al., 2011). MDR A. baumannii isolates pertaining to ST25P have been
reported to be positive for OXA-23-like, OXA-24-like, and/or OXA-58-like (Bonnin et al.,
2011c). One study showed that ST25P is present among A. baumannii isolates originating from
Thailand, Colombia, Argentina, USA, Iraq, United Arab Emirates, Serbia, Sweden,
Netherlands, Greece, and Italy (Karah et al., 2015). Isolates pertaining to ST25P were also
reported from Spain, Italy, Croatia, Taiwan, South Korea, China, and Brazil in another study 
(Zarrilli et al., 2013). Yet another study showed the presence of this clone in Turkey, Greece,
Italy, Netherlands, Singapore, and USA (Karah et al., 2012). A Mediterranean study also
showed that this clone is present in Italy, Greece, and Turkey (Di Popolo et al., 2011). ST25P 
was also detected among two outbreak-related A. baumannii strains in a study that spanned
across 24 hospitals located in Germany, Poland, Turkey, and Sweden (Tomaschek et al., 2016).
Moreover, a recent study in Sweden showed that 7 out of 28 CRAB isolates pertained to this 
sequence type (Karah et al., 2016). ST25P was also found to be widely disseminated in Brazil 
and is considered as one of the major clones circulating in that country (Martins et al., 2016).
Additionally, investigation of 16 CRAB isolates in east Africa reported the presence of this ST 
among these isolates (Revathi et al., 2013). Another study across several Lebanese hospitals 
showed that 3 out of 42 two A. baumannii isolates pertained to ST25P (Rafei et al., 2014a). A 
study from north Lebanon also showed the presence of this clone among six randomly selected
A. baumannii isolates (Rafei et al., 2014b). 
A less widely disseminated clonal complex is CC131B/ST79P. A. baumannii isolates
harboring blaOXA-23-like, and/or blaOXA-58-like have been reported within this clonal complex
(Villalón et al., 2011). A study from USA showed that ST79P represented 76% of A. baumannii 
isolates collected over eighteen years, making it the most prevalent in that country (Munoz-
Price et al., 2013). Moreover, this clone was also found to be pre-dominant in Brazil (Martins
et al., 2016) and Argentina (Stietz et al., 2013). ST79P was also described in Spain and
represented 13.6% of 729 A. baumannii isolates (Villalón et al., 2011). CC104B/CC15P is yet 
another international clonal complex that was detected in 9 countries spread across Europe and 
South America. MDR isolates of this clone were reported to harbor armA, blaOXA-23-like, and/or
blaOXA-58-like (Grosso et al., 2011). An eleven-year study from Spain showed that 1.7% of 729
A. baumannii isolates pertained to this clonal complex (Villalón et al., 2011). Moreover, 6.7% 
of 405 ACB isolates were found to pertain to this sequence type in another study from Spain
(Villalón et al., 2015). A. baumannii isolates pertaining to ST15P are reported to be among the
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major clones disseminated in Brazil (Martins et al., 2016) and the second most prevalent in 
Argentina (Stietz et al., 2013). In Turkey, this clone also seems to be predominant where 41 of 
98 A. baumannii isolates were found to pertain to it (Metan et al., 2013). One isolate of this
clone was also reported in Norway from an imported case from Pakistan (Karah et al., 2011a). 
CC20B is another an international clone which harbors MDR A. baumannii isolates 
producing OXA-23-like and ArmA (Fu et al., 2010). Isolates pertaining to ST20P were detected 
in USA (Karah et al., 2015) and in one CRAB isolate obtained from livestock animals in
Lebanon (Al Bayssari et al., 2015). A. baumannii isolates pertaining to yet another international 
clone called CC110B were detected in Korea, Argentina, and USA. The isolate obtained from
Korea was also resistant to colistin (Park et al., 2010). This clone was also detected among
CRAB isolates obtained from Italy and Lebanon (Di Popolo et al., 2011). CC32P is another 
clone that was detected in several European countries that include Denmark, Sweden, Portugal 
and Spain (Karah et al., 2012). In Spain, 1.7% of 729 A. baumannii isolates pertained to this 
clone (Villalón et al., 2011). Moreover, one CRAB isolate pertaining to this clone was found
to be positive for IMP-5 in a study from Portugal (Da Silva et al., 2010). Additionally, this 
clone was detected in Italy, North Korea, Japan, Singapore, China, India, and Brazil (Zarrilli
et al., 2013).
Some MDR A. baumannii strains pertaining to STs that are limited in geographical 
distribution have caused noteworthy outbreaks and have important clinical significance. One 
such strain is the blaOXA-58-like harboring A. baumannii strain belonging to ST78P that caused an
outbreak lasting for two years in Italy (Giannouli et al., 2010). Another strain belonging to this 
ST was found to be positive for CTX-M and OXA-24-like and was prevalent in the Miami area
in USA. ST229P is another clone that was detected in USA and represented 10% of 144 CRAB
isolates (Munoz-Price et al., 2013). ST96B is another clinically significant strain that caused an 
outbreak in Honk Kong and was positive for OXA-23-like (Ho et al., 2010). Moreover, an A. 
baumannii strain pertaining to ST56B caused an outbreak that started in 2006 and lasted for 
more than 30 months. This outbreak is among the largest to be reported in the literature where
it affected 337 patients in a hospital in Madrid, Spain (Acosta et al., 2011). Moreover, this 
clone was found to be among the predominant clones in a study that assessed the changes in A. 
baumannii infections over a ten-year period in Spain (Garnacho-Montero et al., 2016). Another 
MDR clone that has shown its ability to be transmitted across several Spanish hospitals is 
ST80P. In one study, this clone was detected in 6.7% of 405 ACB isolates collected over 12
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years from a Spanish hospital (Villalón et al., 2015). In another study, this clone was detected
in 20.3% of 729 epidemic strains isolated from 12 Spanish hospitals over an 11-year period
(Villalón et al., 2011). The ST94P clone is a bit more disseminated across countries and was
detected among isolates obtained from India, Iraq, and USA (Karah et al., 2015). Moreover, a 
CRAB isolate pertaining to ST103P that was isolated from a patient transferred from Egypt to
Germany was found to be positive for NDM-2 (Kaase et al., 2011). Other clinically significant
MDR A. baumannii clones include ST115B, ST125B, and ST134B, which are positive for OXA­
23-like, and the CTX-M-15-positive ST117P and ST118P (Karah et al., 2012). As is presented 
above, numerous MDR A. baumannii clones were able to disseminate into wide geographical 
regions and persist for prolonged periods of time. This could be due to an interplay between 
the genetic plasticity of this organism (Antunes et al., 2014) and the different selective
pressures exerted on it (Nemec et al., 2004). These factors give rise to these successful clones
that are capable of wide dissemination and prolonged persistence. Additionally, the 
international dissemination of these clones could be enhanced by the increase in international 
travel and the interchange of patients on a global scale (Peleg et al., 2008). The global spread
of clinically important clones are demonstrated in Figure 6.
Figure 6. Global dissemination of clinically important clones. The Dots within each country are not meant for 
geographical accuracy but are a graphical representation of which clones were reported from that country.
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5.3. Current Global Rates of Resistant Acinetobacter baumannii
MDR, XDR, and even PDR Acinetobacter baumannii isolates are disseminated all 
around the globe, regardless of their ancestral lineage. In a recent worldwide survey
investigating 1,235 A. baumannii isolates obtained from integumentary sources from 2010 to
2014, the rate of MDR isolates was shown to be 43%. Moreover, this rate was shown to increase 
from 29% in 2011 to 56% in 2014. More specifically, resistance to meropenem increased over
these four years from 41% to 63%. The highest rates of resistance were reported from Latin
America (63%) and the Middle East (62%) whereas the lowest rate (33%) was reported from
North America (Tärnberg et al., 2016). Another study that evaluated 1,011 clinical A. 
baumannii isolates obtained from intra-abdominal and urinary tract infections from 48
countries between 2013 and 2014 also showed a regional variation in MDR rates. The highest 
MDR rate exceeded 93% and was detected in Europe and the Middle East, whereas the lowest 
rate (47%) was also detected in North America. MDR rates in Asia, Africa, and Latin America
ranged from 77% to 87%. Moreover, this study showed that susceptibility rates to imipenem
in Europe and the Middle East was below 11% (Lob et al., 2016). Yet another global
surveillance study that included 1,312 clinical A. baumannii isolates obtained from USA, Latin
America, Asia Pacific, Europe, and the Mediterranean regions showed that 81.6% of these
isolates were MDR (Flamm et al., 2016). 
In USA, 50% of combatants injured in conflicts abroad were found to be infected by 
MDR organisms, of which A. baumannii was very notable, especially among those returning
from Iraq (Yun and Murray, 2016). Another study from a hospital in Los Angeles detected 21
MDR A. baumannii isolates over one year, only eight of which were sensitive to imipenem and
two to meropenem (El-Shazly, et al., 2015). In Miami, a study that spanned from 1994 to 2011
showed that the rate of carbapenem resistance was increasing and that the overall rate of 
carbapenem non-susceptibility among 4,484 A. baumannii isolates was 18.9% (Munoz-Price
et al., 2013). In Brazil, 118 clinical A. baumannii isolates collected between 2010 and 2013
from patients hospitalized for a minimum of 72 hours were resistant to carbapenems (Cortivo
et al., 2015). A review study evaluating reports of MDR A. baumannii isolates in Latin America 
from 2002 to 2013 showed that resistance rates to carbapenems ranged from 37% to 92%,
depending on the country. This review also showed a high increase in carbapenem non­
susceptibility in this region between the years 2006 and 2009. Moreover, countries such as
Nicaragua, Bolivia, Dominican Republic, El Salvador, and Honduras showed generally lower
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rates of resistance. On the other hand, Brazil, Argentina, Colombia, Guatemala, Cuba, Panama,
Paraguay and Mexico showed generally higher rates of resistance (Labarca et al., 2016). 
In South Korea, 92 MDR A. baumannii isolates were collected over a five-year period 
from one hospital. All these isolates were then shown to be positive for OXA-23-like (Sung et
al., 2016). A Chinese national survey of bloodstream infections showed that the overall
prevalence of XDR A. baumannii isolates over one year was 13.7%. Of note, 97.4% of these
isolates were resistant to imipenem (Xu et al., 2016). In Japan, 49 MDR A. baumannii isolates
were obtained from 12 hospitals distributed all across the country between July and December
2012 (Tada et al., 2014). A study from 2004 to 2011 covering 33 medical centers spread across
Middle Eastern and African countries showed that 51.3% and 33.2% of 664 A. baumannii
isolates were resistant to imipenem and meropenem, respectively (Kanj et al., 2014). Another 
study evaluating 411 ACB isolates from 14 European and Mediterranean countries showed that
the resistance rate to doripenem was 58.9% (Castanheira, et al., 2014). A study that investigated 
35 representative A. baumannii isolates obtained from 28 outbreaks that took place in Greece,
Turkey, Italy, and Lebanon showed that all these isolates were MDR (Di Popolo et al., 2011).
In South Africa, 86% of 94 A. baumannii isolates obtained from different clinical samples over 
three months were resistant to carbapenems and 90% were resistant to fourth generation 
cephalosporins (Lowings et al., 2015). In a one-year study from Libya, 20% of organisms that
caused 79 cases of device-associated nosocomial infections were A. baumannii, and 56.3% of 
those isolates were MDR (Zorgani et al., 2015). 
In Lebanon, an early study investigating 36 Acinetobacter spp. isolates obtained in a 10 
month period showed that only one of these isolates was resistant to imipenem (Matar et al.,
1992). For many years after this study, reports on MDR A. baumannii isolates on a national
level were limited to a few scattered studies analyzing individual outbreaks (Salem et al., 
2013). Recently, however, the global increased interest in MDR A. baumannii has triggered 
several reports from Lebanon on these isolates. One study showed an increase in incidence of
MDR A. baumannii isolates from 73.5% in 2005 to 77.7% in 2009 among in- and out- patients 
in a Lebanese hospital. Susceptibility to imipenem was shown to decrease from 92.3% in 2006 
to 30% in 2009 in that same study (Hamouche and Sarkis, 2012). Moreover, susceptibility to
imipenem in a study from a tertiary care center in Beirut was 65% among 64 consecutive
clinical Acinetobacter spp. samples (Araj and Ibrahim, 2008). Another study analyzing 42 A. 
baumannii isolates obtained between 2009 and 2012 from different Lebanese hospitals showed
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that 31 of these isolates were resistant to carbapenems (Rafei et al., 2014a). Additionally, 88%
of 724 A baumannii isolates obtained from 9 Lebanese hospitals during 2012 were also shown
to be resistant to imipenem (Hammoudi et al., 2015a). Another multi-center study conducted 
in north Lebanon, where there is a concentration of Syrian refugees, showed that of the 116
isolates collected over two years, 70 were resistant to carbapenems (Rafei et al., 2015b). 
Moreover, a study involving two hospitals from north Lebanon showed the presence of NDM­
1 and OXA-72 among two Acinetobacter pittii isolates (Al Atrouni et al., 2016b). A 
retrospective study involving 257 patients between 2012 and 2013 in a Lebanese tertiary care
center showed that the rate of XDR A. baumannii was 15.6% (Moghnieh et al., 2016). Finally,
a multi-center study across Lebanon and Jordan from 2011 to 2013 showed a disturbing rate of 
resistance among A. baumannii isolates were susceptibility to various antimicrobial agents 
ranged from 4% to 27% (Hayajneh et al., 2015).
One study that spanned 24 hospitals across Turkey, Germany, Sweden, and Poland over 
six years showed that 84 out of 298 clinical A. baumannii isolates were resistant to carbapenems
(Tomaschek et al., 2016). Another study conducted in 39 centers spread across Italy, France, 
Germany, Spain, and the UK showed that susceptibility of A. baumannii was below 90% in 
Italy, Spain, and the UK (Rodloff et al., 2008). Moreover, CRAB isolates detected from two
medical centers in a Turkish study were shown to increase in frequency from 20% to 60% over 
six years (Gur et al., 2008). In Germany, 70 A. baumannii isolates that were resistant to 
carbapenems were collected over four years from a diagnostic laboratory (Rieber et al., 2016).
A comparative study from that same country showed that the rate of CRAB isolates across 15 
medical centers decreased from 96% in 2005 to 76% in 2009 (Schleicher et al., 2013). A study
from southern Poland showed that 80.8% of 125 clinical A. baumannii isolates obtained over
a year were XDR (Chmielarczyk et al., 2016). Another study that spanned across 22 Italian
hospitals showed an increase in the incidence of CRAB isolates from 120 in 2004-2005 to 190 
in 2008-2009 (Mezzatesta et al., 2012). In Hungary, CRAB isolates from one hospital were
shown to dramatically increase in incidence from 6.2% in 2000 to 73% in 2011 (Mózes et al., 
2014). A study from London showed a relatively low rate of CRAB isolates. Nevertheless, 
their incidence increased from 9.1% of 11 isolates in 2011 to 31.2% of 16 in 2013 (Hughes et 
al., 2016). 
The rate of MDR A. baumannii isolates in Spain is notoriously higher than other
European countries (Tomaschek et al., 2016). Surveillance programs in this country have
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shown that worrisome rates of MDR pathogens in the ICU still pose an unresolved problem. 
This, in turn, has recently triggered the launching of national programs aimed at tackling this 
problem (Montero et al., 2015). The issue in this country is further compounded by the lack of
uniformity in applying infection control measures in the hospitals (Garcia-Ortega et al., 2011). 
One study across 25 Spanish hospitals showed that 43% of A. baumannii isolated from 203
patients were resistant to carbapenems (Cisneros et al., 2005). Moreover, in a similar study, 
phenotypic heterogeneous resistance to imipenem was found to be 20% and that of meropenem
was 24% (Fernández Cuenca et al., 2012). A retrospective survey over six years, in which 246
Spanish hospitals per year participated, showed that the average rate of CRAB isolates was 
34.5% and that in ICUs it was 43.8% (Asensio et al., 2008). Additionally, nineteen PDR A.
baumannii isolates that are resistant to all antimicrobial agents, including colistin, where 
collected during an outbreak from a Spanish hospital over around one year (Valencia et al.,
2009). In another study from a Spanish tertiary care center, 61 non-duplicate A. baumannii 
clinical isolates collected over six years were PDR (Arroyo et al., 2009). Moreover, in a study
that investigated representative samples of 729 epidemic A. baumannii isolates obtained from
19 Spanish hospitals over ten years showed that they were all MDR (Villalón et al., 2013).
Another study that investigated the mechanisms of resistance of clinical A. baumannii isolates 
showed the presence of 101 CRAB isolates from a total of 493 isolates obtained from two
Spanish multi-center studies (Mosqueda et al., 2014). A cohort study that compared A.
baumannii isolates obtained ten years apart from several Spanish hospitals showed that the rate 
of susceptibility to imipenem dropped from 33.8% in 2000 to 17.3% in 2010 (Villar et al.,
2014). Moreover, three sequential outbreaks caused by MDR A. baumannii isolates were 
reported from a Spanish hospital. The first outbreak was in 2009 and it affected 38 ICU patients. 
The second and third outbreaks were between 2010 and 2011 and they affected 9 and 11
patients, respectively (Alvargonzalez et al., 2014). Finally, analysis of 405 A. baumannii
isolates collected over eleven years from a Spanish tertiary care hospital showed that 64.7% of 
these isolates were susceptible to carbapenems. 231 of the total isolates obtained formed 15
clonally related groups that were all XDR (Villalón et al., 2015).
6. RELATIONSHIP BETWEEN VIRULENCE AND RESISTANCE
The key factor that causes success of certain clones in terms of dissemination and
persistence is their ability to out-compete other strains in the highly stressful environment that 
is the human body. This environment acts as a bottleneck that allows only the clones that have 
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a certain balance of virulence factors and resistance mechanisms to survive (Martínez and 
Baquero, 2002). Moreover, different virulence factors were shown to be expressed by different 
MDR A. baumannii clones, suggesting an interplay between virulence and resistance (Antunes 
et al., 2011). The differential expression of virulence was also shown to affect mortality with 
different levels (Antunes et al., 2014). The relationship between bacterial virulence, antibiotic
resistance, and fitness will be discussed in this final section.
6.1. Effects of Resistance on Bacterial Fitness and Virulence
The common factor between bacterial mechanisms of resistance and those of virulence
is that they are both needed for the bacterium’s survival. Mechanisms of resistance are crucial 
for overcoming the antimicrobial threat whereas mechanisms of virulence are necessary for 
overcoming the host defense systems (Beceiro et al., 2013). Genes coding virulence and 
resistance could both be disseminated through horizontal gene transfer between organisms,
while sometimes being co-selected for (Burrus and Waldor, 2004). Both these factors have an 
effect on bacterial fitness and the ability of bacteria to grow and divide. The interaction between
resistance, virulence, and fitness seems to be complex and highly dependent on an intricate
balance that would allow certain clones to survive. Moreover, this relationship seems to be
dependent on the species being studied and associations made in one species may not hold true 
for another (Beceiro et al., 2013). 
The involvement of certain cellular components in various metabolic processes is 
bound to result in an interplay between them. One such example is the involvement of porins 
in the uptake of nutrients needed by bacterial cells (Nikaido, 2003), resistance to antimicrobial 
agents (Sugawara and Nikaido, 2012), formation of biofilms (Gaddy et al., 2009), and the 
induction of cell death (Peleg et al., 2008). Down-regulation of porins resulting from antibiotic 
pressure could have an effect on the other mechanisms in which these molecules are involved. 
This was indeed shown to be the case in a PDR A. baumannii isolate having the CarO and
OprD-like porins downregulated. These porins were downregulated in order to convey 
resistance to carbapenems. However, this also resulted in slower growth and attenuated 
virulence of the clone (Fernandez-Cuenca et al., 2011). Production of biofilms is another 
example of the interaction between virulence and resistance. Biofilms are considered as
virulence factors that protect bacteria from eradication and lead to their persistence. However,
biofilms also have a role in antimicrobial resistance since the sequestered bacterial cells will 
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be protected from the action of antibiotics (Patel, 2005). In addition, two-component systems
that respond to environmental changes are also implicated in the regulation of both resistance
and virulence. These systems could act as global regulators that would affect the bacterium’s
metabolism, virulence, and antimicrobial resistance at the same time (Yeung et al., 2011). One 
such example in A. baumannii is the response to high NaCl concentrations in the environment
through the increased production of efflux pumps and the release of outer membrane proteins.
The increase in efflux pumps would in turn lead to resistance to several antimicrobial agents 
while the release of outer membrane proteins would contribute to an increased virulence (Hood 
et al., 2010).
Resistance to antimicrobial agents has been reported to have varying effects on
virulence and bacterial fitness that depends on the mechanism, organism, and even the specific 
strain being investigated (Beceiro et al., 2013). A study investigating changes in pmrA/B in
Salmonella enterica with reduced susceptibility to colistin showed that mutations in pmrA
resulted in a reduced in-vitro fitness, although in-vivo growth rates were not affected (Sun et 
al., 2009). Another study in Escherichia coli showed that the acquisition of certain beta­
lactamases, such as OXA-10 and OXA-24 incurred a fitness cost on the strains and resulted in
reduced virulence by inducing changes in the peptidoglycan layer (Fernández et al., 2012). 
Over-expression of AmpC in Salmonella enterica was also shown to result in reduced fitness,
although no changes in the peptidoglycan layer were detected (Morosini et al., 2000). 
Acquisition of resistance to vancomycin in Staphylococcus aureus through the vanA operon, 
which results in alteration of the target of this antimicrobial agent, was also shown to incur a
great fitness cost on the bacterial cell (Foucault et al., 2009). Other resistance mechanisms
seem to not have any effect on bacterial virulence nor fitness. For instance, high level resistance 
to aminoglycosides mediated by methyltransferases seem to not have an effect on bacterial 
fitness in E. coli (Gutierrez et al., 2012). The acquisition of CTX-M-1, TEM-1, and CTX-M­
32 in E. coli (Dubois et al., 2009; Fernández et al., 2012) and IMP in P. aeruginosa (Aoki et
al., 2004) also seem to not affect the virulence of these organisms. Nevertheless, the effect on
virulence and fitness resulting from the acquisition of beta-lactamases has not been vigorously 
investigated and therefore no global conclusions could be made (Beceiro et al, 2013).
Although it is generally thought that resistance to antimicrobial agents incurs a 
biological cost, some studies have shown increased fitness and virulence of highly resistant
bacteria. Several reasons have been attributed to this phenomenon. One reason is the activation
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of the SOS system as a result of the action of antimicrobial agents. This response would in turn
accelerate the spread and exchange of genetic material, which could harbor genes of resistance 
and virulence, among the bacterial population. As a result, certain strains that have
simultaneously acquired several mechanisms of resistance and virulence could emerge (Ubeda 
et al., 2007). Another mechanism described in E. coli which results in resistant and virulent
strains is the accumulation of alarmones which leads to increased biofilm formation and
tolerance to beta-lactams (Joseleau-Petit et al., 1994). Finally, mobile genetic elements, such 
as plasmids, could carry genes coding for virulence and resistance at the same time. The
acquisition of such elements by bacterial organisms could result in highly resistant and virulent 
strains (Woodford et al., 2009). One example of highly MDR and virulent organisms is E. coli 
strain ST131 which was found to express a wide array of virulence factors in addition to being
positive for NDM-1 (Peirano et al., 2011). Another example is the so called “Liverpool
Epidemic Strain”, a MDR P. aeruginosa strain which has enhanced virulence. This strain was
isolated from cystic fibrosis patients and was found to be resistant to beta-lactams and 
aminoglycosides through the up-regulation of efflux pumps. The over-expressed efflux pumps 
also enhanced the spreading of quorum-sensing molecules that activate several virulence 
mechanism and resulted in an overall enhanced virulence of the strain (Maeda et al., 2012). 
Numerous resistance mechanisms were found to incur a biological cost on the bacterial
cell. However, some strains were found to be able to compensate for this cost and persist, even 
in the absence of antibiotic stress (Andersson and Hughes, 2011). Three major mechanisms
have been proposed as to how bacteria compensate for their resistance. The first is through the 
direct restoration of efficiency of a certain molecule through mutations that revert its negative 
effect on fitness. The second is the replacement of the function that was affected by another
similar function in the cellular metabolic processes. And the third is the reduction in the need 
for a specific function that was affected by resistance (Andersson and Hughes, 2010). These 
compensatory mechanisms could not only lead to the persistence of highly resistant and 
virulent strains, but to actually select for them through the elimination of competing organisms
(Beceiro et al., 2013). The threat of MDR and virulent strains is so great that some researchers 
have proposed the restriction of the use of antimicrobial agents in an attempt to eradicate these 
organisms (Andersson and Levin, 1999). This, along with the fact that the development of new 
antimicrobial agents has almost halted since the 1990s, has led researchers to investigating 
molecules that could have anti-virulence effects (Livermore, 2011). This research is aimed at 
targeting virulence mechanisms of bacteria while administering antibiotic therapy in an attempt 
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to decrease the selective pressure and prevent the emergence of resistance (Rasko and 
Sperandio, 2010). Along these lines, rifampin, an antimicrobial agent that has shown little to
no effect on A. baumannii in terms of inhibition of growth, was able to attenuate the cellular 
damage mediated by MDR and PDR A. baumannii strains (Smani et al., 2011).
Proanthocyanidins are another class of molecules that has been successfully used in the clinical 
practice. These molecules act by binding to the filaments or fimbriae of E. coli and therefore 
prevent successful adherence and recurring urinary tract infections (Lavigne et al., 2011).
Development of new anti-virulence molecules to be used alongside antimicrobial agents could 
be a very promising strategy to combat MDR and/or virulent organisms in the future.
6.2. Biological Cost of Resistance in Acinetobacter baumannii
Several investigations have aimed at determining the biological cost exerted by specific
resistance mechanisms on A. baumannii. One such investigation was mentioned in the previous 
section where the down-regulation of the CarO and OprD-like porins results in slower growth 
and attenuated virulence of the A. baumannii strain (Fernandez-Cuenca et al., 2011). Resistance
to quinolones in A. baumannii through mutations in the topoisomerase and DNA gyrase genes 
was also shown to result in reduced fitness and virulence (Smani et al., 2012). Another study
investigating the effect of the loss of multi-drug efflux pumps on virulence in A. baumannii 
showed that the loss of these pumps would result in increased antibiotic susceptibility.
Additionally, the gained susceptibility was accompanied by a loss of virulence as demonstrated
in a mouse infection model. These findings indicate that increased antimicrobial resistance is 
associated with increased virulence in these strains (Roux et al., 2015). 
Although resistance to beta-lactams among A. baumannii isolates is of great 
importance, very few studies have investigated the impact of this resistance on virulence and
fitness (Beceiro et al., 2013). One study investigating the effect of the acquisition of PER-1 in
A. baumannii showed a positive correlation between the acquisition of this enzyme and cell 
adhesion (Sechi et al., 2004). The penicillin binding protein PBP 7-8, although shown to 
mediate resistance to beta-lactams in P. aeruginosa, was not concretely correlated with 
resistance to these antimicrobial agents in A. baumannii (Cayô et al., 2011). Nevertheless, it
was shown to play a role in the maintenance of cell morphology and survival of A. baumannii 
in infection models. Moreover, alterations in this molecule was found to have a negative effect
on virulence in this organism (Russo et al., 2009). The MDR A. baumannii strain pertaining to 
 
 
  
   
  
    
    
  
   
  
    
  
    
   
 
 
     
   
   
  
    
  
 
      
   
   
   
  
    
    
    
   
  
  
 
 
108
ST56B, which caused one of the largest reported outbreaks, was notorious for its heightened
ability of causing invasive infections. This strain was positive for OXA-24-like and
additionally harbored a plasmid coding for the TonB-dependent receptor, which is involved in 
iron uptake, and the toxin septicolysin (Acosta et al., 2011). This shows that MDR A.
baumannii strains could also maintain their ability to be highly virulent. Another study 
investigating the relationship between the clonality of A. baumannii and virulence showed that
twitching motility is common among MDR isolates pertaining to IC I and strong biofilm
formers. Moreover, swarming motility was associated with isolates that did not pertain to any 
international clone (Eijkelkamp et al., 2011b). Recently, a fatal outbreak in USA, associated
with the death of the majority of infected patients, was shown to pertain to a clone that is 
distinct from the three widely disseminated ICs but similar to clones isolated in California,
Germany, and Czech Republic. This clone was MDR and showed enhanced virulence in terms
of iron metabolism, protein secretion, and glycosylation (Jones et al., 2015).
The effect of colistin resistance on the biological cost in A. baumannii has been
addressed by several studies. The two main mechanisms of colistin resistance that involve
alterations in LPS and Lipid A were shown to have different effects on the bacterial cell. This
is mainly due to the involvement of these molecules in several biological processes that include
pyrogenicity, toxicity, mitogenicity, and the induction of pro-inflammatory responses in the
host (Beceiro et al., 2013). Though not without exceptions, colistin resistance in A. baumannii 
was generally shown to greatly reduce fitness (Lesho et al., 2013). Induction of the complete 
loss of lipid A through in-vitro mutations in the lpx genes was shown to lead to colistin 
resistance in addition to an alteration in the antibiotic resistance profile. This alteration includes
a gained susceptibility to cefepime (Moffat et al., 2010). One clinical case demonstrated that 
an A. baumannii isolate that acquired resistance to colistin during therapy also gained 
susceptibility to cefepime and sulbactam (López-Rojas et al., 2011). Further investigation of 
this isolate showed that it had impaired ability to compete with a colistin sensitive isolate as
demonstrated by competition assays. Moreover, lower in-vivo fitness and virulence was
detected for this isolate (López-Rojas et al., 2013). Another case report from France showed
that a colistin-resistant isolate had reduced in-vivo fitness, lost its infectivity, and had attenuated
virulence (Rolain et al., 2011). Yet another clinical isolate resistant to colistin was shown to 
have impaired virulence and fitness as investigated by a rat pneumonia model (Hraiech et al.,
2013). 
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Resistance to colistin through mutations in the pmrCAB operon have also been shown 
to result in a fitness cost and impaired virulence (Olaitan et al, 2014). Specifically, the P233S
mutation in PmrB was shown to result in decreased invasiveness and growth retardation 
(Pournaras et al., 2014). Conversely, another study investigating colistin resistant A. baumannii
isolates with this same mutation reported that it had no effect on the bacterium in terms of 
fitness and virulence (Durante-Mangoni et al., 2015). Yet another study comparing the
biological cost of colistin resistance between the two main described mechanisms of colistin 
resistance showed that resistance to this antibimicrobial agent through mutations in pmrCAB
had very modest effects on fitness. On the other hand, resistance due to the loss of LPS after 
mutations in the lpx genes was found to incur a much greater biological cost on the bacterial 
cell (Beceiro et al., 2014). Another similar study showed that when colistin resistance is 
acquired through mutations in the lpx genes, a loss of virulence accompanied with 
susceptibility to other antimicrobial agents is observed. This study also showed that when 
resistance is acquired through mutations in pmrB, the mutants retained similar levels of 
virulence as compared to their parental strains (Wand et al., 2015). 
The plethora of resistance and virulence mechanisms found among A. baumannii strains
makes this bacterium a threat to be reckoned with. The wide dissemination of MDR clones, 
especially those showing enhanced virulence, cannot be ignored. Though numerous studies
have addressed this problematic organism, there is still a large amount of information that needs 
to be gathered if we are to one day be able to eradicate this organism from the clinical setting.
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VI. OBJECTIVES AND JUSTIFICATION
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OBJECTIVES AND JUSTIFICATION
Acinetobacter baumannii is a nosocomial opportunistic pathogen that is renowned for
its high capacity to develop resistance, produce virulence determinants, and persist in hospitals 
for prolonged periods of time. Several highly successful MDR clones have disseminated on a 
global scale and are associated with particular mechanisms of resistance. The wide 
dissemination of carbapenem resistant clones that render the use of this potent class of 
antimicrobial agents obsolete, is especially important. This led clinicians to revert to the use of 
colistin, despite its nephrotoxicity, and to the subsequent rise of colistin-resistant strains. 
Highly resistant A. baumannii clones have a detrimental effect on the survival of critically ill 
patients, especially those admitted to the intensive care units. Information about their 
dissemination in particular regions could be crucial for implementing adequate empirical 
therapies, which would have a great effect on patient outcome. In addition, numerous virulence 
factors are associated with clinical A. baumannii isolates but are found to be differentially
expressed among different isolates. Associations between the acquisition of resistance,
especially through beta-lactamases, and their effect on virulence are poorly investigated in A.
baumannii. For this reason, the knowledge of resistance rates and virulence profiles could 
positively affect treatment outcomes and will help in controlling the dissemination of MDR A.
baumannii clones.
The aim of this Doctoral Thesis is the epidemiological, phenotypic, and genotypic
characterization of clinical A. baumannii isolates in two Mediterranean countries in which the 
spread of MDR strains is notoriously high. Additionally, the interplay between certain
mechanisms of resistance and the expression of specific virulence factors will be investigated.
Furthermore, investigations on mechanisms of colistin resistance for two strains that developed 
resistance to this antimicrobial agent during therapy will be performed. Additionally, biofilm
formation patterns for selected isolates with different antimicrobial susceptibility profiles will
be investigated. This will provide clinicians, infection control specialists, and researchers with 
information that could be very valuable in combating this highly successful pathogen and
prevent the further emergence of antimicrobial resistance. In order to achieve the aim of the
study, the following specific objectives have been developed, to:
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- Collect clinical A. baumannii isolates from two hospitals, one of which is Hospital 
Universitario-La Paz, located in Madrid, Spain, and the other is Saint Georges Hospital-
University Medical Center in Beirut, Lebanon.
- Determine the identity of the isolates using both phenotypic and genotypic methods that 
include biochemical identification using 20NE API strips and the amplification of the
intrinsic blaOXA-51-like gene.
- Obtain the antibiotic susceptibility profiles of the isolates according to the CLSI 
guidelines.
- Detect the presence of beta-lactamase genes by PCR.
- Determine the clonality of the isolates using RAPD analysis, PFGE, and multiplex
PCRs that indicate their global lineage.
- Detect the presence of selected genes involved in virulence by PCR.
- Phenotypically detect hemolysis, biofilm formation, siderophore production, surface 
motility, and proteolytic activity of the isolates.
- Perform statistical analyses in order to determine associations between clonality, 
specific mechanisms of resistance, and the virulence factors that were tested for.
- Analyze the mechanisms of colistin resistance in two sets of isolates where resistance 
was acquired during therapy by sequencing the pmrCAB operon and whole-genome
sequencing.
- Determine the effect of colistin resistance on the aforementioned virulence factors.
- Investigate the biofilm formation patterns of selected isolates with varying profiles
through growth on steel coupons followed by confocal laser scanning microscopy.
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1. Phenotypic and Genotypic Characterization of Acinetobacter baumannii
Strains Isolated from a Spanish Hospital
1.1 Abstract
Acinetobacter baumannii is a nosocomial pathogen that is showing increasing rates of 
carbapenem resistance. Multi-Drug Resistant (MDR) International Clones (ICs), associated 
with the production of oxacillinases, are being reported globally. This organism also harbors 
numerous virulence factors. In this study, we aim at characterizing A. baumannii isolated from
a Spanish hospital over a 5 year period in terms of antimicrobial susceptibility, clonality,
carbapenemase genes harbored, and virulence factors expressed. Fifty nine clinical
bloodstream isolates were obtained from 2009 until 2013. Antimicrobial Susceptibility Testing
was performed according to the CLSI guidelines. PFGE and tri-locus PCR typing were then 
performed in order to determine local and international clonality. PCRs for the detection of
blaOXA-23-like, blaOXA-24-like, blaOXA-58-like, blaOXA-48, blaNDM, and blaKPC were also performed.
Production of hemolysis, biofilms, siderophores, surface motility, and proteolysis were 
determined phenotypically. Doubling times for selected strains were also calculated. Finally,
statistical analysis for detecting associations between the tested factors was conducted.
Carbapenem non-susceptibility was as high as 84.75%, suggesting the immediate need for 
intervention. PFGE showed the distribution of the majority of the isolates among 7 clusters.
Although all three ICs were detected, IC II was predominant at 71.19%. blaOXA-24-like was the 
most prevalent carbapenemase (62.71%), followed by blaOXA-58-like (13.56%), and blaOXA-23-like
(11.86%). Strains pertaining to IC II and those harboring blaOXA-24-like, were positively 
associated with α-hemolysis, production of strong biofilms, fast doubling times, and
siderophore production. Harboring blaOXA-23-like and blaOXA-58-like was associated with reduced
virulence, suggesting a lesser toll exerted by these genes on the cell as compared to blaOXA-24­
like. Moreover, weak proteolytic activity was associated with slower doubling times (p<0.05). 
These associations suggest that detection of clonality by two multiplex PCRs could be a
predictive factor for determining the level of virulence of these isolates. An alarmingly high 
rate of carbapenem non-susceptibility has been detected in this study. There was a
predominance of IC II and blaOXA-24-like and those factors were associated with heightened
virulence whereas strains belonging to IC I and IC III were shown to have attenuated virulence. 
This association could be exploited for modifying treatment regimens and for improving on 
infection control protocols.
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1.1. Resumen
Acinetobacter baumannii es un patógeno nosocomial que muestra tasas crecientes de
resistencia a carbapenemas a nivel mundial. Se han descrito cepas con resistencia a múltiples
clases de antibióticos, que pertenecen a clones internacionales y que llevan oxacilinasas. En
este estudio, nuestro objetivo es la caracterización de cepas de A. baumannii obtenidas de un 
hospital español durante 5 años en términos de antibiorresistencia, clonalidad, y factores de
virulencia. Cincuenta y nueve cepas se aislaron de la sangre de pacientes desde 2009 hasta 
2013 en el HU-LP. Se hicieron las pruebas de PFGE para el análisis de clonalidad local y PCR
multiplex para tres genes “housekeeping” para el análisis de clonalidad internacional. La
detección de blaOXA-23-like, blaOXA-24-like, blaOXA-58-like, blaOXA-48, blaNDM, y blaKPC se llevó a cabo 
mediante PCR. Se analizaron fenotípicamente la hemólisis, formación de biofilms, producción 
de sideróforos, motilidad de superficie, y actividad proteolítica. Posteriormente, se
determinaron los tiempos de generación de cepas seleccionadas y se hizo un análisis estadístico
para determinar posibles relaciones entre todos estos factores. El 84,75% de las cepas
analizadas no eran susceptibles a carbapenemas, sugiriendo una necesidad inmediata de
intervención. El análisis del PFGE resultó en la distribución de la mayoría de las cepas en 7
grupos. Se detectaron los tres clones internacionales más comunes, siendo el clon internacional 
II el predominante, representando el 71,19% de las cepas. El gen codificando una
carbapenemasa que se encontró con más frecuencia fue blaOXA-24-like (62,71%), seguida por 
blaOXA-58-like (13,56%), y blaOXA-23-like (11,86%). Las cepas que pertenecían al clon internacional
II y las cepas que llevaban blaOXA-24-like, se asociaron positivamente con hemólisis, producción 
de biofilms densos, tiempos de generación más rápidos, y producción de sideróforos. Los genes 
blaOXA-23-like y blaOXA-58-like se asociaron con reducción de la virulencia, sugiriendo que estas
enzimas pueden ser menos exigentes para las cepas en comparación con blaOXA-24-like. Además, 
la baja actividad proteolítica estaba asociada con tiempos de generación más lentos (p<0,05). 
El clon internacional II y blaOXA-24-like fueron predominantes entre estas cepas y se asociaron 
con una virulencia más alta en comparación con los otros clones y oxacilinasas. Se pueden 
utilizar estas asociaciones entre clonalidad, presencia de carbapenemasas y virulencia para 
mejorar el tratamiento y los protocolos de control de la infección.
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1.2. Introduction
Acinetobacter baumannii is an opportunistic nosocomial pathogen that has caused 
severe outbreaks all around the world (Fishbain and Peleg, 2010). Secondary infections with
A. baumannii could cause ventilator-associated pneumonia, burn wound infections, prosthetic­
related infections, and bacteremia (Gordon and Wareham, 2010). Infections with Multi-Drug
Resistant (MDR) A. baumannii isolates and improper empricial treatments increase mortality
rates among critically ill patients (Ñamendys-Silva et al., 2015). In addition to the wide array
of intrinsic mechanisms of antimicrobial resistance found in A. baumannii, this bacterium has 
a heightened ability of acquiring resistance (Peleg et al., 2008). 
Carbapenems have long been the treatment of choice for MDR A. baumannii. However,
rates of carbapenem resistance are increasing worldwide (Tärnberg et al., 2016). Mortality rates
associated with Carbapenem Resistant Acinetobacter baumannii (CRAB) isolates could reach
as high as 33% (Lemos et al., 2014). Numerous mechanisms of carbapenem resistance were 
identified in A. baumannii. However, Oxacillinases (OXAs), mainly OXA-23-like, OXA-24­
like, and OXA-58-like, are the most common cause of resistance to these antimicrobial agents
(Nowak and Paluchowska, 2016). Moreover, a few globally disseminated International Clones 
(ICs), that include IC I, IC II, and IC III, were found to be the most successful clones causing
outbreaks on a global scale (Karah et al., 2012). CRAB isolates from all three ICs are being 
reported from all around the world (Perez et al., 2010; Tomaschek et al., 2016). In Spain, a
notoriously high incidence of CRAB isolates, with a predominance of IC II, is found (Villalón
et al., 2011; Villalón et al., 2015). One study showed that imipenem resistance among A.
baumannii isolates from Spain increased from 74.2% in 2000 to 89.2% in 2010 (Villar et al., 
2014). A CRAB incidence rate of 43% among patients in Spanish Intensive Care Units (ICUs)
was reported from another study (Cisneros et al., 2005). Moreover, although blaOXA-23 was
reported in some strains (Merino et al., 2014), blaOXA-24 was found to be the predominant OXA 
in Spain (Tena et al., 2013). 
The pathogenicity of A. baumannii is not yet fully understood. However, several factors
have been associated with its virulence (Peleg et al., 2012). One such factor is OmpA which is 
able to bind to epithelial cells and induce eukaryotic cell death (Howard et al., 2012).
Moreover, CsuE, which is part of a chaperon-usher pili assembly system, is also involved in 
biofilm formation in this organism (Tomaras et al., 2003). Additionally, despite its
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classification as a non-motile organism, certain A. baumannii strains have shown twitching 
surface motility (Clemmer et al., 2011). Hemolysis on Sheep Blood Agar (SBA), exoprotease 
activity, and siderophore production were also reported among A. baumannii strains (Antunes
et al., 2011). A complex relationship seems to exist between virulence and antimicrobial
resistance. One study demonstrated reduced virulence after the acquisition of carbapenem
resistance through non-enzymatic means (Fernández-Cuenca et al., 2011). Another study
showed that the acquisition of the PER-1 beta-lactamase actually resulted in increased
virulence (Sechi et al., 2004). Nevertheless, despite the great importance of OXAs in clinical 
A. baumannii isolates, the effect of these enzymes on virulence is not vigorously investigated 
(Beceiro et al., 2013).
In this study, we aim at characterizing A. baumannii nosocomial isolates in terms of 
antimicrobial resistance, virulence determinants, prevalence of carbapenemases, and clonal 
relatedness. We also aim at investigating any association between these factors that could have
an impact on treatment of CRAB infections, in addition to the implementation of successful 
infection control measures. 
1.3. Materials and Methods
1.3.1. Bacterial Strains
Fifty nine consecutive non-repetitive bloodstream isolates were collected from different 
wards of Hospital Universitario-La Paz (HU-LP), Madrid, Spain in a time period spanning
from January 2009 until March 2013. Identification was done using Matrix Assisted Laser
Desorption Ionization - Time of Flight Mass Spectrometry (MALDI-TOF MS) (Bruker 
Daltonik GmbH) as previously described (Romero-Gomez et al., 2012), in addition to the 
detection of the blaOXA-51-like gene by PCR (Tourton et al., 2006). The strains were stored in
Luria-Bertani (LB) Broth with 20% glycerol at -20°C until used. Pseudomonas fluorescens
strain B52 (Richardson and Te Whaiti, 1978) was used as a positive control for surface motility,
siderophore production, and determination of proteolytic activity. This bacterium was
incubated at 30°C instead of 37°C whenever it was used.
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1.3.2. Antimicrobial Susceptibility Testing
Minimum Inhibitory Concentrations (MICs) were determined using Vitek2 with AST­
N-245 cards (BioMérieux Mercy l’Etoile, France). The antimicrobial agents used were
piperacillin (4-128 µg/mL), piperacillin/tazobactam (4/4-128/4 µg/mL), ticarcillin (4-128 
µg/mL), ampicillin/sulbactam (2/2-32/16 µg/mL), cefepime (1-64 µg/mL), ceftazidime (1-64
µg/mL), meropenem (0.25-16 µg/mL), imipenem (0.25-16 µg/mL), colistin (0.5-16 µg/mL),
amikacin (2-64 µg/mL), gentamicin (1-16 µg/mL), tobramycin (1-16 µg/mL), minocycline (1­
16 µg/mL), levofloxacin (0.12-8 µg/mL), ciprofloxacin (0.25-4 µg/mL), and
trimethoprim/sulfamethoxazole (1/19-16/304 µg/mL). E-tests (BioMérieux Mercy l’Etoile,
France) were performed for verification of colistin resistance. The MIC cutoff values were 
implemented according to the Clinical and Laboratory Standards Institute (CLSI, 2014)
guidelines and the results were accordingly reported as resistant, intermediately resistance, or 
susceptible. 
1.3.3. Polymerase Chain Reactions
PCRs were performed for the detection of the OmpA, CsuE, blaOXA-51-like, blaOXA-23-like, 
blaOXA-24-like, blaOXA-58-like, blaOXA-48, blaNDM, and blaKPC genes. The primers used, as well as
the annealing temperatures for each primer pair, are found in Supplementary Table S1. Positive 
controls were obtained for each gene from the clinical microbiology laboratory of HU-LP. One
third of all visualized bands were chosen randomly and sent to Secugen S. L. (Madrid, Spain)
for sequencing in order to verify the amplicon sequence. 
In order to determine the global lineage of the strains, two multiplex PCRs proposed by
Turton et al. (2007) that target specific alleles of the OmpA, CsuE, and blaOXA-51-like genes were
performed. The primers for each Multiplex PCR are listed in Supplementary Table S2. Using
a classification scheme summarized by Karah et al. (2012), the strains were classified as 
belonging to one out of 15 identified groups based on the combination of the different alleles
amplified. Group 1 of this scheme corresponds to IC II, Group 2 to IC I, and Group 3 to IC III
(Karah et al., 2012).
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1.3.4. Pulsed Field Gel Electrophoresis
Pulsed Field Gel Electrophoresis (PFGE) was performed using the ApaI restriction 
enzyme as previously described (Seifert et al., 2005). Restriction fragments were separated in 
1% agarose gels using the Contour-Clamped Homogeneous Electric Field (CHEF) apparatus 
(Bio-Rad, Munich, Germany). The visualized fragments were analyzed using the Bionumerix
software version 6.6 (Applied Maths, St-Martens-Latem, Belgium) and the dendrogram was
constructed using the Unweighted Pair Group Method with Arithmetic Mean (UPGMA) with 
1.5% tolerance and 1.5% optimization. 80% similarity was considered as the cutoff value for 
considering the generated pattern as pertaining to the same cluster.
1.3.5. Surface Motility
In order to detect surface motility, a single colony was grown overnight in LB at 37°C.
The following day, 1µL was plated on 0.3% LB-Agar (Difco, BD, USA) plates and incubated 
at 37°C for 14 hours. The motility rate was calculated as the diameter of the resulting circular 
pattern over time (Clemmer et al., 2011). This, and all subsequent experiments were performed
in independent triplicates.
1.3.6. Biofilm Formation
In order to detect biofilms, inoculation of 1mL LB broth in polystyrene tubes with one 
isolated colony was performed. The tubes were then incubated overnight at 37°C, stained with 
1% crystal violet for 10 minutes, washed with water, and left to dry (Tomaras et al., 2003).
Strong ring formations indicated by a heavy colorization at the liquid-air interface were 
reported as “++” while weak ring formations indicated by a very thin colorized ring were
reported as “+”. The absence of any colorization in the test tube was recorded as “-”.
1.3.7. Hemolytic Activity
In order to detect hemolytic activity, LB broth was inoculated with a single colony from 
the tested strain and incubated at 37°C overnight. The suspension was then adjusted to 106 
CFU/mL and 10µL was plated on 5% Sheep Blood Agar (SBA) (Biomérieux Mercy L’Etoile,
France). The plates were incubated at 37°C and observed for 6 days (Taybali et al., 2012).
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1.3.8. Proteolytic Activity
Proteolytic activity of the tested strains was determined as previously described 
(Antunes et al., 2011). One colony was incubated overnight in Trypticase Soy Broth Dyalisate 
overnight at 37°C with shaking at 200 rpm. The bacterial suspension was then centrifuged at
4000×g for 10 minutes and the supernatant was filter sterilized. 500µL of 1mg/mL Azoalbumin
solution dissolved in 50mM Tris-HCl (pH=7.7) was then incubated with 500µL of the
supernatant at 37°C for 24 hours with gentle shaking. Then, trichloroacetic acid was added to 
each tube with a final concentration of 13% and the tubes were incubated at -20°C for 20 
minutes. This was followed by centrifugation at 15,000×g for 10 minutes and measurement of 
the OD440 of the supernatant. U/L values were calculated as previously described (Ronca-
Testoni, 1983) where one U was defined as the amount of enzyme needed to degrade one 
micromole of Azoalbumin. 
1.3.9. Siderophore Production
For the determination of siderophore production, one colony was used to inoculate 5mL
of the PMS7-Ca medium. The suspension was then incubated for 72 hours with shaking at 200
rpm. Then, the suspensions were centrifuged at 4000×g for 10 minutes and the supernatant was 
filter sterilized. The Chrome Azurol Solution (CAS) was also prepared as described by Louden
et al. (2011). 1 mL of this solution was incubated with 1 mL of the filter sterilized supernatant 
for one hour and the OD630 was measured. Un-inoculated PMS7-Ca and CAS were used as a 
reference measurement and a 10% difference between the sample and the reference was 
considered as positive (Machuca et al., 2003). 
1.3.10. Growth Curves
Doubling times were calculated for representative strains from each cluster with
varying susceptibility profiles. 500µL from bacterial cultures grown overnight at 37°C in LB
broth were diluted in 50mL fresh LB broth. The suspension was then incubated at 37°C with
shaking at 200 rpm for 8 hours and the OD600 was measured, in duplicate, each hour (Hitachi, 
U-1900 Spectrophotometer, Tokyo, Japan). Doubling times were calculated from two
measurements that fall within the exponential phase (Hall et al., 2014). 
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1.3.11. Statistical Analysis
All statistical analyses were performed using the SPSS program, version 17.0 (SPSS 
111 Inc., Chicago, USA). The chi squared test and Fisher’s exact test (two sided) were used in 
order to analyze the qualitative data. Normal distribution of the quantitative data was tested for
using the Shapiro-Wilk test. One-way ANOVA and the student t-tests were performed for the 
comparison of normally distributed data while the Kruskal-Wallis and the Mann-Whitney tests
were used for the comparison of non-normally distributed data. P values of less than 0.05 were 
considered as statistically significant for all the statistical tests performed.
1.4. Results
1.4.1. Distribution of Bacterial Isolates
A total of 59 bloodstream A. baumannii isolates were obtained from HU-LP. Thirty 
(50.85%) of the isolates were collected in 2009, nine (15.25%) in 2010, five (8.47%) in 2011, 
eleven (18.65%) in 2012, and four (6.78%) in 2013. Twenty six (44.07%) of these isolates were
obtained from the ICU, 22 (37.29%) from the Critical Care Nursing Unit (CCNU), two (3.39%) 
from each of the Emergency (EM), Resuscitation (RE), and Internal Medicine (IM) wards, and
one (1.69%) from each of the Nephrology (NE), Hematology/Oncology (HO), Cardio/Thoracic 
(CT), General Surgery (GS), and Neonatal (NEO) wards. 
1.4.2. Antibiotic Susceptibility Profiles
Antibiotic susceptibility profiles were obtained by interpreting the Minimum Inhibitory 
Concentration (MIC) values according to CLSI guidelines (2014). Figure 1 shows the 
percentage of sensitivity, intermediate resistance, and resistance of the tested A. baumannii
isolates. The MIC values are found in Supplementary table S3. More than 80% of the isolates 
were non-sensitive to ticarcillin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam,
ceftazidime, ciprofloxacin, levofloxacin, and trimethoprim/sulfamethoxazole. 84.75% of the
isolates were non-susceptible to carbapenems, 79.66% to cefepime and 16.95% to minocycline. 
Non-susceptibility to aminoglycosides ranged from 18.64% for amikacin to 54.24% for
gentamycin. Only two isolates (3.39%) were resistant to colistin.
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Figure 1. Percentage of sensitive (blue), intermediately resistant (yellow), and resistant (red) isolates to the 
different antimicrobial agents. “TIC” stands for ticarcillin, “PIP” for piperacillin, “A/S” for ampicillin/sulbactam,
“P/T” for piperacillin/tazobactam, “CTZ” for ceftazidime, “CFP” for cefepime, “IMI” for imipenem, “MER” for 
meropenem, “COL” for colistin, “G” for gentamicin, “TO” for tobramycin, “AK” for amikacin, “MIN” for 
minocycline, “CIP” for ciprofloxacin, “LEV” levofloxacin, and “T/S” for trimethoprim/sulfamethoxazole.
1.4.3. Detection of Carbapenemases and Virulence Genes
The intrinsic blaOXA-51-like gene was detected in 56 (94.92%) of the isolates whereas
blaOXA-48, blaNDM, and blaKPC were not detected in any isolate. blaOXA-24-like was the most 
prevalent carbapenemase gene where it was detected in 37 (62.71%) isolates, followed by
blaOXA-58-like in 8 (13.56%) isolates, and blaOXA-23-like in 7 (11.86%) isolates. Isolate 50 harbored
both blaOXA-24-like and blaOXA-58-like. All the isolates were positive for OmpA while 57 strains
(96.61%) were positive for CsuE.
1.4.4. Clusters, Clones and Carbapenemases
PFGE was performed in order to determine the local clonality of the isolates. Tri-locus 
multiplex PCRs were then performed in order to determine the global lineage of the strains. 
Table 1 shows the dendrogram, isolation ward, isolation date, detected carbapenemases, as well 
as the ICs that the isolates pertained to. The isolates were spread across seven distinct clusters 
and five isolates did not belong to any cluster. All the isolates were found to pertain to a 
particular IC or group according to the scheme summarized by Karah et al. (2012), except for 
seven. Of these seven isolates, blaOXA-66 was amplified from the first multiplex and OmpA from
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the second for isolates 12 and 13, OmpA from multiplex 1 and blaOXA-69 from multiplex 2 for
isolate 57, only CsuE from multiplex 1 for isolate 59, and, despite several attempts, no genes 
were amplified from any multiplex for isolates 16, 32, and 46. Of the isolates that did not 
pertain to any IC, only isolates 13, 57, and 32 pertained to a particular cluster by PFGE (Table
1). 
Three out of four isolates from Cluster 1 (C1) pertained to IC III and harbored blaOXA­
24-like. Two of the isolates from Cluster 2 (C2) had a slightly different pulsotype from the other
four in that cluster, pertained to IC II, and had blaOXA-24-like. The other four isolates in C2
pertained to IC I and harbored the blaOXA-58-like gene. All the isolates from this cluster were
isolated in 2009 and none was detected in subsequent years. Cluster 3 (C3) is formed of two
carbapenem sensitive isolates that do not pertain to any IC. Four out of five of the isolates of
Cluster 4 (C4) pertained to IC II and were resistant to carbapenems. The fifth isolate had a 
slightly different pulsotype and harbored blaOXA-23-like instead of the blaOXA-24-like gene harbored
by the others in this cluster. Cluster 5 (C5) included two carbapenem sensitive isolates with
one pertaining to IC II and the other to a less disseminated clone designated as Group 14 (Karah
et al., 2012).
The largest cluster identified, containing 29 isolates, was Cluster 6 (C6). All the isolates 
in this cluster were carbapenem resistant except for isolate 53 which was intermediately
resistant and isolates 26 and 38 which were sensitive. None of the carbapenem sensitive isolates 
harbored any of the tested carbapenemase genes whereas all of the carbapenem non-sensitive
clones of C6 harbored blaOXA-24-like with the exception of isolates 41 and 45 that harbored
blaOXA-58-like instead, and isolate 60 which harbored none of the tested carbapenemase genes.
In addition to blaOXA-24-like, isolate 50 harbored blaOXA-58-like. The majority of isolates were
obtained from the ICU but this clone was also detected in several other hospital wards (Table 
1). Moreover, isolates pertaining to this cluster were detected in 2009, 2010, 2012, and 2013
demonstrating its persistence in the hospital. All the isolates from this cluster belonged to IC
II except for isolate 58 which belonged to IC III and 41 which belonged to IC I. 
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Table 1. Results of the dendrogram obtained from PFGE in addition to which International Clone the tested 
isolated belonged to, which ward they were isolated from, the date of isolation, susceptibility to carbapenems, and 
the detected carbapenemases. The red line on the dendrogram represents the 80% cutoff in similarity. “Carb R.”
stands for carbapenem resistance, “C1 till C7” stand for Cluster 1 to Cluster 7, “IC” stands for international clone, 
“G” stands for group, and “I” stands for intermediate resistance. The wards are as follows: “CCNU” is the Critical
Care Nursing Unit, “ICU” is the Intensive Care Unit, “EM” is Emergencies, “RE” is Resuscitation, “IM” is 
Internal Medicine, “NE” is nephrology, “HO” is Hematology/Oncology, “CT” is Cardio/Thoracic, “GS” is
General Surgery, and “NEO” is Neonatal.
Cluster Clone Ward Isolation Date Carb. R OXA-23 OXA-24 OXA-58
 -  - NE 17/12/2012 - - - -
C1 IC III CCNU 10/6/2009 + - + -
C1 IC III ICU 12/11/2012 + - + -
C1 IC III CCNU 10/10/2012 + - + -
C1  - ICU 26/9/2012 + - + -
 -  - IM 18/5/2010 - - - -
 -  - CCNU 20/8/2012 + - + -
C2 IC II ICU 1/10/2009 + - + -
C2 IC II CCNU 19/9/2009 + - + -
C2 IC I CCNU 15/12/2009 + - - +
C2 IC I CCNU 25/9/2009 + - - +
C2 IC I CCNU 6/10/2009 + - - +
C2 IC I CCNU 7/12/2009 + - - +
C3  - ICU 25/11/2009 - - - -
C3  - CT 24/9/2009 - - - -
C4 IC II ICU 21/12/2011 + + - -
C4 IC II CCNU 29/12/2011 + - + -
C4 IC II ICU 10/1/2012 + - + -
C4 IC II CCNU 22/6/2011 + - + -
C4 IC II CCNU 12/1/2011 + - + -
C5 G 14 CCNU 29/12/2009 - - - -
C5 IC II HO 14/4/2009 - -  -  - 
C6 IC II ICU 25/5/2009 + - + -
C6 IC II ICU 4/5/2010 - - - -
C6 IC III CCNU 24/6/2009 + - + -
C6 IC II CCNU 22/3/2013 + - + -
C6 IC II CCNU 20/3/2013 + - + -
C6 IC II EM 4/2/2013 + - + -
C6 IC II RE 31/3/2009 + - + -
C6 IC II ICU 9/1/2009 + - + -
C6 IC II ICU 28/4/2010 + - - -
C6 IC II ICU 14/1/2009 + - + -
C6 IC II ICU 9/1/2009 + - + -
C6 IC II EM 3/11/2009 I - + -
C6 IC II ICU 21/1/2010 + - + -
C6 IC II ICU 16/12/2009 + - + -
C6 IC II ICU 27/8/2009 + - + +
C6 IC II ICU 3/11/2009 - - - -
C6 IC II RE 16/2/2009 + - + -
C6 IC II ICU 7/1/2009 + - + -
C6 IC II ICU 25/2/2010 + - + -
C6 IC II IM 13/10/2009 + - + -
C6 IC I CCNU 9/12/2009 + - - +
C6 IC II CCNU 23/6/2009 + - + -
C6 IC II CCNU 27/1/2010 + - - +
C6 IC II ICU 21/5/2009 + - + -
C6 IC II ICU 9/6/2010 + - + -
C6 IC II ICU 28/9/2010 + - + -
C6 IC II GS 9/2/2010 + - + -
C6 IC II CCNU 16/9/2009 + - + -
C6 IC II ICU 20/11/2012 + - + -
 -  - NEO 9/9/2009 - - - -
 - IC II ICU 6/11/2009 + - + -
C7 IC II CCNU 9/1/2013 + + - -
C7 IC II CCNU 8/5/2012 + + - -
C7 IC II ICU 21/12/2011 + + - -
C7 IC II CCNU 17/4/2012 + + - -
C7 IC II ICU 15/3/2012 + + - -
C7 IC II ICU 10/1/2012 + + - -
Dendrogram Epidemiological Data Resistance
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The isolates of Cluster 7 (C7) harbored blaOXA-23-like, belonged to IC II, and were
detected in 2011, 2012, and 2013. Of the five isolates that did not belong to any cluster, only
isolate 40 pertained to IC II whereas the rest did not belong to any IC. This isolate had 79% 
similarity with C7 but was not considered as part of the cluster because the cutoff was set at 
80%. Isolates 12 and 40 were resistant to carbapenems and harbored the blaOXA-24-like gene.
Additionally, isolate 12 was resistant to colistin. In total, 5 (8.47%) isolates pertained to IC I, 
42 (71.19%) to IC II, 4 (6.78%) to IC III, 8 (13.56%) didn’t belong to any IC, and one to Group
14. Statistical analysis showed a statistically significant association between IC I and IC II on
one hand, and blaOXA-24-like and blaOXA-58-like on the other (p<0.05). IC III wasn’t statistically 
associated with the production of any oxacillinase in particular.
1.4.5. Determination of the Virulence Factors and Association with Clonality and 
Carbapenemases
The results of the virulence factors tested for, which are biofilm formation, hemolysis, 
siderophore production, surface motility, and proteolytic activity are presented in Table 2. In 
addition, the ICs, clusters they belong to, and the doubling times for selected isolates are shown
in that table. No statistical association was detected when the virulence factors were compared
one to another. However, IC I was negatively associated with α-hemolysis on SBA, siderophore 
production, and strong biofilm formation (p<0.05). IC II on the other hand was positively 
associated with these three factors (p<0.05). Nevertheless, all the isolates of C7, which
pertained to IC II but had blaOXA-23-like, were negative for α-hemolysis on SBA. IC III was 
negatively associated with α-hemolysis on SBA and production of strong biofilms (p<0.05). 
In terms of carbapenemase genes, harboring blaOXA-23-like was negatively associated
with α-hemolysis on SBA while harboring blaOXA-24-like was positively associated with α ­
hemolysis and siderophore production (p<0.05). Harboring blaOXA-58-like was negatively 
associated with siderophore production and α-hemolysis (p<0.05). Proteolytic activity was not 
associated with any of the other factors (p<0.05). The highest level of proteolytic activity
(48.26 ± 11.41 U/L) was detected for the carbapenem resistant isolate 57. This isolate was
negative for α-hemolysis on SBA, a strong biofilm former, produced siderophores, and had the 
highest motility rate (0.616 ± 0.12 µm/sec). The carbapenem resistant, blaOXA-24-like harboring, 
α-hemolytic, siderophore producing, isolate 40 also had high proteolytic activity (47.67 ± 13.68 
U/L). However, it showed a low level of motility (0.047 ± 0.021 µm/sec). Isolates 13 and 62 
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showed the lowest proteolytic activity (9.24 ± 2.06 and 9.24 ± 1.37 U/L, respectively). Both
were α-hemolytic, had comparable motility rates, were resistant to carbapenems, harbored 
blaOXA-24-like, and produced siderophores. The only difference between them was that isolate 13
was a weak biofilm former whereas isolate 62 was a strong biofilm former.
In terms of motility, only isolates 20, 25, 26, 27, 31, and 57 showed a circular diffusion
pattern on 0.3% LB-Agar. The only common factor found among these isolates was that they 
were all strong biofilm formers and that the two that were selected for the calculation of 
doubling times (20 and 26) showed a relatively fast doubling time (0.342 ± 0.077 and 0.350 ±
0.033 hours, respectively). The slowest doubling time was detected for isolate 12 (0.666 ±
0.037 hours) which was resistant to colistin and carbapenems and harbored blaOXA-24-like. This
isolate showed α-hemolysis on SBA and was a strong biofilm former but was negative for 
siderophore production. The two closest isolates to it were isolates 41 and 35 which showed
doubling times of 0.651 ± 0.026 and 0.613 ± 0.082 hours, respectively. Both harbored the 
blaOXA-58-like gene and were negative for α-hemolysis on SBA and siderophore production.
Isolate 35 was a strong biofilm former whereas isolate 41 was a weak biofilm former. The
fastest doubling time was detected for the other colistin resistant isolate, isolate 45 (0.324 ±
0.027 hours). Interestingly, this isolate harbored blaOXA-58-like in addition to being a strong
biofilm former, being positive for α-hemolysis on SBA and siderophore production, and having 
a high proteolytic activity (42.9 ± 7.74 U/L). Finally, isolates pertaining to IC I were associated 
with slower doubling times whereas those of IC II were associated with faster doubling times
(p<0.005).
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Table 2. Results of the virulence factors experiments for the tested strains, in addition to which cluster and
international clone they belong to. “C1 till C7” stand for Cluster 1 to Cluster 7, “IC” stands for international clone, 
“G” stands for group, and “ND” stands for not determined. In the column of hemolysis, “α” designates the type
of hemolysis detected and “D1 to D3” designates the day in which hemolysis was first detected. The averages and
standard deviations presented in the last three columns are a result of 3 independent experiments. 
Strain Cluster Clone Hemolysis Biofilm Siderophores
Motility
(µm/sec)
Proteolytic 
Activity (U/L)
Doubling
Time (hours)
16 - - - ++ + 0.057 ± 0.006 25.92 ± 3.10 ND
56 C1 IC III - + + 0.030 ± 0.013 20.85 ± 8.01 0.386 ± 0.041
15 C1 IC III - + + 0.034 ± 0.000 30.09 ± 1.86 0.559 ± 0.127
14 C1 IC III - + + 0.044 ± 0.010 25.92 ± 1.79 ND
13 C1 - α - D3 + + 0.044 ± 0.010 9.24 ± 2.06 0.461 ± 0.031
59 - - α - D2 ++ + 0.044 ± 0.006 35.15 ± 3.14 0.519 ± 0.079
12 - - α - D3 ++ - 0.024 ± 0.010 12.51 ± 3.58 0.666 ± 0.037
49 C2 IC II α - D2 + + 0.045 ± 0.008 23.54 ± 7.81 0.401 ± 0.023
37 C2 IC II α - D2 ++ + 0.024 ± 0.014 23.24 ± 5.44 0.382 ± 0.018
42 C2 IC I - + - 0.027 ± 0.011 35.45 ± 3.14 ND
36 C2 IC I - + - 0.014 ± 0.010 19.96 ± 2.87 ND
35 C2 IC I - ++ - 0.031 ± 0.037 17.88 ± 3.22 0.613 ± 0.082
34 C2 IC I - ++ - 0.014 ± 0.010 14.60 ± 6.34 ND
57 C3 - - ++ + 0.616 ± 0.120 48.26 ± 11.41 ND
32 C3 - - ++ - 0.027 ± 0.006 17.88 ± 1.55 0.577 ± 0.053
5 C4 IC II - ++ + 0.034 ± 0.010 27.71 ± 3.10 0.436 ± 0.040
6 C4 IC II α - D1 ++ - 0.054 ± 0.010 29.20 ± 10.28 ND
4 C4 IC II α - D2 ++ - 0.070 ± 0.011 34.26 ± 2.58 ND
3 C4 IC II α - D2 ++ + 0.077 ± 0.015 26.81 ± 2.36 0.449 ± 0.042
1 C4 IC II α - D2 ++ - 0.080 ± 0.011 39.62 ± 8.68 ND
31 C5 G 14 - ++ + 0.116 ± 0.047 12.21 ± 5.08 ND
30 C5 IC II - ++ + 0.044 ± 0.006 28.60 ± 7.09 0.384 ± 0.038
27 C6 IC II α - D1 ++ - 0.143 ± 0.060 27.41 ± 2.87 ND
26 C6 IC II α - D2 ++ + 0.116 ± 0.083 35.15 ± 4.41 0.342 ± 0.077
58 C6 IC III - ++ - 0.025 ± 0.008 30.39 ± 9.67 ND
23 C6 IC II - ++ - 0.038 ± 0.005 22.34 ± 3.90 ND
22 C6 IC II - ++ + 0.021 ± 0.006 31.28 ± 1.55 0.340 ± 0.069
21 C6 IC II - ++ + 0.040 ± 0.030 34.86 ± 2.36 ND
33 C6 IC II α - D1 ++ + 0.032 ± 0.013 14.30 ± 3.90 ND
62 C6 IC II α - D2 ++ + 0.035 ± 0.018 9.24 ± 1.37 ND
60 C6 IC II α - D2 ++ - 0.070 ± 0.006 17.88 ± 0.89 ND
55 C6 IC II α - D1 ++ + 0.057 ± 0.015 31.58 ± 19.18 ND
54 C6 IC II α - D2 ++ - 0.060 ± 0.015 24.73 ± 3.14 ND
53 C6 IC II α - D1 ++ + 0.040 ± 0.006 25.03 ± 5.58 0.428 ± 0.017
52 C6 IC II α - D2 ++ + 0.056 ± 0.016 24.13 ± 4.98 0.436 ± 0.088
51 C6 IC II α - D2 ++ + 0.050 ± 0.006 27.41 ± 3.38 ND
50 C6 IC II α - D2 ++ + 0.047 ± 0.006 24.43 ± 2.58 ND
38 C6 IC II - ++ - 0.024 ± 0.000 28.90 ± 4.03 0.482 ± 0.049
29 C6 IC II - ++ + 0.060 ± 0.011 23.24 ± 0.89 ND
61 C6 IC II α - D2 ++ + 0.067 ± 0.006 13.70 ± 7.22 ND
28 C6 IC II α - D2 ++ + 0.057 ± 0.006 24.73 ± 3.14 ND
44 C6 IC II α - D2 ++ + 0.063 ± 0.010 29.49 ± 4.47 ND
41 C6 IC I - + - 0.021 ± 0.006 18.47 ± 1.37 0.651 ± 0.026
25 C6 IC II α - D1 ++ + 0.116 ± 0.066 28.00 ± 2.73 ND
45 C6 IC II α - D2 ++ + 0.057 ± 0.015 42.90 ± 7.74 0.324 ± 0.027
43 C6 IC II α - D2 ++ + 0.057 ± 0.006 31.88 ± 10.66 ND
48 C6 IC II α - D2 ++ + 0.055 ± 0.010 21.15 ± 1.86 ND
47 C6 IC II α - D2 ++ + 0.047 ± 0.006 25.03 ± 4.64 ND
39 C6 IC II α - D2 ++ + 0.044 ± 0.017 29.20 ± 7.71 ND
24 C6 IC II α - D1 ++ + 0.063 ± 0.010 33.37 ± 8.30 ND
17 C6 IC II α - D1 ++ + 0.060 ± 0.021 23.54 ± 2.06 0.462 ± 0.016
46 - - - ++ - 0.052 ± 0.018 24.73 ± 4.22 ND
40 - IC II α - D2 ++ + 0.047 ± 0.021 47.67 ± 13.68 ND
20 C7 IC II - ++ - 0.178 ± 0.253 23.24 ± 3.10 0.350 ± 0.033
10 C7 IC II - ++ + 0.047 ± 0.011 28.00 ± 7.60 ND
11 C7 IC II - ++ + 0.031 ± 0.020 29.49 ± 6.26 ND
9 C7 IC II - ++ + 0.030 ± 0.006 29.20 ± 7.60 0.379 ± 0.019
8 C7 IC II - ++ + 0.040 ± 0.020 36.35 ± 7.22 ND
7 C7 IC II - ++ + 0.030 ± 0.006 37.84 ± 1.86 ND
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1.5. Discussion
This study shows the phenotypic and genotypic characterization of 59 A. baumannii
isolates collected over five years from a Spanish hospital. It shows the predominance of the 
MDR IC II in this hospital and its prolonged persistence, which falls in agreement with national 
and international epidemiological data (Karah et al., 2012; Villalón et al., 2015). The largest 
cluster of isolates (C6), mostly pertaining to IC II, caused a large outbreak in 2009 that persisted
to 2013 and spread to various hospital wards (Table 1). This reflects the reported success of 
this clone to persist in hospitals, whether on abiotic surfaces or in the patients’ gut flora 
(Andersson et al., 2011), and cause repeated infections over prolonged periods of time. IC I 
and IC III were also detected in various clusters but at a lower incidence (Table 1). The
prevalence of these three ICs is very similar to that reported by Villalón et al., (2011) which 
investigated the dissemination of A. baumannii clones in Spain over 11 years. This shows a
degree of uniformity in terms of distribution of these clones in the country. 
A previous study demonstrated that clinical isolates, even those very successful at 
causing nosocomial outbreaks, have varying profiles of virulence (Antunes et al., 2011). This 
is in agreement with our results where the virulence profiles of individual isolates varied 
greatly. Nevertheless, some associations were detected that could help in predicting the degree
of virulence of a certain isolate. Our data show an association between clones pertaining to ICs
I and III and attenuated virulence as compared to those pertaining to IC II (P<0.005). This 
association could be useful for clinicians in terms of adjusting treatment regimens based on the 
expected degree of virulence and the severity of the illness of the patient. Moreover, this 
association could be exploited by infection control specialists through the adaptation of 
eradication protocols to specific clones. 
Most of the isolates (58.85%) in this study were collected in 2009. In general, few 
infections were caused by A. baumannii in subsequent years. This could be an indication of the
implementation of good infection control protocols at this hospital. In terms of carbapenem 
non-susceptibility, an alarmingly high rate of 84.75% over 5 years was detected. This high rate 
is similar to that reported by Perez et al., (2010) with the difference being the predominance of 
blaOXA-24-like in our study as opposed to the predominance of blaOXA-23-like in the other (Perez et 
al., 2010). This rate, however, is much higher than that reported for other European countries
(Tomaschek et al., 2016) revealing a worrisome situation in this country. 
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Even though blaOXA-23-like is the most disseminated oxacillinase among A. baumannii
isolates worldwide, blaOXA-24-like seems to be more prevalent in Spain (Tena et al., 2013). This 
was reflected in our study where blaOXA-24-like was present in 62.71% of the isolates whereas
blaOXA-23-like was only detected in 11.86% of the isolates. Harboring blaOXA-24-like was associated
with increased virulence as compared to harboring blaOXA-23-like or blaOXA-58-like in this study
(p<0.05). This association could also be exploited in a similar manner to that of IC II in
treatment regimens and infection control protocols. Taken together, AST, two multiplex PCRs
for the detection of clonalilty, and one multiplex PCR for the detection of oxacillinases could 
provide a fast, cheap, and non-laborious method that could give clinicians and infection control
specialists valuable tools in predicting the virulence of an isolate and allow them to make
appropriate decisions accordingly.
Some PFGE clusters contained isolates pertaining to different ICs, probably owing to 
the higher discriminatory power of this technique to differentiate between clones as compared 
to tri-locus PCR typing. This observation is demonstrated in C6 where two isolates pertained 
to ICs I and III, respectively, instead of IC II. This cluster also harbored two IC II isolates that 
were sensitive to carbapenems and one CRAB isolate with no carbapenemase gene detected, 
suggesting the acquisition of resistance through means that were not tested for in this study. 
Carbapenem-susceptible A. baumannii isolates pertaining to IC II have been previously
reported (Diancourt et al., 2010) and this could be due to the loss of resistance resulting from
the lack of antibiotic pressure over a period of time (Andersson et al., 2010). Nevertheless, for 
the most part, the strains in this cluster shared similar virulence profiles, furthering the 
observation that clonality could be indicative of the degree of virulence.
Most isolates in this study remain susceptible to amikacin and colistin. Susceptibility
to the latter antibiotic is especially important due to the international trend to use colistin in the
treatment of MDR A. baumannii infections (Chen et al., 2015). Colistin resistance among A.
baumannii has been previously reported in Spain (López-Rojas et al., 2013), though at low 
incidence. Two colistin resistant isolates were encountered in this study and they were isolates
12, which did not belong to any cluster nor IC, and 45, which was part of C6 and pertained to 
IC II. Interestingly, the former showed the slowest doubling time while the latter showed the 
fastest. Both showed α-hemolysis, although isolate 12 was slower in the development of 
hemolysis. Both were also relatively non-motile. Isolate 12 harbored blaOXA-24-like and did not
produce siderophores while isolate 45 harbored blaOXA-58-like, had a greater exoprotease 
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production, and produced siderophores. Isolate 45 only remained susceptible to amikacin and 
minocycline whereas isolate 12 was susceptible to ampicillin/sulbactam, amikacin, netilmycin,
and minocycline. Further genetic characterization of these isolates could help in understanding
the different mechanisms in play that made isolate 45 highly virulent, highly resistant, and with 
a very fast doubling time. Additionally, it is worth mentioning that the isolate pertaining to
Group 14 was sensitive to carbapenems as opposed to its counterpart which was first detected 
in Romanian hospitals and was carbapenem-resistant and harbored blaOXA-58-like (Bonin et al., 
2011).
Doubling times are clearly affected by much more factors than are in the scope of this
study since they are affected by the entire metabolism of the cell. Therefore, the doubling times
were calculated for a few isolates with varying profiles and, when no pattern was detected, 
determination of doubling times for all the isolates was discontinued. Nevertheless, the 
doubling times calculated showed an association between slower doubling times and weak
proteolytic activity (p<0.05) suggesting a direct interaction between these two factors that 
could be investigated in the future. Finally, it is worth mentioning that the highly susceptible 
sporadic isolate 57 showed the highest motility rate and proteolytic activity, produced strong
biofilms, and was positive for siderophore production. Although the interplay between 
resistance and virulence seems to be a highly complex one, this observation could suggest that 
its lack of resistance could be attributing to its increased virulence. Performing a similar study 
on more sporadic isolates, and isolates from different origins and clonality could reveal further 
clinically important associations and help better understand the interaction between
antimicrobial resistance and virulence.
1.6. Conclusions
In conclusion, a very high level of carbapenem non-susceptibility was detected in this 
Spanish hospital over a period of five years. IC II and blaOXA-24-like were predominant in this
hospital although other ICs and OXAs were detected. IC II and blaOXA-24-like were also 
associated with increased virulence as compared to other ICs and OXAs. This association could 
be exploited by clinicians and infection control specialists in order to improve treatment
outcomes, especially since determination of clonality and presence of blaOXA-24-like could be
performed rapidly. Future investigations using larger pools of isolates with different clonal 
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lineages could shed light on these associations and help in better understand the complex
 
interactions that affect virulence and antibiotic resistance.
 
Table S1. Primers used with their respective annealing temperatures.
 
Primer Sequence
Annealing
Temperature 
Reference
OmpA-F
OmpA-R
5’-CAATTGTTATCTCTGGAG-3’
5’-ACCTTGAGTAGACAAACGA-3’
50˚C
Turton et
al., 2007
CsuE-F
CsuE-R
5’-ATGCATGTTCTCTGGACTGATGTTGAC-3’
5’-CGACTTGTACCGTGACCGTATCTTGATAAG-3’
65˚C
Turton et
al., 2007
Oxa-51-like-F
Oxa-51-like-R
5’-ATGAACATTAAAGCACTC-3’
5’-CTATAAAATACCTAATTGTTC-3’
46˚C
Turton et
al., 2007
Oxa-23-like-F
Oxa-23-like-R
5’-GATCGGATTGGAGAACCAGA-3’
5’-ATTTCTGACCGCATTTCCAT-3’
53˚C
Mostachio 
et al., 2009
Oxa-24-like-F
Oxa-24-like-R
5’-GGTTAGTTGGCCCCCTTAAA-3’
5’-AGTTGAGCGAAAAGGGGATT-3’
53˚C
Mostachio 
et al., 2009
Oxa-58-like-F
Oxa-58-like-R
5’-AAGTATTGGGGCTTGTGCTG-3’
5’-CCCCTCTGCGCTCTACATAC-3’
53˚C
Mostachio 
et al., 2009
KPC-F
KPC-R
5’-CGTCTAGTTCTGCTGTCTTG-3’
5’-CTTGTCATCCTTGTTAGGCG-3’
52˚C
Poirel et
al., 2011
NDM-F
NDM-R
5’-GGTTTGGCGATCTGGTTTTC-3’
5’-CGGAATGGCTCATCACGATC-3’
52˚C
Poirel et
al., 2011
Oxa-48-F
Oxa-48-R
5’-GCGTGGTTAAGGATGAACAC-3’
5’-CATCAAGTTCAACCCAACCG-3’
52˚C
Poirel et
al., 2011
Table S2. Primers used in the identification of the global lineages of the strains.
Multiplex 1
Primer Sequence Amplicon Size (bp)
Group1ompAF306 5’-GATGGCGTAAATCGTGGTA-3’
355
Group1and2ompAR660 5’-CAACTTTAGCGATTTCTGG-3’
Group1csuEF 5’-CTTTAGCAAACATGACCTACC-3’
702
Group1csuER 5’-TACACCCGGGTTAATCGT-3’
Gp1OXA66F89 5’-GCGCTTCAAAATCTGATGTA-3’
559
Gp1OXA66R647 5’-GCGTATATTTTGTTTCCATTC-3’
Multiplex 2
Group2ompAF378 5’-GACCTTTCTTATCACAACGA-3’
343
Group1and2ompAR660 5’-CAACTTTAGCGATTTCTGG-3’
Group2csuEF 5’-GGCGAACATGACCTATTT-3’
580
Group2csuER 5’-CTTCATGGCTCGTTGGTT-3’
Gp2OXA69F169 5’-CATCAAGGTCAAACTCAA-3’
162
Gp2OXA69R330 5’-TAGCCTTTTTTCCCCATC-3’
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Table S3. Minimum Inhibitory Concentrations (MICs) of the tested antimicrobial agents along with the 
interpretation according to CLSI guidelines. “R” stands for Resistant, “I” stands for Intermediately Resistant, and 
“S” stands for susceptible. “TIC” stands for ticarcillin, “PIP” for piperacillin, “A/S” for ampicillin/sulbactam,
“P/T” for piperacillin/tazobactam, “CTZ” for ceftazidime, “CFP” for cefepime, “IMI” for imipenem, “MER” for 
meropenem, “COL” for colistin, “G” for gentamicin, “TO” for tobramycin, “AK” for amikacin, “MIN” for 
minocycline, “CIP” for ciprofloxacin, “LEV” levofloxacin, and “T/S” for trimethoprim/sulfamethoxazole. 
Strain MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S
1 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
3 > 64 R > 64 R 16 I > 64/4 R >32 R 16 I >8 R >8 R ≤0.5 S ≤1 S ≤1 S ≤2 S 2 S >2 R >4 R >4/76 R
4 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 8 I ≤1 S ≤2 S 2 S >2 R >4 R >4/76 R
5 > 64 R > 64 R 16 I > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R >8 R >32 R 8 I >2 R >4 R >4/76 R
6 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 8 I ≤1 S ≤2 S 2 S >2 R >4 R >4/76 R
7 > 64 R > 64 R 16 I > 64/4 R >32 R >32 R >8 R >8 R 2 S >8 R >8 R >32 R 8 I >2 R >4 R >4/76 R
8 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R >8 R >32 R 8 I >2 R >4 R >4/76 R
9 > 64 R > 64 R 16 I > 64/4 R >32 R 32 R >8 R >8 R 2 S >8 R >8 R >32 R 8 I >2 R >4 R >4/76 R
10 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R 2 S >8 R >8 R >32 R 8 I >2 R >4 R >4/76 R
11 > 64 R > 64 R 16 I > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R >8 R >32 R 8 I >2 R >4 R >4/76 R
12 64 I > 64 R 4 S > 64/4 R 16 I 32 R >8 R >8 R >8 R >8 R >8 R 8 S ≤1 S >2 R >4 R >4/76 R
13 > 64 R > 64 R 16 I > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R >8 R 16 S ≤1 S >2 R >4 R >4/76 R
14 > 64 R > 64 R 16 I > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R >8 R 16 S ≤1 S >2 R >4 R >4/76 R
15 > 64 R > 64 R 16 I > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R >8 R 16 S ≤1 S >2 R >4 R >4/76 R
16 32 I 16 S ≤2/1 S 8 S 16 I 2 S ≤1 S 1 S ≤0.5 S ≤1 S ≤1 S ≤2 S ≤1 S >2 R 1 S ≤2/38 S
17 > 64 R > 64 R 16 I > 64/4 R 32 R >32 R >8 R >8 R ≤0.5 S >8 R >8 R >32 R ≤1 S >2 R >4 R >4/76 R
20 > 64 R > 64 R 16 I > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R >8 R >32 R 8 I >2 R >4 R >4/76 R
21 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R 2 S >32 R >8 R >2 R >4 R >4/76 R
22 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R 2 S >32 R >8 R >2 R >4 R >4/76 R
23 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R >8 R >32 R >8 R >2 R >4 R >4/76 R
24 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
25 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
26 32 I > 64 R 4 S > 64/4 R >32 R 16 I ≤1 S 1 S 1 S ≤1 S ≤1 S ≤2 S 2 S >2 R >4 R >4/76 R
27 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
28 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 2 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
29 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
30 > 64 R > 64 R 4 S 64 I 16 I 16 I 2 S 2 S ≤0.5 S >8 R 8 I 4 S ≤1 S >2 R >4 R >4/76 R
31 16 S 16 S 4 S 16 S 4 S 2 S ≤1 S 1 S ≤0.5 S ≤1 S ≤1 S ≤2 S ≤1 S ≤0.25 S ≤0.12 S ≤2/38 S
32 ≤8 S 16 S ≤2/1 S ≤4/4 S 4 S 2 S ≤1 S ≤0.25 S ≤0.5 S ≤1 S ≤1 S ≤2 S ≤1 S ≤0.25 S ≤0.12 S ≤2/38 S
33 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 8 I ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
34 > 64 R > 64 R >16/8 R > 64/4 R 32 R 16 I >8 R >8 R ≤0.5 S >8 R >8 R ≤2 S ≤1 S >2 R >4 R >4/76 R
35 > 64 R > 64 R >16/8 R > 64/4 R 32 R 8 S >8 R 8 I ≤0.5 S >8 R >8 R ≤2 S ≤1 S >2 R >4 R >4/76 R
36 > 64 R > 64 R >16/8 R > 64/4 R 32 R 16 I >8 R 8 I ≤0.5 S >8 R >8 R ≤2 S ≤1 S >2 R >4 R >4/76 R
37 > 64 R > 64 R >16/8 R > 64/4 R 32 R 8 S >8 R 8 I ≤0.5 S >8 R >8 R ≤2 S ≤1 S >2 R >4 R >4/76 R
38 ≤8 S 8 S ≤2/1 S ≤4/4 S 4 S 2 S ≤1 S ≤0.25 S ≤0.5 S ≤1 S ≤1 S ≤2 S ≤1 S ≤0.25 S ≤0.12 S ≤2/38 S
39 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
40 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
41 > 64 R > 64 R >16/8 R > 64/4 R 32 R 8 S >8 R >8 R ≤0.5 S >8 R >8 R ≤2 S ≤1 S >2 R >4 R >4/76 R
42 > 64 R > 64 R >16/8 R > 64/4 R 32 R 8 S >8 R >8 R ≤0.5 S >8 R >8 R ≤2 S ≤1 S >2 R >4 R >4/76 R
43 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
44 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
45 > 64 R > 64 R >16/8 R > 64/4 R 16 I 8 S >8 R 4 I >8 R >8 R 8 I ≤2 S 2 S >2 R >4 R >4/76 R
46 16 S 16 S 4 S ≤4/4 S 4 S 2 S ≤1 S ≤0.25 S ≤0.5 S ≤1 S ≤1 S ≤2 S ≤1 S ≤0.25 S ≤0.12 S ≤2/38 S
47 > 64 R > 64 R 16 I > 64/4 R >32 R 16 I >8 R >8 R ≤0.5 S ≤1 S ≤1 S ≤2 S 2 S >2 R >4 R >4/76 R
48 > 64 R > 64 R >16/8 R > 64/4 R 16 I 32 R >8 R >8 R 2 S 8 I ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
49 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 8 I ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
50 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 2 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
51 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
52 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
53 > 64 R > 64 R 4 S > 64/4 R 16 I 16 I 8 I 8 I ≤0.5 S >8 R >8 R 16 S ≤1 S >2 R >4 R >4/76 R
54 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
55 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
56 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R 8 I 8 S ≤1 S >2 R >4 R >4/76 R
57 8 S 16 S ≤2/1 S ≤4/4 S 4 S 2 S ≤1 S ≤0.25 S ≤0.5 S ≤1 S ≤1 S ≤2 S ≤1 S ≤0.25 S ≤0.12 S ≤2/38 S
58 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S >8 R 8 I 8 S ≤1 S >2 R >4 R >4/76 R
59 ≤8 S 8 S ≤2/1 S ≤4/4 S 2 S 2 S ≤1 S ≤0.25 S ≤0.5 S ≤1 S ≤1 S ≤2 S ≤1 S ≤0.25 S ≤0.12 S ≤2/38 S
60 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
61 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
62 > 64 R > 64 R >16/8 R > 64/4 R >32 R >32 R >8 R >8 R ≤0.5 S 4 S ≤1 S ≤2 S ≤1 S >2 R >4 R >4/76 R
CTZTIC PIP A/S P/T T/SCFP IMI MER COL G TO AK MIN CIP LEV
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2. Phenotypic and Genotypic Characterization of Acinetobacter baumannii
Strains Isolated from a Lebanese Hospital
2.1 Abstract
Acinetobacter baumannii is a nosocomial pathogen that usually affects critically ill 
patients. High mortality rates have been associated with MDR A. baumannii infections.
Carbapenem resistance among these isolates is increasing worldwide and is associated with
certain International Clones (ICs) and oxacillinases (OXAs). Moreover, this organism
possesses a wide range of virulence factors, whose expression is not yet fully understood. In
this study, clinical A. baumannii isolates are characterized in terms of antibiotic resistance,
mechanisms of carbapenem resistance, clonality, and virulence. A. baumannii clinical isolates
(n=90) where obtained from a tertiary care center in Beirut, Lebanon. API 20NE strips in
addition to the amplification of blaOXA-51-like was used for identification. Antibiotic
susceptibility testing by disk diffusion was then performed in addition to PCRs for the detection 
of the most commonly disseminated carbapenemases. Clonality was determined by tri-locus 
PCR typing and doubling times were determined for isolates with varying susceptibility 
profiles. Biofilm formation, hemolysis, siderophore production, proteolytic activity, and
surface motility was then determined for all the isolates. Statistical analysis was then performed
for the determination of associations. 81 (90%) of the isolates were resistant to carbapenems.
These high rates are similar to other multi-center studies in the country suggesting the need of 
intervention on a national level. 76 (93.8%) of the isolates harbored blaOXA-23-like, including two 
that also harbored blaOXA-24-like. 80 (88.9%) isolates pertained to ICII and three other 
international clones were detected, showing the wide dissemination of clones into 
geographically distinct locations. Virulence profiles were highly diverse and no specific pattern
was observed. Nevertheless, an association between motility, siderophore production, and
biofilm formation was detected (p<0.05). A very high rate of carbapenem resistance was
detected, showing the need for immediate intervention. IC II and OXA-23-like were the most
disseminated, reflecting their international dissemination. No specific associations were made
between virulence and resistance, but instead associations among certain virulence factors were
found. Investigating a more clonally diverse pool of isolates could help in the determination of 
associations between virulence and resistance.
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2.1. Resumen
Acinetobacter baumannii es un patógeno nosocomial que afecta a las personas
críticamente enfermas. Altas tasas de mortalidad se han asociado con infecciones producidas
por cepas de A. baumannii resistentes a múltiples antibióticos. La resistencia a carbapenemas
en estas cepas ha aumentado a nivel mundial y se han asociado con algunos clones
internacionales y presencia de oxacilinasas. A. baumannii muestra una gran amplitud de 
factores de virulencia pero su manera de expresarlos todavía se encuentra en estudio. En
nuestro trabajo, se aislaron cepas clínicas de A. baumannii y se caracterizaron en base a su
antibiorresistencia, mecanismos de resistencia a carbapenemas, clonalidad, y virulencia. 
Noventa cepas de A. baumannii se aislaron de un Hospital Universitario situado en Beirut, 
Líbano, y se identificaron utilizando tiras API 20NE y amplificación de blaOXA-51 mediante 
PCR. Posteriormente, se realizaron las pruebas de sensibilidad a los antibióticos por difusión
en disco, y PCR para la detección de las carbapenemasas más frecuentes. Se determinó la
clonalidad por amplificación diferencial de genes “housekeeping” mediante dos PCRs
multiplex. Posteriormente, se determinó la producción de biofilms, hemólisis, y sideróforos, 
así como la actividad proteolítica, movilidad en la superficie, y el tiempo de generación para
ciertas cepas seleccionadas. A continuación, se realizó un análisis estadístico para determinar 
las posibles asociaciones entre estos factores. 81 cepas (90%) resultaron resistentes a
carbapenemas. Este alto porcentaje es similar al porcentaje de resistencia obtenido en otros 
estudios en este país, sugiriendo la gran necesidad de intervención a nivel nacional. 76 de las
cepas resistentes a carbapenemas (93,8%) fueron positivas para el gen blaOXA-23, incluyendo
dos que además contenían blaOXA-24. 80 cepas (88.9%) pertenecieron al clon internacional II,
mientras que el resto pertenecieron a otros tres clones internacionales. Los perfiles de
virulencia variaron mucho entre las cepas y no se detectó un patrón específico entre los mismos.
Sin embargo, se detectó una asociación entre movilidad, producción de sideróforos, y 
formación de biofilms (p<0.05). En conclusión, existe un alto porcentaje de resistencia a
carbapenemas en A. baumannii en este hospital libanés. El clon internacional II y OXA-23
fueron los más frecuentes entre las cepas analizadas. No se encontraron correlaciones
estadísticas significativas entre resistencia antibiótica, clonalidad, y virulencia en estas cepas,
lo que sugiere que la asociación entre estos factores puede ser un hallazgo local y no
internacional. Sin embargo, se encontraron asociaciones entre ciertos factores de virulencia,
cuyas investigaciones futuras pueden ayudar a entender mejor los mecanismos patogénicos en
A. baumannii. 
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2.2. Introduction
Acinetobacter baumannii is a nosocomial pathogen that could cause severe secondary
infections among critically ill patients (Gordon and Wareham, 2010). This organism has a wide
range of intrinsic resistance mechanisms and a heightened ability to acquire resistance to a
broad range of antimicrobial agents (Peleg et al., 2012). Mortality rates among critically ill
patients infected with Multi-Drug Resistant (MDR) A. baumannii are high, especially when 
improper empirical treatments are given (Ñamendys-Silva et al., 2015). 
Carbapenems have been the treatment of choice for treating critically ill patients with
MDR A. baumannii infections (Breilh et al., 2013). However, the increasing rates of 
Carbapenem Resistant Acinetobacter baumannii (CRAB) isolates (Tärnberg et al., 2016) have 
limited their efficacy and increased mortality rates among infected patients (Lemos et al., 
2014). Oxacillinases (OXAs) are the most commonly identified mechanism of carbapenem
resistance among A. baumannii isolates. These OXAs include OXA-23-like, OXA-24-like, and
OXA-58-like (Nowak and Paluchowska, 2016). A few globally disseminated International 
Clones (ICs) have been found to cause most CRAB infections worldwide and have been
associated with the presence of these OXAs (Karah et al., 2012). 
A global surveillance program showed that the Mediterranean regions harbored the
highest rate of MDR A. baumannii isolates (Flamm et al., 2016). Moreover, IC II was found to
be widely disseminated among these countries (Di Popolo et al., 2011). This clone was also
found to be largely disseminated in Lebanon (Rafei et al., 2014a). Moreover, CRAB isolates
were found to increase in prevalence in this country throughout the past decade (Hamouche 
and Sarkis, 2012). In 2012, 88% of 724 A. baumannii isolates recovered from various Lebanese 
hospitals were found to be resistant to imipenem (Hammoudi et al., 2015a). Although OXA­
24-like (Hammoudi et al., 2015b) and OXA-58-like (Zarrilli et al., 2008) have been detected 
in this country, OXA-23-like seems to be the most prevalent among CRAB isolates (Rafei et 
al., 2015b). 
In addition to the various mechanisms of resistance detected among A. baumannii 
isolates, this organism can deferentially express various virulence factors. These factors include 
biofilm formation, surface motility, hemolysis on blood agars, siderophore production, and 
exoprotease activity (Antunes et al., 2011). The relationship between virulence and 
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antimicrobial resistance seems to be a highly complex one that is still not completely 
understood (Peleg et al., 2012). Importantly, the effect of harboring OXAs on virulence in A.
baumannii is not well defined (Beceiro et al., 2013). 
The aim of this study is to characterize A. baumannii isolates obtained from a Lebanese 
hospital in terms of antibiotic susceptibility, carbapenemases harbored, clonality, and virulence 
determinants. Moreover, the relationship between virulence and carbapenem resistance will be 
explored. This would help in providing clinicians and infection control specialists with crucial 
data that would allow for the development of successful empirical treatments and infection 
control measures. Moreover, our findings could open the way for the exploitation of the 
interplay between virulence and resistance in the clinical setting.
2.3. Materials and Methods
2.3.1. Bacterial Strains
Ninety five non-repetitive Acinetobacter spp. isolates were obtained from Saint George 
University – University Medical Center (SGH-UMC) over a period extending from June 2013
until August 2014. The strains were identified using 20NE API strips (BioMérieux, France) in
addition to the detection of the blaOXA-51-like gene by PCR (Turton et al., 2006). The isolates 
were then stored at -20°C in Luria-Bertani (LB) Broth supplemented with 20% glycerol until
used.
2.3.2. Antimicrobial Susceptibility Testing
The Kirby Bauer disk diffusion method was performed according to the CLSI
guidelines (2014) in order to determine the Antibiotic Susceptibility Profiles (ASTs) of the
isolates. The results were interpreted according to the cutoff values of the CLSI document
M100-S24 (CLSI, 2014). Antimicrobial agents tested for were cefotaxime (30µg), ceftazidime
(30µg), cefepime (30µg), piperacillin/tazobactam (100µg/10µg), meropenem (10µg), 
imipenem (10µg), trimethoprim/sulfamethoxazole (1.25µg/23.75µg), ciprofloxacin (5µg), 
gentamycin (10µg), and colistin (10µg). In order to verify resistance to colistin, E-tests
(BioMérieux Mercy l’Etoile, France) and minimum inhibitory concentrations by broth
microdilution were performed for isolates that showed narrow inhibition zones around the 
colistin disks. 
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2.3.3. Polymerase Chain Reactions
PCRs for the detection of blaOXA-51-like (Turton et al., 2006); blaOXA-23-like, blaOXA-24-like, 
and blaOXA-58-like (Mostachio et al., 2009); and blaOXA-48, blaNDM, and blaKPC (Poirel et al., 2011)
as previously described by the respective authors were performed. Random amplicons were
sequenced in order to verify the accuracy of the amplified genetic product. International lineage
was determined using tri-locus PCR typing as described by Turton et al. (2007). The table
summarized by Karah et al., (2012) was used in order to assign the international clonality of 
the tested isolates.
2.3.4. Growth Curves
In order to calculate the doubling time for selected isolates with varying antibiotic 
susceptibility profiles, 1:100 dilutions from overnight cultures liquid cultures in fresh LB broth
were performed. The fresh suspensions were then incubated at 37°C with shaking at 200 rpm 
for 8 hours. Each hour, the OD600 was measured and the doubling times were calculated from
the resulting curve as previously described (Hall et al., 2014). The growth curves and all the 
following experiments were performed in triplicates.
2.3.5. Biofilm Formation
Biofilm formation was detected in polystyrene tubes after staining with crystal violet 
as previously described (Tomaras et al., 2003). Briefly, 1mL of inoculated LB broth was 
incubated overnight at 37°C and then washed and stained with 1% crystal violet for 10 minutes. 
The dye was then rinsed away and biofilms were visualized and graded as “++” if heavy stains 
were observed and as “+” if faint stains were observed.
2.3.6. Hemolytic Activity
Hemolytic activity on blood agar plates were tested for by inoculating 10µL of a
bacterial suspension adjusted to 106 CFU/mL in the center of these plates. The plates were then 
incubated for 6 days at 37°C and observed daily (Taybali et al., 2012).
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2.3.7. Siderophore Production
Siderophore production in a liquid medium using the Chrome Azurol Solution (CAS) 
was performed as previously described (Louden et al., 2011). 5mL of the PMS7-Ca medium
was inoculated and incubated for 72 hours. The suspension was then centrifuged at 4000×g for 
10 minutes and 1mL of the filter-sterilized supernatant was incubated 1:1 with the CAS. The
OD630 was then measured and a 10% difference between the sample and un-inoculated PMS7­
Ca with CAS was considered as positive (Machuca et al., 2003). 
2.3.8. Surface Motility
Surface motility was detected by inoculating 1µL of the bacterial suspension on freshly
prepared 0.3% LB-Agar (Difco, BD, USA) plates. The plates were then incubated at 37°C for
14 hours and the diameter of the circular diffusion pattern was measured. Motility rates were
reported as the diameter of diffusion divided by incubation time (Clemmer et al., 2011). 
2.3.9. Proteolytic Activity
Proteolytic activity was determined by inoculating 5mL of Trypticase Soy Broth
Dyalisate with one colony and incubating it overnight at 37°C with shaking at 200 rpm. The
following day, the suspension was centrifuged at 4,000×g for 10 minutes and 500µL of the 
filter-sterilized supernatant was incubated with 500µL of 1mg/mL Azoalbumin dissolved in 
50mM Tris-HCl (pH=7.7). This preparation was incubated at 37°C for 24 hours and 13% 
trichloroacetic acid was then added. The tubes were incubated at -20°C for 20 minutes and
centrifuged at 15,000×g for 10 minutes. The OD440 of the supernatant was then measured and 
U/L values were calculated where one U was the amount of enzyme needed to degrade one
micromole of Azoalbumin (Antunes et al., 2011; Ronca-Testoni, 1983)
2.3.10. Statistical Analysis
Normality of the data, when applicable, was tested for using the Shapiro-Wilk test. One­
way ANOVA and student t-tests were performed for normally distributed data while the 
Kruskal-Wallis and Mann-Whitney tests were performed for non-normally distributed data. 
Qualitative data was analyzed using the chi squared and the two-sided Fisher’s exact tests. P 
values of less than 0.05 were considered as statistically significant and all tests were performed
using the SPSS program, version 17.0 (SPSS 111 Inc., Chicago, USA).
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2.4. Results
2.4.1. Bacterial Isolates
In total, 95 Acinetobacter spp. isolates were collected. Of these isolates, three were 
Acinetobacter haemolyticus, one was Acinetobacter junii/johnsonii, and one was Acinetobacter
radioresistens/lwofﬁi as identified by the API strips. The rest of the isolates (n= 90) were 
Acinetobacter baumannii as identified by API and the amplification of blaOXA-51-like (Turton et 
al., 2006). Thirty five (38.9%) A. baumannii isolates were collected in 2013 while fifty five
(61.1%) were collected in 2014. Fifty eight (64.5%) of the A. baumannii isolates were collected 
from sputum, 17 (18.9%) from pus, 9 (10%) from urine, and 4 (4.4%) from blood samples.
Two (2.2%) isolates were collected from catheters. 
2.4.2. Antibiotic Susceptibility
Antibiotic susceptibility profiles were obtained after testing by the Kirby Bauer disk 
diffusion method according to CLSI guidelines (2014). Eighty one (90%) of the A. baumannii 
isolates were resistant to both meropenem and imipenem. Only one isolate was resistant to 
colistin. Susceptibility to other antimicrobial agents tested for was very low and did not exceed 
14.4% (Table 1). Complete antibiotic susceptibility profiles are found in Supplementary Table
S1.
Table 1. Antibiotic susceptibility profiles for 90 A. baumannii isolates collected over a one-year period. CTX 
stands for cefotaxime, CAZ for ceftazidime, FEP for cefepime, TZP for piperacillin/tazobactam, MEM for 
meropenem, IMP for imipenem, SXT for trimethoprim/sulfamethoxazole, CIP for ciprofloxacin, GT for 
gentamycin, and COL for colistin.
Antimicrobial Agent
CTX CAZ FEP TZP MEM
n % n % n % n % n %
Resistant 79 87.8 78 86.7 58 64.4 81 90 81 90
Intermediate 9 10 1 1.1 19 21.1 2 2.2 0 0
Sensitive 2 2.2 11 12.2 13 14.4 7 7.8 9 10
Antimicrobial Agent
IMP SXT CIP GT COL
n % n % n % n % n %
Resistant 81 90 83 92.2 84 93.3 77 85.6 1 1.1
Intermediate 0 0 0 0 0 0 0 0 0 0
Sensitive 9 10 7 7.8 6 6.7 13 14.4 89 98.9
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2.4.3. Dissemination of Carbapenemases and International Clones
PCRs for the detection of the most common carbapenemases among A. baumannii were 
performed in addition to tri-locus PCR typing which determines international clonality. blaOXA­
51-like was amplified from all the isolates identified as A. baumannii using the API strips. Of the
81 A. baumannii isolates that showed resistance to carbapenems, 76 (93.8%) harbored blaOXA­
23-like. Two of these isolates additionally harbored blaOXA-24-like. These are isolates 42 and 49.
None of the other carbapenemases tested for were detected. Seven isolates were resistant to
carbapenems but did not harbor any of the tested carbapenemases (Isolates 54, 59, 68, 72, 83,
84, and 85). Two isolates were sensitive to carbapenems but harbored blaOXA-23-like (Isolates 17
and 87).
Eighty A. baumannii isolates (88.9%) pertained to IC II, whereas six (6.7%) pertained 
to group 4 (Isolates 11, 25, 39, 62, 82, and 91), one (1.1%) to group 10 (Isolate 56), and two
(2.2%) to group 14 (Isolates 42 and 72), as summarized by Karah et al., (2012) (Table 2). One 
A. baumannii isolate showed a pattern that did not pertain to any IC where CsuE and blaOXA-66
were amplified from the first multiplex, and the other allele of CsuE was also amplified from
the second multiplex.
2.4.4. Virulence Determinants in Relation with Clonality and Carbapenem Susceptibility
The result of the various virulence determinants, in addition to international clonality 
and carbapenem resistance, are shown in Table 2. Seventy seven (85.6%) of the A. baumannii 
isolates showed strong biofilm formations while 10 (11.1%) showed weak formations and 3 
(3.3%) showed no biofilm formation. Forty two (46.7%) of the A. baumannii isolates showed 
α-hemolysis on blood agar plates while one isolate showed β-hemolysis. Seventy two (80%) 
A. baumannii isolates showed a diffusion pattern indicating surface motility on 0.3% LB-Agar
while 52 (57.8%) isolates were positive for siderophore production. Proteolytic activity ranged
from 4.4 ± 1.63 U/L to 61.97 ± 12.65 U/L and the doubling times for selected isolates ranged 
from 0.262 ± 0.021 to 0.653 ± 0.049 hours. 
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Table 2. Virulence determinants of 90 A. baumannii isolates in addition to international clonality and carbapenem
resistance. IC stands for international clone, Carb R. for carbapenem resistance, Bio for biofilm production, Hemo 
for hemolysis where the type of hemolysis and the day (D1-D3) on which it was first observed was recorded, 
Sidero for siderophore production, Proteo for proteolytic activity, and DT for doubling times. ND stands for Not
Determined.
Isolate IC Carb R. Bio Hemo Sidero Motility (µm/sec) Proteo (U/L) DT (hours)
2 2 + + - + 0.095 ± 0.017 7.66 ± 1.81 ND
3 2 + ++ - + 0.083 ± 0.025 25.32 ± 4.22 ND
4 2 + ++ - + 0.125 ± 0.013 28.9 ± 6.34 0.594 ± 0.036
5 2 + ++ β / D1 + 0.238 ± 0.126 61.97 ± 12.65 ND
7 2 + ++ α / D3 + 0.098 ± 0.033 23.68 ± 10.74 ND
8 2 + + α / D2 + 0.105 ± 0.035 20.56 ± 7.32 0.471 ± 0.067
10 2 + ++ α / D2 + 0.277 ± 0.156 5.59 ± 3.68 ND
11 4 - ++ - + 0.061 ± 0.020 21.15 ± 2.06 ND
12 2 + ++ - + 0.090 ± 0.031 3.33 ± 1.61 ND
13 2 + + α / D3 + 0.844 ± 0.131 7.47 ± 2.98 0.403 ± 0.056
14 2 + ++ α / D2 + 0.089 ± 0.027 26.22 ± 1.86 ND
15 2 + ++ - - 0.094 ± 0.027 32.28 ± 5.44 0.539 ± 0.063
16 2 + ++ α / D3 + 0.181 ± 0.092 23.48 ± 1.96 ND
17 2 - ++ - + 0.381 ± 0.043 16 ± 1.39 0.283 ± 0.031
18 - - ++ - + 0.411 ± 0.001 22.47 ± 3.39 ND
19 2 + ++ - + 0.193 ± 0.028 23.24 ± 4.1 ND
20 2 + ++ α / D2 + 0.549 ± 0.091 30.69 ± 6.94 ND
21 2 + ++ - + 0.748 ± 0.132 27.26 ± 0.63 0.377 ± 0.031
22 2 - + - + 0.067 ± 0.027 5.98 ± 5.45 0.310 ± 0.063
23 2 + ++ α / D2 + 0.071 ± 0.026 24.71 ± 3.38 ND
24 2 + ++ - + 0.267 ± 0.035 5.26 ± 1.42 ND
25 4 + ++ α / D2 + 0.435 ± 0.055 21.45 ± 3.9 ND
26 2 + ++ - + 0.466 ± 0.065 8.72 ± 0.3 ND
27 2 + ++ - + 0.377 ± 0.048 18.32 ± 0.63 ND
28 2 + ++ α / D2 - 0.462 ± 0.082 10.53 ± 4.43 0.653 ± 0.049
29 2 + ++ - + 0.457 ± 0.061 32.27 ± 10.28 ND
30 2 + ++ - + 0.302 ± 0.041 7.08 ± 3.31 ND
31 2 + ++ - + 0.387 ± 0.019 27.71 ± 3.9 ND
32 2 + ++ - - 0.511 ± 0.041 23.77 ± 1.77 ND
33 2 + ++ α / D2 + 0.649 ± 0.112 19.04 ± 2.15 ND
34 2 + ++ - + 0.416 ± 0.049 23.24 ± 9.42 ND
35 2 + ++ - + 0.402 ± 0.040 26.51 ± 1.86 ND
36 2 + ++ α / D2 + 0.716 ± 0.102 7.49 ± 4.58 ND
37 2 + ++ - + 0.488 ± 0.031 23.24 ± 4.47 ND
38 2 + ++ - + 0.426 ± 0.063 10.59 ± 3.46 ND
39 4 + - α / D3 - 0.112 ± 0.059 6.9 ± 2.4 ND
40 2 + ++ - + 0.458 ± 0.045 6.68 ± 1.93 ND
41 2 + ++ α / D2 - 0.382 ± 0.041 9.09 ± 2.32 0.401 ± 0.030
42 14 + ++ - + 0.38 ± 0.016 20.85 ± 4.92 ND
43 2 + + α / D3 + 0.516 ± 0.048 21.15 ± 7.6 ND
44 2 + ++ - - 0.541 ± 0.046 19.48 ± 2.78 0.467 ± 0.039
45 2 + ++ - + 0.484 ± 0.036 4.72 ± 2.17 ND
46 2 + ++ - + 0.416 ± 0.049 11.05 ± 4.5 ND
47 2 + ++ α / D2 + 0.519 ± 0.043 15.94 ± 6.88 ND
48 2 + ++ α / D2 + 0.433 ± 0.052 11.65 ± 4.2 ND
49 2 + ++ - + 0.291 ± 0.043 11.72 ± 4.99 0.343 ± 0.120
51 2 + ++ - + 0.367 ± 0.034 24.43 ± 2.73 ND
52 2 + ++ α / D2 + 0.431 ± 0.027 9.43 ± 3.22 ND
53 2 + ++ α / D2 + 0.386 ± 0.007 11.4 ± 4.09 ND
54 2 + ++ - - 0.328 ± 0.036 16.22 ± 5.1 ND
55 2 + ++ - + 0.336 ± 0.035 30.47 ± 10 ND
56 10 - ++ α / D3 + 0.533 ± 0.057 11.64 ± 2.02 ND
57 2 + + α / D2 - 0.357 ± 0.053 25.32 ± 2.73 ND
58 2 + - α / D1 - 0.16 ± 0.017 24.49 ± 4.55 ND
59 2 + ++ α / D2 - 0.361 ± 0.048 13.81 ± 4.49 ND
60 2 + ++ - - 0.406 ± 0.035 8.37 ± 2.92 ND
61 2 + ++ α / D3 + 0.355 ± 0.054 21.61 ± 0.24 ND
62 4 - ++ α / D2 - 0.381 ± 0.043 7.3 ± 0.21 ND
63 2 + ++ α / D1 - 0.160 ± 0.015 4.4 ± 1.63 ND
64 2 - + α / D1 - 0.208 ± 0.034 10.6 ± 1.45 0.339 ± 0.065
 
 
           
           
           
          
          
           
          
           
           
           
           
           
          
          
          
           
           
          
          
          
          
          
          
          
           
           
          
           
           
          
 
  
   
       
  
 
   
 
 
 
  
     
 
 
   
   
  
146
65 2 + ++ α / D2 - 0.417 ± 0.033 7.38 ± 3.81 ND
66 2 + ++ α / D2 - 0.451 ± 0.029 27.41 ± 2.87 0.369 ± 0.021
67 2 + ++ α / D2 + 0.517 ± 0.06 22.94 ± 2.87 ND
68 2 + ++ - - 0.504 ± 0.042 22.64 ± 7.44 ND
69 2 + ++ - - 0.526 ± 0.028 28.3 ± 2.1 0.385 ± 0.056
70 2 + ++ α / D2 - 0.549 ± 0.085 22.05 ± 6.94 ND
71 2 + ++ - - 0.474 ± 0.045 26.81 ± 3.1 ND
72 14 + ++ α / D3 + 0.326 ± 0.036 22.34 ± 2.36 ND
73 2 + ++ α / D1 - 0.59 ± 0.055 11.08 ± 5.56 ND
74 2 + ++ α / D2 - 0.476 ± 0.076 9.17 ± 0.93 ND
75 2 + ++ α / D2 - 0.361 ± 0.024 8.45 ± 3.1 0.328 ± 0.076
76 2 + ++ α / D3 + 0.406 ± 0.035 27.41 ± 4.03 0.311 ± 0.021
77 2 + ++ - + 0.251 ± 0.035 12.02 ± 1.96 ND
78 2 + ++ - - 0.610 ± 0.088 12.94 ± 2.61 0.262 ± 0.021
79 2 + ++ - + 0.555 ± 0.082 11.13 ± 0.69 ND
80 2 + + α / D2 - 0.607 ± 0.101 22.94 ± 2.87 ND
81 2 + ++ α / D3 - 0.491 ± 0.077 26.81 ± 0.89 ND
82 4 + - - - 0.161 ± 0.016 8.28 ± 0.33 ND
83 2 + + - - 0.479 ± 0.029 20.85 ± 4.5 ND
84 2 + ++ - - 0.484 ± 0.036 3.21 ± 3.04 ND
85 2 + ++ - - 0.833 ± 0.133 8.49 ± 2.85 ND
86 2 + ++ - - 0.407 ± 0.047 6.54 ± 4.7 ND
87 2 - ++ - + 0.383 ± 0.025 13.9 ± 4.48 ND
89 2 + ++ - - 0.717 ± 0.103 21.81 ± 8.09 ND
90 2 + ++ α / D2 - 0.833 ± 0.104 23.56 ± 10.31 ND
91 4 + + α / D3 - 0.253 ± 0.026 25.14 ± 2.31 ND
92 2 + ++ - - 0.716 ± 0.124 6.04 ± 3.49 ND
93 2 + ++ α / D3 - 0.769 ± 0.111 24.55 ± 9.35 ND
94 2 - ++ α / D2 - 2.605 ± 0.461 26.37 ± 4.42 ND
95 2 + ++ - - 0.809 ± 0.113 23.65 ± 8.61 0.414 ± 0.025
No general pattern was observed between the doubling times and antibiotic
susceptibility profiles. The slowest doubling time was determined for isolate 28 which was 
carbapenem-resistant, α-hemolytic, produced strong biofilms, showed a motility pattern,
harbored blaOXA-23-like, and pertained to IC II. Nevertheless, other isolates with similar profiles
showed faster doubling times (Table 2). One such example is isolate 78 which incidentally had 
the fastest doubling time. The colistin-resistant isolate 75 showed a similar antibiotic
susceptibility pattern and virulence profile to the aforementioned two isolates and had a 
relatively fast doubling time of 0.328 ± 0.076 hours. 
Isolate 94 showed the highest motility rate (2.605 ± 0.461µm/sec), produced strong 
biofilms, showed hemolysis on blood agars, and had a relatively high proteolytic activity (26.37 
± 4.42 U/L). This isolate was susceptible to carbapenems and pertained to IC II. Isolate 5 was 
the only isolate that showed β-hemolysis and it had the highest proteolytic activity. It also
showed a motility diffusion pattern, produced strong biofilms and siderophores, pertained to 
IC II, and harbored blaOXA-23-like. Isolates 2, 3, 4, 11, 12, and 82 showed very modest to no 
motility diffusion patterns and were negative for hemolysis. Isolate 4 also had a slow doubling
time (0.594 ± 0.036 hours). However, not all isolates that had similar motility rates shared
similarities with the rest of the virulence profile of these isolates. 
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Two of the isolates that pertained to group 4 were susceptible to carbapenems and four
out of six isolates of this group were negative for siderophore production. Moreover, two other
isolates of this group were negative for biofilm formation. Four of the six isolates pertaining to
this group harbored blaOXA-23-like and were resistant to carbapenems. One isolate pertaining to
group four was susceptible to carbapenems and showed elevated levels of virulence 
determinants. Both isolates pertaining to Group 14 had similar profiles but one was negative 
for blaOXA-23-like and positive for hemolysis whereas the other harbored blaOXA-23-like and blaOXA­
24-like but was negative for hemolysis. Isolate 18, which did not pertain to any of the international 
clones by tri-locus sequence typing, was susceptible to carbapenems and had similar virulence
profiles as isolates pertaining to IC II. Both isolates that harbored blaOXA-24-like in addition to
blaOXA-23-like were negative for hemolysis and had similar virulence profiles. 
2.4.5. Associations between Virulence and Resistance
IC II was positively associated with both carbapenem resistance and harboring blaOXA­
23-like (p<0.01). All the isolates that did not produce biofilms were also negative for siderophore
production. The isolates that showed moderate motility diffusion patterns were associated with
strong biofilm formation (p<0.01) while those that were either highly motile or non-motile
showed a positive association with siderophore production (p<0.05). No other statistical 
association was made.
2.5. Discussion
In this study, A. baumannii isolates obtained from a major tertiary care center in Beirut, 
Lebanon were characterized in terms of antibiotic susceptibility, clonality, and virulence 
determinants. An extremely high rate of carbapenem resistance (90%) was detected among the 
A. baumannii isolates. This rate, however, is very similar to that reported from a nation-wide
study (Hammoudi et al., 2015a) where the prevalence of CRAB isolates was 88%. These 
findings suggest an immediate need for the implementation of effective infection control
measures and antibiotic stewardship programs in Lebanese hospitals. This need is even more
urgent due to the high resistance rates of these isolates to other antimicrobial agents that were
tested for in this study (Table 1). The low rate of resistance to colistin among these isolates
hold a viable alternative for treatment. Nevertheless, its nephrotoxic effects (Bergen et al., 
2012) and the ability of A. baumannii to develop resistance towards this antimicrobial agent 
during therapy (Valencia et al., 2009) limits its effectiveness.
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In accordance with other studies performed in Lebanon, IC II was, by far, the most
prevalent clone among the A. baumannii isolates (Rafei et al., 2014a), and OXA-23-like the 
most disseminated (Rafei et al., 2015b). These findings are also similar to those reported from
other Mediterranean countries (Di Popolo et al., 2011). Interestingly, although an outbreak
caused by blaOXA-58-like harboring CRAB isolates was reported from SGH-UMC a few years 
ago (Zarrilli et al., 2008), this carbapenemase was not detected among our isolates. This could 
be an indication of the successful eradication of the clone that caused the outbreak at the time
of that study. 
The presence of blaOXA-23-like in two carbapenem-sensitive isolates suggest that either
the expression of this gene in these isolates is very modest or that it harbors a mutation that 
renders it ineffective. Further characterization of these isolates by sequencing the genetic 
environment of blaOXA-23-like and preforming RT-PCRs could help in better understanding why 
no carbapenem resistance was detected in these isolates. The seven CRAB isolates in which no 
carbapenemase was detected could be expressing resistance through carbapenemases that were 
not tested for in this study and/or through alteration of membrane permeability and efflux pump
over-expression (Peleg et al., 2008). 
Ten CRAB isolates pertaining to PCR group 4 were first identified in a study
investigating A. baumannii isolates from several European countries (Towner et al., 2008). In 
our study, two out of the six isolates pertaining to this group were susceptible to carbapenems.
Similarly, the isolate pertaining to group 10 was sensitive to carbapenems as opposed to the 
detection of carbapenem resistance among isolates pertaining to this group where it was first 
identified in Portugal (Grosso et al., 2008). The two isolates pertaining to group 14 were both 
resistant to carbapenems. One of them did not harbor any of the tested carbapenemases while 
the other had both OXA-23-like and OXA-24-like. This group was first identified in a study
from Romanian hospitals and the isolate pertaining to this group harbored blaOXA-58-like (Bonnin
et al., 2011). The diversity of profiles between the isolates pertaining to these groups, in 
addition to the diversity seen among isolates pertaining to IC II, reflect the plasticity of the A.
baumannii genome (Antunes et al., 2014). Moreover, the presence of these clones, in addition 
to the presence of the globally disseminated IC II (Karah et al., 2012), demonstrate the global 
expansion of A. baumannii clones that are present across wide geographical areas.  
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A study by Antunes et al., (2011) showed that different A. baumannii clinical isolates
are able to display different virulence profiles. This was indeed shown to be the case in our 
study where no specific pattern of virulence was associated with a specific clone (Table 2). The
A. baumannii isolates investigated had a high degree of variability in terms of virulence 
profiles. Moreover, no associations between antibiotic susceptibility profiles and doubling
times were detected. These findings suggest that each isolate should be treated as a unique case 
and no general assumptions could be made based on clonality and AST. This also shows that
the relationship between virulence and antibiotic resistance is indeed a complex one and 
warrants further investigation (Peleg et al., 2012). Nevertheless, the low diversity of clones
among the tested isolates could be obscuring associations between clonality and virulence,
since some isolates within a group showed similar virulence profiles but their numbers might
have been too few for the detection of statistical associations. Further investigating these
associations using larger and more clonally diversified pools could shed further light on the 
matter.
Finally, while comparing virulence factors one to another, an association between 
motility on one hand, and biofilm formation and siderophore production on the other, was
determined. The relationship between motility and strong biofilm formation has been
previously reported among MDR A. baumannii isolates (Eijkelkamp et al., 2011). Moreover,
the association detected between motility and siderophore production is not surprising since
the former factor was associated with biofilm production while the latter allows for iron
acquisition that is crucial for biofilm formation (Gentile et al., 2014). These associations reveal 
a highly complex interplay between the different virulence determinants in A. baumannii, 
especially those that are multi-factorial. 
2.6. Conclusions
In conclusion, a very high rate of carbapenem resistance was detected among clinical 
A. baumannii isolates obtained from a Lebanese tertiary care center. IC II was the most
prevalent clone and OXA-23-like was the most prevalent carbapenemase. The isolates showed 
highly varied virulence profiles that were not associated with any specific clone or oxacillinase 
gene. However, associations between motility, biofilm formation, and siderophore production 
have been found. Increasing the diversity of the pool of isolates could reveal associations 
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between clonality and virulence that could allow for the prediction of pathogenicity of a clinical
A. baumannii isolate.
Supplementary Table S1. Antibiotic susceptibility profiles as interpreted according to the CLSI guidelines
(2014). R stands for resistant, S for Susceptible, I for Intermediate resistance, and mm for the diameter of the 
inhibition zone in millimeters. CTX stands for cefotaxime, CAZ for ceftazidime, FEP for cefepime, TZP for 
piperacillin/tazobactam, MEM for meropenem, IMP for imipenem, SXT for trimethoprim/sulfamethoxazole, CIP
for ciprofloxacin, GT for gentamycin, and COL for colistin. The * indicates that the determination of susceptibility 
to colistin was performed using the broth microdilution method.
Antibiotic Susceptibility Testing Carbapenemases
CTX CAZ FEP TZP MEM IMP SXT CIP GT COL*
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3. Genomic and Phenotypic Characterization of two Colistin Resistant
Acinetobacter baumannii Clinical Isolates in Comparison to their Sensitive 
Counterparts
3.1 Abstract
Acinetobacter baumannii is a concerning nosocomial pathogen worldwide. Multi-drug 
resistance among A. baumannii isolates led to use of colistin, in turn resulting in colistin­
resistant isolates. In this study, the genetic and phenotypic profiles of two A. baumannii isolates 
that acquired resistance during therapy from two different patients are investigated. Two A.
baumannii isolates where obtained from Patient 1 (C071 and C440) and three from Patient 2 
(C080, C314, and C428). Colistin resistance was determined using Vitek-2 and E-test.
Clonality was determined by RAPD analysis and global-lineage multiplex PCRs. The pmrCAB
operon was sequenced and common carbapenemases were screened for by PCR. Doubling
times, hemolysis, surface motility, biofilm formation, siderophore production, and proteolytic 
activity were then determined phenotypically. Finally, whole-genome sequencing was 
performed for all the isolates. C440 and C428 were resistant to colistin and clonally identical 
to their sensitive counterparts. The sole cause of colistin resistance was traced to the previously
described P233S mutation in pmrB of C440 and a novel ΔIle19 mutation in pmrB of C428.
blaOXA-58-like and blaGES-5 from the strains of Patients 1 and 2, respectively were also detected. 
C440 had attenuated proteolytic activity and increased siderophore production as compared to
C071 whereas no difference in in-vitro virulence determinants was detected between C080,
C314, and C428. One common and one novel mutations were encountered in pmrB from two
distinct A. baumannii colistin resistant isolates. These mutations caused colistin resistance
during therapy in two distinct clones and only one of them had altered in-vitro virulence. 
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3.1. Resumen
Acinetobacter baumannii es un preocupante patógeno nosocomial. Los elevados 
niveles de resistencia a varios antibióticos han conducido al uso de colistina en la clínica, lo 
que a su vez, ha producido el desarrollo de resistencia frente a este antibiótico en cepas clínicas 
de A. baumannii. En este estudio se investigan los perfiles genéticos y fenotípicos de dos cepas
de A. baumannii resistentes a colistina, aisladas de dos pacientes y se comparan con las cepas
sensibles. Dos cepas fueron tomadas de un primer paciente (C071 y C440) y tres cepas de un
segundo paciente (C080, C314, y C428). Se determinó la susceptibilidad a colistina  mediante
Vitek-2 y E-test. La clonalidad se determinó mediante las técnicas de RAPD y PCR multiplex 
para tres genes “housekeeping”. A continuación, se secuenció el operón pmrCAB y se
amplificaron las carbapenemasas por PCR. Posteriormente, se determinaron los tiempos de
generación, formación de biofilms, producción de sideróforos, movilidad en superficie,
hemólisis, y actividad proteolítica. Finalmente, se secuenció el genoma completo de las cinco
cepas. Las cepas C440 y C428 resultaron resistentes a colistina y fueron idénticas a las cepas
sensibles obtenidas del paciente respectivo. La única causa de resistencia a colistina fue una
mutación de P233S en PmrB de la cepa C440. Esta mutación es bien conocida entre cepas
clínicas de A. baumannii resistentes a colistina. La segunda mutación encontrada en PmrB, en
la otra cepa resistente a colistina (C428), fue ΔIle19. Esta mutación ha sido un descubrimiento 
original que no había sido publicado anteriormente. El gen blaOXA-58-like fue detectado en las
cepas C071 y C440 y blaGES-5 se amplificó por primera vez en A. baumannii a partir de las
cepas C080, C314, C428. La cepa C440 presentó menor actividad proteolítica que la cepa
C071 y fue positiva para la producción de sideróforos, mientras que C071 fue negativa. Esto
puede indicar que la mutación P233S en PmrB afecta a la virulencia en A. baumannii, por lo
que es necesario un estudio más profundo para saber exactamente el mecanismo de la 
interrelación de ambos procesos. No se encontraron diferencias de virulencia entre las cepas
C080, C314, y C428. En conclusión, dos mutaciones en PmrB, de las cuales una es nueva, son 
las responsables de la resistencia a colistina en A. baumannii durante el tratamiento con este
antibiótico. La mutación P233S afecta a la virulencia de A. baumannii, mientras que la 
mutación ΔIle19 parece no afectar. La investigación en profundidad de los mecanismos de
virulencia y resistencia a colistina en estas cepas puede conducir a una mejor compresión de
los procesos de intercambio de información entre virulencia y antibiorresistencia.
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3.2. Introduction
Acinetobacter baumannii is a versatile nosocomial pathogen that has a heightened
ability to adapt to its environment and acquire resistance to antimicrobial agents. This organism
commonly infects critically ill patients and is implicated in ventilator associated pneumonia,
wound infections, bacteremia, meningitis, and urinary tract infections (Antunes et al., 2014).
Multi Drug Resistant (MDR) A. baumannii isolates are becoming a common finding all over 
the world (Peleg et al., 2012). The high prevalence of carbapenem resistance among MDR A.
baumannii isolates has forced clinicians to use colistin, despite its nephrotoxic effects. This, in
turn, led to an increase in the rate of colistin resistance among A. baumannii isolates (Napier et 
al., 2013). 
Colistin is a cationic peptide that acts upon Gram-negative bacteria through the 
disruption of the negatively charged outer membrane (Vaara et al., 1985). Several different 
mutations that result in the reduction of the net negative charge of the outer membrane lead to
colistin resistance. Mutations in the pmrCAB operon, that is involved in Lipid A modifications
in response to environmental stimuli, have been most commonly implicated with colistin
resistance in A. baumannii (Olaitan et al., 2014). Moreover, mutations in genes involved in
lipid A biosynthesis (lpxA, lpxC, and lpxD) also cause colistin resistance (Beceiro et al., 2014).
Finally, the plasmid mediated mcr-1 gene has been recently associated with colistin resistance.
This gene was only recently discovered but retrospective studies showed that it is widely 
disseminated among Gram-negative bacteria (Skoc and Monnet, 2016).
Colistin resistance among A. baumannii clinical isolates has been sporadically reported
from countries all over the world (Cai et al., 2012). Although most studies report rates below 
7%, a study from Spain reported a resistance rate of 40.7% (Arroyo et al., 2009). Moreover, a
colistin resistant A. baumannii strain caused a pan-drug resistant nosocomial outbreak in a 
Spanish university hospital in 2009 (Valencia et al., 2009). These reports highlight the potential 
of A. baumannii to cause threatening outbreaks.
Pathogenicity of A. baumannii is not yet fully understood but has been linked to several
virulence factors. These include its ability to produce biofilms, hemolysis, siderophores,
proteolysis, and twitching motility (Antunes et al., 2014). Some studies suggest a negative
correlation between colistin resistance and virulence in A. baumannii (Lopez-Rojas et al., 2011; 
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Rolain et al., 2011). Nevertheless, the exact effect of colistin resistance on virulence is still not 
very well defined (Pogue et al., 2015). 
In this study, we aim at investigating the mechanisms of colistin resistance in A.
baumannii and its subsequent effect on virulence. To that end, genotypic and phenotypic
characterization of two clonally distinct strains that developed colistin resistance during 
treatment was performed. 
3.3. Materials and Methods
3.3.1. Bacterial Strains
Five strains were isolated from two different patients from Hospital Universitario La
Paz, Madrid, Spain. Identification of the strains and antibiotic susceptibility testing using AST­
N-245 cards were performed using the Vitek2 system (BioMérieux Mercy l’Etoile, France) 
(Granzer et al., 2016). The breakpoint criteria were established in accordance with Clinical and 
Laboratory Standards Institute guidelines (M100-S20) (CLSI, 2011). Resistance to colistin was 
confirmed using E-test strips (BioMérieux Mercy L’Etoile, France). The strains were stored in 
brain heart infusion broth (Oxoid, UK) with 15% glycerol at -80°C until used.
3.3.2. Determination of Clonality
Clonality of the isolates was initially tested for by Random Amplified Polymorphic
DNA (RAPD) analysis (Hsueh et al., 1998). The primers used were OPA-2 (5’ ­
TGCCGAGCTG-3’), OPA-18 (5’-AGGTGACCGT-3’), and OPA-12 (5'-TCGGCGATAG-3'). 
The PCR conditions were an initial denaturation at 94°C followed by 45 cycles of 94°C for 1
minute, 37°C for 1 minute, and 72°C for 2 minutes; with a final extension at 72°C for 2 minutes.
Then, in order to determine the global lineages of the strains, two multiplex PCRs described
by Turton et al. (2007) targeting different alleles of the intrinsic OmpA, CsuE, and blaOXA-51­
like genes were performed. 
3.3.3. Sequencing of the pmrCAB Operon
In order to sequence the pmrCAB operon, DNA was extracted using a commercial kit 
(Qiagen, Netherlands). The primers described by Adams et al. (2009) were used in order to
amplify various segments of the pmrCAB operon under standard PCR conditions. Additional 
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primers were designed in this study in order to fill the gaps in the sequences obtained
(Supplementary Table 1). Primers G2F, G2R, G3F, and G3R where designed to also include
an insertion sequence between pmrA and pmrB that was discovered in the two strains isolated 
from Patient 1. PCR products were purified using a kit (Qiagen, Netherlands) and sent to
Secugen S. L. (Madrid, Spain) for sequencing. The online tool “Oligo Calc”
(http://www.basic.northwestern.edu/biotools/oligocalc.html) was used in order to check for the 
integrity of the primers designed in this study. The BioEdit software version 7.2.5 (Ibis 
Biosciences), Serial Cloner software version 2.6.1 (Serial Basics), and the NCBI BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) tools were used in order to analyze the sequences, 
construct the operon, and detect mutations.
3.3.4. Polymerase Chain Reactions
PCRs were performed in order to detect the blaOXA-51-like, blaOXA-23-like, blaOXA-24-like, 
blaOXA-58-like, blaOXA-48, blaNDM, and blaKPC genes. The primer sequences, annealing
temperatures, and expected amplicon sizes are published by Tourton et al. (2007), for blaOXA­
51-like, Mostachio et al. (2009) for the subsequent three genes, and Poirel et al. (2011) for the
final three genes. Previously verified and sequenced template DNAs for each of the respective
genes was obtained from the hospital’s strain library for use as positive controls.
3.3.5. Full Genome Sequencing
In order to rule out any other mutation that might be affecting colistin resistance, full
genome sequencing of all five isolates was performed. DNA was extracted using a kit (Qiagen,
Netherlands) from an overnight culture concentrated by centrifugation at 8,000×g for two
minutes. It was then quantified using the Qubit fluorimeter and the Quant-it kit (Invitrogen, 
USA). Purified DNA was sent to Eurofins Genomics (GmbH) and 2x125 paired-end reads were
obtained in a HiSeq 2500 Illumina system using the HiSeq SBS Kit, v4. Contigs were 
assembled using the Geneious assembler within the Geneious package, version 9.1.5. The 
MLST (version 1.8), Resfinder (version 2.1) and Plasmidfinder (version 1.3) services available 
at the website of the Center of Genomic Epidemiology (http://www.genomicepidemiology.org) 
were used in order to determine the sequence types of the strains, acquired resistance genes, 
and plasmids present, respectively. The Geneious software was used for comparison of whole
genomes and the Rapid Annotation using Subsystem Technology (RAST) 
(http://rast.nmpdr.org/rast.cgi) tool (version 2.0) was used for annotation. Genome sequences
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for C071, C440, C080, C314, and C428 were uploaded to Genbank with accession numbers
MEDG00000000, MEDH00000000, MDTR00000000, MDTT00000000, and 
MDTS00000000, respectively. The sequences were then automatically annotated with the
NCBI Prokaryotic Genome Annotation Pipeline. 
3.3.6. Growth Curves 
In order to determine doubling times, one colony was suspended in Luria-Bertani (LB)
Broth and was incubated at 37°C overnight. The following day, a 1:100 dilution in 50mL LB
broth was made and the suspension was incubated at 37°C with shaking at 200 rpm for 8 hours.
Each hour, the OD600 was spectrophotometrically measured and the doubling times were
calculated as previously described (Hall et al., 2014). Three independent experiments were
performed for this, and all subsequent experiments.
3.3.7. Hemolysis
Hemolysis was tested for by inoculating 10µL of a suspension adjusted to 103CFU/mL
on 5% Sheep Blood Agar (SBA) (Biomérieux Mercy L’Etoile, France). The plates were then 
incubated at 37°C and hemolytic activity was monitored for 6 days (Antunes et al., 2011). 
3.3.8. Biofilm Formation
Biofilm formation was determined by inoculating 10µL from an overnight culture into 
1mL LB broth in 12x75mm polystyrene tubes followed by an overnight incubation at 37°C. 
The bacterial suspension was then aspirated and the tube rinsed with water and stained with
1% crystal violet for 10 minutes. Visualization of a ring at the air-liquid interface after washing
the dye was indicative of biofilm formation (Toamaras et al., 2003).
3.3.9. Motility
Surface motility was tested by plating 1µL of an overnight culture on 0.3% LB-Agar 
(Difco, BD, USA). The plates were subsequently incubated at 37°C and the diameter of the
distance travelled was measured at 14 hours (Antunes et al., 2011). The motility rate is 
presented as this diameter divided by time. Pseudomonas fluorescens strain B52 was used as a 
positive control for this experiment, in addition to the two following ones. The incubation 
temperature for this strain was 30°C. 
 
 
 
     
 
 
  
  
     
  
 
 
 
  
  
  
 
    
 
 
 
 
  
  
  
  
  
  
   
   
159
3.3.10. Proteolytic Activity
Proteolytic activity was measured via the Azoalbumin assay. One colony from each
isolate was incubated in Trypticase Soy Broth Dyalisate overnight at 37°C with shaking at 200 
rpm. The suspension was then centrifuged at 4,000xg for 10 minutes and 500µL of the filter­
sterilized supernatant was incubated with 500µL of a 1mg/mL Azoalbumin solution (in 50mM
Tris-HCl, pH=7.7), at 37°C for 24 hours. Trichloroacetic Acid with a final concentration of 
13% was then added and the tubes were placed at -20°C for 20 minutes. The tubes were then 
centrifuged at 15,000xg for 10 minutes and the OD440 of the supernatant was measured
(Antunes et al., 2011). Results were presented in U/L where one U was defined as the amount
of enzyme needed to degrade one micromole of Azoalbumin. 
3.3.11. Siderophore Production
Detection of siderophores was performed using the liquid Chrome Azurol S (CAS) 
assay. One colony was used to inoculate the PMS7-Ca medium and was incubated at 37°C for
72 hours with shaking at 200 rpm. The suspension was then centrifuged at 4000xg and 1mL of 
the filter sterilized supernatant was incubated with 1mL of the CAS solution for 1 hour. A blank
was prepared using sterile PMS7-Ca and CAS solution. The OD630 was then measured and a
10% difference between the blank and the sample was considered as positive (Louden et al.,
2011). 
3.4. Results
3.4.1. Patient History 
Patient 1 had non-Hodgkin lymphoma complicated with graft versus host disease and
was admitted to the Burns Unit with epidermolysis progressing to 100% of the body surface.
The patient required assisted ventilation which was later complicated by pneumonia, septic 
shock, and multiple organ failure. On the first day of admission, treatment was started with
meropenem 2g/8h, tigecycline 100mg/12h, and liposomal amphotericin B 300mg/24h.
Bronchial aspirate and blood samples were obtained and A. baumannii (C071) was identified 
in both samples. The patient was switched to colistin with a loading dose of 4.5 MU IV and a
maintenance dose of 3 MU IV per 8 hours while retaining the tigecycline treatment. A second 
isolate from the same patient (C440) was obtained from blood on the 16th day and was found 
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to be resistant to colistin. It was only susceptible to amikacin and minocycline (Table 1). The 
patient died on day 18.
Table 1. Antibiotic susceptibility testing of the five A. baumannii isolates. “MIC” represents Minimum Inhibitory
Concentration expressed in µg/mL, “R” represents Resistant, “I” represents Intermediate resistance, and “S” represents 
Susceptible. “*” indicates that the results were verified by the E-test.
Antimicrobial Agent
Patient 1 Patient 2
C071 C440 C080 C314 C428
MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S MIC R-I-S
Ampicillin/Sulbactam
Ticarcillin
Piperacillin /Tazobactam
Ceftazidime
Cefepime
Imipenem
Meropenem
Ciprofloxacin
Levofloxacin
Gentamicin
Tobramycin
Amikacin
Colistin*
Minocycline
Tigecycline
Trimethoprim/Sulfamethoxazole
>16/8 R >16/8 R
>64 R >64 R
>64/4 R >64/4 R
16 I 16 I
8 I 8 I
>8 R >8 R
>8 R 8 I
>2 R >2 R
>4 R >4 R
>8 R >8 R
>8 R >8 R
≤2 S ≤2 S
≤0.5 S 8 R
≤1 S 2 S
≤0.5 - 4 -
>4/76 R >4/76 R
>16/8 R
>64 R
>64/4 R
>16 R
>16 R
>8 R
>8 R
>2 R
>4 R
>8 R
>8 R
≤2 S
≤0.5 S
≤1 S
1 -
>4/76 R
>16/8 R
>64 R
>64/4 R
>16 R
>16 R
>8 R
>8 R
>2 R
>4 R
>8 R
>8 R
≤2 S
≤0.5 S
≤1 S
2 -
>4/76 R
>16/8 R
>64 R
>64/4 R
>16 R
>16 R
>8 R
>8 R
>2 R
>4 R
8 I
>8 R
≤2 S
12 R
≤1 S
2 -
>4/76 R
Patient 2 was a diabetic patient with kidney failure that required dialysis and renal 
transplant five years before admission. The patient was admitted to the Intensive Care Unit 
presenting with paraventricular brain haemorrhage and subarachnoid hematoma that required
external ventricular drainage. On the first day of admission, the patient was started on 
meropenem 2g/8h and linezolid 600mg/8h IV. A Cerebrospinal Fluid (CSF) sample was taken
wherein A. baumannii (C080) was isolated. The patient was switched to colistin with a loading 
dose of 4.5 MU IV and a maintenance dose of 3 MU IV per 8 hours on the 3rd day. A second
A. baumannii isolate (C314) was obtained from the CSF on the 8th day which remained
susceptible to colistin. In the 12th day, a third isolate (C428) was obtained that was resistant to 
all beta-lactams, fluoroquinolones, trimethoprim-sulfamethoxazole, and colistin (Table 1). The
intraventricular catheter was changed on the 13th day and the following culture of a CSF sample
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was sterile. The patient recovered and was discharged on the 37th day (Table 1). Figure 1 shows 
the timeline of treatment and strain isolation of each patient.
Figure 1. Timeline of treatment and strain isolation of each patient.
3.4.2. Sequencing of the pmrCAB Operon
The pmrCAB operon of the five strains was amplified by PCR and sequenced. Both the 
sensitive (C071) and resistant (C440) strains obtained from Patient 1 had an ISAba1 sequence
inserted between pmrA and pmrB in the opposite sense as compared to the rest of the operon. 
This sequence was lacking from all three strains isolated from Patient 2 (C080, C314, and 
C428). Strain C440 had a C to T change at nucleotide 697 of the pmrB gene as compared to 
C071 that resulted in a P233S mutation. As for the strains obtained from Patient 2, deletion of 
the nucleotides 55-57 in pmrB, resulting in the deletion of Isoleucine at position 19 of the
protein, was detected in the colistin resistant strain C428 as compared to C080 and C314. 
3.4.3. Detection of Carbapenemases by PCR
PCRs for the detection of the intrinsic and acquired carbapenemases were performed.
blaOXA-51-like was amplified from all 5 isolates. In addition, blaOXA-58-like was detected in C071
and C440. None of the other tested genes were amplified. 
3.4.4. Clonality Analysis
In order to determine the clonality of the strains, RAPD analysis and global lineage 
multiplex PCRs were performed. RAPD analysis showed that the two strains isolated from
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Patient 1 were identical to each other and distinct from those isolated from Patient 2. The
isolates obtained from Patient 2 were also identical to each other. The multiplex PCRs showed
that C071 and C440 pertained to International Clone (IC) IC I while C080, C314, and C428
pertained to IC II. 
3.4.5. Whole-Genome Sequencing
The Multi-Locus Sequence Typing (MLST) tool showed that strains C071 and C440 
pertained to sequence type (ST) ST81 using the Pasteur scheme (Diancourt et al., 2010) while
C080, C314, and C428 pertained to ST2. Table 2 shows the antibiotic resistance genes 
identified by ResFinder. The aminoglycoside resistance genes aac(6')Ib-cr and aadB, as well
as the sulphonamide resistance gene sul1 were detected in all strains. blaOXA-58-like was detected
in strains C071 and C440 while blaGES-5 was detected in strains C080, C314, and C428. The
blaOXA-69 and blaOXA-66 genes, which belong to the blaOXA-51-like family (Turton et al., 2007), 
were also detected. Moreover, the Ser83Leu in gyrA and Ser80Leu in parC that are responsible 
for fluoroquinolone resistance were detected in the genome of all five strains (Warner et al.,
2016). Other than the mutations previously described in the pmrCAB operon, no significant 
mutations that affect colistin resistance, nor the mcr-1 gene were detected. 
Table 2. Resistance genes as detected in the different strains by the ResFinder service.
Patient 1 (Strains C071 and C440) Patient 2 (Strains C080, C314, and C428)
Gene Function % Identity
Aminoglycoside
aacA4
resistance
Aminoglycoside 
aadB
resistance
Aminoglycoside 
aph(3')-Ic
resistance
Aminoglycoside 
aac(6')Ib-cr
resistance
Sulphonamide 
sul1
resistance
blaOXA-69 beta–lactamase
blaOXA-58 beta–lactamase
100.00
98.88
100.00
99.61
100.00
100.00
100.00
Gene Function % Identity
aadA2
Aminoglycoside 
resistance
100.00
aadB
Aminoglycoside 
resistance
100.00
strB
Aminoglycoside 
resistance
99.04
aac(6')Ib-cr
Aminoglycoside 
resistance
99.42
sul1
Sulphonamide 
resistance
100.00
sul2
Sulphonamide
resistance
100.00
blaOXA-66 beta–lactamase 100.00
blaGES-5 beta–lactamase 100.00
cmlA1
Phenicol 
resistance
99.60
dfrA7
Trimethoprim
resistance
100.00
Plasmidfinder and Genbank searches showed that C071 and C440 harbor two small
plasmids. The first was around 8 Kb long and did not harbor any resistance gene. It had high 
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similarity with plasmid pAC12 (Genbank accession number: CP007550). The second plasmid 
was around 6Kb long and was identical to plasmid pRAY* (Genbank accession number: 
KU869529) which harbors the aadB aminoglycoside resistance gene cassette. C080, C314, and 
C428 harbored a large plasmid of around 75 Kb that was similar to plasmid p1AB5075
(Genbank accession number: CP008707.1) but was missing a segment to be identical to that
plasmid. Almost all the resistance genes detected in these three strains were in this plasmid.
Several genes associated with virulence in A. baumannii were detected in all five
isolates. They include genes coding for the type IV pili and fimbriae assembly systems, in 
addition to pilA, pilB, and pilT, all of which are involved in twitching motility (Harding et al.,
2013). The pgaA, pgaB, pgaC, and pgaD genes involved in biofilm formation (Choi et al., 
2009) were also detected. Genes coding for the assembly of the siderophore Achromobactin as 
well as its receptor were detected in all isolates. C080, C314, and C428 additionally had two
genes that are part of the operon coding for the assembly of the siderophore Anthrachelin. 
Finally, genes coding for several hemolysins in addition to the phospholipases C and D have
been found in all five strains. 
3.4.6. Generation times and in-vitro Virulence
Generation times and phenotypic detection of virulence factors were determined for all 
five strains. Generation times seem not to be affected by resistance to colistin when the colistin 
resistant strains were compared to their sensitive counterparts. Strain C314 showed a slightly 
reduced motility rate as compared to C080 and C428. Nevertheless, none of the tested strains
showed any diffusion pattern on the agar surface and should be considered as negative as 
compared to other studies (Antunes et al., 2011). C080, C314, and C428 showed α-hemolysis 
on SBA that started on day two whereas C071 and C440 showed no hemolysis on SBA. All
the tested strains were able to develop biofilms in polystyrene tubes. Strain C440 was the only 
strain that was positive for in-vitro production of siderophores and had almost half the 
proteolytic activity as compared to C071 (Table 3). 
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1
2
Table 3. Generation times (in minutes), motility, hemolysis, biofilm formation, siderophore production, and proteolytic 
activity of the five tested strains. “D” stands for the day in which hemolysis was observed and “α” and “β” refer to the type of 
hemolysis observed.
Patient Generation Motility Proteolytic 
Hemolysis Biofilms Siderophores
Time (min) (µm/s) Activity (U/L)
C071 39.3 ± 7.98 0.019 ± 0.007 - + - 30.69 ± 5.82
 
C440 44.7 ± 5.1 0.021 ± 0.011 - + + 15.49 ± 2.73
 
Patient Generation Motility Proteolytic 
Hemolysis Biofilms Siderophores
Time (min) (µm/s) Activity (U/L)
C080 30 ± 4.68 0.066 ± 0.009 α since D2 + - 29.89 ± 3.83
C314 24.42 ± 0.6 0.044 ± 0.008 α since D2 + - 35.45 ± 5.39
C428 27.78 ± 4.74 0.052 ± 0.007 α since D2 + - 25.03 ± 7.64
3.5. Discussion
The pmrCAB operon contains the two-component response regulator and sensor kinase
pmrA/B that responds to changes in Fe3+ and Mg2+ levels in the environment. This system is
also involved in lipid A modifications through the phosphoethanolamine transferase coded by
pmrC (Arroyo et al., 2011). Several mutations in pmrCAB, especially in pmrB, lead to colistin
resistance in A. baumannii (Olaitan et al., 2014; Adams et al., 2009). In our study, two distinct 
A. baumannii isolates have been shown to acquire resistance to colistin through mutations in 
pmrB. The lack of other significant mutations in their genomes and of mcr-1 demonstrates that
these mutations are solely responsible for this resistance. The P233S mutation in pmrB of C440 
is commonly reported among colistin resistant clinical isolates (Olaitan et al., 2014; Adams et
al., 2009; Arroyo et al., 2011; Pournaras et al., 2014; Durante-Mangoni et al., 2015). It is an
activating mutation located within the histidine kinase domain of PmrB and is involved in
dimerization (Durante-Mangoni et al., 2015). The other mutation detected was the ΔIle19 
deletion in pmrB of C428. This mutation is positioned in the center of the first trans-membrane
helix of PmrB and, to the best of our knowledge, has not been reported elsewhere. It is possible
that this mutation causes PmrB to be permanently activated which in turn could lead to colistin
resistance in a manner similar to the hyperactive kinase mechanism (Arroyo et al., 2011). 
Further characterization regarding the effect of this mutation on the proteins coded by pmrCAB 
could help better understand the mechanisms of colistin resistance. ISAba1 was present within
pmrCAB of both the sensitive and resistant strains obtained from Patient 1 indicating no direct 
effect on colistin resistance. 
Acinetobacter baumannii is notorious for its ability to acquire DNA and adapt its
genetic expression depending on a wide range of factors (Antunes et al., 2014). Different 
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strains were shown to be able to adapt differently to the same stress conditions through
mechanisms that are not yet fully understood (Antunes et al., 2011). This was demonstrated in 
our study where different virulence profiles were obtained for the different A. baumannii
strains. This becomes especially evident in the lack of motility and siderophore production in
C080, C314, and C428, despite the presence of the required genes. Plasticity of the A.
baumannii regulation systems could also have led to the conflicting reports regarding the effect
of colistin resistance on virulence. Some studies report reduced virulence after acquisition of 
colistin resistance (Olaitan et al., 2014; Lesho et al., 2013), especially after mutations involving
the lpxA, lpxC, or lpxD genes (Beceiro et al., 2014). As for the P233S mutation, one study
reports that it causes reduced virulence (Pournaras et al., 2014) whereas another reports it to 
not affect virulence (Durante-Mangoni et al., 2015). In our study, the colistin resistant strain 
C440 harboring the P233S mutation showed an increase in siderophore activity and almost half
of the proteolytic activity of C071 (Table 3), despite having the rest of the genome identical.
Since pmrB is involved in iron regulation, this mutation could have resulted in alterations in
iron regulation, which in turn led to an over-production of siderophores, allowing for their
phenotypic detection. Moreover, proteolytic activity in C440 seems to be negatively affected.
These findings suggest an interplay between the mechanisms governing these virulence factors 
and colistin resistance in this strain that could be due to the detected mutations, the strain’s 
genetic background, or some other factors. Further investigation into this matter could help 
better understand the interplay between colistin resistance and virulence in A. baumannii. The
other colistin strain (C428) does not seem to have a difference in the tested virulence factors as
compared to its sensitive counterparts.
Siderophore assembly and recovery systems in A. baumannii are still not fully 
characterized but the presence of such systems, similar to those of Achromobactin, have been 
identified in this bacterium (Penwell et al., 2015). Such systems have been identified in all the 
tested isolates. In addition, the asbA and asbB genes were detected in C080, C314, and C428. 
These genes are part of a putative siderophore biosynthesis operon that was first described in 
Bacillus anthracis and belongs to the same group as that of Achromobactin (Challis et al.,
2005). However, siderophore production was not phenotypically detected in these isolates
possibly indicating a low level expression of these genes.
C071 and C440 pertained to the MDR ST81 which was encountered in 10.2% of 729
A. baumannii isolates obtained from various Spanish hospitals in an 11-year study (Villalon et 
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al., 2011). It is different from IC I (also known as ST1) by a single allele that is not tested for 
by the multiplex PCRs used in this study, explaining why it was reported as pertaining to this 
clone. Carbapenem resistance in C071 and C440 is a result of the blaOXA-58-like gene they harbor 
that is commonly reported among A. baumannii (Mostachio et al., 2009). C080, C314, and
C428 were found to harbor blaGES-5 and they belong to the widely spread MDR sequence type 
ST2, also known as IC II. blaGES-5 has been reported in several other species (Bonnin et al.,
2011), but, to the extent of our knowledge, was never reported in A. baumannii. Nevertheless,
the blaGES-5 genes detected by Resfnder in these strains differed by only one nucleotide from
some sequences of blaGES-14 deposited in Genbank. The ability of strains from different widely 
disseminated MDR lineages to develop resistance to colistin presents a great threat on the 
continued use of this antibiotic and highlights the potential of pan-drug resistant A. baumannii
outbreaks.
3.6. Conclusions 
In conclusion, the previously reported P233S and the novel ΔIle19 mutations in pmrB
were identified as sole genetic mutations that lead to colistin resistance in two distinct isolates
pertaining to widely disseminated international clones. The former mutation resulted in a 
change in the virulence profile of the colistin resistant isolate whereas the latter did not produce 
any change. In addition to colistin resistance, one set of isolates harbored blaOXA-58-like and the
other set harbored blaGES-5. Further investigations into the interlocking mechanisms involved
in colistin resistance and virulence could lead the way for the development of antimicrobial
agents that could attenuate one or the other, if not both.
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Supplementary Table S1. Primers used for the amplification and sequencing of the pmrCAB operon.
Primer Sequence (5’ to 3’) Reference Primer Sequence (5’ to 3’) Reference
pmrBAC_L GCGAGGAGCACATTTCCTAA
Adams et 
al., 2009
G1F CCTGATGCGGGGTGTAC This study
pmrBAC_R TGTAGTCACTCACGATGCTGAA
Adams et 
al., 2009
G1R CGAACACCTGTGACTGC This study
pmrBAC_L2 TTAAAGTTACATCTTGCTTTGCC
Adams et 
al., 2009
G2F GGTGCCCCAAATCAGTCG This study
pmrBAC_L2c GGCAAAGCAAGATGTAACTTTAA
Adams et 
al., 2009
G2R CTCTCTGTCTGCGAACAC This study
pmrBAC_R2 TCGATGAAATTCTAGATACTCAAATG
Adams et 
al., 2009
G3F AGCGCTTCTTTGCAGGTC This study
pmrBAC_L3 CCCAAATATCGATAAACAGATCTTC
Adams et 
al., 2009
G3R GAGCGAAGCTGGGTAAAG This study
pmrBAC_R3 TTGAAGCAGATCCGTCAAAG
Adams et 
al., 2009
G4F TACTCCACTACGGCGTAG This study
pmrBAC_L4 TGCACCCAAATTTAAACCATC
Adams et 
al., 2009
G4R GTTTGAGGTGGAATGGGTC This study
pmrBAC_R4 CCGACTTGTGATACGAATGC
Adams et 
al., 2009
G5F GTGTTTGTTGGCTCGGTG This study
pmrBAC_L5 TCATTTGGCTTAATACATGGTCTG
Adams et 
al., 2009
G5R CGTGCGGGTTACCAAGTG This study
pmrBAC_R5 GGATGATTTCACCGCAAAATAG
Adams et 
al., 2009
G6F GGCACGTGCCGTTTCACC This study
pmrBAC_R5c CTATTTTGCGGTGAAATCATCC
Adams et 
al., 2009
G6R GTAGTCACTCACGATGCTG This study
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4. Different Patterns and Kinetics of Biofilms Produced by Acinetobacter 
baumannii clinical isolates with Different Antibiotic Susceptibility Profiles
4.1 Abstract
Acinetobacter baumannii is an organism that has been implicated in several nosocomial
infections. Biofilm production in this species is key for its persistence for prolonged periods of 
time in hospitals. In this study, the biofilm formation patterns and rates among clinical A.
baumannii isolates are investigated in light of different antibiotic susceptibility patterns. Our
aim is to investigate a possible link between antimicrobial susceptibility and specific biofilm
formation patterns that would help clinicians and infection control specialist combat this 
pathogen. Biofilms were cultured on steel coupons immersed in Brain Heart Infusion broth at 
37 °C for 48 hours. The attached viable cells were counted after 5, 24 and 48 hours. Confocal
Laser Scanning Microscopy (CLSM) images were then obtained for two isolates that produced 
a brown pigment while being cultured and two others that did not show pigmentation. The 
images were analyzed using image analysis software and biofilm volume and substratum
coverage were estimated. This study, though preliminary, shows a possible link between 
aminoglycoside susceptibility and quick rates of biofilm formation. It also shows a link 
between carbapenem resistance and thicker, more uniform surface coverage of the produced
biofilms. Since the investigated isolates were relatively few in number, future studies involving
larger pools of isolates could help consolidate the findings of this study.
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4.1. Resumen
Acinetobacter baumannii es un organismo implicado en infecciones nosocomiales. Su
capacidad de producir biofilms es clave en su capacidad de persistir durante periodos 
prolongados de tiempo en el ambiente hospitalario. En este estudio se investigan los patrones
y velocidad de formación de biofilms de cepas clínicas de A. baumannii con diferentes perfiles
de resistencia a antibióticos. Nuestro objetivo es determinar una posible asociación entre
resistencia a determinados antibióticos y cierto patrón de formación de biofilms para ayudar a 
la comunidad médica y los especialistas en el control de infecciones para combatir este
patógeno. Se cultivaron doce cepas clínicas de A. baumannii en soportes de acero inoxidables,
inmersos en caldo de BHI durante 48 horas a 37 °C. Las células bacterianas adjuntas a los 
soportes se contaron tras 5, 24, y 48 horas de incubación. A continuación, se analizaron las 
imágenes obtenidas por Microscopía Confocal Láser de Barrido para dos cepas que formaron
pigmentos durante el cultivo y dos que no los formaron. El volumen del biofilm y la cobertura 
de sustrato fueron analizados utilizando un programa informático. Nuestros resultados
preliminares muestran una relación entre las tasas rápidas de formación de biofilms y la 
susceptibilidad a aminoglicósidos. Además, se observó una relación entre la resistencia a 
carbapenemas y la formación densa de biofilms con cobertura uniforme del sustrato. A pesar
de que el número de cepas investigadas no es suficiente para elaborar conclusiones globales,
investigaciones futuras que incluyan un mayor número de cepas en el estudio, podrían 
consolidar los resultados de este trabajo.
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4.2. Introduction
Acinetobacter spp. are Gram-negative bacteria that could act as bioremediation agents,
oil extraction aids, and even as antibiotic-resistant nosocomial pathogens. They possess an
outstanding chemical ability in degrading xenobiotic compounds that include alkanes, 
herbicides, and pharmaceuticals (Doughari et al., 2011; Touchon et al., 2014). In addition to
its intrinsic resistance to numerous antibiotics, A. baumannii can easily acquire resistance to
various antimicrobials by over-expressing efflux pumps, down-regulating porins, producing 
antibiotic-degrading enzymes, and/or modifying the target of antibiotics (Tenover et al., 2006; 
Antunes et al., 2014). These resistance mechanisms have resulted in considering A. baumannii 
as one of the most dangerous nosocomial pathogens, implicated in ventilator-associated 
pneumonia, as well as bloodstream-, burn-, wound- and catheter-related infections. 
Antimicrobial agent resistance among A. baumannii clinical isolates are very frequent and
mortality rates caused by infections with these resistant strains could be as high as 60% (Peleg
et al., 2008, McConnell et al., 2013; Doi et al., 2015).
The ability of the clinical isolates of A. baumannii to produce biofilms at different rates 
and patterns is often reported (Rodriguez-Baño et al., 2008; Lee et al., 2008; Longo et al., 
2014). Regulation of the formation mechanisms of biofilms, including the involvement of 
quorum sensing molecules, is progressively being characterized (Gaddy et al., 2009; Rumbo-
Feal et al., 2013; Liou et al., 2014). Several genes, including CsuE and OmpA have been found
to be involved in biofilm formation (Choi et al., 2009). Biofilms provide bacteria with 
protection against hazards that range from antimicrobial agents to stress conditions, such as
desiccation. They have also been found to assist in the development of antibiotic recalcitrance
by different mechanisms that mainly involve the facilitation of the exchange of genetic
elements that contain resistance genes (Doi et al., 2015; Ciofu et al., 2011; Lebeaux et al.,
2014; Olsen et al., 2014). Moreover, biofilms provide diffusion limitations due to the charged
macromolecular mesh of their matrix and act as protective barriers for the cells embedded 
within. Moreover, the slowly dividing cells at the deep layers of the biofilm are scarcely
susceptible to antimicrobial agents that hinder cell division. In addition, due to high cell
densities within the biofilms, antimicrobial exposure give rise to small subpopulations of 
persister cells that survive the antimicrobial treatment and that will eventually repopulate the 
biofilm (Bhargava et al., 2014).
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Antibiotic resistance and biofilm formation both depend on genetic diversity and
genetic expression within the individual strains. Understanding the connections among these
phenomena has great potential to understand the persistence of A. baumannii in the hospital 
environment and its colonization of medical equipment (Badmasti et al., 2015). In this study, 
12 clinical isolates, with different antimicrobial susceptibility profiles, chosen from a set of
isolates collected from Hospital Universitario – La Paz, were investigated in terms of the 
kinetics and structure of biofilm formation on abiotic surfaces. The patterns obtained were then 
analyzed in light of the antibiotic susceptibility profiles, presence of CsuE and OmpA, and
production of siderophores and pigments. The association between clinical findings and the 
ability to attach and form biofilms on abiotic surfaces is clinically important, especially from
an infection control perspective, where special care could be taken for strains that are expected
to have certain patterns to biofilm formation based on antibiotic susceptibility profiles. This 
could lead to avoiding the persistence of these isolates for prolonged periods of time in the 
hospital.
4.3. Materials and Methods
4.3.1. Bacterial Strains
Acinetobacter baumannii bloodstream isolates were obtained from patients with 
different conditions and primary sites of infection. Pseudomonas fluorescens B52, originally 
isolated from cold bulk raw milk (Richardson and Te Whaiti, 1978), was used as a control 
strain.
The BactecTM (Becton Dickinson, Franklin Lakes, NJ, US) automated system was used
in order to process blood cultures. The isolates were identified using Matrix Assisted Laser
Desorption-Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS) (Bruker Daltonik 
GmbH). Positive blood cultures were centrifuged at 140×g for 5 minutes. The supernatant was 
then centrifuged at 16,000×g for 10 minutes and the supernatant was discarded. The pellet was
washed with 1 mL deionized water and a solution containing 300 µL water and 900 µL absolute 
ethanol was added. The suspension was centrifuged at 29,000×g for 2 minutes, the supernatant
discarded, and the pellet re-suspended in 20 µL of 70% (v/v) formic acid. Then, 20 µL of 
acetonitrile was added to the mixture and the solution was centrifuged at 29,000×g for 1 minute.
1µL of the supernatant was transferred unto a steel target plate and gently mixed with 1µL α ­
cyano-4-hydroxy-cinnamic acid matrix solution in an organic solvent containing 50% 
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acetonitrile and 2.5% trifluoroacetic acid. The plates were allowed to air dry and mass spectra 
were obtained using a Microflex LT Mass Spectrometer (Burker Daltonik, GmbH) (Romero-
Gómez et al., 2012). The spectra were compared to reference libraries provided by the 
manufacturer (Reference library 3.0.10) in the MALDI-BIOTYPER 2.0 software (Bruker 
Daltonik, GmbH).
The strains were stored at -20°C in Tryptone Soy Broth (TSB, Oxoid) supplemented 
with 15% glycerol until used. Pre-inocula were obtained after overnight incubation at 37ºC in 
Brain Heart Infusion broth (BHI, Oxoid). Cells were harvested by centrifugation at 4000×g for 
10 min and washed twice in sterile BHI. Their OD600 was then adjusted so as to obtain 103 
CFU/mL of each strain after inoculation.
4.3.2. Biofilm Experimental System
Biofilms were cultured in BHI broth at 37ºC on disposable 24-well microtiter plates 
(Thermo Fisher Scientific) with 10x10mm 304 Stainless Steel (SS) coupons as substratum 
surfaces placed in each well. Before use, coupons were gently swabbed with a postsurgical 
toothbrush and soap solution, rinsed with distilled water, and autoclaved while inside glass 
Petri dishes. In each well, one sterile coupon was immersed into 1mL of bacterial suspension.
The whole system was wrapped in aluminum foil and a tray filled with water was placed under
the microplate in order to avoid evaporation. Only the upper side of the SS coupon was
considered for quantification of attached biofilm forming cells whereas the lower side was
marked and remained downwards all along the assay.
4.3.3. Cell Recovery and Counting
For cell recovery and counting, at 5, 12, and 24 hours after incubation, the surface of 
the steel coupon was repeatedly scraped in several directions in order to recover as much of the
attached cells as possible. The cells were then transferred into a tube containing 1.5 mL peptone
water and vigorously stirred using a vortex so as to break up the cell aggregates. Serial dilutions
in peptone water was then done and 10µL from each tube were plated on Tryptone Soy Agar
(TSA, Oxoid). The TSA plates were then incubated at 37ºC and viable cells were counted after 
24 hours. Two SS coupons for each time point were taken per strain and the entire experiment
was independently repeated three times. 
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4.3.4. Siderophore Determination in CAS Solution
While performing the experiment, some strains appeared to be pigmented while others 
did not. Therefore, differential expression of siderophore production was suspected and
siderophores were tested for. In order to detect siderophore production, the 12 A. baumannii
clinical isolates, in addition to P. fluorescens strain B52 were cultured in an iron free mineral 
medium (PMS7-Ca) that contains, per liter: 10.7g of N,N-bis-(2-hydroxymetyl)-2­
aminoethanesulfonic acid (BES), 11g of sodium pyruvate, 0.86g of dibasic potassium
phosphate, 0.65g of ammonium chloride, and 0.2g of magnesium sulphate. The solution was 
then adjusted to pH 7.0, autoclaved, and supplemented with 0.111 g/L of filter-sterilized
calcium chloride. After incubation in this medium, the cells were harvested by centrifugation
at 4,000 × g for 10 min, washed twice with the same medium, and diluted in order to reach an 
initial concentration of 103 CFU/mL after inoculation. Cultures were carried out for 24h, at 
37ºC for A. baumannii strains, and at 21ºC for P. fluorescens B52. 
For siderophore detection, the Chrome Azurol S (CAS) assay was used (Schwyn and
Neilands, 1987). In order to prepare the CAS solution, three solutions were prepared. 0.06g
CAS powder (Sigma Aldrich) were dissolved in 50 mL ultra-pure water and labeled Solution
1. Solution 2 consisted of 0.0027g FeCl3-6H2O dissolved in 10 mM HCl. 0.073 g of hexadecyl 
trimethyl ammonium bromide (HDTMA) were dissolved in 40 mL ultra-pure water in yet 
another solution labelled Solution 3. Then, Solution 1 was mixed with 9 ml of Solution 2 and
then mixed with Solution 3, resulting in a mixture with an intense blue color. The mixture was
stored in a plastic container and protected from light until used. For siderophore detection, 1
mL of cell-free supernatant resulting from growing the strain in PMS7-Ca was mixed with 1 
mL of the CAS solution. A negative control was prepared with 1mL of sterile PMS7-Ca 
medium instead of the culture’s supernatant and P. fluorescens B52’s supernatant was used as
a positive control for siderophore production. A blue to green change in color of the CAS
solution was indicative of the presence of siderophores (Louden et al., 2011).
4.3.5. Antibiotic Susceptibility Testing
The Minimum Inhibitory Concentrations (MICs) were determined by broth 
microdilution using the automated Vitek2 system with AST-N-245 cards (bioMérieux, Marcy
l’Etoile, France). The results were interpreted according to contemporary Clinical and 
Laboratory Standards Institute (CLSI) standards. The results were reported as “R” if the strain
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had an MIC value higher than the cutoff value for resistance, “I” if it the MIC was between the 
cutoff values of resistance and susceptibility, and “S” if the MIC value was below the cutoff 
value for susceptibility for each antibiotic. The ranges of the antimicrobial agents tested for
were: Ticarcillin (4-128µg/mL), piperacillin (4-128µg/mL), ampicillin/sulbactam (2/2­
32/16µg/mL), piperacillin/tazobactam (4/4-128/4µg/mL), ceftazidime (1-64µg/mL), cefepime
(1-64µg/mL), imipenem (0.25-16µg/mL), meropenem (0.25-16µg/mL), colistin (0.5­
16µg/mL), gentamicin (1-16µg/mL), tobramycin (1-16µg/mL), amikacin (2-64µg/mL), 
minocycline (1-16µg/mL), ciprofloxacin (0.25-4µg/mL), levofloxacin (0.12-8µg/mL), and 
trimethoprim/ sulfamethoxazole (1/19-16/304µg/mL). 
4.3.6. Polymerase Chain Reaction
DNA was extracted from the tested strains according to manufacturer’s instructions 
using a commercial kit (Qiagen, Netherlands). Polymerase Chain Reaction (PCR) in order to 
detect the presence of the OmpA and CsuE genes was then performed. The PCR mix contained
1X PCR Buffer with 1.5mM MgCl2, 12.5pmol of each primer, 200µM dNTPs, and 1 U Taq
polymerase. The primers used for the OmpA gene were: 5’CAATTGTTATCTCTGGAG3’ and
5’ACCTTGAGTAGACAAACGA3’. The primers for the CsuE gene were 
5’ATGCATGTTCTCTGGACTGATGTTGAC3’ and 5’CGACTTGTACCGTGACCG­
TATCTTGATAAG3’. PCR conditions were 94°C for 3 minutes, followed by 35 cycles of 
94°C for 45 seconds, 50°C and 65°C for OmpA and CsuE respectively for 45 seconds, 72°C
for 1 minute, and a final extension step at 72°C for 5 minutes (Turton et al., 2007). PCR 
products were then run on 1.5% agarose gels and visualized using a gel documentation system 
(BioRad, Germany).
4.3.7. Confocal Laser Scanning Microscopy (CLSM)
For CLSM observations, biofilms developed on SS coupons were rinsed with sterile 
0.9% NaCl and then stained with Syto 13 (S7575, Life Technologies) after 24 hours of 
incubation at 37°C. This stain labels all the bacteria present. Calcofluor White (18909, Fluka),
a non-specific fluorochrome that binds to cellulose, chitin, and other polysaccharides
commonly present in the biofilm matrix was then added. The green color observed in CLSM
images corresponds to bacterial cells, whereas the blue color corresponds to Extracellular 
Polymeric Substances (EPS). CLSM images of the SS coupons were obtained using a
Fluoview® FV 1200 Laser Scanning Confocal Microscope (Olympus) with an oil immersion 
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60X objective lens. Three- dimensional projections (Maximun Intensity Projection, MIP) were 
reconstructed from z-stacks using IMARIS® 7.7 software (Bitplane AG, Zurich, Switzerland).
The whole image was then segmented into channels and analyzed to obtain the total volume
occupied by cells (green) and EPS (blue). Biofilm ratios were then calculated using the
MeasurementPro module of the IMARIS software.
4.3.8. Statistical Analysis
Three independent experiments for biofilm attachment on steel coupons were 
performed and two coupons were sampled at each time point (in total, n=6). One-way ANOVA
using the STATGRAPHICS PLUS 5.0 software (Statistical Graphics Corporation, Rockville,
Md., USA) was performed in order to check for statistical associations. A multiple range test 
was also performed in order to check if there were differences among strains in terms of biofilm
formation rates. Mean comparisons were carried out to determine significant differences at a 
95% confidence level (p < 0.05).
4.4. Results
4.4.1. Antibiotic Susceptibility and Characteristics of the Strains
All the strains were bloodstream isolates and were deliberately chosen for their 
heterogeneity in antibiotic susceptibility and clinical history. Their origin, according to the
patient’s unit assignment and/or treatment, is shown in Table 1. Five isolates were obtained
from the Intensive Care Unit (ICU) and four from the Burn Unit. Strain 30 was obtained from
Hematology/Oncology and strain 59 from Internal Medicine. Strain 20 also was from Internal 
Medicine, but the patient was not previously admitted to the ICU. Two thirds of the isolates
were from patients previously exposed to mechanical ventilation and catheterization. All the
patients, except those from whom isolates 9, 20, and 38 were obtained, had undergone 
antibiotic treatment in the 15 days prior to isolation of the strain. 
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Table 1. Clinical data of the patients harboring the isolates. Risk factors that may contribute to biofilm formation
("MV= Mechanical Ventilation; CVC= Central Venous Catheterization, and UC= Urethral Catheterization),
previous antibiotic treatment (15 days prior to isolation), primary infection prior to bacteremia, underlying disease
and clinical outcome of the patient.
Previous
Risk Patient 
Strain
Factors
Antimicrobial Disease Primary infection
Outcome
Treatment
3 MV Carbapenems 2nd degree burns on 70% Unknown Recovered
CVC of body surface
UC
9 None None Rapidly progressive Urinary Tract Recovered
glomerulonephritis Infection
12 MV Carbapenems Flame burn on 26% of Respiratory Infection Died
CVC Colistin the body surface
UC Linezolid
15 MV Carbapenems Amputation of left leg Respiratory Infection Recovered
CVC Colistin and Soft Tissue 
UC Linezolid Infection
20 None None Multifactorial chronic anemia Soft Tissue Infection Recovered
Septic shock
26 MV Carbapenems Bilateral eosinophilic Respiratory Infection Recovered
CVC Linezolid Pneumonia
30 None Carbapenems Severe combined Unknown Recovered
Vancomycin immunodeficiency
Bone marrow transplant
35 MV Carbapenem Flame burn on 70% of Respiratory Infection Died
CVC Colistin the body surface
UC Linezolid
38 MV None Intracranial hematoma Respiratory Infection Recovered
CVC
UC
45 MV Carbapenems Non-Hodgkin lymphoma Respiratory Infection Died
CVC Colistin Allogeneic transplant
UC Tigecycline
52 MV Carbapenems Acute lymphoblastic leukemia Respiratory Infection Died
CVC Colistin Bone marrow transplant
UC Vancomycin
59 None Piperacillin/ Crohn’s Disease Unknown Recovered
Tazobactam
According to AST data (Table 2), the only fully susceptible strains were 38 and 59. The
rest of the strains were all resistant to beta-lactams and quinolones and eight of the twelve 
strains were resistant to carbapenems. Strains 12 and 45 were additionally resistant to colistin. 
All strains tested here were still relatively susceptible to some aminoglycosides and 
tetracyclins. The exceptions were strains 9 and 20 that were resistant to all aminoglycosides
and had an intermediate resistance to tetracyclins. According to the definitions proposed by
Magiorakos et al. (2011), strains 9, 12, 15, 20, 35 and 45 would be classified as Extensively
Drug Resistant (XDR) and strains 3, 26, 30 and 52 as Multi Drug Resistant (MDR) while strains 
38 and 59 remain susceptible. 
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Table 2. Resistance of the A. baumannii strains to antimicrobials agents. “MIC” is the Minimum Inhibitory Concentration
acquired in µg mL−1. "R" stands for Resistant, "I" stands for Intermediate resistance, and "S" stands for Susceptible, as
interpreted according to the CLSI guidelines. "TIC" stands for Ticarcillin, "PIP" for Piperacillin, "A/S" for
Ampicillin/Sulbactam, "P/T" for Piperacillin/Tazobactam, "CTZ" for Ceftazidime, "CFP" for Cefepime, "IMI" for Imipenem, 
"MER" for Meropenem, "COL" for Colistin, "G" for Gentamycin, "TO" for Tobramycin, "AK" for Amikacin", "MIN" for
Minocycline, "CIP" for Ciprofloxacin, "LEV" for Levofloxacin, and "T/S" for Trimethoprim/Sulfamethoxazole".
S
tr
a
in
 
Antimicrobial Agents
Beta-Lactams Polymyxin Aminoglycosides Tetracyclin Fluoroquinolones
Folic Acid 
Synthesis 
Inhibitors
TIC PIP A/S P/T CTZ CFP IMI MER COL G TO AK MIN CIP LEV T/S
3
M
IC
S
-I
-R
>64
R
>64
R
16/8
I
>64/4 >32
R R
16
I
>8
R
>8
R
≤0.5
S
≤1 ≤1 ≤2
S S S
2
S
>2 >4
R R
>4/76
R
9
M
IC
S
-I
-R
>64
R
>64
R
16/8
I
>64/4 >32
R R
32
R
>8
R
>8
R
≤0.5
S
>8 >8 >32
R R R
8
I
>2 >4
R R
>4/76
R
12
M
IC
S
-I
-R
64
I
>64
R
4/2
S
>64/4 16
R I
32
R
>8
R
>8
R
16
R
>8 >8 8
R R S
≤1
S
>2 >4
R R
>4/76
R
15
M
IC
S
-I
-R
>64
R
>64
R
16/8
I
>64/4 >32
R R
>32
R
>8
R
>8
R
≤0.5
S
>8 >8 16
R R S
≤1
S
>2 >4
R R
>4/76
R
20
M
IC
S
-I
-R
>64
R
>64
R
16/8
I
>64/4 >32
R R
>32
R
>8
R
>8
R
≤0.5
S
>8 >8 >32
R R R
8
I
>2 >4
R R
>4/76
R
26
M
IC
S
-I
-R
32
I
>64
R
4/2
S
>64/4 >32
R R
16
I
≤1
S
1
S
≤0.5
S
≤1 ≤1 ≤2
S S S
2
S
>2 >4
R R
>4/76
R
30
M
IC
S
-I
-R
>64
R
>64
R
4
S
64/4 16
I I
16
I
2
S
2
S
≤0.5
S
>8 8 4
R I S
≤1
S
>2 >4
R R
>4/76
R
35
M
IC
S
-I
-R
>64
R
>64
R
>16/8
R
>64/4 >16
R R
8
I
>8
R
8
I
≤0.5
S
>8 >8 ≤2
R R S
≤1
S
>2 >4
R R
>4/76
R
38
M
IC
S
-I
-R
≤8
S
≤8
S
≤2/1
S
≤4/2 4
S S
2
S
≤1
S
≤0.25
S
≤0.5
S
≤1 >8 ≤2
S S S
≤1
S
≤0.25 ≤0.12
S S
≤2/38
S
45
M
IC
S
-I
-R
>64
R
>64
R
>16
R
>64/4 >32
R R
8
I
>8
R
8
I
8
R
>8 8 ≤2
R I S
2
S
>2 >4
R R
>4/76
R
52
M
IC
S
-I
-R
>64
R
>64
R
>16/8
I
>64/4 >32
R R
>32
R
>8
R
>8
R
≤0.5
S
4 ≤1 ≤2
S S S
≤1
S
>2 >4
R R
>4/76
R
59
M
IC
S
-I
-R
≤8
S
≤8
S
≤2/1
S
≤4/2 2
S S
2
S
≤1
S
1
S
≤0.5
S
≤1 ≤1 ≤2
S S S
≤1
S
≤0.25 ≤0.12
S S
≤2/38
S
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4.4.2. Patterns of Biofilm Formation among the Different Strains
The strains were tested for their biofilm formation ability on steel coupons at 5, 24, and
48 hours. As shown in Figure 1, all of the strains were able to attach to SS coupons at 37ºC, 
though with different development kinetics. The strains were classified into three different
groups according to the density of attached cells per surface unit after 5 hours of incubation
(Figure 1a). Group 1 (circled in red) includes strains 26, 52 and 59 and were designed as quick 
biofilm formers. These strains had counts of more than 5 Log CFU/cm2 at this time point.
Group 3 (circled in green) represented a single slow biofilm-forming isolate, isolate 30, which
attained just around 2 Log CFU/cm2 after 5h. The rest of the strains, having intermediate
attached cell densities, constituted Group 3. 
Figure 1. Attached cell density of each A. baumannii strain, after 5 h (A), 24h (B) and 48h (C) incubation. Dots
represent the average of three independent experiments (n=6) where two coupons were sampled for each time 
point in each experiment, while the bars represent the standard deviation.
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After 24h incubation (Figure 1b) most strains attained similar counts of viable biofilm
forming cells. After 48h (Figure 1c), dispersal caused a decrease in the number of attached
cells. Attached cell densities continued to increase between 24 to 48 hours for only two out of 
the twelve tested strains (strains 20 and 30). In terms of the presence of the biofilm-related
genes, all the strains were positive for OmpA and all but strains 12 and 59 were positive for 
CsuE. 
4.4.3. Pigment Production, Siderophores, and Biofilm Structure
While testing for the rate of biofilm formation, strains 3, 26, 45 and 52 were noted to
produce a brown pigment while the others presented a neutral hue (Figure 2). All the strains,
except for strain 30, were positive for siderophore production. Confocal Laser Scanning 
Microscopy (CLSM) images of 24-hour biofilms of two pigment producing strains (52 and 45) 
and two non-pigmented strains (30 and 38) were then obtained in order to see if a relationship
exists between pigmentation and biofilm structure. The images were then analyzed in order to
estimate substratum surface coverage and biofilm thickness and volume (Table 3). Pigmented
strains showed thicker biofilm structures than non-pigmented ones and covered almost the 
whole surface of the available substratum (Figure 3). The biofilms of strain 45 had the highest
biovolume value after 24 hours and both pigmented strains gave rise to relatively homogeneous 
biofilms with wide surface coverage. On the other hand, the non-pigmented strains, gave rise 
to biofilms with small volumes that did not homogeneously cover the substratum surface.
Strain 38 had a heterogeneous biofilm mostly consisting of scattered colonies unable to cover
the whole surface. Strain 30 had a light and thin homogeneous coating and had a higher
proportion of matrix to cells than the others (Table 3). 
Table 3. Structural parameters of Acinetobacter baumannii biofilms (n=2).
Biovolume distribution
A. baumannii Biofilm thickness Biovolume 
strain (µm) (µm3)
Cells
(%)
Matrix
38 6 1.6*103 90 10
30 2 3.3*103 51 49
45 9 112*103 83 17
52 9 12.3*103 73 27
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Figure 2. Pigment production during incubation of strain 52 (above) and 38 (below).
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Figure 3. CLSM images (zenithal view) of 24h-biofilms formed by A. baumannii strains pigment (+): 45 and 52
and pigment (-): 30 and 38. Cells were in green and EPS in blue.
4.5. Discussion
The twelve clinical isolates included in this study were obtained from different origins 
in an attempt to assess the effect of origin on biofilm formation patterns. Nevertheless, since 
most A. baumannii infections occur in the ICU, most of the isolates where from the ICU and 
were from patients that were exposed to mechanical ventilation and catheterization. Both these
factors are considered risk factors for biofilm formation and subsequent A. baumannii infection
(McConnell et al., 2013), making the fact that all the isolates produced biofilms, an expected
one. No direct relationship between the source of the isolate and the rate of biofilm formation
seems to exist. The XDR and MDR profiles obtained is also not surprising due to the vast array 
of intrinsic resistance mechanisms in A. baumannii and its outstanding ability to acquire 
resistance (Peleg et al., 2008). The most concerning of the observed resistances is resistance
towards carbapenems since, in addition to being globally reported at increasing rates, it is 
associated with increased mortality (Lemos et al., 2014). Additionally, the two colistin resistant
strains are troubling from a clinical perspective since this antibiotic is one of the few available
alternatives for dealing with carbapenem resistant A. baumannii isolates (Fishbain and Peleg, 
2010). Even more concerning, the pigmented isolates that were resistant to carbapenems with
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one being also resistant to colistin showed dense and voluminous biofilms by CLSM. How
much of the extensive antibiotic resistance exhibited by these strains could be due to the
protection provided by these biofilms, is hard to determine at this point. This is mainly due to
the lack of information regarding whether the biofilm was forming while the antimicrobial
susceptibility profile was being tested for. The non-pigmented carbapenem sensitive strains 
produced biofilms with low densities and the colonies within were dispersed and did not cover
the entire SS coupon. This pattern usually results from separate adhered cells that could later 
rapidly divide and give rise to cell stacks. 
Different rates of biofilm formation on abiotic surfaces has been previously shown
among clinical A. baumannii strains (Lee et al., 2008; McQueary et al., 2011; Orsinger-
Jacobsen et al., 2013). Additionally, the ability to form biofilms was reported to be differential 
among A. baumannii clinical isolates (De Breij et al., 2010). However, in general, a positive
relationship seems to exist between biofilm formation and resistance to antimicrobial agents 
(Rao et al., 2008; Gurung et al., 2013). The variations in the rates of biofilm formation among
different strains could be a result of the differential regulation of the genes involved in biofilm
formation or quorum sensing among the different isolates. This is further consolidated by the
fact that all the strains were positive for OmpA and most of them for CsuE, which are key genes 
involved in biofilm formation, but showed different patterns of biofilm formation. One of the 
strains that was negative for CsuE, strain 59, was obtained from a Crohn’s disease patient. 
Studies have shown that these patients usually select for strongly adherent microbial strains
(Chassaing et al., 2015). Therefore, further investigating the mechanisms of biofilm formation
in this strain could help further our understanding of this complex phenomenon. Moreover,
despite the crucial involvement of CsuE in biofilm formation, studies have shown that some A.
baumannii strains are still able to attach to epithelial cells and form biofilms despite the absence 
of this gene (Gaddy et al., 2009; De Breij et al., 2009). Determining how exactly these strains 
are able to achieve this could shed new light on alternative mechanisms of biofilm formation 
in A. baumannii.
Quick biofilm formation patterns are presumably due to earlier adherence to the surface, 
which is a bottleneck step for attached cell division and surface colonization. The speed of 
attachment and subsequent biofilm formation on abiotic surfaces reflect the bacterium’s ability
to quickly adhere unto surfaces in the hospital setting and form biofilms. This, in turn, leads to
a longer persistence of A. baumannii and a possible source of repeated infections and outbreaks. 
 
 
  
 
  
  
  
  
   
     
  
 
   
   
     
    
  
   
    
  
  
  
    
 
 
 
   
  
  
    
 
    
  
  
 
184
The different rates of biofilm formation after 5 hours of incubation observed in our study 
reflects the different abilities possessed by the different strains to overcome this bottleneck 
step. Interestingly, the strains of group 1 were all susceptible to aminoglycosides and only
strain 52 was resistant to carbapenems. Though aminoglycoside-susceptible isolates are found 
in other groups, this could suggest a link between susceptibility to this class of antimicrobial
agents and a fast rate of biofilm formation. Sub-inhibitory concentrations of aminoglycosides 
have also been reported to induce biofilm formation in Pseudomonas aeruginosa and
Escherichia coli that is inhibited by GTP (Hoffman et al., 2005). It was postulated that biofilm
formation could act as a defensive mechanism against antibiotic exposure, and whose 
molecular basis is linked to alterations in the level of c-di-GMP. In A. baumannii, previous 
aminoglycoside use was associated with biofilm forming isolates formation (Rodriguez-Baño 
et al. 2008), whereas, unlike what we observed in our study, treatment in an intensive care unit
and isolation from respiratory samples were associated with lack of biofilm formation
(Rodriguez-Baño et al. 2008). However, our small sample size does not allow for the 
generalization of our results. A correlation between biofilm formation and use of levofloxacin 
was also reported by He et al. (2015). Moreover, these authors reported a correlation between
biofilm induction and upregulation of the transcription of the gene encoding the adeG efflux
pump. They suggested that a link exists between low doses of antimicrobial agents and 
infection by biofilm forming A. baumannii. These studies demonstrate the link between biofilm
formation and antimicrobial resistance. Though this is demonstrated in our study, further
investigations on larger pools of isolates could help determine if the relationship between
aminoglycoside susceptibility and fast biofilm formation is related to A. baumannii in general 
or is an observation that is only applicable to these particular strains. 
The only slow biofilm former was obtained from an oncology immunodeficient patient 
not previously exposed to catheterization. It was sensitive to carbapenems, resistant to 
gentamycin and moderately resistant to tobramycin. However, though these factors may be
indicative of a predisposition of such a profile to be slow in forming biofilms, no general
conclusions could be drawn since it was the only case. Nevertheless, this strain continued 
growing after 24 hours and eventually showed higher densities of biofilm forming cells. Also
of note, all the XDR isolates pertained to Group 2 and had similar rates of biofilm formation, 
possibly suggesting a tradeoff in terms of energy allocation between this rate and the 
mechanisms of resistance. Combined, our preliminary information could be useful in terms of 
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infection control were specialists could expect the rate of biofilm formation by certain strains
based on their antibiotic susceptibility and act accordingly. 
4.6. Conclusions
Though our conclusions could only be preliminary due to the low number of strains 
involved, several conclusions could be drawn. First, the tested A. baumannii strains showed
fast, moderate, and slow biofilm forming rates on steel coupons after 5 hours of growth. The
fast biofilm forming group seems to be associated with aminoglycoside susceptibility. Second,
pigmented XDR strains produced more homogenous and voluminous biofilms, suggesting an 
interplay between the density of the formed biofilms and resistance to carbapenems and/or 
colistin. This also highlights the importance of biofilm forming abilities among MDR A.
baumannii strains that could result in their persistence in the hospital for prolonged periods of 
time. Third, there was no association between pigmentation and siderophore production was 
found but rather that pigmented strains produced more voluminous and homogeneous biofilms.
Fourth, all the tested strains were positive for OmpA and all except two were positive for CsuE. 
Further investigation into the mechanisms of biofilm formation for the strains lacking CsuE
could be of interest for future studies. Finally, investigation of a broader set of clinical isolates 
is need in order to shed a clearer light on the interplay between the various clinical and 
laboratory findings and biofilm formation patterns.
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1. Prevalence of Carbapenem Non-Sensitive Isolates
Characterization of clinical A. baumannii isolates in terms of antimicrobial 
susceptibility showed an alarmingly high rate of carbapenem resistance (84.75%) in HU-LP.
The high prevalence of CRAB isolates seems to be a common finding in Spain where several 
studies have reported similar rates (Perez et al., 2010; Villar et al., 2014; Rodloff et al., 2008). 
These rates are much higher than those reported from most other European countries, such as
Germany and the UK (Tomaschek et al., 2016; Hughes et al., 2016), but somewhat similar to
reports from Italy, Greece, and Poland (Rodloff et al., 2008; Chmielarczyk et al., 2016). This
high rate raises an alarm that requires direct intervention. This alarm has actually reached the
Spanish government where it officially launched the “Zero Resistance” project, aiming at 
reducing the incidence of MDR organisms through improving prescription, prevention of 
cross-contamination, and eradication of reservoirs (Montero et al., 2015). The high CRAB
incidence rate could partly be due to the heightened ability of A. baumannii in persisting
through adherence to biotic and abiotic surfaces and/or through the presence of CRAB isolates
in the patient’s gut flora (Gordon et al., 2010). In addition, a study has shown a general lack of 
uniformity in applying infection control measures in Spanish hospitals (Garcia-Ortega et al., 
2011). Taken together, these factors could have been contributing to the persistence of CRAB
isolates in this hospital and could also result in repeated infections, and a subsequent increase
in the rate of CRAB infections. The fact that most infections over a five-year period in this
hospital were produced by a handful of clones further supports this hypothesis. Nevertheless, 
the reduced incidence of CRAB isolates during the latter years of the study is a positive 
indicator of the implementation of adequate infection control measures.
OXA-23-like is the most widely disseminated OXA in the world (Karah et al., 2012). 
In Spain, though CRAB isolates harboring blaOXA-23-like were reported to cause outbreaks 
(Mosqueda et al., 2013; Merino et al., 2014), blaOXA-24-like remains the most prevalent OXA 
(Villalón et al., 2013; Acosta et al., 2011; Tena et al., 2013). This was reflected in this study
were OXA-24-like was present in 62.71% of the isolates whereas OXA-23-like was only 
detected in 11.86%. In fact, OXA-24 was first discovered in Spain (Bou et al., 2000c) and has
remained highly prevalent in the Iberian Peninsula ever since (Manageiro et al., 2012; 
Mosqueda et al., 2014; Villalón et al., 2015). This carbapenemase has been detected in several 
CRAB outbreaks, including in neighboring France (Barnaud et al., 2010), but its predominance 
seems to be restricted to the Iberian Peninsula. This could actually prove to be advantageous 
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due to the positive associations that were made with hemolysis and siderophore production, in
a sense that it would help clinicians expect a high degree of virulence while dealing with CRAB 
infections in Spain. This would allow them to tailor their treatment approaches accordingly and
could result in an increased chance of survival for the patient. This association could also be
advantageous in other countries that also have this carbapenemase highly disseminated, such 
as Serbia (Novovic et al., 2015).
In Lebanon, the rate of carbapenem non-susceptible isolates was even higher than that
of Spain (90%) and the most disseminated OXA among these isolates was OXA-23-like. Our
findings fall in line with other studies performed in this country, where it was detected in 
97.89% of 142 CRAB isolates obtained over one year (Hamoudi et al., 2015a). Though even
higher rates have been reported worldwide, such as in China, where CRAB isolates were
reported to 97.4% in one study (Xu et al., 2016), this rate is much higher than the average rate
of CRAB among Middle Eastern and African countries, where it was reported to be 51.3% 
(Kanj et al., 2014). Due to legal and logistical problems, it was not possible to transfer the 
bacterial strains isolated in Lebanon to Spain in order to perform the PFGE and MALDI TOFF
MS experiments. Access to facilities that contained the appropriate machines for performing
these experiments was also not possible in Lebanon. Therefore, the identification was
performed in a different manner for the Lebanese set of isolates and clonality by PFGE was
not possible in order to determine whether similar clones were causing these infections. 
Nevertheless, the rate of carbapenem resistance detected reveals the need for immediate 
intervention on national and local levels through the implementation of successful infection
control protocols and antibiotic stewardship programs. Government interference on a level 
similar to that that is being performed in Spain is highly encouraged in Lebanon in an attempt 
to decrease these very high rates of carbapenem resistance. In accordance with our findings,
the Middle Eastern region is generally reported to have higher rates of carbapenem resistance 
as compared to the rest of the world (Tärnberg et al., 2016). Global studies have reported 
susceptibility rates to carbapenems some countries in this region to be lower than 11% (Lob et 
al., 2016). Moreover, this region generally has higher CRAB incidence rates than the rest of 
the Mediterranean region (Kanj et al., 2014; Castanheira, et al., 2014). This could be due to the 
lack of proper implementation of infection protocols and proper antibiotic prescription in
Middle Eastern countries. However, further confirmation through surveillance studies and
questionnaires are needed before confirming this hypothesis. 
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There were some isolates from both sets that were resistant to carbapenems but did not 
have a positive result for any of the tested carbapenemase genes. These isolates could have 
acquired the resistance through the presence of carbapenemases that were not tested for, over­
expression of blaOXA-51-like, down-regulation of outer membrane porins, and/or up-regulation of 
multi-drug efflux pumps (Peleg et al., 2008). Further investigation is needed before 
determining the cause of carbapenem resistance among these isolates. Moreover, though 
blaOXA-51-like was detected in the vast majority of isolates, a few isolates were negative for this 
gene. This is not uncommon since a subset of A. baumannii isolates testing negative for this
gene have been previously described (Turton et al., 2006). Interestingly, two isolates from the
Lebanese set of isolates tested positive for blaOXA-23-like but were sensitive to carbapenems. This
could suggest the presence of a mutation in this gene that make it less effective, or in its genetic 
environment that caused it to be under-expressed. Sequencing of this gene and its genetic
environment could help shed further light on the matter. However, due to limited accessibility
to sequencing services in Lebanon, such investigations were not possible.
The AST data collected from both Spain and Lebanon also show very high rates of 
cross-resistance to other antimicrobial agents among CRAB isolates. This could be due to the 
co-acquisition of resistance determinants on mobile genetic elements (Fournier et al., 2006).
Moreover, the plasticity of the A. baumannii genome allows for the incorporation of a wide
range of genetic elements, allowing it to acquire resistance to a wide range of antimicrobial
agents at the same time (Antunes et al., 2014). Despite the very high rates of resistance detected 
among both sets of isolates, most of them remain susceptible to colistin. This is especially 
important since the use of this antimicrobial agent was re-emerged in the treatment of MDR
organisms (Cai et al., 2012). However, colistin has a nephrotoxic effect (Bergen et al., 2012) 
and A. baumannii isolates have shown an ability to develop resistant to this antimicrobial agent 
during therapy (Valencia et al., 2009). Moreover, resistance to colistin is usually accompanied
by co-resistance to the innate cationic antimicrobials produced by the host (Napier et al., 2013). 
Nevertheless, the high susceptibility rates to this antimicrobial agent make it a viable option 
when no other alternatives for the treatment of infections caused by CRAB isolates exist. 
Finally, since the use of antibiotics is one of the main driving factors for the development of 
resistance (He et al., 2015), the proper use of these agents through antibiotic stewardship 
programs might be the best option for safeguarding them for future use. This should also be 
accompanied by rigorous implementation of infection control protocols in order to eliminate
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the existing reservoirs and prevent the re-emergence of CRAB clones that cause repeated 
infections.
2. Prevalence of International Clones
Clonality analysis revealed that IC II is by far the most predominant clone among the
isolates obtained from both Lebanon and Spain. This finding is in agreement with international 
reports that indicate that IC II is the most globally disseminated clone (Karah et al., 2012).
Moreover, it is in agreement with local data in Lebanon (Rafei et al., 2014a), Spain (Villalón
et al., 2015), and throughout the Mediterranean region (Di Popolo et al., 2011). Additionally, 
the percentages of prevalence of each IC among the Spanish set of isolates are very similar to
another study conducted in Spain. In our study, the percentages were 8.47% for IC I, 71.19% 
for IC II, and 6.78% for IC III as opposed to 10.2% for IC I, 47.5% for IC II, and 5.1% for IC 
III in the other study (Villalon et al., 2011). The global success of IC II could be partially 
attributed to the ability of isolates pertaining to this IC to harbor all three most commonly
disseminated OXAs (Karah et al., 2012). This would allow these isolates to incorporate any of 
the aforementioned carbapenemases and gain a competitive edge on other carbapenem­
sensitive clones, or clones that might not have this kind of genetic flexibility. The selective
pressure produced by the extensive use of carbapenems also helps in the elimination of
competitive organisms and aid in the persistence of these clones, and their eventual 
dissemination (Nemec et al., 2004). In addition, these clones could cross international borders
and continents due to the global interchange of patients and the increase in international travel 
(Peleg et al., 2008). Finally, the lack of proper infection control protocols could allow for these
clones to persist in the hospital and cause repeated infections. They could even persist in the 
gut flora (Gordon et al., 2010) and eventually use the host as a transport to far-away
destinations.
PFGE analysis showed that isolates showing different pulsotypes could pertain to the 
same IC, as shown in the Spanish set of isolates. This is due to the higher resolution provided
by PFGE as compared to the detection of clonality by tri-locus PCR typing. While the latter 
technique capitalizes on difference in three housekeeping genes, the former takes differences
in the entire genome into account. Nevertheless, the grouping of several isolates with different
pulsotypes into the same international clone demonstrates the plasticity of the isolates
pertaining to this clone. This observation unfortunately could not be verified for the Lebanese
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set of isolates due to the difficulties that were mentioned in the first section of the discussion. 
PFGE analysis for the Spanish set of isolates also showed the ability of a single clone to persist
for prolonged periods of time (Cluster 6). In regard to this cluster, isolates 26 and 38 pertained 
to IC II but were susceptible to carbapenems. Isolate 38 was susceptible to almost all tested 
antimicrobial agents while isolate 26 was resistant to most beta-lactams, ciprofloxacin,
levofloxacin, and trimethoprim/sulfamethoxazole. This finding, though rare, is not the first of
its kind since isolates pertaining to all three ICs have been reported elsewhere to be susceptible 
to carbapenems and to no have MDR profiles (Diancourt et al., 2010). One hypothesis that 
could explain this susceptibility is that these strains may have been “hiding” in the hospital 
environment for so long so that they have lost their resistance genes due to lack of antibiotic
pressure. Those that have lost the plasmid encoding the carbapenemases might have then 
outcompeted their resistant counterparts in the population and caused these infections
(Andersson et al., 2011; Andersson et al., 2010). 
PFGE analysis of the Spanish set of isolates also showed the dissemination of clones
of the same cluster of pulsotypes in several hospital wards. This observation has been
previously reported where, though A. baumannii infections are most commonly reported from
the ICU (Perez et al., 2010), they have been detected in other hospital wards as well
(Rodriguez-Baño et al., 2005). Additionally, a study has reported the co-existence of sporadic 
and epidemic clones at the same time in different settings, including the hospital (Abbo et al., 
2005). This indeed was found to be true in our dataset where several isolates from both the
Spanish and Lebanese set of isolates seem to be sporadic and did not pertain to any IC nor did
they share a common pulsotype with any of the other isolates. Of the isolates that did not belong 
to any cluster, only isolates 12, 13, and 40 from the Spanish set of isolates were resistant to
carbapenems. All other isolates did not pertain to any IC and were susceptible to most tested 
antimicrobial agents. This suggests that most, but not all, sporadic infections do not cause a 
great threat in terms of treatment. Performing MLST for these strains could help in determining 
their international clonality and whether they are truly sporadic or they belong to a clone that
could not be detected by tri-locus sequence typing.
Among the Spanish set of isolates, ICs III and I were shown to cause several infections,
as was evident from the first and second PFGE clusters, respectively. However, these infections
were much less frequent and were confined to a one-year period as compared to those caused 
by IC II. All the isolates of IC III expressed OXA-24-like and all those of IC I expressed OXA­
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58-like. Nevertheless, the isolates of IC II expressed all three oxacillinases tested for in
different combinations. These findings are similar to those of the Lebanese set of isolates where 
IC II was by far predominant and caused the vast majority of infections over one year.
However, in contrast to the isolates of the Spanish set, the majority of the Lebanese set of 
isolates expressed OXA-23-like. The prevalence of different OXAs among isolates of IC II
suggest that these OXAs are not directly related to clonality, but rather to availability in the 
surrounding environment. This is further supported by the fact that these OXAs could be bourn 
on plasmids and could be horizontally exchanged by bacterial organisms (Corvec et al., 2007). 
Moreover, the data could also suggest the superior ability of IC II to persist and cause repeated
infections in the hospital. In-vitro competition assays could be performed in the future in order
to verify this anecdotal data, where isolates pertaining to IC II could be placed in competition 
with isolates pertaining to other ICs, including IC I and III. 
Isolates that pertained to tri-locus PCR groups 4, 10, and 14 were also detected in this
study. These clones are not as globally disseminated as the ICs I, II, and III, but were reported 
to be MDR when they were first discovered (Karah et al., 2012). Nevertheless, not all the
isolates that were part of these groups where MDR in our study. Isolate 31 from the Spanish 
set of isolates, which pertained to G14, was sensitive to carbapenems as opposed to the 
carbapenem-resistant isolate that was first described within this group from a Romanian 
hospital (Bonin et al., 2011). Similarly, two isolates from the Lebanese set pertaining to G4 
and the isolate pertaining to G10 were sensitive to carbapenems as opposed to the CRAB
isolates pertaining to this group that were described in several European countries (Towner et
al., 2008; Grosso et al., 2008). Although the relatively low prevalence of these isolates does
not allow for a global conclusion, these isolate demonstrate the high plasticity of A. baumannii
isolates in producing different profiles, even when pertaining to the same clone.
3. Relationship between Virulence and Resistance
The virulence profiles obtained in this study for both sets of isolates were highly 
variable. Differentially expressing virulence factors was previously shown between A.
baumannii isolates with different ancestral clonality (Antunes et al., 2011). In our study, this
difference was also evident among isolates with the same clonal lineage, and even among
isolates having the same pulsotypes. This further highlights the high adaptability and plasticity 
of A. baumannii and could be the reason behind its clinical success as a pathogen. No statistical 
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association between the different virulence factors tested for in the Spanish set of isolates was
detected. However, an association was detected among the Lebanese set of isolates between 
moderate motility and strong biofilm formation, and also between highly motile and non-motile
isolates on one hand and siderophore production on the other (p<0.05). Moreover, all the 
isolates in this set that were negative for biofilm formation were also negative for siderophore 
production. The association between biofilm formation and motility has been described
elsewhere (Eijkelkamp et al., 2011). Nevertheless, the lack of association between the tested 
virulence factors among the Spanish set of isolates suggests further mechanisms at play that 
are resulting in the differential expression of virulence determinants among the different 
isolates. Since most virulence factors tested for in this study are multi-factorial, direct
correlations between different factors were not be possible at the species-level, but should be 
considered on an individual level. 
In terms of statistical associations between virulence factors and ICs, associations
between IC II on one hand and hemolysis, siderophore production, and strong biofilm
formation (p<0.05) on the other were detected among the Spanish set of isolates. In
comparison, isolates pertaining to ICs I and III were associated with reduced virulence. 
Similarly, harboring blaOXA-24-like was associated with hemolysis and production of 
siderophores while blaOXA-23-like was negatively associated with hemolysis (p<0.05). These 
associations, however, were absent from the isolates of the Lebanese set. The virulence profiles 
generated for these latter isolates were highly variable and variation in clonality was not as
prominent as that of the Spanish set. This could have contributed to the lack of detection of 
associations among these isolates. Another likely explanation is the effect of the different 
environments from which the isolates were obtained. A link between antibiotic consumption 
and virulence has been previously described (He et al., 2015). This link could be due to the 
presence of common factors in the mechanisms of antibiotic resistance and virulence where an
interplay between these phenomena could take place (Yeung et al., 2011). The difference in
the hospital protocols between the Spanish and Lebanese hospitals could result in different
antibiotic prescription regimens that, in turn, expose the strains to different antimicrobial
agents. This could result in the differential adaptation of the individual isolates to the different 
antimicrobial agents they get exposed to. Moreover, the ability of A. baumannii to horizontally 
acquire genes for both resistance and virulence (Burrus, and Waldor, 2004) could result in the
acquisition of different genes in different countries, based on the availability of genetic material 
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in the bacteria’s environment. All these factors combined could have resulted in the lack of 
associations in one country while encountering associations in another. 
In lines of what was mentioned in the previous paragraph, sub-populations within the 
Spanish set of isolates seem to deviate from the detected associations. This was evident in
Cluster 7 where all the isolates of this cluster pertained to IC II but none was positive for
hemolysis. Moreover, very few strains from the Spanish set showed surface motility as
compared to the Lebanese strains, even among the isolates pertaining to IC II. Moreover, the 
Spanish set of isolates on average had a slightly higher average proteolytic activity (26.6 ± 8.4
U/L) as compared to the Lebanese isolates (17.7 ± 9.5 U/L). Since the materials were purchased 
from the same companies and the experiments performed by the same person, the difference in 
these factors could be attributed to the strains themselves. These findings further demonstrate 
the “locality” of the virulence to be expected and the need to perform a local study before being 
able to predict virulence in the clinical setting.
Among the Spanish set of isolates, 69.5% produced siderophores, 84.4% produced 
strong biofilms, and 54.2% showed hemolysis. Among the Lebanese isolates, 57.8% of the
isolates produced siderophores, 85.6% produced strong biofilms, and 47.8% showed
hemolysis. Though a larger percentage of isolates seem to produce siderophores and hemolysis
among the Spanish isolates, these percentages seem to not be very different between both
populations. Of note, in both populations, some isolates that were MDR, XDR, and even PDR
(such as isolate 12 from the Spanish set of isolates) showed highly virulent profiles. This further
demonstrates that resistance and virulence could be acquired simultaneously (Burrus, and
Waldor, 2004) and that, based on our findings, acquiring one does not necessarily diminish the
chances of acquiring the other. The doubling times that were tested for both populations
showed similar ranges (0.324 ± 0.027 to 0.666 ± 0.037 hours for the Spanish isolates and 0.262 
± 0.021 to 0.653 ± 0.049 hours for the Lebanese isolates). Also, in both populations, no
associations between these times and particular profiles were made. Since doubling times are
affected by the entire metabolic processes of the bacterial cell, such an observation is not
surprising. Moreover, since no clear association was detected among the selected isolates, and 
due to the laborious and time consuming nature of the experiment, determining the doubling 
times for the entire set of isolates was abandoned.
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Based on our findings, a global conclusion regarding a link between virulence on one
hand, and clonality or presence of certain OXAs on other, is not recommended. Rather, local 
associations within a hospital or a precise geographical region need to be determined before
being used in the prediction of virulence of a certain clone. These local associations could be
vital if anti-virulence drugs are to be developed and assessed for their usefulness, since they
may result in different effects based on the different virulence profiles of the isolates. After
determining the local associations, a clinician could predict the usefulness of such agents based 
on the expected virulence of the isolate and thus restrain from using them in case the prediction 
is unfavorable. This also means that the results of clinical or in-vitro trials of anti-virulence 
drugs will be highly influenced by the local virulence epidemiology and care should be taken
before interpreting such results. Moreover, if, after local investigation, low virulence of a 
particular clone is expected, the use of less aggressive antibiotic treatment approaches, and
ultimately the safeguarding of crucial antimicrobial agents, would be possible. Finally,
performing this study on a much larger scale that includes more countries and hospitals could
result in global conclusions of associations that may have been missed in our study due to the 
relatively small populations investigated.
4. Mechanisms of Colistin Resistance in Two Sets of Clinical Isolates
Two sets of isolates were obtained from two distinct patients undergoing colistin
therapy in HU-LP, Madrid, Spain. Isolates C071 and C440 were obtained from Patient 1 
whereas isolates C080, C314, and C428 were obtained from Patient 2. Isolates C440 and C428
from patients 1 and 2, respectively were resistant to colistin. These isolates were not part of the
investigated Spanish set of isolates since they were recovered at an earlier time and kept in the 
hospital’s freezer until the time of this study. Clonality analysis showed that the respective 
isolates obtained from the same patient are clonally identical, while sequencing of the pmrCAB
operon showed specific mutations in pmrB in the colistin resistant isolates that were absent 
from the colistin sensitive isolates. Full genome sequencing then showed the lack of other
significant mutations in the genomes of the colistin resistant mutants as compared to their
sensitive counterparts. Moreover, no difference in the tested virulence factors was detected 
among the isolates from Patient 2, while decreased proteolytic activity and increased 
siderophore production was detected in isolate C440, as compared to C071.
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Two mechanisms have been proposed as a mode of action for colistin. The first 
mechanism consists of targeting the negatively charged LPS molecules found on the bacterial 
cell’s outer membrane. This subsequently disrupts the stability of the membrane by displacing
the divalent cations that bridge LPS molecules together and enables self-promoted uptake 
across the membrane (Arroyo et al., 2011). The second mechanism is inducing rapid killing 
through the activation of a hydroxyl radical death pathway in the bacterial cell (Sampson et al., 
2012). These mechanisms often work together in order to induce the rapid killing of Gram­
negative bacterial cells. The pmrCAB operon contains the two-component response regulator
and sensor kinase pmrA/B that responds to environmental changes, and is involved in lipid A
modifications through pmrC (Gunn, 2008; Arroyo et al., 2011). In Salmonella spp., the pmrA/B 
system was found to be involved in the modification of Lipid A, the LPS anchor, by the addition 
of phosphoethanolamine and this, in turn, conveys resistance to colistin. It is also thought that
the aminoarabinose biosynthetic pathways in Salmonella spp. play a role in this resistance 
(Murray et al., 2007). Similar mechanisms have been described in Pseudomonas spp.
(Moskowitz et al., 2004). However, the aminoarabinose biosynthetic pathways were not found 
to play a role in colistin resistance in Acinetobacter spp. since they lack the target enzymes for
this mechanism. This is unlike mutations in the pmrCAB operon which are thought to convey
high level colistin resistance in this organism (Olaitan et al., 2014). 
One study showed that down-regulating the expression of the pmrCAB operon could
revert colistin resistance (Harris et al., 2014). Another recent study showed that six genes, that 
include pmrA, pmrB, and pmrC, and other genes involved in lipopolysaccharide synthesis or 
electrostatic changes in the bacterial cell membrane, are linked to colistin resistance (Park et
al., 2015). Deletion of pmrB was found to revert resistance to colistin, making this gene
essential for this mechanism in A. baumannii (Adams et al., 2009). Although mutations in the 
pmrCAB operon, and especially in pmrB, have been reported to cause resistance to colistin, a 
study in 2011 showed that increased expression in the pmrAB sensor kinase system could lead
to colistin resistance without any mutations (Park et al., 2011). 
The pmrB gene is found to be the most commonly mutated gene among colistin
resistant A. baumannii strains (Olaitan et al., 2014). Our study has shown that two different
mutations in two distinct A. baumannii strains originating from two separate patients occurred 
in pmrB and caused resistance to colistin. The P233S mutation that is located within pmrB of 
the resistant strain taken from Patient 1 has been reported in several other clinical isolates
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(Pournaras et al., 2014; Beceiro et al., 2011; Adams et al., 2009; Kim et al., 2014; Arroyo et 
al., 2011; Durante-Mangoni et al., 2015). This mutation is located in the histidine kinase 
domain of PmrB and is thought to be involved in dimerization (Arroyo et al., 2011). It has been
defined as an activating mutation (Durante-Mangoni et al., 2015). Both the resistant and
sensitive strains isolated from Patient 1 contained the insertion sequence between pmrB and
pmrA, suggesting that this sequence does not affect colistin resistance nor susceptibility. The 
deletion of Isoleucine at position 19 found in pmrB of the colistin resistant strain obtained from
Patient 2 has not been reported elsewhere, to the best of our knowledge. This mutation is 
positioned in the center of the first trans-membrane helix of PmrB. It is possible that this
mutation causes PmrB to be permanently activated, which in turn could lead to colistin
resistance in a manner similar to the hyperactive kinase mechanism reported elsewhere (Arroyo
et al., 2011). Further characterization of the effect of this mutation is required before a definite
conclusion regarding how it affects colistin resistance could help better understand the 
mechanisms of resistance to this antimicrobial agent. No differences in the lpxA, lpxC, and 
lpxD genes, as well as the genes reported by Park et al. (2015), were detected in the resistant 
strains as compared to their sensitive counterparts. Moreover, mcr-1 was not present among
the colistin-resistant isolates, thus ruling out a plasmidic origin for colistin resistance in C440
and C428. The only other mutation that resulted in an amino acid change was the Ala1648Val 
mutation in aconitate hydratase in strain C428. This enzyme is involved in the tricarboxylic
acid cycle (Pirog et al., 2003) and is unlikely to have a role in mediating colistin resistance.
This leads us to conclude that the reported mutations in the pmrCAB operon are causing colistin 
resistance in these strains. Moreover, this study presents a novel clinically significant mutation 
that allows A. baumannii isolates to acquire resistance to colistin during treatment. 
The sequence type ST-81P identified according to the Pasteur scheme in isolates C071 
and C440 has been previously encountered in 10.2% of 729 A. baumannii isolates obtained 
from various Spanish hospitals. This sequence type was found to be different from the
international clone ST-1P (also known as IC I) in a single allele, justifying the result that these
strains pertained to IC I as tested by the multiplex PCRs. Strains belonging to this clone were
previously encountered in northeastern Spain from 1992 to 2002 and were all found to be
sensitive to colistin. This ST was not detected after 2002 in this 11 year-long study (Villalon 
et al., 2011). This clone seems to have gone undetected since then only to re-appear several 
years later in Madrid, as is detected in our study. Resistance to carbapenems in isolates C071
and C440 is due to the presence of the blaOXA-58-like gene which codes for a carbapenem
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hydrolyzing oxacillinase (Mostachio et al., 2009). Isolates C080, C314, and C428 belong to
the widely spread sequence type ST-2P which is also commonly known as IC II (Karah et al.,
2012). In addition to being spread all over the world, some isolates belonging to this sequence
type were shown to be resistant to colistin (Tan et al., 2013). Although the gene blaGES-5 was
detected in several bacterial species, including Pseudomonas aeruginosa (Mataseje et al., 
2012), it hasn’t been previously detected in A. baumannii, to the best of our knowledge. This 
gene coding for the carbapenemase hydrolyzing GES-5 (Bonnin et al., 2011) has been detected
in all three strains isolated from Patient 2. This not only explains the resistance to carbapenems
among these strains, but could also be an important indication of inter-species exchange of
resistance genes and warrants further investigation. Nevertheless, the blaGES-5 genes detected 
in these strains differed by only one nucleotide from some sequences of blaGES-14 deposited in
Genbank. This latter gene is commonly reported to exist among A. baumannii isolates and is 
known to hydrolyze imipenem (Bogaerts et al., 2010). Therefore, even though the detected 
gene had 100% identity with blaGES-5 in Genbank, its extremely high similarity to blaGES-14
requires further investigation into the similarities between the products of these two genes
before reaching a definite conclusion on the matter.
In terms of the effect of colistin resistance on virulence in A. baumannii, conflicting 
reports exist regarding the fitness cost and reduced virulence of colistin resistant A. baumannii
isolates. Generally, it is thought that resistance to colistin incurs a fitness cost on the cell and
causes decreased virulence (Olaitan et al., 2014). One study shows that there is a markedly
reduced fitness in colistin resistant A. baumannii strains as compared to the sensitive ones, with
a few exceptions (Lesho et al., 2013). In particular, the P233S mutation is thought to cause
decreased invasiveness and growth retardation in A. baumannii (Pournaras et al., 2014). On the
other hand, mutations in the pmrCAB operon in Salmonella spp. has shown to produce a very 
low fitness cost (Sun et al., 2009). A recent study surprisingly showed that XDR A. baumannii
isolates could actually show enhanced virulence (Jones et al., 2015). Durante-Mangoni et al.
(2015) showed in another recent study that the P233S mutation in pmrB incurred no cost on
the bacterial cell in terms of fitness nor virulence (Durante-Mangoni et al., 2015). Finally, a 
study showed that colistin resistance due to mutations in the pmrCAB operon showed very
modest decreases in virulence as opposed to mutations in the lpxA, lpxC, or lpxD genes that
lead to total loss of the LPS and sensitivity to other antimicrobial agents (Beceiro et al., 2014).
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In our study, the mutations causing colistin resistance seem to not have any effect on
the bacterial cell when the sensitive strains were compared to the resistant ones, with the 
exception of the decreased proteolytic activity of strain C440 and its production of 
siderophores. Genes involved in siderophore assembly and uptake were detected for all 5 
isolates, but this was not represented in the phenotypic test. One explanation for the increased
production of siderophores, allowing for their phenotypic detection, in C440 is the involvement
of PmrB in iron acquisition (Arroyo et al., 2011). The P233S mutation might be affecting PmrB
in a way that decreases intake of iron, resulting in the increased production of siderophores in 
order to compensate for low intracellular iron levels. This could in turn have had an effect on 
the reduced proteolytic activity detected in this isolate where less energy is expended on 
exoproteases in order to increase siderophore expression. RT-PCR analyses on the genes 
involved in the production of both siderophores and exoproteases could help shed further light
on the matter.
These results demonstrate the ability of clones originating from different ICs to develop 
resistance to colistin independently from one another, suggesting that the unique driving factor
for the development of this resistance is the selective pressure exerted by colistin itself. Based 
on this, it is recommended that close monitoring of the patients and the strain infecting them
be performed during colistin therapy through frequent isolations and susceptibility testing. The
early discovery of colistin-resistant isolates could be a main factor in the prevention of the
spread of PDR clones through the sequestration of the patient. It could also contribute to better 
treatment outcome through switching the therapy to other antimicrobial agents or through using
combination therapies as soon as resistance is detected. 
5. Biofilm Formation Patterns among Acinetobacter baumannii Isolates
Twelve isolates from the Spanish set of strains were chosen, having different pulsotypes 
and antibiotic susceptibility profiles in order to further investigate the relationship between 
antibiotic resistance and biofilm formation. The objective of this investigation is to test if the 
rate of biofilm formation could be predicted by the antibiotic susceptibility profile alone, so as
to provide clinicians and infection control specialists with quick insight regarding this factor.
Eight of those isolates were resistant to carbapenems. Isolates 12 and 45 were additionally
resistant to colistin. All these isolates produced biofilms on steel coupons, but at varying rates. 
However, all the isolates included in this study showed reduced attached cell densities after 48 
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hours, caused by dispersal. Eight of the patients from which these isolates were obtained were
previously exposed to mechanical ventilation and catheterization, both of which are recognized 
as risk factors for the development of biofilms (McConnell et al., 2013). Moreover, all the 
patients, except for three, had previous antibiotic therapy, another factor associated with 
biofilm formation (Rodriguez-Baño et al., 2008). These associations could be the first piece of 
useful information, where specialists could expect isolates from similar backgrounds to form
biofilms and act accordingly. 
Three distinct groups with different rates of biofilm formation were identified. Isolates
26, 52, and 59 were under the “fast biofilm formers” group; isolate 30 was alone in the “slow 
biofilm former” group; while the rest of the isolates where in the “intermediate biofilm
formers” group. Interestingly, all three isolates that were fast biofilm formers were susceptible
to aminoglycosides. Nevertheless, isolates 3 and 38 also were susceptible to aminoglycosides
but pertained to the intermediate group. This observation is based on a small sample and a 
general conclusion could not be made based only on these isolates but it could open the way
for further investigation. Though our study was more directed towards carbapenem resistance 
due to the globally increasing rates of resistance to these antimicrobial agents and their clinical 
importance (Tärnberg et al., 2016), future studies could be directed towards isolates with
differing aminoglycoside resistance patterns. The only isolate that pertained to the slow biofilm
former group was obtained from a patient that was not previously exposed to catheterization. 
This isolate was also sensitive to carbapenems but since it was the only case, and because other 
isolates with similar profiles pertained to other groups, no specific associations could be made
with slow rates of biofilm formation. However, this strain continued to increase its cell density
on steel coupons until it reached the same cell densities as the other isolates at 48 hours. This
indicates that, even at a slow rates, A. baumannii isolates are able to eventually produce
biofilms able to cover abiotic surfaces.
All the isolates of the intermediate group, expect for isolate 38, were resistant to 
carbapenems, and all the patients from which these isolates were recovered died, except for
one. Moreover, this group contained two colistin resistant isolates. These findings could 
indicate a role for biofilm formation in mortality and is in disagreement with the findings of 
Rodriguez-Baño et al. (2008). In the latter study, 89 A. baumannii isolates were studied and
negative associations between carbapenem resistance and mortality on one hand and biofilm
formation on the other was detected. That study contained a much larger pool of isolates than
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our study and therefore statistical correlation in that study is more representative. Nevertheless,
our small pool of isolates show that this is not always the case and these associations should
not be taken for granted while treating a patient. Moreover, as opposed to the other study, we 
studied biofilm formation over time, and quantified the attached cells, which could have made
it possible to detect biofilms that were missed by the other study which employed a
spectrophotometric technique in the detection of biofilms.
Our results are similar to other studies, in a sense that diverse biofilm formation patterns
were observed after 24 hours of incubation. Lee et al., (2008) showed a positive correlation 
between biofilm formation and the expression of the carbapenemase PER-1. Though PER-1 
was not screened for in our set of isolates due to the lack of a positive control, a relationship
between biofilm formation and carbapenem resistance seems to exit. This relationship was
evident by the CLSM analysis performed after 24 hours of growth on steel coupons where
carbapenem resistant isolates had denser biofilms than carbapenem sensitive ones. De Breij et 
al., (2010) showed that biofilm formation patterns differed between the different A. baumannii 
ICs. Though there were only one representative from each of ICs I and III included in our study,
this observation was not true for our isolates. The difference in biofilm pattern rather seems to
be related to another factor that we still haven’t pinpointed. Involvement of quorum sensing
molecules could be this factor affecting the differential expression of biofilms (Niu et al., 
2008), but this warrants further investigation. Our results are also similar to the results reported 
by Rao et al. (2008) and Gurung et al. (2013) were a relationship between MDR profiles and
biofilm formation was detected. Our results indeed show that isolates with MDR and XDR
profiles, though variable in their patterns, were able to show intermediate to fast rates of biofilm
formation patterns. This also falls in agreement with a study performed by Orsinger-Jacobsen
et al. (2013) were differing CLSM profiles were obtained for 13 isolates grown on steel 
coupons. Moreover, this group showed that the bacterial cells grown on steel coupons were 
significantly more resistant to disinfectants than their planktonic counterparts. All of this
indicates that our preliminary study falls in agreement with other similar studies and open the
way for a future large-scale investigations that could determine associations between specific 
antibiotic resistance profiles and biofilm formation patterns.
All the isolates were positive for OmpA and all except for isolates 12 and 59 were 
positive for CsuE. It has been shown that Crohn’s disease patients have altered normal flora,
allowing for the selection of strongly adherent strains (Chassaing et al., 2015). This was indeed
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shown to be the case in our study where isolate 59 was obtained from a Crohn’s disease patient
and pertained to the fast biofilm former group although it lacked CsuE. Further investigation 
regarding the exact mechanisms of biofilm formation in this isolate, and in isolate 12, could 
help better understand the complex cellular interactions that result in biofilm formation in A.
baumannii. Moreover, the negative result for CsuE for these isolates could be due to them being
sporadic, and therefore harboring an allele for this gene that was not detected by the primers
we used.
Isolates 3, 26, 45, and 52 produced a brown pigment that was evident at the time of
performing the experiment. Pigment formation does not seem to affect the rate of biofilm
formation since these isolates were spread across different groups of biofilm formation rates. 
Testing for siderophores among this population did not show a statistical association with
pigment formation, thus ruling it out as the cause of pigmentation. However, since pigment 
formation has been associated with virulence in a study in Argentina (Vilacoba et al., 2013),
two pigment-forming and two non-pigment-forming isolates were chosen for CLSM analysis
in order to further investigate the biofilm structure of these isolates. The two carbapenem 
resistant pigmented isolates (45 and 52) produced denser biofilms as compared to the 
carbapenem sensitive non-pigmented ones (30 and 38). This result could be indicative that the 
density of the biofilm could be related to pigmentation. Performing this analysis on larger 
populations could further clarify the matter. This result could also be an indicator of an
interplay between carbapenem resistance and dense biofilm formation patterns. This
information is particularly useful for infection control specialists where they can implement
aggressive approaches while eradicating biofilms caused by CRAB isolates. Moreover, future 
research assessing the different molecules being evaluated for their effectiveness in eradicating
biofilms, such as some essential oils (Kavanaugh and Ribbeck, 2012) and dynamic nanoparticle 
platforms (Wu et al., 2009), could be evaluated against pathogens with different biofilm
formation patterns in order to check for a relationship between the usefulness of such molecules 
and specific patterns. 
No statistical significance was detected between the biofilm forming groups and any of 
the tested virulence factors, carbapenemases, clonality, and doubling times (p<0.05). The
resulting profiles of the isolates included in this study were highly variable one from another.
Moreover, specific factors looked upon individually do not seem to pertain to any biofilm group
in particular, but rather similar profiles could be found in distinct groups. Due to the time­
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consuming and labor-intensive nature of these experiments, performing this study on the entire 
set of isolates was not possible. However, such an investigation could prove insightful in the
future. Nevertheless, the preliminary associations between dense biofilms and carbapenem
resistance show promise for future consolidation of this association and for gaining insight on
how biofilms could act as both virulence and antibiotic resistance determinants.
In conclusion, high rates of CRAB isolates were detected in both HU-LP and SGH­
UMC. There was a predominance of IC II in both hospitals but sporadic isolates, as well as
isolates pertaining to other ICs, were able to produce XDR and MDR infections. blaOXA-24-like
was predominant among isolates from HU-LP whereas blaOXA-23-like was predominant among
the isolates of SGH-UMC. The virulence profiles obtained were highly variable, but an 
association between IC II and blaOXA-24-like on one hand, and increased virulence on the other,
was detected among the HU-LP isolates. This association was not detected in the isolates of 
SGH-UMC, suggesting that these associations could only be used locally. Additionally, a novel 
mutation (ΔIle19) in PmrB was shown to lead to colistin resistance without affecting the 
virulence of the strain. Another mutation detected in this study (P233S in PmrB) also led to 
colistin resistance but had an effect on siderophore production and proteolytic activity. Finally, 
preliminary associations between aminoglycoside sensitivity and fast rates of biofilm
formation; and between carbapenem resistance and dense biofilm formations, were detected in 
this study. The data presented in this Doctoral Thesis could be very valuable for clinicians,
researchers, and infection control specialists in terms of understanding the complex
mechanisms and relationships between virulence and antimicrobial resistance. This would, in 
turn, lead to better prescription regimens and infection control protocols that are based on
certain expectation, resulting in safeguarding important antimicrobial agents for future use and
in the eradication of MDR organisms from the hospital.
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The following conclusions have been achieved in this Doctoral Thesis:
Las conclusiones de esta Tesis Doctoral son las siguientes:
First: Carbapenem resistance among A. baumannii strains isolated from Hospital Universitario
– La Paz (HU-LP) in Madrid (Spain) was 84.75%. These isolates showed very high rates of
resistance to other antimicrobial agents where more than 80% of the isolates were non-sensitive
to ticarcillin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ceftazidime,
ciprofloxacin, levofloxacin, and trimethoprim/sulfamethoxazole. Additionally, 79.66% of the
isolates were non-susceptible to cefepime and 16.95% to minocycline. Non-susceptibility to 
aminoglycosides ranged from 18.64% for amikacin to 54.24% for gentamycin. Only two
isolates (3.39%) were resistant to colistin.
Primero: Se encuentra un elevado nivel de resistencia a carbapenemas (84,75%) en las cepas
de A. baumannii aisladas del Hospital Universitario – La Paz (HU-LP) en Madrid (España). 
Estas cepas muestran además altos niveles de resistencia a otros antibióticos, siendo más del
80% de las cepas resistentes a ticarcilina, piperacilina, ampicilina/sulbactam, piperacilina/
tazobactam, ceftazidima, ciprofloxacino, levofloxacino, y trimetoprim/sulfametoxazol.
Asimismo, el 79,66% de las cepas no resultaron susceptibles a cefepima y el 16,95% no fueron 
susceptibles a minociclina. El 18,64% y 54,24% de las cepas no fueron susceptibles a los 
aminoglicósidos, amikacina y gentamicina, respectivamente. Sólo dos cepas (3,39%) fueron
resistentes a colistina.
Second: IC II was the most prevalent clone at 71.19% among the isolates analyzed from HU­
LP. Additionally, 8.47% of these isolates pertained to IC I, 6.78% to IC III, 13.56% didn’t 
belong to any IC, and one isolate pertained to group 14. These isolates were distributed among
7 clusters as defined by PFGE where Cluster 6 was the largest and five isolates were sporadic 
and did not pertain to any cluster.
Segundo: El clon internacional II fue el más frecuente, correspondiendo al 71,19% de las cepas 
analizadas del HU-LP. Además, el 8,47% de las cepas pertenecieron al clon internacional I, el 
6,78% al clon internacional III, una cepa al grupo 14, y el 13,56% no perteneció a ningún clon 
internacional. Estas cepas fueron distribuidas entre 7 grupos definidos por PFGE, incluyendo
el grupo 6 la mayoría de las cepas. Cinco de las cepas no pertenecieron a ningún grupo de 
PFGE.
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Third: OXA-24-like was the most commonly disseminated carbapenemase among the HU-LP
isolates at 62.71%, while OXA-23-like and OXA-58-like were detected at lower frequencies; 
11.86% and 13.56%, respectively.
Tercero: La familia de oxacilinasa OXA-24 fue la más frecuente, en las cepas analizadas del 
HU-LP, detectándose en el 62,71% de éstas, mientras que las familias OXA-23 y OXA-58 se
detectaron únicamente en el 11,86% y 13,56%, respectivamente.
Fourth: Isolates pertaining to IC II were associated with increased virulence as compared to 
isolates pertaining to ICs I and III. In particular, they were positively associated with hemolysis, 
siderophore production, and strong biofilm formation (p<0.05).
Cuarto: Las cepas del clon internacional II se asociaron con un nivel de virulencia más alto en
comparación con las cepas de los clones internacionales I y III. Particularmente, se asociaron 
positivamente con hemólisis, producción de sideróforos, y formaciones intensas de biofilms 
(p<0,05).
Fifth: Presence of OXA-24-like was also associated with increased virulence as compared to
the presence of OXA-23-like and OXA-58-like where harboring blaOXA-24-like was positively 
associated with α-hemolysis and siderophore production (p<0.05).
Quinto: La presencia de la familia de OXA-23 se asoció positivamente con un nivel de
virulencia más alto, en comparación con su presencia en otras familias de oxacilinasas. La
presencia de la familia OXA-23 se asoció con hemólisis y producción de sideróforos (p<0,05).
Sixth: The A. baumannii isolates obtained from Saint Georges Hospital – University Medical 
Center (SGH-UMC) in Beirut (Lebanon) showed even higher rates of carbapenem resistance:
90%. Susceptibility to other tested antimicrobial agents did not exceed 14.4% among these
isolates, but only one isolate was resistant to colistin. 
Sexto: Las cepas de A. baumannii aisladas del Hospital Saint Georges – University Medical
Center (HSG-UMC) en Beirut mostraron aún mayores niveles de resistencia a carbapenemas
(90%). La susceptibilidad de estas cepas a otros antibióticos fue inferior al 14,4%, pero sólo
una cepa resultó resistente a colistina. 
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Seventh: Similarly to the set of isolates obtained from HU-LP, IC II was the most predominant
clone at 88.9% among the isolates obtained from SGH-UMC, while 6.7% of the isolates 
pertained to group 4, 2.2% to group 14, 1.1% to group 10, and one isolate did not pertain to 
any defined clone.
Séptimo: Al igual que las cepas aisladas de HU-LP, el clon internacional II fue el más frecuente
en las cepas aisladas del HSG-UMC, donde representó el 88,9% de las cepas. Entre las otras
cepas estudiadas, el 6,7% pertenecieron al grupo 4, el 2,2% al grupo 14, el 1,1% al grupo 10,
y una cepa no perteneció a ninguno grupo internacional. 
Eighth: Unlike the data obtained from HU-LP, OXA-23-like was the most prevalent
carbapenemase among the CRAB isolates obtained from SGH-UMC (93.8%), while OXA-24­
like was only detected in two isolates and OXA-58-like was not detected.
Octavo: La familia de OXA-23 fue la más frecuente entre las cepas resistentes a carbapenemas
(93,8%) aisladas en HSG-UMC, a diferencia de las cepas aisladas en HU-LP. Además, en las 
cepas analizadas, la familia de OXA-24 fue detectada en sólo dos cepas y la familia OXA-58 
no fue detectada en ninguna. 
Ninth: Among the Lebanese set of isolates, phenotypic associations between motility,
siderophore production, and biofilm formation have been found (p<0.05). 
Noveno: Se encontraron asociaciones fenotípicas positivas entre movilidad, producción de
sideróforos, y formación de biofilms en las cepas del HSG-UMC (p<0,05). 
Tenth: The isolates obtained from Lebanon failed to show the associations previously
mentioned between clonality and virulence detected in the Spanish set of isolates. Therefore, 
the globalization of data, based on these results, could not be possible. 
Décimo: No se encontraron asociaiones entre clonalidad y virulencia si comparamos las cepas
del HU-LP y las del HSG-UMC. Esto significa que los datos obtenidos a partir de las cepas del 
HU-LP son locales y no se pueden considerar globales. 
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Eleventh: A novel mutation in the pmrCAB operon (Δ19Ile in PmrB) was pinpointed as the 
cause of colistin resistance among a set of A. baumannii isolates that developed resistance to 
colistin during therapy. Another mutation in that operon (P233S in PmrB) was also detected in
another set of isolates that developed resistance to this antimicrobial agent.
Undécimo: Una mutación en el operón pmrCAB (Δ19Ile en PmrB) ha sido descrita por primera
vez en nuestro estudio y es la responsable de causar resistencia a colistina en un set de cepas
clínicas de A. baumannii. Otra mutación en este operón (P233S en PmrB) fue también descrita
en otro set de cepas que desarrollan resistencia a colistina durante el tratamiento terapéutico.
Twelfth: The colistin resistant isolate that had the P233S mutation had an altered virulence 
profile in comparison to its sensitive counterpart, where is was positive for siderophore
production and had reduced proteolytic activity. The ΔIle19 mutation did not seem to affect
the virulence of the colistin resistant isolate as compared to its sensitive counterparts. 
Duodécimo: La cepa con la mutación P233S resistente a colistina mostró un perfil de 
virulencia alterado en comparación con la cepa sensible, en cuanto a la producción de 
sideróforos y su inferior actividad proteolítica. Comparando la cepa con la mutación ΔIle19 
con las cepas sensibles a colistina, se observó que la mutación no afectaba a la virulencia. 
Thirteenth: blaGES-5 was identified for the first time in A. baumannii in one of the two sets of 
isolates that developed colistin resistance during therapy isolated from HU-LP.  
Decimotercero: El gen blaGES-5 ha sido descrito por primera vez en A. baumannii en las cepas
aisladas de uno de los pacientes del HU-LP. 
Fourteenth: The studies performed on selected isolates from the Spanish set regarding biofilm
formation showed an association between dense biofilm formation and carbapenem resistance. 
Decimocuarto: Los estudios realizados con las cepas españolas en la formación de biofilms
indican que hay una asociación entre formaciones densas de biofilms y resistencia a 
carbapenemas. 
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Fifteenth: Investigating the rates of biofilm formation also showed three distinct rates of 
biofilm formation, where three isolates were dubbed as fast biofilm formers, one as a slow
biofilm former, and the others as intermediate biofilm formers. 
Decimoquinto: La investigación de los patrones de formación de biofilms mostró que se
encuentran tres patrones distintos. Tres cepas fueron formadoras rápidas de biofilms, una fue
lenta, y las otras fueron intermedias. 
Sixteenth: The isolates that were carbapenem resistant all had fast or moderate biofilm
formation rates, and the three fast biofilm formers were susceptible to aminoglycosides.
Decimosexto: Todas las cepas resistentes a carbapenemas fueron formadoras rápidas o
intermedias de biofilms y las que fueron rápidas fueron también susceptibles a 
aminoglicósidos. 
Seventeenth: Some strains for which biofilm formation patterns were investigated showed 
pigmentation that was not associated with siderophore production. The pigmented isolates 
showed denser biofilms on steel coupons as assessed by CLSM, as opposed to the non­
pigmented isolates. 
Decimoséptimo: Algunas cepas en las que se estudiaron patrones de formación de biofilms
mostraron una pigmentación no asociada a la formación de sideróforos. Las cepas pigmentadas
dieron lugar a biofilms más densos bajo observación por microscopia confocal, mientras que 
las no pigmentadas crearon estructuras mucho más débiles. 
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